Updated on 2024/07/11

写真a

 
MINAMIMOTO Ryogo
 
Organization
Graduate School of Medicine Designated professor
Title
Designated professor
 

Papers 277

  1. Prevalence and associated factors of low vigor in patients living with HIV and hemophilia in Japan: A cross-sectional observational study

    Komatsu Kensuke, Kimura Sota, Kiryu Yoko, Watanabe Aki, Kinai Ei, Oka Shinichi, Kimura Satoshi, Fujitani Junko, Ogata Mikiko, Minamimoto Ryogo, Hotta Masatoshi, Yokoyama Kota, Noguchi Tomoyuki, Imai Koubun

    Global Health & Medicine   Vol. 6 ( 3 ) page: 174 - 182   2024.6

     More details

    Language:English   Publisher:National Center for Global Health and Medicine  

    <p>People living with human immunodeficiency virus (HIV) are at high risk of mental health problems. However, little is known about this risk in HIV-infected patients with hemophilia (HPH) who contracted the virus through blood products. This cross-sectional, observational study assessed patients' mood states and the factors associated with them among Japanese HPH to evaluate the need for psychosocial support. HPH completed self-administered questionnaires (Profile of Mood States [POMS] and General Health Questionnaire-28), neuropsychological tests, and brain magnetic resonance imaging (MRI) and fluorodeoxyglucose positron emission tomography/computerized tomography scans. HIV-infected patients with no hemophilia (HPnH) completed POMS and neuropsychological tests. Socio-demographic characteristics and HIV- and hemophilia-related data were obtained from participants' medical records and interviews. A Mann–Whitney <i>U</i> test and chi-squared analyses were conducted. Fifty-six HPH and 388 HPnH completed the questionnaires and neuropsychological tests. HPH had a significantly lower prevalence of tension–anxiety (HPH, 7%; HPnH, 18%; <i>p</i> = 0.049) and a significantly higher prevalence of low vigor (HPH, 63%; HPnH, 32%; <i>p </i>< 0.001). Low vigor in HPH was significantly associated with impaired executive function (low vigor, 66%; high vigor, 33%; <i>p</i> = 0.019) and a social dysfunction score ≥ 3 (moderate; low vigor, 26%; high vigor, 5%; <i>p</i> = 0.047). Our results highlight the high prevalence of low vigor among HPH, leading to impairments in executive and social functions. Therefore, healthcare workers need to pay attention to the vigor, executive function, and social function of HPH. </p>

    DOI: 10.35772/ghm.2023.01108

    PubMed

    CiNii Research

  2. Clinical Effectiveness of Preoperative 18F-FDG PET/CT in Predicting Pathological Tumor Grade in Patients with Pseudomyxoma Peritonei Originating from Appendix: A Retrospective Cohort Study. International journal

    Kenta Aso, Yoshimasa Gohda, Masatoshi Hotta, Ryogo Minamimoto, Yosuke Shimizu, Yukari Uemura, Hideaki Yano

    Annals of surgical oncology   Vol. 31 ( 3 ) page: 1990 - 1995   2024.3

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND: Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy is the standard treatment for patients with pseudomyxoma peritonei (PMP). In some malignancies, the standard uptake value of positron emission tomography with 2-deoxy-2-18F-fluoro-D-glucose integrated with computed tomography (18F-FDG PET/CT) is now accepted as a reliable indicator of neoplastic behavior. This study aimed to evaluate the association between the maximum standardized uptake value (SUVmax) and pathological grade in patients with PMP and to investigate the significance of SUVmax in the preoperative assessment of these patients. PATIENTS AND METHODS: In this retrospective single-center study, consecutively enrolled patients diagnosed with PMP of appendiceal origin underwent preoperative 18F-FDG PET/CT. SUVmax was calculated as the highest SUVmax value in the abdomen excluding the primary site. SUVmax was compared with the pathological grade (low or high grade) of PMP tumors according to the World Health Organization classification and further analyzed with respect to the estimated cutoff point, sensitivity, specificity, and receiver operating characteristic. RESULTS: In total, 160 patients were included. CRS was successfully performed in 93 patients and palliative debulking surgery in 67 patients. The pathological grade was high in 45 patients and low in 115. High-grade patients had a higher median SUVmax on 18F-FDG PET/CT than did low-grade patients (3.83 versus 2.34, p < 0.001). The highest area under the curve was 0.81, with a sensitivity of 77.8%, specificity of 72.3%, and cutoff point of 2.63. CONCLUSION: This study suggests that the SUVmax of preoperative 18F-FDG PET/CT is associated with the pathological grade in patients with PMP.

    DOI: 10.1245/s10434-023-14755-y

    Scopus

    PubMed

  3. Clinical decision-making based on 11C-methionine PET in recurrent Cushing's disease with equivocal MRI findings. International journal

    Atsushi Ishida, Koichiro Kaneko, Ryogo Minamimoto, Masatoshi Hotta, Naoko Inoshita, Koji Takano, Shozo Yamada

    Journal of neurosurgery   Vol. 139 ( 6 ) page: 1671 - 1680   2023.12

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    OBJECTIVE: Diagnosis and accurate localization of recurrent tumors in Cushing's disease (CD) are challenging, especially after multiple transsphenoidal surgeries (TSSs) or radiosurgery. Even experts face difficulties in detecting these recurrent tumors, and a favorable surgical outcome is not guaranteed. In this report, the authors aimed to determine the usefulness of 11C-methionine positron emission tomography (MET-PET) for evaluating patients with recurrent CD with inconclusive magnetic resonance imaging (MRI) lesions and to develop a treatment protocol for these cases. METHODS: In this retrospective study of patients with recurrent CD in the period between April 2018 and December 2022, the authors assessed the usefulness of MET-PET in determining whether equivocal MRI findings were recurrent tumors or postsurgical cavities and deciding further treatment options. All patients had undergone at least one TSS, and most had undergone multiple TSSs and had pathologically confirmed corticotroph tumors with hypercortisolemia. RESULTS: Overall, 15 patients with recurrent CD (10 females and 5 males) were included, all of whom had undergone MET-PET. All patients had been subjected to multiple treatments, including TSSs or radiosurgeries. Their MRI scans demonstrated less-enhanced lesions that were not confirmed as recurrences even with cutting-edge MRI because they could not be distinguished from postsurgical changes with confidence. MET uptake was positive in 8 patients (9 examinations) and negative in 7. Following MET-PET, repeat TSS was performed in 5 patients. Corticotroph tumors were identified in all 5 patients, even though one of them had negative MET uptake. The MET uptake precisely identified a tumor location on the opposite side of the MRI-suspected lesion in 2 patients. Meanwhile, patients with negative uptake and mild hypercortisolism were only observed. Nonsurgical options were also used in other patients: temozolomide (TMZ) was administered in 2 patients owing to a prior history of multiple TSSs and radiosurgery and the drug-resistant nature of the disease. TMZ was highly effective in these patients; their Cushing's symptoms ameliorated, and their adrenocorticotropic hormone and cortisol levels continued to decline. Interestingly, MET uptake disappeared following TMZ treatment. CONCLUSIONS: MET-PET is extremely useful for confirming equivocal lesions on MRI in patients with recurrent CD and for deciding further treatment options. The authors propose a novel protocol based on MET-PET results for treating patients with relapsing CD in whom the recurrent tumors cannot be confirmed with MRI.

    DOI: 10.3171/2023.5.JNS23179

    Scopus

    PubMed

  4. Prostate-specific antigen doubling time predicts the efficacy of site-directed therapy for oligoprogressive castration-resistant prostate cancer

    Kawai T., Taguchi S., Nozaki K., Kimura N., Oshina T., Iwaki T., Matsui H., Niimi A., Kamei J., Akiyama Y., Yamada Y., Sato Y., Yamada D., Kaneko T., Sawayanagi S., Nakayama H., Minamimoto R., Yamashita H., Miyazaki H., Fujimura T., Nakagawa T., Kume H.

    Prostate International   Vol. 11 ( 4 ) page: 239 - 246   2023.12

     More details

    Language:English   Publisher:Prostate International  

    Background: In recent years, site-directed therapies (SDTs) targeting progressive lesions in patients with oligometastatic prostate cancer have attracted attention. However, whether they effectively treat oligoprogressive castration-resistant prostate cancer (CRPC) remains unclear. Here, we investigated the efficacy of SDT in patients with oligoprogressive CRPC and identified prognostic factors. Methods: We reviewed 59 patients with oligoprogressive CRPC who underwent SDT targeting prostate or metastatic lesions between April 2014 and March 2022. We evaluated the associations between several pretreatment clinical variables and treatment procedures and a >50% prostate-specific antigen (PSA) response, progression-free survival (PFS), and time to next treatment (TTNT). Results: A PSA response of >50% was observed in 66% of patients. The median PFS and TTNT were 8.3 months and 9.9 months, respectively. Patients with PSA doubling time ≥6 months showed a higher >50% PSA response rate (87% vs. 45%; P < 0.001), longer PFS (median, 15.0 vs. 5.0 months; P < 0.001), and longer TTNT (median, 16.3 vs. 5.9 months; P < 0.001) than patients with PSA doubling time <6 months. In multivariate analyses, a PSA doubling time of ≥6 months independently predicted a >50% PSA response, favorable PFS, and TTNT (P = 0.037, 0.025, and 0.017, respectively). Conclusion: PSA doubling time of ≥6 months may be a key indicator of the favorable efficacy of SDT for oligoprogressive CRPC.

    DOI: 10.1016/j.prnil.2023.10.002

    Scopus

    PubMed

  5. External Beam Radiotherapy in Advanced Pheochromocytoma and Paraganglioma: An Observation of a Rare Abscopal Effect. International journal

    Aiko Terakawa, Akiyo Tanabe, Hidetsugu Nakayama, Ryogo Minamimoto

    JCEM case reports   Vol. 1 ( 5 ) page: luad111   2023.9

     More details

    Language:English  

    Metastatic pheochromocytoma and paraganglioma are incurable, and effective treatment of systemic symptoms resulting from catecholamine excess and local symptoms from tumor growth are crucial to prolong survival and improve quality of life. We report the first case of metastatic pheochromocytoma wherein external beam radiotherapy (EBRT) demonstrated efficacy in both target and nontarget lesions, demonstrating the "abscopal effect." EBRT reduced tumor volume and catecholamine secretion and improved catecholamine excess-related complications, including glycemic control. EBRT is an effective treatment option for metastatic pheochromocytoma and paraganglioma because of its minimal invasiveness, safety, and potential for the rare abscopal effect.

    DOI: 10.1210/jcemcr/luad111

    PubMed

  6. 特集 FDG-PET保険収載20周年と今後 炎症PETの推進

    南本 亮吾

    臨床放射線   Vol. 68 ( 7 ) page: 667 - 674   2023.7

     More details

    Publisher:金原出版  

    DOI: 10.18888/rp.0000002388

    CiNii Research

  7. Case of adult large vessel vasculitis after SARS-CoV-2 infection. International journal

    Ryohei Oda, Takeshi Inagaki, Masahiro Ishikane, Masatoshi Hotta, Akira Shimomura, Mitsuhiro Sato, Takato Nakamoto, Yutaro Akiyama, Kei Yamamoto, Ryogo Minamimoto, Hiroshi Kaneko, Norio Ohmagari

    Annals of the rheumatic diseases   Vol. 82 ( 1 ) page: e25   2023.1

     More details

  8. Optimal use of the FDG-PET/CT in the diagnostic process of fever of unknown origin (FUO): a comprehensive review

    Minamimoto R.

    Japanese Journal of Radiology   Vol. 40 ( 11 ) page: 1121 - 1137   2022.11

     More details

    Language:English   Publisher:Japanese Journal of Radiology  

    Numerous studies have clarified the usefulness of 18F-fluorodeoxyglucose (FDG)-PET/CT (positron emission tomography) for diagnosing the cause of fever of unknown origin (FUO). Various types of disease can cause FUO, but the cause remains unknown in a certain proportion of FUO, even when the advanced diagnostic methodologies are used. FDG-PET/CT is regarded as a second-line modality in the diagnostic process of FUO, and its potential to identify the cause of FUO will be maximized when the appropriate clinical considerations are understood. Accordingly, this review presents basic knowledge regarding FUO, and reports the current status of FDG-PET/CT applied to diagnosing the cause of FUO, including diagnostic performance, test protocols, possible factors influencing the diagnostic result, outcomes, and cost-effectiveness. This knowledge will enable effective future use of FDG-PET/CT to improve outcomes in patients with FUO.

    DOI: 10.1007/s11604-022-01306-w

    Scopus

    PubMed

  9. Variation in blood pressure and heart rate of radiological technologists in worktime tracked by a wearable device: A preliminary study

    Minamimoto R., Yamada Y., Sugawara Y., Fujii M., Kotabe K., Iso K., Yokoyama H., Kurihara K., Iwasaki T., Horikawa D., Saito K., Kajiwara H., Matsunaga F.

    PLoS ONE   Vol. 17 ( 11 November ) page: e0276483   2022.11

     More details

    Language:English   Publisher:PLoS ONE  

    The aim of this preliminary study was to measure the systolic BP (SBP) and diastolic BP (DBP) and heart rate (HR) of radiological technologists by WD, and evaluate variation among individuals by worktime, day of the week, job, and workplace. Measurements were obtained using a wristwatch-type WD with optical measurement technology that can measure SBP and DBP every 10 minutes and HR every 30 minutes. SBP, DBP, and HR data obtained at baseline and during work time were combined with the hours of work, day of the week, job, and workplace recorded by the participants in 8 consecutive weeks. We calculated the mean, the ratio to baseline and coefficient of variation [CV(%)] for SBP, DBP, and HR. SBP, DBP, and HR values were significantly higher during work hours than at baseline (p<0.03). The ratio to baseline values ranged from 1.02 to 1.26 for SBP and from 1.07 to 1.30 for DBP. The ratio to baseline for SBP and DBP showed CV(%) of approximately 10% according to the day of the week and over the study period. For HR, ratio to baseline ranged from 0.95 to 1.29. The ratio of mean BP to baseline was >1.2 at the time of starting work, middle and after lunch, and at 14:00. The ratio to baseline of SBP were 1.2 or more for irradiation, equipment accuracy control, registration of patient data, dose verification and conference time, and were also working in CT examination room, treatment planning room, linac room, and the office. CV(%) of BP and HR were generally stable for all workplaces. WD measurements of SBP, DBP, and HR were higher during working hours than at baseline and varied by the individuals, work time, job, and workplace. This method may enable evaluation of unconscious workload in individuals.

    DOI: 10.1371/journal.pone.0276483

    Scopus

    PubMed

  10. Oncology and cardiology positron emission tomography/computed tomography faced with COVID-19: A review of available literature data

    Minamimoto R.

    Frontiers in Medicine   Vol. 9   page: 1052921   2022.10

     More details

    Language:English   Publisher:Frontiers in Medicine  

    The COVID-19 pandemic has forced people to significantly change their lifestyles and attitudes, and has greatly burdened healthcare delivery systems worldwide. The redistribution of the medical delivery system to maintain normal medical care while responding generously to COVID-19 is a continuing challenge that weighs heavily on medical institutions. Among imaging modalities, chest X-rays and computed tomography (CT) examinations have clearly made a large contribution to treatment of COVID-19. In contrast, it is difficult to express the standpoint of nuclear medicine examinations in a straightforward manner, as the greatest emphasis in this modality has been on how necessary medical care can continue to be provided. Many clinical reports of nuclear medicine examinations related to COVID-19 have been published, and knowledge continues to accumulate. This review provides a summary of the current state of oncology and cardiology positron emission tomography (PET) examinations related to COVID-19, and includes preparation of the nuclear medicine department, trends in PET examinations, specific imaging findings on 18F-fluorodeoxyglucose (FDG) PET/CT, imaging of complications of COVID-19, PET tracers other than FDG, and the effects of vaccines on PET imaging findings.

    DOI: 10.3389/fmed.2022.1052921

    Scopus

    PubMed

  11. 18F-FSPG PET/CT Imaging of System xC- Transporter Activity in Patients with Primary and Metastatic Brain Tumors. International journal

    Mirwais Wardak, Ida Sonni, Audrey P Fan, Ryogo Minamimoto, Mehran Jamali, Negin Hatami, Greg Zaharchuk, Nancy Fischbein, Seema Nagpal, Gordon Li, Norman Koglin, Mathias Berndt, Santiago Bullich, Andrew W Stephens, Ludger M Dinkelborg, Ty Abel, H Charles Manning, Jarrett Rosenberg, Frederick T Chin, Sanjiv Sam Gambhir, Erik S Mittra

    Radiology   Vol. 303 ( 3 ) page: 620 - 631   2022.6

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Background The PET tracer (4S)-4-(3-[18F]fluoropropyl)-l-glutamate (18F-FSPG) targets the system xC- cotransporter, which is overexpressed in various tumors. Purpose To assess the role of 18F-FSPG PET/CT in intracranial malignancies. Materials and Methods Twenty-six patients (mean age, 54 years ± 12; 17 men; 48 total lesions) with primary brain tumors (n = 17) or brain metastases (n = 9) were enrolled in this prospective, single-center study (ClinicalTrials.gov identifier: NCT02370563) between November 2014 and March 2016. A 30-minute dynamic brain 18F-FSPG PET/CT scan and a static whole-body (WB) 18F-FSPG PET/CT scan at 60-75 minutes were acquired. Moreover, all participants underwent MRI, and four participants underwent fluorine 18 (18F) fluorodeoxyglucose (FDG) PET imaging. PET parameters and their relative changes were obtained for all lesions. Kinetic modeling was used to estimate the 18F-FSPG tumor rate constants using the dynamic and dynamic plus WB PET data. Imaging parameters were correlated to lesion outcomes, as determined with follow-up MRI and/or pathologic examination. The Mann-Whitney U test or Student t test was used for group mean comparisons. Receiver operating characteristic curve analysis was used for performance comparison of different decision measures. Results 18F-FSPG PET/CT helped identify all 48 brain lesions. The mean tumor-to-background ratio (TBR) on the whole-brain PET images at the WB time point was 26.6 ± 24.9 (range: 2.6-150.3). When 18F-FDG PET was performed, 18F-FSPG permitted visualization of non-18F-FDG-avid lesions or allowed better lesion differentiation from surrounding tissues. In participants with primary brain tumors, the predictive accuracy of the relative changes in influx rate constant Ki and maximum standardized uptake value to discriminate between poor and good lesion outcomes were 89% and 81%, respectively. There were significant differences in the 18F-FSPG uptake curves of lesions with good versus poor outcomes in the primary brain tumor group (P < .05) but not in the brain metastases group. Conclusion PET/CT imaging with (4S)-4-(3-[18F]fluoropropyl)-l-glutamate (18F-FSPG) helped detect primary brain tumors and brain metastases with a high tumor-to-background ratio. Relative changes in 18F-FSPG uptake with multi-time-point PET appear to be helpful in predicting lesion outcomes. Clinical trial registration no. NCT02370563 © RSNA, 2022 Online supplemental material is available for this article.

    DOI: 10.1148/radiol.203296

    Scopus

    PubMed

  12. Change in cancer diagnosis during the COVID-19 pandemic: Trends estimated from FDG-PET/CT

    Minamimoto Ryogo, Hotta Masatoshi, Okafuji Takashi, Tsutui Soichiro, Tsukuda Masaaki, Nakayama Hidetsugu, Shida Yoshitaka, Tajima Tsuyoshi

    Global Health & Medicine   Vol. 4 ( 2 ) page: 108 - 115   2022.4

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:National Center for Global Health and Medicine  

    <p>The aim of this study is to clarify changes in the circumstances of cancer diagnoses during the COVID-19 pandemic in Tokyo, Japan, estimated from [<sup>18</sup>F]-2-fluoro-2-deoxy-D-glucose (FDG) -positron emission tomography/computed tomography (PET/CT) for cancer patients. Cancer diagnosis in pandemic status (PANS) was evaluated by retrospective review of the findings of FDG-PET/CT examinations performed between 11 March 2020 and 28 December 2021 for initial staging and restaging for malignancy. Evaluation of cancer diagnosis in pre-pandemic status (pPANS) was conducted similarly in FDG-PET/CT examinations performed between 4 January 2018 and 10 March 2020. Of these, patients with malignant lymphoma (ML), lung cancer, esophageal cancer, and colorectal cancer who had a pathologically proven diagnosis or clinical diagnosis following therapy of the disease were selected for analysis. Initial cancer staging was determined by the diagnostic report of FDG-PET/CT. Change in cancer stage and in the number of FDG-PET/CT examinations performed was evaluated between pPANS and PANS, and according to term of the pandemic and vaccination status. The COVID-19 epidemic influenced the number of cancer patients who underwent FDG-PET/CT. There was a marked decrease in the number of cancer patients receiving FDG-PET/CT in Terms 1-3 (March 2020 to February 2021), but it recovered in Terms 4-6 (March 2021 to December 2021). There was no significant difference between PANS and pPANS in terms of the initial stage of cancer, but Stage IV ML and Stage II esophageal cancer were more frequent in PANS. Initial staging of ML, lung cancer, and esophageal cancer revealed more advanced cancer stages in Terms 4-6 compared with Terms 1-3. The number of patients receiving FDG-PET/CT in Tokyo was influenced by the COVID-19 epidemic. Staging based on FDG-PET/CT shifted to more advanced cancer stage during the pandemic compared with pre-pandemic. </p>

    DOI: 10.35772/ghm.2022.01016

    PubMed

    CiNii Research

  13. Association Between Time Since Administration of Pegylated G-CSF (Pegfilgrastim) and Bone Marrow Uptake on FDG PET/CT: Determination of a Minimum Interval. International journal

    Ryogo Minamimoto, Lucia Baratto, Andrei Iagaru

    AJR. American journal of roentgenology   Vol. 218 ( 2 ) page: 351 - 358   2022.2

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND. Pegfilgrastim administration after chemotherapy increases bone marrow and spleen FDG uptake. Consensus is lacking regarding the optimal interval between pegfilgrastim administration and FDG PET/CT. OBJECTIVE. The purpose of this study was to assess the association between bone marrow and spleen uptake and the interval between pegfilgrastim administration and FDG PET/CT. METHODS. This retrospective study included 70 oncology patients (mean age, 64 ± 12 [SD] years; 48 men, 22 women) receiving chemotherapy who underwent FDG PET/CT (study scan) within 35 days after pegfilgrastim administration and who underwent additional FDG PET/CT at least 4 months before pegfilgrastim initiation or at least 3 months after last pegfilgrastim administration (reference scan). A nuclear medicine physician recorded the SUVmean for normal osseous structures and spleen and assessed bone marrow uptake using a 4-point visual scale (1, no abnormal uptake; 2, clinically insignificant uptake; 3, clinically significant uptake possibly interfering with interpretation; 4, clinically significant uptake expected to interfere with interpretation). RESULTS. Percentage change in SUVmean between reference and study scans significantly increased (p < .05) as the interval increased for five sites (i.e., for patients with interval of 7-13 vs 29-35 days, mean percentage change was 32.3% ± 18.2% vs 11.5% ± 17.3% for cervical vertebra, 42.2% ± 18.3% vs 21.3% ± 14.2% for thoracic vertebra, 47.2% ± 19.8% vs 19.1% ± 13.9% for lumbar vertebra, 51.1% ± 25.8% vs 12.7% ± 11.3% for pelvis, and 53.0% ± 25.6% vs 4.4% ± 14.1% for lower extremity); percentage change was not associated with the interval for upper extremity or spleen (p > .05). Visual uptake scores of 4, 3, 2, and 1 were observed in days 7-21, 12-22, 12-28, and 14-35, respectively. Percentage of patients with a score of 3 or 4 was 94.4% for days 7-13, 58.1% for days 14-21, 6.7% for days 22-28, and 0% for days 29-35. A total of 71.4% of patients had a score of 3 or 4 on day 7-21, whereas 4.8% had a score of 3 and 0% had a score of 4 on days 22-35. CONCLUSION. A visual uptake score of 3 or 4 was consistently observed throughout an approximately 3-week interval following pegfilgrastim administration, without any such case beyond 22 days. CLINICAL IMPACT. We recommend a preferred interval of at least 3 weeks after pegfilgrastim administration before PET/CT.

    DOI: 10.2214/AJR.21.26480

    Scopus

    PubMed

  14. Amino Acid and Proliferation PET/CT for the Diagnosis of Multiple Myeloma

    Ryogo Minamimoto

    Frontiers in Nuclear Medicine   Vol. 1   2022

     More details

    Publishing type:Research paper (scientific journal)  

    DOI: 10.3389/FNUME.2021.796357

    Scopus

  15. Determining the extent of tumor resection at surgical planning with 18F-fluciclovine PET/CT in patients with suspected glioma: multicenter phase III trials.

    Toshihiko Wakabayashi, Yuichi Hirose, Keisuke Miyake, Yoshiki Arakawa, Naoki Kagawa, Tadashi Nariai, Yoshitaka Narita, Ryo Nishikawa, Naohiro Tsuyuguchi, Tadateru Fukami, Hikaru Sasaki, Takashi Sasayama, Akihide Kondo, Toshihiko Iuchi, Hiroshi Matsuda, Kazuo Kubota, Ryogo Minamimoto, Takashi Terauchi, Yoichi Nakazato, Kan Kubomura, Masatoshi Wada

    Annals of nuclear medicine   Vol. 35 ( 12 ) page: 1279 - 1292   2021.12

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    OBJECTIVE: Glioma is the most common type of central nervous system tumor reported worldwide. Current imaging technologies have limitations in the diagnosis and assessment of glioma. The present study aimed to confirm the diagnostic efficacy and safety of anti-1-amino-3-[18F]fluorocyclobutane carboxylic acid (18F-fluciclovine; anti-[18F]FACBC) as a radiotracer for patients undergoing combined positron emission tomography and computed tomography (PET/CT) for suspected glioma. METHODS: Combined data from two multicenter, open-label phase III clinical trials were evaluated for this study. The two trials enrolled patients with suspected high- or low-grade glioma on the basis of clinical symptoms, clinical course, and magnetic resonance imaging findings, and who were scheduled for tumor resection surgery. Patients fasted for ≥ 4 h and received 2 mL of 18F-fluciclovine (radioactivity dose 78.3-297.0 MBq), followed by a 10-min PET scan 10-50 min after injection. The primary efficacy endpoint was the positive predictive value (PPV) of the gadolinium contrast-enhanced T1-weighted image negative [Gd (-)] and 18F-fluciclovine PET-positive [PET ( +)] area of the scans, using the histopathological diagnosis of the tissue sampled from that area as the standard of truth. All adverse events reported during the study were recorded for safety analysis. RESULTS: A total of 45 patients aged 23-89 years underwent 18F-fluciclovine PET; 31/45 patients (68.9%) were male, and 30/45 patients (66.7%) were suspected to have high-grade glioma. The PPV of 18F-fluciclovine PET in the Gd (-) PET ( +) area was 88.0% (22/25 areas, 95% confidence interval: 70.0-95.8). The extent of planned tumor resection was modified in 47.2% (17/36 cases) after 18F-fluciclovine PET scan, with an extension of area in 30.6% (11/36 cases) and reduction in 16.7% (6/36 cases). Furthermore, tissue samples collected from PET ( +) areas tended to have a higher malignancy grade compared with those from PET (-) areas. Overall, 18F-fluciclovine was well tolerated. CONCLUSION: 18F-fluciclovine PET/CT is useful for determining the extent of tumor resection at surgical planning, and may serve as a safe and effective diagnostic tool for patients with suspected glioma. TRIAL REGISTRATION: These trials were registered in the Japan Pharmaceutical Information Center Clinical Trials Information (JapicCTI-152986, JapicCTI-152985).

    DOI: 10.1007/s12149-021-01670-z

    Web of Science

    Scopus

    PubMed

  16. Proliferation PET/CT imaging of salivary gland tumor

    Minamimoto R.

    Diagnostics   Vol. 11 ( 11 )   2021.11

     More details

    Language:English   Publisher:Diagnostics  

    Salivary gland tumors are rare neoplasms which vary in terms of origin and malignant potential. 2-[18F]-fluoro-2-deoxy-d-glucose (FDG)-positron emission tomography (PET) has limited ability to differentiate between different types of salivary gland tumors because both Warthin’s tumors and pleomorphic adenomas usually show increased FDG uptake, with no statistically significant difference in standardized uptake value (SUV) compared with malignant salivary gland tumors. Here, we discuss 4′-[methyl-11C]-thiothymidine (4DST) PET, which provides cell proliferation imaging capable of demonstrating intense uptake in parotid carcinoma and Warthin’s tumor, but no uptake in parotid pleomorphic adenoma. This is the first report of the potential of proliferation PET/ computed tomography (CT) imaging for characterizing salivary gland tumors based on the molecular pathogenesis of the tumor.

    DOI: 10.3390/diagnostics11112065

    Scopus

    PubMed

  17. A Case of polychondritis-onset refractory organizing pneumonia with cytopaenia diagnosed as VEXAS syndrome: the disease course of 7 years. International journal

    Maki Sakuma, Akira Tanimura, Satsuki Yasui, Kenji Ishiguro, Toshiaki Kobayashi, Yusuke Ohshiro, Hideki Miyazaki, Ryogo Minamimoto, Takashi Okafuji, Katsuyoshi Shimozawa, Go Ogura, Akiyoshi Miwa, Hiroyuki Yamashita, Hiroshi Kaneko

    Rheumatology (Oxford, England)   Vol. 60 ( 10 ) page: e356-e359 - E359   2021.10

     More details

  18. Predicting tumor response and prognosis to neoadjuvant chemotherapy in esophageal squamous cell carcinoma patients using PERCIST: a multicenter study in Japan

    Kaida H., Kitajima K., Nakajo M., Ishibashi M., Matsunaga T., Minamimoto R., Hirata K., Nakatani K., Hung A., Hattori S., Yasuda T., Ishii K.

    European Journal of Nuclear Medicine and Molecular Imaging   Vol. 48 ( 11 ) page: 3666 - 3682   2021.10

     More details

    Language:English   Publisher:European Journal of Nuclear Medicine and Molecular Imaging  

    Purpose: To investigate the usefulness of the positron emission tomography response criteria in solid tumors 1.0 (PERCIST1.0) for predicting tumor response to neoadjuvant chemotherapy and prognosis and determine whether PERCIST improvements are necessary for esophageal squamous cell carcinoma (ESCC) patients. Patients and methods: We analyzed the cases of 177 ESCC patients and examined the association between PERCIST and their pathological responses. Associations of whole-PERCIST with progression-free survival (PFS) and overall survival (OS) were evaluated by a Kaplan-Meier analysis and Cox proportional hazards model. To investigate potential PERCIST improvements, we used the survival tree technique to understand patients’ prognoses. Results: There were significant correlations between the pathologic response and PERCIST of primary tumor (p < 0.001). The optimal cutoff value of the primary tumors’ SULpeak response to classify pathologic responses was −50.0%. The diagnostic accuracy of SULpeak response was 87.3% sensitivity, 54.1% specificity, 68.9% accuracy, positive predictive value 60.5%, and negative predictive value 84.1%. Whole-PERCIST was significantly associated with PFS and OS. The survival tree results indicated that a high reduction of the whole SULpeak response was significantly correlated with the patients’ prognoses. The cutoff values for the separation of prognoses were − 52.5 for PFS and − 47.1% for OS. Conclusion: PERCIST1.0 can help predict tumor responses and prognoses. However, 18F-FDG-PET/CT tends to underestimate residual tumors in histopathological response evaluations. Modified PERCIST, in which the partial metabolic response is further classified by the SULpeak response (−50%), might be more appropriate than PERCIST1.0 for evaluating tumor responses and stratifying high-risk patients for recurrence and poor prognosis.

    DOI: 10.1007/s00259-021-05365-5

    Scopus

    PubMed

  19. Proliferation PET tracer <sup>11</sup>C-4DST PET/CT depicts hibernating myocardium

    Minamimoto R., Nakajima K., Okazaki O.

    Journal of Nuclear Cardiology   Vol. 28 ( 5 ) page: 2379 - 2383   2021.10

     More details

    Language:English   Publisher:Journal of Nuclear Cardiology  

    DOI: 10.1007/s12350-020-02196-z

    Scopus

    PubMed

  20. Cell Proliferation PET Imaging with 4DST PET/CT in Colorectal Adenocarcinoma and Adenoma. International journal

    Ryogo Minamimoto, Hisako Endo

    Diagnostics (Basel, Switzerland)   Vol. 11 ( 9 )   2021.9

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    An age of 70-year-old man was incidentally found two focal high 2-[18F]-fluoro-2-deoxy-d-glucose (FDG) uptake in the descending colon and in the sigmoid colon. We observed the feature of these two areas in the preplanned 4'-[methyl-11C]-thiothymidine (4DST) positron emission tomography (PET)/computed Tomography (CT)providing cell proliferation imaging. A mass forming high 4DST uptake in the descending colon and focal moderate 4DST uptake in the sigmoid colon was confirmed, and that were proven pathologically as adenocarcinoma and moderate to severe type tubular adenoma, respectively. This is the first report to present that colorectal adenoma can be visualized by proliferation PET imaging and the degree of uptake may enable discrimination of colorectal adenoma from adenocarcinoma, based on pathological considerations.

    DOI: 10.3390/diagnostics11091658

    Scopus

    PubMed

  21. 18F-Fluorothymidine PET is an early and superior predictor of progression-free survival following chemoimmunotherapy of diffuse large B cell lymphoma: a multicenter study. International journal

    Ryogo Minamimoto, Luis Fayad, Julie Vose, Jane Meza, Ranjana Advani, Jordan Hankins, Felix Mottaghy, Homer Macapinlac, Alexander Heinzel, Malik E Juweid, Andrew Quon

    European journal of nuclear medicine and molecular imaging   Vol. 48 ( 9 ) page: 2883 - 2893   2021.8

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    PURPOSE: To determine whether interim 3'-deoxy-3'-[18F]fluorothymidine (iFLT) PET/CT is a superior predictor of progression-free survival (PFS) compared with interim 18F-fluorodeoxyglucose (iFDG) PET/CT in patients with diffuse large B cell lymphoma (DLBCL) treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) or rituximab, etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (R-EPOCH). METHODS: Ninety-two prospectively enrolled patients with DLBCL underwent both FLT-PET/CT and FDG-PET/CT 18-24 days after two cycles of R-CHOP/R-EPOCH. Deauville-criteria, PERCIST1.0, standardized uptake value (SUV), total lesion glycolysis (TLG), and metabolic tumor volume were used to interpret iFDG-PET/CT while dichotomous visual interpretation was used to interpret iFLT-PET/CT and the results were compared with the 3- and 5-year PFS. RESULTS: iFLT-PET/CT was negative in 67 (73%) and positive in 25 (27%) patients. iFDG-PET/CT by Deauville criteria was negative (Deauville scores [DS] of 1-3) in 53 (58%) and positive (DS = 4-5) in 39 (42%) patients. Of the 67 iFLT-PET/CT-negative patients, 7 (10.4%) progressed at a median of 14.1 months whereas 14/25 (56.0%) iFLT-PET/CT-positive patients progressed at a median of 7.8 months (P < .0001). Of the 53 Deauville-negative patients, 9 (17.0%) progressed at a median of 14.1 months whereas 12/39 (30.8%) Deauville-positive patients progressed at a median of 5.6 months (P = .11). In multivariate analysis, including iFLT-PET/CT, PERCIST, interim TLG, and interim SUVmax, only iFLT-PET/CT was an independent predictor for 3- and 5-year PFS (P < .0001 and P = .001, respectively). CONCLUSIONS: In patients with DLBCL given R-CHOP/R-EPOCH, iFLT-PET/CT is a superior independent predictor of outcome compared with iFDG-PET/CT.

    DOI: 10.1007/s00259-021-05353-9

    Scopus

    PubMed

  22. Correlation of 18-fluorodeoxyglucose PET/computed tomography parameters and clinical features to predict outcome for diffuse large B-cell lymphoma. International journal

    Lucia Baratto, Fengyu Wu, Ryogo Minamimoto, Negin Hatami, Tie Liang, Jean Sabile, Ranjana H Advani, Erik Mittra

    Nuclear medicine communications   Vol. 42 ( 7 ) page: 792 - 799   2021.7

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    PURPOSE: To determine if the correlation between different metabolic parameters along with clinical features can create an improved model of prognostication for diffuse large B-cell lymphoma (DLBCL) patients. METHODS: We retrospectively evaluated 89 patients with DLBCL. All patients had a baseline and an interim 18F-FDG PET/CT. Seventy-nine also had an end-of-treatment PET/CT (EOT-PET). For each scan, we collected standardized uptake value (SUVmax, SUVmean, SUVpeak), metabolic tumor volume (MTV), total lesion glycolysis (TLG), SUVmaxsum, SUVmeansum, MTVsum, and TLGsum. These metabolic parameters were combined with clinical features in order to identify a new prognostic model. The predictive value of interim PET and EOT-PET using Deauville score was also determined. RESULTS: Baseline SUVmaxsum and SUVmeansum were significantly correlated to overall survival (OS) (P value = 0.012 and 0.011, respectively). The percentage change of MTV and TLG sum from baseline to EOT was predictive of progression-free survival (PFS) (P value = 0.003 and 0.022, respectively). The combination of either Deauville score at the EOT and SUVmaxsum at baseline significantly predicted OS (P value <0.001); Eastern Cooperative Oncology Group performance status, presence of extranodal disease and percentage change of MTVsum from baseline to EOT were significant predictors of PFS (P value = 0.001). CONCLUSIONS: SUVmaxsum and SUVmeansum at baseline and percentage change in MTV and TLG sum from baseline to EOT are predictors of outcome in DLBCL patients. These metabolic parameters combined to Deauville score and some clinical features could be used together to stratify patients.

    DOI: 10.1097/MNM.0000000000001398

    Scopus

    PubMed

  23. Efficacy of cell proliferation imaging with 4DST PET/CT for predicting the prognosis of patients with esophageal cancer: a comparison study with FDG PET/CT. International journal

    Masatoshi Hotta, Ryogo Minamimoto, Jun Toyohara, Kyoko Nohara, Kazuhiko Nakajima, Kei Takase, Kazuhiko Yamada

    European journal of nuclear medicine and molecular imaging   Vol. 48 ( 8 ) page: 2615 - 2623   2021.7

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    PURPOSE: 4'-[Methyl-11C] thiothymidine (4DST) incorporates into DNA directly and is a PET tracer used for cell proliferation imaging. The aim of this study was to evaluate the prediction of prognosis with pretreatment 4DST PET/CT compared to fluorodeoxyglucose (FDG) PET/CT in patients with esophageal cancer. METHODS: In this prospective study, we analyzed 46 patients (68.2 ± 10.0 years old) with pathologically proven esophageal squamous cell cancer who underwent pretreatment 4DST and FDG PET/CT. The maximum standardized uptake value (SUVmax), metabolic tumor volume (MTV), total lesion glycolysis (TLG), and total lesion proliferation (TLP) were measured for FDG and 4DST PET. The study endpoints were progression-free survival (PFS) and overall survival (OS). Patients' clinical backgrounds, including age, histological type, clinical stage, and surgical treatment, were adjusted using the Cox proportional-hazards model. RESULTS: In the follow-up period (median 18.8 (interquartile range: 10.1-29.0) months), 26 and 19 patients showed disease progression and cancer-related death, respectively. After adjusting for clinical variables, only the 4DST parameters (SUVmax (p = 0.001) and TLP (p = 0.022)) were statistically significant for predicting PFS. FDG MTV (p = 0.031), 4DST SUVmax (p = 0.022), and TLP (p = 0.023) were statistically significant for predicting OS. Of the PET parameters, 4DST SUVmax yielded the highest adjusted hazard ratio for both PFS (4.88, 95% confidence intervals (CI): 1.83-12.97) and OS (4.19, 95% CI: 1.23-14.20). CONCLUSION: Higher accumulation of 4DST in the primary tumor may lead to shorter OS and PFS. 4DST PET/CT is useful for predicting prognosis and may outperform FDG PET/CT.

    DOI: 10.1007/s00259-020-05179-x

    Scopus

    PubMed

  24. Prognostic value of <sup>18</sup>F-FDG PET/CT with texture analysis in patients with rectal cancer treated by surgery

    Hotta M., Minamimoto R., Gohda Y., Miwa K., Otani K., Kiyomatsu T., Yano H.

    Annals of Nuclear Medicine   Vol. 35 ( 7 ) page: 843 - 852   2021.7

     More details

    Language:English   Publisher:Annals of Nuclear Medicine  

    Purpose: The aim of this study was to evaluate the ability of texture analysis using pretreatment 18F-FDG PET/CT to predict prognosis in patients with surgically treated rectal cancer. Methods: We analyzed 94 patients with pathologically proven rectal cancer who underwent pretreatment 18F-FDG PET/CT and were subsequently treated with surgery. The volume of interest of the primary tumor was defined using a threshold of 40% of the maximum standardized uptake value (SUVmax), and conventional (SUVmax, metabolic tumor volume [MTV], total lesion glycolysis [TLG]) and textural PET features were extracted. Harmonization of PET features was performed with the ComBat method. The study endpoints were overall survival (OS) and progression-free survival (PFS), and the prognostic value of PET features was evaluated by Cox regression analysis. Results: In the follow-up period (median 41.7 [interquartile range, 30.5–60.4] months), 21 (22.3%) and 30 (31.9%) patients had cancer-related death or disease progression, respectively. Univariate analysis revealed a significant association of (1) MTV, TLG, and gray-level co-occurrence matrix (GLCM) entropy with OS; and (2) SUVmax, MTV, TLG, and GLCM entropy with PFS. In multivariate analysis including clinical characteristics, GLCM entropy (≥ 2.13) was the only relevant prognostic PET feature for poor OS (hazard ratio [HR]: 4.16, p = 0.035) and PFS (HR: 2.70, p = 0.046). Conclusion: GLCM entropy, which indicates metabolic intratumoral heterogeneity, was an independent prognostic factor in patients with surgically treated rectal cancer. Compared with conventional PET features, GLCM entropy has better predictive value and shows potential to facilitate precision medicine.

    DOI: 10.1007/s12149-021-01622-7

    Scopus

    PubMed

  25. Effects of COVID-19 vaccination on FDG-PET/CT imaging: A literature review

    Minamimoto Ryogo, Kiyomatsu Tomomichi

    Global Health & Medicine   Vol. 3 ( 3 ) page: 129 - 133   2021.6

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:National Center for Global Health and Medicine  

    <p>COVID-19 vaccination using mRNA technology began at the end of 2020 in several countries, approximately 9 months after the WHO declared the new coronavirus a pandemic, and began in Japan at the end of February 2021. Several studies have reported FDG avidity in enlarged axillary lymph nodes as a specific feature of FDG-PET/CT imaging after COVID-19 vaccination. A major concern is that this finding could lead to a misdiagnosis in patients with various types of malignancy. We review the impact of COVID-19 vaccination on the management of patients scheduled for FDG-PET/CT in the setting of nationwide mass vaccination. </p>

    DOI: 10.35772/ghm.2021.01076

    PubMed

    CiNii Research

  26. Series of myocardial FDG uptake requiring considerations of myocardial abnormalities in FDG-PET/CT

    Minamimoto R.

    Japanese Journal of Radiology   Vol. 39 ( 6 ) page: 540 - 557   2021.6

     More details

    Language:English   Publisher:Japanese Journal of Radiology  

    Distinct from cardiac PET performed with preparation to control physiological FDG uptake in the myocardium, standard FDG-PET/CT performed with 4–6 h of fasting will show variation in myocardial FDG uptake. For this reason, important signs of myocardial and pericardial abnormality revealed by myocardial FDG uptake tend to be overlooked. However, recognition of possible underlying disease will support further patient management to avoid complications due to the disease. This review demonstrates the mechanism of FDG uptake in the myocardium, discusses the factors affecting uptake, and provides notable image findings that may suggest underlying disease.

    DOI: 10.1007/s11604-021-01097-6

    Scopus

    PubMed

  27. Differentiating Dementia with Lewy Bodies and Alzheimer's Disease by Deep Learning to Structural MRI. International journal

    Kiyotaka Nemoto, Hiromasa Sakaguchi, Wataru Kasai, Masatoshi Hotta, Ryotaro Kamei, Tomoyuki Noguchi, Ryogo Minamimoto, Tetsuaki Arai, Takashi Asada

    Journal of neuroimaging : official journal of the American Society of Neuroimaging   Vol. 31 ( 3 ) page: 579 - 587   2021.5

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND AND PURPOSE: Dementia with Lewy bodies (DLB) is the second most prevalent cause of degenerative dementia next to Alzheimer's disease (AD). Though current DLB diagnostic criteria employ several indicative biomarkers, relative preservation of the medial temporal lobe as revealed by structural MRI suffers from low sensitivity and specificity, making them unreliable as sole supporting biomarkers. In this study, we investigated how a deep learning approach would be able to differentiate DLB from AD with structural MRI data. METHODS: Two-hundred and eight patients (101 DLB, 69 AD, and 38 controls) participated in this retrospective study. Gray matter images were extracted using voxel-based morphometry (VBM). In order to compare the conventional statistical analysis with deep-learning feature extraction, we built a classification model for DLB and AD with a residual neural network (ResNet) type of convolutional neural network architecture, which is one of the deep learning models. The anatomically standardized gray matter images extracted in the same way as for the VBM process were used as inputs, and the classification performance achieved by our model was evaluated. RESULTS: Conventional statistical analysis detected no significant atrophy other than fine differences on the middle temporal pole and hippocampal regions. The feature extracted by the deep learning method differentiated DLB from AD with 79.15% accuracy compared to the 68.41% of the conventional method. CONCLUSIONS: Our results confirmed that the deep learning method with gray matter images can detect fine differences between DLB and AD that may be underestimated by the conventional method.

    DOI: 10.1111/jon.12835

    Scopus

    PubMed

  28. Proliferation imaging with <sup>11</sup>C-4DST PET/CT for the evaluation of cardiac sarcoidosis, compared with FDG-PET/CT given a long fasting preparation protocol

    Minamimoto R., Hotta M., Hiroe M., Awaya T., Nakajima K., Okazaki O., Yamashita H., Kaneko H., Hiroi Y.

    Journal of Nuclear Cardiology   Vol. 28 ( 2 ) page: 752 - 755   2021.4

     More details

    Language:English   Publisher:Journal of Nuclear Cardiology  

    DOI: 10.1007/s12350-020-02069-5

    Scopus

    PubMed

  29. Clinical practice guidelines for high-resolution breast PET, 2019 edition.

    Yoko Satoh, Masami Kawamoto, Kazunori Kubota, Koji Murakami, Makoto Hosono, Michio Senda, Masayuki Sasaki, Toshimitsu Momose, Kengo Ito, Terue Okamura, Keiichi Oda, Yuji Kuge, Minoru Sakurai, Ukihide Tateishi, Yasuhisa Fujibayashi, Yasuhiro Magata, Takeshi Yoshida, Atsuo Waki, Katsuhiko Kato, Teisuke Hashimoto, Mayuki Uchiyama, Seigo Kinuya, Tatsuya Higashi, Yasuhiro Magata, Akihiro Machitori, Hirotaka Maruno, Ryogo Minamimoto, Keiichiro Yoshinaga

    Annals of nuclear medicine   Vol. 35 ( 3 ) page: 406 - 414   2021.3

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Breast positron emission tomography (PET) has had insurance coverage when performed with conventional whole-body PET in Japan since 2013. Together with whole-body PET, accurate examination of breast cancer and diagnosis of metastatic disease are possible, and are expected to contribute significantly to its treatment planning. To facilitate a safer, smoother, and more appropriate examination, the Japanese Society of Nuclear Medicine published the first edition of practice guidelines for high-resolution breast PET in 2013. Subsequently, new types of breast PET have been developed and their clinical usefulness clarified. Therefore, the guidelines for breast PET were revised in 2019. This article updates readers as to what is new in the second edition. This edition supports two different types of breast PET depending on the placement of the detector: the opposite-type (positron emission mammography; PEM) and the ring-shaped type (dedicated breast PET; dbPET), providing an overview of these scanners and appropriate imaging methods, their clinical applications, and future prospects. The name "dedicated breast PET" from the first edition is widely used to refer to ring-shaped type breast PET. In this edition, "breast PET" has been defined as a term that refers to both opposite- and ring-shaped devices. Up-to-date breast PET practice guidelines would help provide useful information for evidence-based breast imaging.

    DOI: 10.1007/s12149-021-01582-y

    PubMed

  30. Comparison of 18F-FDG PET/CT and 67Ga-SPECT for the diagnosis of fever of unknown origin: a multicenter prospective study in Japan.

    Kazuo Kubota, Noriko Tanaka, Yoko Miyata, Hiroshi Ohtsu, Tadaki Nakahara, Setsu Sakamoto, Takashi Kudo, Yoshihiro Nishiyama, Ukihide Tateishi, Koji Murakami, Yuji Nakamoto, Yasuyuki Taki, Tomohiro Kaneta, Joji Kawabe, Shigeki Nagamachi, Tsuyoshi Kawano, Jun Hatazawa, Youichi Mizutani, Shingo Baba, Kazukuni Kirii, Kunihiko Yokoyama, Terue Okamura, Masashi Kameyama, Ryogo Minamimoto, Junwa Kunimatsu, On Kato, Hiroyuki Yamashita, Hiroshi Kaneko, Satoshi Kutsuna, Norio Ohmagari, Akiyoshi Hagiwara, Yoshimi Kikuchi, Masao Kobayakawa

    Annals of nuclear medicine   Vol. 35 ( 1 ) page: 31 - 46   2021.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    OBJECTIVE: The aim of this multicenter prospective study was to compare the sensitivity of 18F-fluorodeoxyglucose (FDG)-positron emission tomography/computed tomography (PET/CT) with that of 67Ga single photon emission computed tomography (SPECT) for the identification of the site of greatest importance for the final diagnosis of the cause of fever of unknown origin (FUO). METHODS: The study participants consisted of patients with an axillary temperature ≥ 38.0 °C on ≥ 2 occasions within 1 week, with repeated episodes for ≥ 2 weeks prior to providing consent, and whose final diagnosis after undergoing specific examinations, including a chest-to-abdomen CT scan, was uncertain. All the patients underwent FDG-PET/CT imaging first, followed by 67Ga-SPECT imaging within 3 days. The results of the FDG-PET/CT and 67Ga-SPECT examinations were reviewed by the central image interpretation committee (CIIC), which was blinded to all other clinical information. The sensitivities of FDG-PET/CT and 67Ga-SPECT were then evaluated with regard to identifying the site of greatest importance for a final diagnosis of the cause of the fever as decided by the patient's attending physician. The clinical impacts (four grades) of FDG-PET/CT and 67Ga-SPECT on the final diagnosis were evaluated. RESULTS: A total of 149 subjects were enrolled in this study between October 2014 and September 2017. No adverse events were identified among the enrolled subjects. Twenty-one subjects were excluded from the study because of deviations from the study protocol. Among the 128 remaining subjects, a final diagnosis of the disease leading to the appearance of FUO was made for 92 (71.9%) subjects. The final diagnoses in these 92 cases were classified into four groups: noninfectious inflammatory disease (52 cases); infectious disease (31 cases), malignancy (six cases); and other (three cases). These 92 subjects were eligible for inclusion in the study's analysis, but one case did not meet the PET/CT image acquisition criteria; thus, PET/CT results were analyzed for 91 cases. According to the patient-based assessments, the sensitivity of FDG-PET/CT (45%, 95% CI 33.1-58.2%) was significantly higher than that for 67Ga-SPECT (25%, 95% CI 15.5-37.5%) (P = 0.0029). The clinical impact of FDG-PET/CT (91%) was also significantly higher than that for 67Ga-SPECT (57%, P < 0.001). CONCLUSIONS: FDG-PET/CT showed a superior sensitivity to 67Ga-SPECT for the identification of the site of greatest importance for the final diagnosis of the cause of FUO.

    DOI: 10.1007/s12149-020-01533-z

    Scopus

    PubMed

  31. SUV-based quantification of I-131-6-biodomethyl-norcholesterol SPECT/CT for the diagnosis of the responsible adrenal glands in patient with primary hyperaldosteronism: a preliminary result

    Ryogo Minamimoto

    Journal of Nuclear Medicine     2021

     More details

    Publishing type:Research paper (scientific journal)  

    Web of Science

  32. Prognostic value of FDG-PET radiomics with machine learning in pancreatic cancer

    Toyama Y., Hotta M., Motoi F., Takanami K., Minamimoto R., Takase K.

    Scientific Reports   Vol. 10 ( 1 ) page: 17024   2020.12

     More details

    Language:English   Publisher:Scientific Reports  

    Patients with pancreatic cancer have a poor prognosis, therefore identifying particular tumor characteristics associated with prognosis is important. This study aims to investigate the utility of radiomics with machine learning using 18F-fluorodeoxyglucose (FDG)-PET in patients with pancreatic cancer. We enrolled 161 patients with pancreatic cancer underwent pretreatment FDG-PET/CT. The area of the primary tumor was semi-automatically contoured with a threshold of 40% of the maximum standardized uptake value, and 42 PET features were extracted. To identify relevant PET parameters for predicting 1-year survival, Gini index was measured using random forest (RF) classifier. Twenty-three patients were censored within 1 year of follow-up, and the remaining 138 patients were used for the analysis. Among the PET parameters, 10 features showed statistical significance for predicting overall survival. Multivariate analysis using Cox HR regression revealed gray-level zone length matrix (GLZLM) gray-level non-uniformity (GLNU) as the only PET parameter showing statistical significance. In RF model, GLZLM GLNU was the most relevant factor for predicting 1-year survival, followed by total lesion glycolysis (TLG). The combination of GLZLM GLNU and TLG stratified patients into three groups according to risk of poor prognosis. Radiomics with machine learning using FDG-PET in patients with pancreatic cancer provided useful prognostic information.

    DOI: 10.1038/s41598-020-73237-3

    Scopus

    PubMed

  33. Current status of radioligand therapy and positron-emission tomography with prostate-specific membrane antigen.

    Masayuki Inubushi, Hiroyuki Miura, Ichiei Kuji, Kimiteru Ito, Ryogo Minamimoto

    Annals of nuclear medicine   Vol. 34 ( 12 ) page: 879 - 883   2020.12

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Prostate-specific membrane antigen (PSMA) is a transmembrane glycoprotein highly expressed by prostate cancer cells. PSMA-based radioligand therapy (RLT) emerged as a promising therapeutic option for prostate cancer in the early 2000s, and has been clinically validated with great enthusiasm during these past two decades. Last year, the European Association of Nuclear Medicine (EANM) published the procedure guidelines for the safe clinical practice of Lutetium-177 (177Lu)-labelled PSMA RLT. In addition, PSMA RLT with alpha-ray-emitting radioisotopes has been also developed recently. Following the clinical use of 177Lu-PSMA RLT, PSMA-targeted positron-emission tomography (PET) with Gallium-68 (68Ga) has been performed inevitably for "theranostics" for the last decade; prostate cancer is going to be treated with PSMA-RLT based on the diagnosis by PSMA-PET. Furthermore, the diagnostic usefulness of 68Ga-PSMA PET has been documented in various diseases beyond prostate cancer more recently. Regrettably, Japan is behind European countries and the United States in this field, and has just made a belated start of their clinical trials. In this review article, we briefly overviewed the current status of PSMA RLT and PSMA PET. We hope that this topic will be a particular focus of attention for most ANM readers in Japan, and that our efforts will help to facilitate the early approval of PSMA RLT and PSMA PET by the Japanese government even if only slightly.

    DOI: 10.1007/s12149-020-01549-5

    Scopus

    PubMed

  34. Nivolumab-Induced Periaortitis Demonstrated by FDG PET/CT

    Hotta M., Naka G., Minamimoto R., Takeda Y., Hojo M.

    Clinical Nuclear Medicine   Vol. 45 ( 11 ) page: 910 - 912   2020.11

     More details

    Language:English   Publisher:Clinical Nuclear Medicine  

    A 66-year-old man with a history of non-small cell lung cancer treated with nivolumab underwent contrast-enhanced CT and FDG PET/CT. No recurrence was demonstrated; however, soft-tissue thickening that showed delayed contrast enhancement and FDG uptake was detected around an abdominal aortic aneurysm. After discontinuation of nivolumab, the periaortic lesion disappeared within 2 months, indicating nivolumab-induced periaortitis. Immune checkpoint inhibitors such as nivolumab can cause vasculitis and periaortitis, a potentially fatal condition, as immune-related adverse events. The underlying aortic aneurysm may have contributed to genesis of periaortitis. FDG PET/CT can be useful for detecting periaortitis and excluding other forms of vasculitis.

    DOI: 10.1097/RLU.0000000000003215

    Scopus

    PubMed

  35. Radionuclide imaging of cardiac amyloidosis and sarcoidosis: Roles and characteristics of various tracers

    Hotta M., Minamimoto R., Awaya T., Hiroe M., Okazaki O., Hiroi Y.

    Radiographics   Vol. 40 ( 7 ) page: 2029 - 2041   2020.11

     More details

    Language:English   Publisher:Radiographics  

    Amyloidosis and sarcoidosis are systemic diseases that affect multiple organ systems. Accurate diagnosis of cardiac amyloidosis and sarcoidosis is particularly important because cardiac involvement can be fatal. Amyloidosis is characterized by the deposition of amyloid fibrils, and cardiac amyloidosis is classified into amyloid im-munoglobulin light chain (AL) and amyloid transthyretin (ATTR) types. Radionuclide tracers for amyloidosis include (a) bone trac-ers, (b) amyloid-directed molecules, and (c) PET amyloid agents. Bone tracers are particularly sensitive in detection of ATTR type amyloidosis, whereas PET amyloid agents show a higher affinity for the AL type. In sarcoidosis, gallium 67 (67Ga) citrate scintigraphy and fluorine 18 (18F) fluorodeoxyglucose (FDG) PET are pivotal to diagnosis of cardiac sarcoidosis, and18F-FDG PET/CT has particularly high efficacy in detection of sarcoidosis and monitoring of response to therapy. A major limitation of18F-FDG is physiologic uptake in the myocardium, which can remain in approximately 20% of patients even after elaborate preparation (eg, prolonged fasting >12–18 hours, modification to a high-fat and low-carbohy-drate diet, and injection of unfractionated heparin). This limitation has led to a search for potential new tracers. Recently introduced tracers that show promise include those used in somatostatin receptor imaging and cellular proliferation imaging, which provide detectability as high as that for18F-FDG without requiring dietary restrictions and have potential for monitoring disease activity.

    DOI: 10.1148/rg.2020200068

    Scopus

    PubMed

  36. FDG-PET/CT images of COVID-19: a comprehensive review

    Minamimoto Ryogo, Hotta Masatoshi, Ishikane Masahiro, Inagaki Takeshi

    Global Health & Medicine   Vol. 2 ( 4 ) page: 221 - 226   2020.8

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:National Center for Global Health and Medicine  

    <p>Following a lot of reports of coronavirus disease 2019 (COVID-19) CT images, the feature of FDG-PET/CT imaging of COVID-19 was reported in several articles. Since FDG accumulates in activated inflammatory cells, FDG-PET/CT has huge potential for diagnosing and monitoring of inflammatory disease. However, FDG-PET/CT cannot be routinely used in an emergency setting and is not generally recommended as a first choice for diagnosis of infectious diseases. In this review, we demonstrate FDG-PET/CT imaging features of COVID-19, including our experience and current knowledge, and discuss the value of FDG-PET/CT in terms of estimating the pathologic mechanism.</p>

    DOI: 10.35772/ghm.2020.01056

    PubMed

    CiNii Research

  37. BRAF V600E mutation mediates FDG-methionine uptake mismatch in polymorphous low-grade neuroepithelial tumor of the young. International journal

    Kensuke Tateishi, Naoki Ikegaya, Naoko Udaka, Jo Sasame, Takahiro Hayashi, Yohei Miyake, Tetsuhiko Okabe, Ryogo Minamimoto, Hidetoshi Murata, Daisuke Utsunomiya, Shoji Yamanaka, Tetsuya Yamamoto

    Acta neuropathologica communications   Vol. 8 ( 1 ) page: 139 - 139   2020.8

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    We present a case of a 14-year old boy with tumor-associated refractory epilepsy. Positron emission tomography imaging demonstrated a region with heterogeneous high 11C-methionine uptake and a region with homogenous low 18F-fluorodeoxyglucose uptake within the tumor. Histopathological and genomic analyses confirmed the tumor as BRAF V600E-mutated polymorphous low-grade neuroepithelial tumor of the young (PLNTY). Within the high-methionine-uptake region, we observed increased protein levels of L-type amino acid transporter 1 (LAT1), a major transporter of methionine; c-Myc; and constituents of the mitogen-activated protein kinase (MAPK) pathway. We also found that LAT1 expression was linked to the BRAF V600E mutation and subsequent activation of MAPK signaling and c-Myc. Pharmacological and genetic inhibition of the MAPK pathway suppressed c-Myc and LAT1 expression in BRAF V600E-mutated PLNTY and glioblastoma cells. The BRAF inhibitor dabrafenib moderately suppressed cell viability in PLNTY. Collectively, our results indicate that BRAF V600E mutation-activated MAPK signaling and downstream c-Myc induces specific metabolic alterations in PLNTY, and may represent an attractive target in the treatment of the disease.

    DOI: 10.1186/s40478-020-01023-3

    Scopus

    PubMed

  38. Performance of <sup>99m</sup>Tc-aprotinin scintigraphy for diagnosing light chain (AL) cardiac amyloidosis confirmed by endomyocardial biopsy

    Awaya T., Minamimoto R., Iwama K., Kubota S., Hotta M., Hirai R., Yamamoto M., Okazaki O., Hara H., Hiroi Y., Hiroe M., Moroi M.

    Journal of Nuclear Cardiology   Vol. 27 ( 4 ) page: 1145 - 1153   2020.8

     More details

    Language:English   Publisher:Journal of Nuclear Cardiology  

    Background: Light chain (AL) cardiac amyloidosis is associated with a poor prognosis. Diagnosing at an early stage is critical for treatment and the management of cardiac complication. Purpose: We aimed to evaluate the diagnostic performance of 99mTc-aprotinin images in patients with AL cardiac amyloidosis. Methods and Results: 99mTc-aprotinin scintigraphy and endomyocardial biopsy were performed in 10 patients with suspected amyloidosis. Endomyocardial biopsy showed amyloid deposits in 5 of 10 patients. 99mTc-aprotinin (planer image) was positive in 4 of 5 patients who had amyloid deposits in endomyocardial biopsy. On the other hand, all 5 patients without amyloid deposits were negative in planer image. 99mTc-aprotinin (SPECT/CT image) was positive in all 5 patients who had amyloid deposits. Conclusions: 99mTc-aprotinin scintigraphy is valuable for the non-invasive diagnosis of AL cardiac amyloidosis.

    DOI: 10.1007/s12350-019-01868-9

    Scopus

    PubMed

  39. Pseudomyxoma peritonei: visceral scalloping on CT is a predictor of recurrence after complete cytoreductive surgery

    Hotta M., Minamimoto R., Gohda Y., Tajima T., Kiyomatsu T., Yano H.

    European Radiology   Vol. 30 ( 8 ) page: 4193 - 4200   2020.8

     More details

    Language:English   Publisher:European Radiology  

    Objectives: Pseudomyxoma peritonei (PMP) is characterized by peritoneal dissemination of gelatinous ascites following rupture of a mucinous tumor. Treatment by cytoreductive surgery (CRS) has improved its prognosis. Although visceral scalloping, notably liver scalloping, on computed tomography (CT) is a typical feature of PMP, its prognostic value remains unknown. We aimed to investigate the efficacy of liver scalloping in predicting recurrence in PMP patients. Methods: Among 159 consecutive patients with PMP who had contrast-enhanced CT between September 2012 and December 2018, 64 treatment-naïve patients who subsequently underwent CRS with complete resection (i.e., completeness of cytoreduction score (CC)-0 or CC-1), were included in analysis. Presence of liver scalloping and maximum thickness of mucin deposition at the liver surface were evaluated on CT. Disease-free survival (DFS) was determined based on the combination of postoperative CT features and tumor marker values. Results: Median follow-up was 24.3 months. CT revealed liver scalloping in 40/64 (63.4%) patients. Kaplan–Meier analysis showed significantly shorter DFS in patients with scalloping than in those without (p = 0.001; hazard ratio, 4.3). In patients with scalloping, greater mucin deposition (thickness ≥ 20 mm) significantly correlated with poorer DFS (p = 0.042). In multivariate Cox proportional hazards regression including CC status, pathologic type, and tumor markers, the presence of scalloping independently and significantly correlated with DFS (p = 0.031). Conclusions: Liver scalloping was an independent predictor even after adjusting for clinical covariates. The presence of liver scalloping can lead to a high recurrence rate after CRS. Key Points: • The presence of liver scalloping is a prognostic factor independent of histological grade and tumor markers. • Greater mucin deposition (thickness ≥ 20 mm at the liver surface) is associated with higher recurrence rates in patients with liver scalloping.

    DOI: 10.1007/s00330-020-06756-2

    Scopus

    PubMed

  40. Correction to: Performance of 99mTc-aprotinin scintigraphy for diagnosing light chain (AL) cardiac amyloidosis confirmed by endomyocardial biopsy. International journal

    Toru Awaya, Ryogo Minamimoto, Kentaro Iwama, Shuji Kubota, Masatoshi Hotta, Risen Hirai, Masaya Yamamoto, Osamu Okazaki, Hisao Hara, Yukio Hiroi, Michiaki Hiroe, Masao Moroi

    Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology   Vol. 27 ( 4 ) page: 1154 - 1154   2020.8

     More details

    Language:English  

    This prospective study was conducted according to the principles outlined within the Declaration of Helsinki, and approved by the Ethics Review Board of National Center for Global Health and Medicine (NCGM-G-00839-01, NCGM-G-00839-02).

    DOI: 10.1007/s12350-020-02229-7

    Scopus

    PubMed

  41. Assessment of tumor response to definitive chemoradiotherapy and prognosis prediction in patients with esophageal cancer judged by PET response criteria in solid tumors: multicenter study in Japan. International journal

    Kazuhiro Kitajima, Hayato Kaida, Koya Nakatani, Mana Ishibashi, Takahiro Morita, Masatoyo Nakajo, Yukihisa Tamaki, Ryogo Minamimoto

    Nuclear medicine communications   Vol. 41 ( 5 ) page: 443 - 451   2020.5

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    OBJECTIVES: The aim of the study was to evaluate PET response criteria in solid tumors (PERCIST) to indicate therapeutic response to definitive chemoradiotherapy, as well as prediction of recurrence and death in patients with esophageal cancer. METHODS: Before and after recieving definitive chemoradiotherapy, 181 patients with esophageal cancer underwent fluorodeoxyglucose-PET/computed tomography (FDG-PET/CT). PERCIST, reduction rates of tumor uptake and volume of whole lesions, tumor node metastasis (TNM) staging regarding progression-free survival (PFS), and overall survival (OS) were analyzed using log-rank and Cox methods. RESULTS: Complete metabolic response (CMR), partial metabolic response (PMR), stable metabolic disease (SMD), and progressive metabolic disease (PMD) shown by PERCIST were seen in 42 (23.2%), 113 (62.4%), 14 (7.7%), and 12 (6.6%) patients, respectively. Progression developed in 137 (75.7%) patients and 101 (56.1%) patients died (median follow-up 16.9, range 3.2-124.9 months). Those who achieved CMR showed significantly longer PFS and OS as compared with patients who did not (PMR, SMD, and PMD) (both P < 0.0001). In univariate analysis, initial clinical T status (P = 0.0048), N status (P = 0.011), and TNM stage (P = 0.0006), PERCIST (P < 0.0001), and reduction rate of peak lean body mass standardized uptake value (P < 0.0001), of metabolic tumor volume (P < 0.0001), and of total lesion glycolysis (TLG) (P < 0.0001) were associated with significantly increased OS. Multivariate analysis confirmed PERCIST [hazard ratio (HR): 13.15, 95% confidence interval (CI), 4.54-55.8; P < 0.0001], and TLG reduction rate (HR: 2.21, 95% CI, 1.04-4.68; P = 0.040) as independent OS predictors. CONCLUSION: PERCIST is useful for evaluating therapeutic response to definitive chemoradiotherapy, and predicting progression and death in patients with esophageal cancer.

    DOI: 10.1097/MNM.0000000000001168

    Scopus

    PubMed

  42. Response to: Letter to the Editors: Re: Simultaneous PET/MRI in the Evaluation of Breast and Prostate Cancer Using Combined Na[18F]F and [18F]FDG: A Focus on Skeletal Lesions. International journal

    Ida Sonni, Ryogo Minamimoto, Lucia Baratto, Andrei Iagaru

    Molecular imaging and biology   Vol. 22 ( 2 ) page: 221 - 222   2020.4

     More details

  43. Simultaneous PET/MRI in the Evaluation of Breast and Prostate Cancer Using Combined Na[18F] F and [18F]FDG: a Focus on Skeletal Lesions. International journal

    Ida Sonni, Ryogo Minamimoto, Lucia Baratto, Sanjiv S Gambhir, Andreas M Loening, Shreyas S Vasanawala, Andrei Iagaru

    Molecular imaging and biology   Vol. 22 ( 2 ) page: 397 - 406   2020.4

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    PURPOSE: The purpose of this study is to prospectively evaluate the performance of sodium 18F]fluoride (Na[18F]F)/2-deoxy-2-[18F]fluoro-D-glucose ([18F]FDG) simultaneous time-of-flight enabled positron emission tomography (PET)/magnetic resonance imaging (MRI) for the detection of skeletal metastases in selected patients with advanced breast and prostate cancers. PROCEDURE: The institutional review board approved this HIPAA-compliant protocol. Written informed consent was obtained from each patient. A total of 74 patients (23 women and 51 men with breast and prostate cancer, respectively) referred for standard-of-care whole-body bone scintigraphy (WBBS) were enrolled in this prospective study. All patients underwent a [99mTc]methyldiphosphonate ([99mTc]MDP) WBBS followed by Na[18F]F/[18F]FDG PET/MRI. Lesions detected by each imaging modality were tabulated and a lesion-based and patient-based analysis was conducted. RESULTS: On a patient-based analysis, [99mTc]MDP WBBS identified skeletal lesions in 37 patients and PET/MRI in 45 patients. On a lesion-based analysis, WBBS identified a total of 81 skeletal lesions, whereas PET/MRI identified 140 lesions. Additionally, PET/MRI showed extra-skeletal lesions in 19 patients, including lymph nodes (16), prostate (4) lung (3), and liver (2) lesions. CONCLUSIONS: The ability of Na[18F]F/[18F]FDG PET/MRI to identify more skeletal lesions than 99mTc-MDP WBBS and to additionally identify extra-skeletal disease may be beneficial for patient care and represent an alternative to the single modalities performed separately. Na[18F]F/[18F]FDG PET/MRI is a promising approach for evaluation of skeletal and extra-skeletal lesions in a selected population of breast and prostate cancer patients.

    DOI: 10.1007/s11307-019-01392-9

    Scopus

    PubMed

  44. Neurocognitive dysfunction and brain FDGPET/CT findings in HIV-infected hemophilia patients and HIV-infected non-hemophilia patients

    Imai K., Kimura S., Kiryu Y., Watanabe A., Kinai E., Oka S., Kikuchi Y., Kimura S., Ogata M., Takano M., Minamimoto R., Hotta M., Yokoyama K., Noguchi T., Komatsu K.

    PLoS ONE   Vol. 15 ( 3 ) page: e0230292   2020.3

     More details

    Language:English   Publisher:PLoS ONE  

    This single-institution cross-sectional study aimed to grasp the prevalence and features of neurocognitive dysfunction in HIV-infected hemophilia patients in Japan. We conducted neuropsychological tests and medical examinations in 56 HIV-infected hemophilia patients who received outpatient treatment at the AIDS Clinical Center, National Center for Global Health and Medicine. A total of 388 HIV-infected non-hemophilia patients who received outpatient treatment at the same institution were included as a control group. To investigate sites responsible for neurocognitive dysfunction in HIV-infected hemophilia patients using brain FDG-PET/CT scans, the accumulation of FDG in each brain region was compared. Approximately 50% of HIV-infected hemophilia patients had neurocognitive dysfunction. The prevalence of asymptomatic neurocognitive impairment was high (34%). Neurocognitive dysfunction was associated with educational level in HIV-infected hemophilia patients. In the symptomatic group, hemophilic arthropathy and history of cerebrovascular disorders were associated with neurocognitive dysfunction. Left temporal lobe function was reduced in the symptomatic group.

    DOI: 10.1371/journal.pone.0230292

    Scopus

    PubMed

  45. Significance of <sup>11</sup>C-PIB PET/CT in cardiac amyloidosis compared with <sup>99m</sup>Tc-aprotinin scintigraphy: A pilot study

    Minamimoto R., Awaya T., Iwama K., Hotta M., Nakajima K., Hirai R., Okazaki O., Hiroi Y.

    Journal of Nuclear Cardiology   Vol. 27 ( 1 ) page: 202 - 209   2020.2

     More details

    Language:English   Publisher:Journal of Nuclear Cardiology  

    Background: This study was to investigate the significance of 11C-Pittsburgh B (PIB) PET/CT in patients with suspected cardiac amyloidosis compared with 99mTc-aprotinin scintigraphy. Methods: Thirteen consecutive patients with suspected cardiac amyloidosis were considered for enrolment in this prospective pilot study. Participants were scheduled to undergo a series of 11C-PIB PET/CT and 99mTc-aprotinin within a 2-month period. Finally, we evaluated nine cases who underwent both imaging modalities, and compared imaging results with clinical and pathological results and prognosis. Results: Six of the 9 patients who underwent both imaging modalities were diagnosed with amyloidosis, of whom 3 patients were diagnosed with cardiac amyloidosis from endomyocardial biopsy. These 3 patients with positive 11C-PIB uptake at the left ventricle wall showed worsening of cardiac function progressing in the short term or death caused by acute exacerbation of chronic heart failure. Six of 8 patients with positive uptake on 99mTc-aprotinin presented with amyloid deposition in the left ventricle wall, but symptoms remained stable if results of 11C-PIB were not positive. Conclusion: In a small sample of subjects, the present study showed that 11C-PIB accumulation in myocardium indicated cardiac amyloidosis with poor prognosis. Uptake of 11C-PIB may be related to progressive amyloid deposition to the heart and can predict patient prognosis.

    DOI: 10.1007/s12350-018-1260-5

    Scopus

    PubMed

  46. The clinical value of PERCIST to predict tumour response and prognosis of patients with oesophageal cancer treated by neoadjuvant chemoradiotherapy

    Nakajo M., Kitajima K., Kaida H., Morita T., Minamimoto R., Ishibashi M., Yoshiura T.

    Clinical Radiology   Vol. 75 ( 1 ) page: 79.e9 - 79.e18   2020.1

     More details

    Language:English   Publisher:Clinical Radiology  

    AIM: To examine whether Positron Emission Tomography Response Criteria in Solid Tumours (PERCIST) is useful to predict tumour response and prognosis of patients with oesophageal cancer who received neoadjuvant chemoradiotherapy (NACRT) followed by surgery. MATERIALS AND METHODS: This multicentre retrospective study included 60 patients with oesophageal cancer who underwent 2-[18F]-fluoro-2-deoxy-D-glucose positron-emission tomography/computed tomography (18F-FDG-PET/CT) before and after NACRT prior to surgery from January 2007 and June 2016. The correlation between pathological response and PERCIST was assessed by χ2 test. The prognostic significance was assessed by the Kaplan–Meier method and Cox regression analysis. RESULTS: There were 30 responders and 30 non-responders pathologically. The complete metabolic response (CMR), partial metabolic response (PMR), stable metabolic disease (SMD), and progressive metabolic disease (PMD) were seen in 22, 29, seven, and two patients, respectively. There was a significant correlation between pathological response and PERCIST (p<0.001). Forty patients showed eventual progression, and 20 patients were alive without progression between the start of NACRT and last clinical follow-up (median follow-up period; 27 months [range, 3–107]). Pathological stage and PERCIST were significant for progression-free survival (PFS; p=0.044 and 0.006, respectively) and also significant for overall survival (OS; p=0.009 and 0.001, respectively) at univariate analysis. Pathological lymph node staging was also significant for OS at univariate analysis (p=0.018). At multivariate analysis, PERCIST remained significant and independent for PFS (hazard ratio [HR]: 1.59, p=0.046) and OS (HR: 1.82, p=0.008). CONCLUSION: PERCIST may be useful for predicting tumour response and prognosis of patients with oesophageal cancer who received NACRT.

    DOI: 10.1016/j.crad.2019.09.132

    Scopus

    PubMed

  47. An Experience of PET/CT Examination in the Patient with a Recent History of COVID-19 Infection

    Saito Kaori, Horikawa Daisuke, Takeuchi Tomoya, Mizunuma Hisayoshi, Yamada Yui, Hironaka Satsuki, Kajiwara Hironori, Hotta Masatoshi, Matsunaga Futoshi, Minamimoto Ryogo

    Japanese Journal of Radiological Technology   Vol. 76 ( 7 ) page: 761 - 767   2020

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)   Publisher:Japanese Society of Radiological Technology  

    DOI: 10.6009/jjrt.2020_jjrt_76.7.761

    PubMed

    CiNii Research

  48. Fluorodeoxyglucose PET/CT of Arthritis in Rheumatic Diseases: A Pictorial Review. International journal

    Masatoshi Hotta, Ryogo Minamimoto, Hiroshi Kaneko, Hiroyuki Yamashita

    Radiographics : a review publication of the Radiological Society of North America, Inc   Vol. 40 ( 1 ) page: 223 - 240   2020

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Rheumatic diseases are various painful conditions that affect joints, bones, cartilage, tendons, ligaments, and muscles. Arthritis is a typical condition of rheumatic disease. Although rheumatoid arthritis is a representative rheumatic disease, various diseases other than rheumatoid arthritis can also affect joints, and differential diagnosis of rheumatic diseases is often difficult owing to the similar clinical manifestations. However, accurate diagnosis is crucial for an appropriate treatment strategy. The utility of fluorine 18 fluorodeoxyglucose (FDG) PET/CT has been established, and it is widely used for assessing malignancies. In addition to accumulating in tumor cells, FDG also accumulates in inflammatory tissue, allowing FDG PET/CT to demonstrate arthritis. PET/CT allows evaluation of whole-body articular and extra-articular lesions in one examination, representing a key advantage over US and MRI, which allow assessment of only a few regions because of their limited field of view. Although FDG PET/CT is sensitive for detecting inflammatory lesions, the uptake itself is nonspecific; therefore, knowledge of characteristic uptake patterns is necessary to narrow the differential diagnosis in rheumatic disease. Furthermore, pathognomonic extra-articular findings such as vasculitis, skin lesions, lymphadenopathy, and chondritis play an important role in achieving accurate diagnosis. The authors present the FDG PET/CT appearances of (a) rheumatoid arthritis and allied disorders (polymyalgia rheumatica, remitting seronegative symmetrical synovitis with pitting edema, adult-onset Still disease), (b) spondyloarthritis (ankylosing spondylitis, psoriatic arthritis, reactive arthritis, inflammatory bowel disease arthritis, SAPHO [synovitis, acne, pustulosis, hyperostosis, and osteitis] syndrome, chronic recurrent multifocal osteomyelitis), and (c) miscellaneous systemic disorders with arthropathy (relapsing polychondritis, multicentric reticulohistiocytosis, amyloidosis, sarcoidosis, hemophilia). ©RSNA, 2020.

    DOI: 10.1148/rg.2020190047

    Scopus

    PubMed

  49. Risk of radiation pneumonitis in patients with emphysema after stereotactic body radiotherapy for non-small cell lung cancer assessed by quantitative CT

    Uchiyama F., Nakayama H., Takeda Y., Wang W., Minamimoto R., Tajima T.

    Molecular and Clinical Oncology   Vol. 13 ( 3 ) page: 1 - 6   2020

     More details

    Language:English   Publisher:Molecular and Clinical Oncology  

    Quantitative CT assessment of patients with pulmonary emphysema is used to measure pulmonary function. The present study evaluated whether the quantitative CT value can accurately estimate the risk of radiation pneumonitis (RP) after stereotactic body radiotherapy (SBRT) for non-small cell lung cancer (NSCLC) in patients with and without emphy-sema. A total of 80 patients with stage I NSCLC receiving SBRT at a dose of 50 or 60 Gy in five fractions at our hospital between November 2003 and October 2015 were included in the analysis. A total of 33 (41%) patients were diagnosed with emphysema on CT examination. Dosimetric parameters, quantitative CT percentage value of low attenuation area (LAA%) in the whole lung, and average whole lung CT density values were used to examine the risk of RP. Among the 80 patients, 26 (33%) and 3 (4%) experienced Grade 1 and Grade 2 RP, respectively, during the median observation period of 18.8 (1.8-106.8) months. The RP rate for patients with a LAA% (<-910 HU) of ≤25% was significantly higher than that of subjects with LAA% (<-910 HU) >25% (P=0.037). The RP rate in subjects with an average HU value of >-790 HU was significantly higher compared with that of patients with ≤-790 HU (P=0.036). Age (hazard ratio [HR]=2.46; P=0.03) and average HU (HR=3.39; P=0.02) were significantly associated with RP, whereas mean lung dose was not identified to be significant in multivariate analysis. The quantitative CT value was associated with RP after SBRT.

    DOI: 10.3892/mco.2020.2073

    Scopus

    PubMed

  50. DNA synthesis PET imaging with 4DST: A radiomics approach for predicting prognosis in patients with esophageal cancer

    Ryogo Minamimoto

    European Journal of Nuclear Medicine and Molecular Imaging     2020

     More details

    Publishing type:Research paper (scientific journal)  

    Web of Science

  51. Orbital Adult T-Cell Leukemia/lymphoma with Skin Involvement Demonstrated on FDG PET/CT

    Hotta M., Minamimoto R.

    Clinical Nuclear Medicine   Vol. 44 ( 12 ) page: 993 - 994   2019.12

     More details

    Language:English   Publisher:Clinical Nuclear Medicine  

    An 85-year-old woman presented with decreased visual acuity. MRI of the brain revealed bilateral orbital masses, and FDG-PET/CT demonstrated moderate to intense uptake in the orbital tumors and thickened skin on the left lower leg. Biopsies of the orbital and cutaneous lesions revealed infiltration by T-cell lymphoma, and the presence of human T-cell lymphotropic virus type 1 antigens confirmed the diagnosis of adult T-cell leukemia/lymphoma (ATLL). Although orbital ATLL is rare, the skin is a common site of extranodal involvement of T-cell lymphomas, including ATLL, and FDG uptake by a cutaneous lesion can facilitate early diagnosis.

    DOI: 10.1097/RLU.0000000000002773

    Scopus

    PubMed

  52. 特集 内科医が押さえておくべき-検査の考えかたと落とし穴 よくオーダーするのに案外知らない検査の基本 FDG-PET検査

    堀田 昌利, 南本 亮吾

    medicina   Vol. 56 ( 12 ) page: 2037 - 2041   2019.11

     More details

    Publisher:株式会社医学書院  

    DOI: 10.11477/mf.1402226595

    CiNii Research

  53. Non-AIDS-defining malignancies in Japanese hemophiliacs with HIV-1 infection

    Oka Shinichi, Ogata Mikiko, Takano Misao, Minamimoto Ryogo, Hotta Masatoshi, Tajima Tsuyoshi, Nagata Naoyoshi, Tsukada Kunihisa, Teruya Katsuji, Kikuchi Yoshimi, Gatanaga Hiroyuki, the Cancer Screening in Hemophiliac/HIV Patient Study Group

    Global Health & Medicine   Vol. 1 ( 1 ) page: 49 - 54   2019.10

     More details

    Language:English   Publisher:National Center for Global Health and Medicine  

    <p>Along improvement of prognosis of HIV-1-infected patients due to successful anti-retroviral therapy, main causes of death in the patients have been changing from AIDS to non-AIDS defining malignancies (NADM) recently. However, little is known about the prevalence and incidence of NADM in patients, and especially in HIV-1-infected hemophiliacs. We prospectively conducted NADM screening with FDG-PET, chest CT, upper gastrointestinal endoscopy, tumor markers, and stool occult blood in hemophiliacs with a mean age of 48.9 years. Screening was done twice from December 2016 through March 2019; the first screening was used to calculate prevalence in 69 patients and the second was used to calculate incidence in 56 patients. The first screening revealed 4 cases of malignancies; three were cases of thyroid cancer and one was a case of a neuroendocrine tumor in the pancreas; prevalence was 5.8% (95% CI: 0.2-11.4%). During a mean follow-up of 1.2 years with 68.2 person-years (PYs), cancer was diagnosed in 2 cases (pancreatic and liver cancer) during the second screening. Incidence was 2.99/100 PY. It can be speculated that there might be around 40 cases of undiagnosed NADM currently and 20 cases of new NADM annually in this population, because 718 HIV-1-infected hemophiliacs are surviving in Japan according to the 2018 Nationwide Survey on Coagulation Disorders. Screening for NADM in HIV-1-infected hemophiliacs at other hospitals is strongly recommended.</p>

    DOI: 10.35772/ghm.2019.01015

    PubMed

    CiNii Research

  54. 11C-methionine-PET for differentiating recurrent brain tumor from radiation necrosis: radiomics approach with random forest classifier. International journal

    Masatoshi Hotta, Ryogo Minamimoto, Kenta Miwa

    Scientific reports   Vol. 9 ( 1 ) page: 15666 - 15666   2019.10

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Differentiating recurrent brain tumor from radiation necrosis is often difficult. This study aims to investigate the efficacy of 11C-methionine (MET)-PET radiomics for distinguishing recurrent brain tumor from radiation necrosis, as compared with conventional tumor-to-normal cortex (T/N) ratio evaluation. We enrolled 41 patients with metastatic brain tumor or glioma treated using radiation therapy who underwent MET-PET. The area with a standardized uptake value > 1.3 times that of the normal brain cortex was contoured. Forty-two PET features were extracted and used in a random forest classifier and the diagnostic performance was evaluated using a 10-fold cross-validation scheme. Gini index was measured to identify relevant PET parameters for classification. The reference standard was surgical histopathological analysis or more than 6 months of follow-up with MRI. Forty-four lesions were used for the analysis. Thirty-three and 11 lesions were confirmed as recurrent brain tumor and radiation necrosis, respectively. Radiomics and T/N ratio evaluation showed sensitivities of 90.1% and 60.6%, and specificities of 93.9% and 72.7% with areas under the curve of 0.98 and 0.73, respectively. Gray level co-occurrence matrix dissimilarity was the most pertinent feature for diagnosis. MET-PET radiomics yielded excellent outcome for differentiating recurrent brain tumor from radiation necrosis, which outperformed T/N ratio evaluation.

    DOI: 10.1038/s41598-019-52279-2

    Scopus

    PubMed

  55. Active Inflammation Imaging with Somatostatin Receptor Scintigraphy in Patients with Cardiac Sarcoidosis

    Awaya Toru, Minamimoto Ryogo, Kubota Kazuo, Kubota Shuji, Okazaki Toru, Okazaki Osamu, Hara Hisao, Hiroi Yukio, Hiroe Michiaki, Moroi Masao

    The Japanese Journal of Sarcoidosis and Other Granulomatous Disorders   Vol. 39 ( 1_2 ) page: 55 - 58   2019.10

     More details

    Language:Japanese   Publisher:Japan Society of Sarcoidosis and Other Granulomatous Disorders  

    DOI: 10.7878/jjsogd.39.1_2_55

    CiNii Research

  56. Carbon 11-choline positron emission tomography/computed tomography and palliative local therapy for castration-resistant prostate cancer. International journal

    Keina Nozaki, Taketo Kawai, Tetsuya Fujimura, Hotaka Matsui, Taro Teshima, Takahiro Oshina, Atsuko Takahashi, Yusuke Sato, Daisuke Yamada, Takeshi Azuma, Masatoshi Hotta, Kazuhiko Nakajima, Hidetsugu Nakayama, Ryogo Minamimoto, Haruki Kume

    International urology and nephrology   Vol. 51 ( 10 ) page: 1763 - 1769   2019.10

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    PURPOSE: Carbon 11-choline positron emission tomography/computed tomography (11C-choline PET/CT) and subsequent local therapy for oligometastatic prostate cancer have been reported to be effective, but their effectiveness in castration-resistant prostate cancer (CRPC) remains unclear. Here, we evaluated the findings of 11C-choline PET/CT in CRPC patients and the efficacy of local treatments in correspondence of the pathologic choline uptake. METHODS: We collected 12 cases of CRPC patients who underwent 11C-choline PET/CT between 2014 and 2016. The outcomes assessed included age, the prostate-specific antigen (PSA) value, the findings of 11C-choline PET/CT, the subsequent treatments, the PSA response following the treatments, and the progression-free survival (PFS). RESULTS: Seven of 12 cases (median PSA, 3.29 ng/mL) had local prostate cancer and/or one or two metastatic lesions detected by the choline PET/CT. These localized lesions were treated with radiotherapy or lymphadenectomy. PSA decreased in all the seven cases and median PSA response was 86% (range, 23-100%). Median PFS was 8.5 months (range, 2.8-25.3 months). The other five cases (median PSA, 7.41 ng/mL) had multiple metastases and systemic therapies were continued in those cases. CONCLUSIONS: 11C-choline PET/CT and the correspondent local treatments may play an important role in the treatment sequence of CRPC in selected patients.

    DOI: 10.1007/s11255-019-02233-y

    Scopus

    PubMed

  57. Impact of a modified peritoneal cancer index using FDG-PET/CT (PET-PCI) in predicting tumor grade and progression-free survival in patients with pseudomyxoma peritonei. International journal

    Masatoshi Hotta, Ryogo Minamimoto, Yoshimasa Gohda, Toru Igari, Hideaki Yano

    European radiology   Vol. 29 ( 10 ) page: 5709 - 5716   2019.10

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    OBJECTIVES: The peritoneal cancer index (PCI) is widely used for assessing pseudomyxoma peritonei (PMP) in surgery. The aim of this study was to evaluate the utility of a modified PCI using 18F-fluorodeoxyglucose (18F-FDG)-PET/CT (PET-PCI) for predicting pathologic grade and progression-free survival (PFS) in patients with PMP. METHODS: Thirty-five patients who underwent 18F-FDG-PET/CT before cytoreductive surgery and/or hyperthermic intraperitoneal chemotherapy were enrolled. PET-PCI was determined by summing up the visually scored 18F-FDG uptake of PMP lesions in 13 specific abdominal-pelvic regions. Uptake score was defined as 0, no lesion or lesion without uptake; 1, slight uptake less than or equivalent to mediastinal blood pool; 2, moderate uptake above mediastinal but below or equal to liver; and 3, intense uptake moderately to markedly higher than liver. SUVmax of the lesion was also evaluated. RESULTS: Pathologic diagnosis revealed 19 patients with low-grade PMP and 16 patients with high-grade PMP. Patients with high-grade PMP showed significantly higher PET-PCI and SUVmax than patients with low-grade PMP (PET-PCI 14.8 vs. 8.7, p = 0.007; SUVmax 3.6 vs. 2.6, p = 0.013). Using a cutoff PET-PCI of 12, Kaplan-Meier analyses showed a significant difference in PFS between patients with high and low PET-PCI (p < 0.001; hazard ratio (HR), 12.4). For SUVmax, the optimal cutoff was 2.7 and the correlation with PFS was also significant (p = 0.008; HR, 4.7). In multivariate Cox proportional-hazards regression, PET-PCI was independently and significantly correlated with PFS. CONCLUSIONS: PET-PCI can reflect histopathologic features and appears useful for predicting recurrence in patients with PMP. KEY POINTS: • Peritoneal cancer index using 18F-FDG-PET/CT (PET-PCI) has great potential for predicting progression-free survival in patients with pseudomyxoma peritonei. • PET-PCI provides higher prognostic performance than maximum standardized uptake value (SUVmax). • PET-PCI shows high correlation with histopathologic grade of pseudomyxoma peritonei.

    DOI: 10.1007/s00330-019-06102-1

    Scopus

    PubMed

  58. 特集 注意したいFDG-PET/CTでの見逃しと読み過ぎ 胸部領域

    南本 亮吾, 堀田 昌利

    臨床放射線   Vol. 64 ( 9 ) page: 1127 - 1137   2019.8

     More details

    Publisher:金原出版  

    DOI: 10.18888/rp.0000000976

    CiNii Research

  59. Efficacy of 4'-[methyl-11C] thiothymidine PET/CT before and after neoadjuvant therapy for predicting therapeutic responses in patients with esophageal cancer: a pilot study. International journal

    Masatoshi Hotta, Ryogo Minamimoto, Kazuhiko Yamada, Kyoko Nohara, Daisuke Soma, Kazuhiko Nakajima, Jun Toyohara, Kei Takase

    EJNMMI research   Vol. 9 ( 1 ) page: 10 - 10   2019.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND: 4'-[Methyl-11C] thiothymidine (4DST) has been introduced as a new cell proliferation imaging PET tracer that incorporates into DNA directly. The aim of this prospective study was to evaluate the efficacy of 4DST PET/CT for predicting responses to neoadjuvant therapy in patients with esophageal cancer comparing with FDG PET/CT. METHODS: Twenty-six patients who had pre- and post-therapeutic 4DST and FDG PET/CT and underwent esophagectomy following neoadjuvant therapy were used for the analysis. Based on pathological findings, patients were divided into two groups: non-responders and responders. The maximum standardized uptake value (SUVmax), metabolic tumor volume, total lesion glycolysis, and total lesion proliferation of the primary lesion were measured for FDG and 4DST PET. RESULTS: The pathological diagnosis revealed 16 responders and 10 non-responders. Non-responders showed significantly higher 4DST post-therapeutic SUVmax (postSUVmax) than responders, whereas FDG postSUVmax showed no statistically significant difference (non-responders vs. responders: 4DST, 6.7 vs. 3.3, p = 0.001; FDG, 6.1 vs. 4.5, p = 0.11). Responders showed a greater reduction in percentage changes of 4DST and FDG SUVmax (ΔSUVmax) from baseline to post-therapeutic PET (non-responders vs. responders: 4DST, - 2.9% vs. - 56.7%, p < 0.001; FDG, - 36.3% vs. - 72.6%, p < 0.001). In ROC analysis, ΔSUVmax and postSUVmax with 4DST provided great diagnostic performance for predicting responses (area under the curve: 4DST ΔSUVmax = 0.92, 4DST postSUVmax = 0.88). CONCLUSIONS: 4DST PET/CT has a great potential for predicting pathologic response to neoadjuvant therapy in patients with esophageal cancer; it may be slightly superior to that with FDG PET/CT.

    DOI: 10.1186/s13550-019-0478-9

    Scopus

    PubMed

  60. 18F-FDG and 11C-4DST PET/CT for evaluating response to platinum-based doublet chemotherapy in advanced non-small cell lung cancer: a prospective study. International journal

    Ryogo Minamimoto, Yuichiro Takeda, Masatoshi Hotta, Jun Toyohara, Kazuhiko Nakajima, Go Naka, Haruhito Sugiyama

    EJNMMI research   Vol. 9 ( 1 ) page: 4 - 4   2019.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND: 4'-[Methyl-11C] thiothymidine (4DST) PET/CT provides DNA synthesis imaging, which represented a higher correlation with the proliferation in advanced non-small cell lung cancer (NSCLC) than that from imaging with FDG. The aim of this prospective study was to evaluate the potential of 4DST in early therapy monitoring for advanced NSCLC, and to compare the results with those from CT and FDG PET/CT. RESULTS: Patients who had been pathologically diagnosed with advanced NSCLC and were scheduled to receive platinum-doublet chemotherapy (PT-DC) were eligible. PET/CT imaging with 4DST and with FDG, and CT were performed at baseline and after 2 cycles of PT-DC (interim). Patients were evaluated semi-quantitatively after the 2 cycles of PT-DC using several PET parameters, response evaluation criteria in solid tumors (RECIST) 1.1 based on CT measurements, European Organization for Research and Treatment of Cancer (EORTC) criteria and PET Response Criteria in Solid Tumors (PERCIST) 1.0 based on PET/CT measurements. Baseline measurement data and metabolic response were compared between patients with progression-free survival (PFS) > 4 months and ≤ 4 months, and PFS and overall survival (OS) were compared between patients with and without metabolic response measured with each of the different parameters, using Kaplan-Meier statistics and log-rank testing. A total of 22 patients were included in this study. For predicting PFS > 4 months and ≤ 4 months, metabolic tumor volume (MTV) of baseline 4DST showed the highest area under the curve (0.73), positive predictive value (80.0%), negative predictive value (66.7%), and accuracy (72.7%) among baseline measurement data and metabolic responses from 4DST PET/CT, FDG PET/CT, and CT. Kaplan-Meier curves and log-rank tests for PFS with MTV of baseline FDG and baseline 4DST, and for OS with MTV of baseline FDG and baseline TLG, and MTV of baseline 4DST revealed significant results. CONCLUSIONS: MTV of baseline 4DST PET/CT along with MTV of baseline FDG PET/CT represent promising predictors of PFS, and MTV of baseline 4DST PET/CT along with MTV and TLG of baseline FDG PET/CT are possible predictors of OS in patients with advanced NSCLC.

    DOI: 10.1186/s13550-019-0472-2

    Scopus

    PubMed

  61. PI3K/AKT/mTOR pathway alterations promote malignant progression and xenograft formation in oligodendroglial tumors

    Tateishi K., Nakamura T., Juratli T.A., Williams E.A., Matsushita Y., Miyake S., Nishi M., Miller J.J., Tummala S.S., Fink A.L., Lelic N., Koerner M.V.A., Miyake Y., Sasame J., Fujimoto K., Tanaka T., Minamimoto R., Matsunaga S., Mukaihara S., Shuto T., Taguchi H., Udaka N., Murata H., Ryo A., Yamanaka S., Curry W.T., Dias-Santagata D., Yamamoto T., Ichimura K., Batchelor T.T., Chi A.S., John Iafrate A., Wakimoto H., Cahill D.P.

    Clinical Cancer Research   Vol. 25 ( 14 ) page: 4375 - 4387   2019

     More details

    Language:English   Publisher:Clinical Cancer Research  

    Purpose: Oligodendroglioma has a relatively favorable prognosis, however, often undergoes malignant progression. We hypothesized that preclinical models of oligodendroglioma could facilitate identification of therapeutic targets in progressive oligodendroglioma. We established multiple oligodendroglioma xenografts to determine if the PI3K/AKT/mTOR signaling pathway drives tumor progression. Experimental Design: Two anatomically distinct tumor samples from a patient who developed progressive anaplastic oligodendroglioma (AOD) were collected for orthotopic transplantation in mice. We additionally implanted 13 tumors to investigate the relationship between PI3K/AKT/mTOR pathway alterations and oligodendroglioma xenograft formation. Pharmacologic vulnerabilities were tested in newly developed AOD models in vitro and in vivo. Results: A specimen from the tumor site that subsequently manifested rapid clinical progression contained a PIK3CA mutation E542K, and yielded propagating xenografts that retained the OD/AOD-defining genomic alterations (IDH1R132H and 1p/19q codeletion) and PIK3CAE542K, and displayed characteristic sensitivity to alkylating chemotherapeutic agents. In contrast, a xenograft did not engraft from the region that was clinically stable and had wild-type PIK3CA. In our panel of OD/AOD xenografts, the presence of activating mutations in the PI3K/AKT/mTOR pathway was consistently associated with xenograft establishment (6/6, 100%). OD/ AOD that failed to generate xenografts did not have activating PI3K/AKT/mTOR alterations (0/9, P < 0.0001). Importantly, mutant PIK3CA oligodendroglioma xenografts were vulnerable to PI3K/AKT/mTOR pathway inhibitors in vitro and in vivo—evidence that mutant PIK3CA is a tumorigenic driver in oligodendroglioma. Conclusions: Activation of the PI3K/AKT/mTOR pathway is an oncogenic driver and is associated with xenograft formation in oligodendrogliomas. These findings have implications for therapeutic targeting of PI3K/AKT/mTOR pathway activation in progressive oligodendrogliomas.

    DOI: 10.1158/1078-0432.CCR-18-4144

    Scopus

    PubMed

  62. The clinical utility of phase-based respiratory gated PET imaging based on visual feedback with a head-mounted display system

    Mitsumoto T., Minamimoto R., Sunaoka F., Kishimoto S., Inoue K., Fukushi M.

    British Journal of Radiology   Vol. 92 ( 1098 ) page: 20180233   2019

     More details

    Language:English   Publisher:British Journal of Radiology  

    Objective: We developed a new respiratory-gated positron emission tomography (PET) imaging method (RGVPET) that phase-based respiratory gated PET imaging (RG-PET) combine with head-mounted display (HMD)- guided "visual feedback." The purpose of this study was to investigate whether RGV-PET is effective at improving the quantitative measurement of tracer uptake in tumors using the phase-based respiratory gating method. Methods: Of the 41 enrolled patients with hepatobiliary or pancreatic cancer, 20 patients underwent RGV-PET and the remaining 21 patients underwent RG-PET. We measured the peak standardized uptake value (SUVpeak) of the primary lesion in each five bins obtained from both RG-PET and RGV-PET. The SUVpeak change rate calculated based on the ungated PET imaging. To evaluate the quantitative variation, the coefficient of variation of the SUVpeak change rate was compared between RG-PET and RGV-PET. In addition, we performed qualitative evaluation using visual score for the incidence of artifacts on four-dimensional-CT. Results: The coefficient of variation of the average SUVpeak change rate in RGV-PET was 7.01 ± 4.43, which was significantly lower than the values in RG-PET (10.72 ± 5.74, p < 0.05). A significant improvement in the SUVpeak change rate of RGV-PET was obtained in bins 1 and 2 compared to RG-PET (p < 0.05). The visual score of RGV-PET was significantly lower than RG-PET (p < 0.05). Conclusion: RGV-PET was effective for respiratory stabilization and improved respiratory gating imaging quality.

    DOI: 10.1259/bjr.20180233

    Scopus

    PubMed

  63. 平成28・29 年度 ワーキンググループ報告

    北島 一宏, 南本 亮吾, 平田 健司, 山根 登茂彦, 甲斐田 勇人, 中條 正豊, 森田 敬裕, 中谷 航也, 石橋 愛

    核医学   Vol. 56 ( 1 ) page: 45 - 46   2019

     More details

    Language:Japanese   Publisher:一般社団法人 日本核医学会  

    DOI: 10.18893/kakuigaku.wgr.1977

    CiNii Research

  64. Dose Discrepancy between the Gross Tumor Volume and the Planning Target Volume By Surrounding Density in Stereotactic Body Radiotherapy for Stage I Non-Small Cell Lung Cancer

    Ryogo Minamimoto

    International Journal of Radiation Oncology Biology Physics     2019

     More details

    Publishing type:Research paper (scientific journal)  

    DOI: 10.1016/J.IJROBP.2019.06.2450

    Web of Science

  65. Texture analysis f C-11-methionine PET images can distinguish recurrent brain tumors from radiation necrosis

    Ryogo Minamimoto

    Journal of Nuclear Medicine     2019

     More details

    Publishing type:Research paper (scientific journal)  

    Web of Science

  66. Potential of bone marrow uptake of 4DST for the assessment of multiple myeloma

    Ryogo Minamimoto

    Journal of Nuclear Medicine     2019

     More details

    Publishing type:Research paper (scientific journal)  

    Web of Science

  67. Methionine PET Imaging For Differentiation Between Recurrent Brain Tumor And Radiation Necrosis: Radiomics Approach With Random Forest Classifier

    Ryogo Minamimoto

    European Journal of Nuclear Medicine and Molecular Imaging     2019

     More details

    Publishing type:Research paper (scientific journal)  

    Web of Science

  68. FDG-PET/CT radiomics for survival prediction in patients with rectal cancer treated with surgery

    Ryogo Minamimoto

    Journal of Nuclear Medicine     2019

     More details

    Publishing type:Research paper (scientific journal)  

    Web of Science

  69. The evaluation of tumor response to neoadjuvant chemotherapy for esophageal cancer using PERCIST 1.0-multicenter study

    Ryogo Minamimoto

    European Journal of Nuclear Medicine and Molecular Imaging     2019

     More details

    Publishing type:Research paper (scientific journal)  

    Web of Science

  70. The Relationship with Radiation Pneumonitis Followed By Stereotactic Body Radiotherapy and Emphysema Evaluated By CT

    Ryogo Minamimoto

    International Journal of Radiation Oncology Biology Physics     2019

     More details

    Publishing type:Research paper (scientific journal)  

    DOI: 10.1016/J.IJROBP.2019.06.2451

    Web of Science

  71. FDG PET/CT Findings in TAFRO Syndrome. International journal

    Masatoshi Hotta, Ryogo Minamimoto, Arisa Yashima, Masahiro Nakano, Hiroyuki Yamashita

    Clinical nuclear medicine   Vol. 43 ( 11 ) page: 828 - 829   2018.11

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    A 67-year-old woman with prolonged fever, thrombocytopenia, and renal dysfunction underwent FDG PET/CT to evaluate underlying causes, including malignancy. PET/CT showed FDG uptake in ascites, subcutaneous edema, lymph nodes, spleen, and bone marrow. Subsequent bone marrow biopsy revealed myelofibrosis, and laboratory testing showed elevated concentrations of interleukin 6 in serum and ascites. These findings led to the diagnosis of TAFRO syndrome, a variant of multicentric Castleman disease, characterized by thrombocytopenia, anasarca, fever, reticulin myelofibrosis, and organomegaly. Because TAFRO syndrome is potentially fatal, accurate diagnosis is crucial. Characteristic FDG PET/CT findings facilitate the diagnosis of TAFRO syndrome, which is generally challenging.

    DOI: 10.1097/RLU.0000000000002278

    Scopus

    PubMed

  72. Nuclear Medicine Imaging Techniques for Detection of Skeletal Metastases in Breast Cancer

    Iagaru A., Minamimoto R.

    PET Clinics   Vol. 13 ( 3 ) page: 383 - 393   2018.7

     More details

    Language:English   Publisher:PET Clinics  

    Bone is the most common site of metastases from advanced breast cancer. Whole-body bone scintigraphy has been most frequently used in the process of managing cancer patients; its advantage is that it provides rapid whole-body imaging for screening of osteoblastic or sclerotic/mixed bone metastases at reasonable cost. Recent advanced techniques, such as single-photon emission computed tomography (SPECT)/CT, quantitative analysis, and bone scan index, contribute to better understanding of the disease state. More recent advances in machines and PET drugs improve the staging of the skeleton with higher sensitivity and specificity.

    DOI: 10.1016/j.cpet.2018.02.002

    Scopus

    PubMed

  73. 11C-4DST PET/CT Imaging of Cardiac Sarcoidosis: Comparison With 18F-FDG and Cardiac MRI. International journal

    Masatoshi Hotta, Ryogo Minamimoto, Shuji Kubota, Toru Awaya, Yukio Hiroi

    Clinical nuclear medicine   Vol. 43 ( 6 ) page: 458 - 459   2018.6

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    A 75-year-old woman with a history of sarcoidosis presenting with low cardiac output and complete right bundle-branch block underwent 4'-[methyl-C]-thiothymidine (4DST) PET/CT after cardiac MRI and FDG PET/CT for the evaluation of suspected cardiac sarcoidosis (CS) before treatment. Cardiac MRI revealed late gadolinium enhancement on the anterior-to-lateral and posterior wall, indicating CS. FDG uptake was shown on the anterior-to-lateral wall, but not on the posterior wall. In contrast, 4DST uptake was demonstrated on both anterior-to-lateral and posterior walls. Use of 4DST appears promising for detecting CS without dietary restriction, due to the lack of physiological uptake in myocardium.

    DOI: 10.1097/RLU.0000000000002059

    Scopus

    PubMed

  74. Prospective Evaluation of 68Ga-RM2 PET/MRI in Patients with Biochemical Recurrence of Prostate Cancer and Negative Findings on Conventional Imaging. International journal

    Ryogo Minamimoto, Ida Sonni, Steven Hancock, Shreyas Vasanawala, Andreas Loening, Sanjiv S Gambhir, Andrei Iagaru

    Journal of nuclear medicine : official publication, Society of Nuclear Medicine   Vol. 59 ( 5 ) page: 803 - 808   2018.5

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    68Ga-labeled DOTA-4-amino-1-carboxymethyl-piperidine-d-Phe-Gln-Trp-Ala-Val-Gly-His-Sta-Leu-NH2 (68Ga-RM2) is a synthetic bombesin receptor antagonist that targets gastrin-releasing peptide receptor (GRPr). GRPr proteins are highly overexpressed in several human tumors, including prostate cancer (PCa). We present data from the use of 68Ga-RM2 in patients with biochemical recurrence (BCR) of PCa and negative findings on conventional imaging. Methods: We enrolled 32 men with BCR of PCa, who were 59-83 y old (mean ± SD, 68.7 ± 6.4 y). Imaging started at 40-69 min (mean, 50.5 ± 6.8 min) after injection of 133.2-151.7 MBq (mean, 140.6 ± 7.4 MBq) of 68Ga-RM2 using a time-of-flight-enabled simultaneous PET/MRI scanner. T1-weighted, T2-weighted, and diffusion-weighted images were acquired. Results: All patients had a rising level of prostate-specific antigen (PSA) (range, 0.3-119.0 ng/mL; mean, 10.1 ± 21.3 ng/mL) and negative findings on conventional imaging (CT or MRI, and a 99mTc-methylene diphosphonate bone scan) before enrollment. The observed 68Ga-RM2 PET detection rate was 71.8%. 68Ga-RM2 PET identified recurrent PCa in 23 of the 32 participants, whereas the simultaneous MRI scan identified findings compatible with recurrent PCa in 11 of the 32 patients. PSA velocity was 0.32 ± 0.59 ng/mL/y (range, 0.04-1.9 ng/mL/y) in patients with negative PET findings and 2.51 ± 2.16 ng/mL/y (range, 0.13-8.68 ng/mL/y) in patients with positive PET findings (P = 0.006). Conclusion:68Ga-RM2 PET can be used for assessment of GRPr expression in patients with BCR of PCa. High uptake in multiple areas compatible with cancer lesions suggests that 68Ga-RM2 is a promising PET radiopharmaceutical for localization of disease in patients with BCR of PCa and negative findings on conventional imaging.

    DOI: 10.2967/jnumed.117.197624

    Scopus

    PubMed

  75. A case of cardiac sarcoidosis mimicking cardiac amyloidosis on cardiovascular magnetic resonance. International journal

    Kazunori Takemura, Ryuta Nakamura, Kazuhito Shimazu, Youichiro Sugimoto, Tetsuro Takase, Minamimoto Ryogo, Michiaki Hiroe

    ESC heart failure   Vol. 5 ( 2 ) page: 306 - 310   2018.4

     More details

    Language:English  

    A 52-year-old male visited our hospital with abnormal electrocardiogram and exertional fatigue. The electrocardiogram showed first-degree atrioventricular block, complete right bundle branch block, and inverted T waves in Leads II, III, aVF, V3, and V4. Echocardiography showed biventricular wall thickening involving granular sparkling of the interventricular septum. Late gadolinium enhancement on cardiovascular magnetic resonance (CMR) was found at the circumferential right ventricular wall and patchy regions of the left ventricle. Although these findings strongly suggested cardiac amyloidosis, he was finally diagnosed with systemic sarcoidosis due to the following. First, endomyocardial biopsy revealed non-caseating epithelioid granuloma with giant cells. Second, 18 F-fluorodeoxyglucose positron emission tomography showed uptake in bilateral hilar lymph nodes, para-aortic lymph nodes, and the biventricular wall of the heart. Although echocardiography and CMR are very useful tools for diagnosis of cardiomyopathies, their specificity and accuracy need to be considered.

    DOI: 10.1002/ehf2.12263

    PubMed

  76. FDG PET/CT after first molecular targeted therapy predicts survival of patients with renal cell carcinoma. International journal

    Noboru Nakaigawa, Keiichi Kondo, Tomohiro Kaneta, Ukihide Tateishi, Ryogo Minamimoto, Kazuhiro Namura, Daiki Ueno, Kazuki Kobayashi, Takeshi Kishida, Ichiro Ikeda, Hisashi Hasumi, Kazuhide Makiyama, Narihiko Hayashi, Kimito Osaka, Kentaro Muraoka, Koji Izumi, Takashi Kawahara, Jun-Ichi Teranishi, Yasuhide Miyoshi, Yasushi Yumura, Hiroji Uemura, Tomio Inoue, Masahiro Yao

    Cancer chemotherapy and pharmacology   Vol. 81 ( 4 ) page: 739 - 744   2018.4

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    PURPOSE: We investigated prospectively whether 18F-2-fluoro-2-deoxyglucose positron emission tomography/computed tomography (FDG PET/CT) can predict the overall survival (OS) of patients with advanced renal cell carcinoma (RCC) previously treated by molecular targeted therapies. METHODS: Between 2009 and 2016, 81 patients who had received single molecular targeted therapies (43 sorafenib, 27 sunitinib, 8 temsirolimus and others) and were scheduled for second line molecular targeted therapies for advanced RCC were enrolled in this prospective study. FDG PET/CT was performed after first line molecular targeted therapies, the max SUVmax (highest standardized uptake value for each patient) recorded, and its association with OS compared with those of known risk factors. The median follow-up was 15.4 months (range 0.9-97.4 months). RESULTS: The max SUVmax of the 81 subjects ranged from undetectable to 23.0 (median 7.1). Patients with high max SUVmax had a poor prognosis and multivariate analysis with established risk factors showed that it was an independent predictor of survival (p < 0.001; hazard ratio 1.156; 95% confidence interval 1.080-1.239). Subclassification of patients by max SUVmax showed that the median OS of patients with max SUVmax < 7.0 (39), 7.0-12.0 (30), and ≥ 12.0 (12) were 32.8, 15.2, and 6.0 months, respectively. These differences are statistically significant (< 7.0 versus 7.0-12.0: p = 0.0333, 7.0-12.0 versus ≥ 12.0: p = 0.0235). CONCLUSIONS: The max SUVmax by FDG PET/CT of patients with RCC evaluated after their first molecular targeted therapy predicts OS. FDG PET/CT is a useful "imaging biomarker" for patients with advanced RCC planning sequential molecular targeted therapies.

    DOI: 10.1007/s00280-018-3542-7

    Scopus

    PubMed

  77. Diagnostic performance of 18F-FDG PET/CT using point spread function reconstruction on initial staging of rectal cancer: a comparison study with conventional PET/CT and pelvic MRI. International journal

    Masatoshi Hotta, Ryogo Minamimoto, Hideaki Yano, Yoshimasa Gohda, Yasutaka Shuno

    Cancer imaging : the official publication of the International Cancer Imaging Society   Vol. 18 ( 1 ) page: 4 - 4   2018.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND: Accurate staging is crucial for treatment selection and prognosis prediction in patients with rectal cancer. Point spread function (PSF) reconstruction can improve spatial resolution and signal-to-noise ratio of PET imaging. The aim of this study was to evaluate the effectiveness of 18F-FDG PET/CT with PSF reconstruction for initial staging in rectal cancer compared with conventional PET/CT and pelvic MRI. METHODS: A total of 59 patients with rectal cancer underwent preoperative 18F-FDG PET/CT and pelvic MRI. The maximum standardized uptake value (SUVmax) and lesion to background (L/B) ratio of possible metastatic lymph nodes, and metabolic tumor volumes (MTVs) of primary tumors were calculated. For N and T (T1-2 vs T3-4) staging, sensitivities, specificities, positive predictive values, negative predictive values, and accuracies were compared between conventional PET/CT [reconstructed with ordered subset expectation maximization (OSEM)], PSF-PET/CT (reconstructed with OSEM+PSF), and pelvic MRI. Histopathologic analysis was the reference standard. RESULTS: For N staging, PSF-PET/CT provided higher sensitivity (78.6%) than conventional PET/CT (64.3%), and pelvic MRI (57.1%), and all techniques showed high specificity (PSF-PET: 95.4%, conventional PET: 96.7%, pelvic MRI: 93.5%). SUVmax and L/B ratio were significantly higher in PSF-PET/CT than conventional-PET/CT (p < 0.001). The accuracy for T staging in PSF-PET/CT (69.4%) was not significantly different to conventional PET/CT (73.5%) and pelvic MRI (73.5%). MTVs of PSF and conventional PET showed a significant difference among T stages (p < 0.001), with higher values in advanced stages. In M staging, both PSF and conventional PET/CT diagnosed all distant metastases correctly. CONCLUSIONS: PSF-PET/CT produced images with higher lesion-to-background contrast than conventional PET/CT, which allowed improved detection of lymph node metastasis without compromising specificity, and showed comparable diagnostic value to MRI in local staging. PSF-PET/CT is likely to have a great value for initial staging in rectal cancer.

    DOI: 10.1186/s40644-018-0137-9

    Scopus

    PubMed

  78. Impact Of PET-PCI Using FDG PET CT For Predicting Tumour Grade And Recurrence In Pseudomyxoma Peritonei

    Ryogo Minamimoto

    European Journal of Nuclear Medicine and Molecular Imaging     2018

     More details

    Publishing type:Research paper (scientific journal)  

    Web of Science

  79. Ga-68-RM2 PET vs. Ga-68-PSMA-11 PET: Prospective Comparison in Patients with Biochemical Recurrence of Prostate Cancer

    Ryogo Minamimoto

    European Journal of Nuclear Medicine and Molecular Imaging     2018

     More details

    Publishing type:Research paper (scientific journal)  

    Web of Science

  80. Active inflammation imaging with 111In-pentetreotide in patients with cardiac sarcoidosis: comparition with other imaging modalities

    Ryogo Minamimoto

    European Heart Journal     2018

     More details

    Publishing type:Research paper (scientific journal)  

    Web of Science

  81. Differences of quantitative indexes for PET/CT between analysis software using modified

    Ryogo Minamimoto

    European Journal of Nuclear Medicine and Molecular Imaging     2018

     More details

    Publishing type:Research paper (scientific journal)  

    Web of Science

  82. Present and future roles of FDG-PET/CT imaging in the management of gastrointestinal cancer: An update

    Kitajima K., Nakajo M., Kaida H., Minamimoto R., Hirata K., Tsurusaki M., Doi H., Ueno Y., Sofue K., Tamaki Y., Yamakado K.

    Nagoya Journal of Medical Science   Vol. 79 ( 4 ) page: 527 - 543   2017.11

     More details

    Language:English   Publisher:Nagoya Journal of Medical Science  

    Positron emission tomography/computed tomography (PET/CT) integrated with 2-[18F]fluoro-2-deoxy- D-glucose (FDG) is a useful tool for acquisition of both glucose metabolism and anatomic imaging data, as only a single device and one diagnostic session is required, thus opening a new field in clinical oncologic imaging. FDG-PET/CT has been successfully used for initial staging, restaging, assessment of early treatment response, evaluation of metastatic disease response, and prognostication of intestinal cancer as well as various malignant tumors. We reviewed the current status and role of FDG-PET/CT for management of patients with esophageal cancer, gastric cancer, and colorectal cancer, with focus on both its usefulness and limitations.

    DOI: 10.18999/nagjms.79.4.527

    Scopus

    PubMed

  83. Semiquantitative Assessment of 18F-FDG Uptake in the Normal Skeleton: Comparison Between PET/CT and Time-of-Flight Simultaneous PET/MRI. International journal

    Ryogo Minamimoto, Guofan Xu, Mehran Jamali, Dawn Holley, Amir Barkhodari, Greg Zaharchuk, Andrei Iagaru

    AJR. American journal of roentgenology   Vol. 209 ( 5 ) page: 1136 - 1142   2017.11

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    OBJECTIVE: Differences in the attenuation correction methods used in PET/CT scanners versus the newly introduced whole-body simultaneous PET/MRI reportedly result in differences in standardized uptake values (SUVs) in the normal skeleton. The aim of the study was to compare the semiquantitative FDG uptake in the normal skeleton using time-of-flight (TOF) PET/MRI versus PET/CT with and without TOF. SUBJECTS AND METHODS: Participants received a single FDG injection and underwent non-TOF and TOF PET/CT (n = 23) or non-TOF PET/CT and TOF PET/MRI (n = 50). Mean SUV (SUVmean) and maximum SUV (SUVmax) were measured from all PET scans for nine normal regions of the skeleton. Pearson correlation coefficients (r) were used to evaluate the SUVmax and SUVmean of normal skeleton between non-TOF and TOF PET/CT, as well as between non-TOF PET/CT and TOF PET/MRI. In addition, percentage differences in SUVmax and SUVmean of the normal skeleton between non-TOF and TOF PET/CT and between non-TOF PET/CT and TOF PET/MRI were evaluated. RESULTS: The SUVmax and SUVmean in the normal skeleton significantly increased between non-TOF and TOF PET/CT, but they significantly decreased between non-TOF PET/CT and TOF PET/MRI. The SUVmax and SUVmean in normal skeleton showed good correlation between non-TOF PET/CT and TOF PET/MRI (SUVmax, r = 0.88; SUVmean, r = 0.91) and showed a similar trend between non-TOF and TOF PET/CT (SUVmax, r = 0.88; SUVmean, r = 0.94). CONCLUSION: In the normal skeleton, SUVmax and SUVmean showed high correlations between PET/MRI and PET/CT. The MRI attenuation correction used in TOF PET/MRI provides reliable semiquantitative measurements in the normal skeleton.

    DOI: 10.2214/AJR.17.18044

    Scopus

    PubMed

  84. Prediction of EGFR and KRAS mutation in non-small cell lung cancer using quantitative 18F FDG-PET/CT metrics. International journal

    Ryogo Minamimoto, Mehran Jamali, Olivier Gevaert, Sebastian Echegaray, Amanda Khuong, Chuong D Hoang, Joseph B Shrager, Sylvia K Plevritis, Daniel L Rubin, Ann N Leung, Sandy Napel, Andrew Quon

    Oncotarget   Vol. 8 ( 32 ) page: 52792 - 52801   2017.8

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    This study investigated the relationship between epidermal growth factor receptor (EGFR) and Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations in non-small-cell lung cancer (NSCLC) and quantitative FDG-PET/CT parameters including tumor heterogeneity. 131 patients with NSCLC underwent staging FDG-PET/CT followed by tumor resection and histopathological analysis that included testing for the EGFR and KRAS gene mutations. Patient and lesion characteristics, including smoking habits and FDG uptake parameters, were correlated to each gene mutation. Never-smoker (P < 0.001) or low pack-year smoking history (p = 0.002) and female gender (p = 0.047) were predictive factors for the presence of the EGFR mutations. Being a current or former smoker was a predictive factor for the KRAS mutations (p = 0.018). The maximum standardized uptake value (SUVmax) of FDG uptake in lung lesions was a predictive factor of the EGFR mutations (p = 0.029), while metabolic tumor volume and total lesion glycolysis were not predictive. Amongst several tumor heterogeneity metrics included in our analysis, inverse coefficient of variation (1/COV) was a predictive factor (p < 0.02) of EGFR mutations status, independent of metabolic tumor diameter. Multivariate analysis showed that being a never-smoker was the most significant factor (p < 0.001) for the EGFR mutations in lung cancer overall. The tumor heterogeneity metric 1/COV and SUVmax were both predictive for the EGFR mutations in NSCLC in a univariate analysis. Overall, smoking status was the most significant factor for the presence of the EGFR and KRAS mutations in lung cancer.

    DOI: 10.18632/oncotarget.17782

    Scopus

    PubMed

  85. Improved 123I-Ioflupane Binding After Immunotherapy in Anti-NAE Antibody-Positive Hashimoto Encephalopathy That Clinically Mimicked Multiple System Atrophy. International journal

    Juuri Otsuka, Ayumi Hida, Kamiyu Ogyu, Ryogo Minamimoto, Sousuke Takeuchi

    Clinical nuclear medicine   Vol. 42 ( 8 ) page: e390-e391 - e391   2017.8

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    We describe an 84-year-old man with anti-NH2-terminal of α-enolase antibody-positive Hashimoto encephalopathy that clinically mimicked multiple system atrophy who underwent investigation by dopamine transporter SPECT before and after immunotherapy. Before treatment, dopamine transporter SPECT showed reduced striatal I-ioflupane binding, with a mean specific binding ratio of 2.42, even though he had no apparent parkinsonism. After immunotherapy, mean specific binding ratio was improved to 3.22. Dopamine transporter SPECT was useful in this case to detect subclinical striatal dysfunction, and evaluation both before and after immunotherapy helped to distinguish between neurodegenerative disease and neuroimmunological disorder.

    DOI: 10.1097/RLU.0000000000001728

    Scopus

    PubMed

  86. Multicentric Reticulohistiocytosis Mimicking Malignancy on 18F-FDG PET/CT

    Hotta M., Minamimoto R., Suzuki D., Takahashi A.

    Clinical nuclear medicine   Vol. 42 ( 7 ) page: 567 - 568   2017.7

     More details

    Language:English   Publisher:Clinical nuclear medicine  

    We report the case of a 75-year-old woman who underwent F-FDG PET/CT to evaluate the recurrence of urothelial carcinoma. PET/CT showed F-FDG-avid muscles and lymph nodes, mimicking recurrence. However, F-FDG uptake was also seen in multiple joints and subcutaneous tissue, representing an uncommon finding for recurrence. Further history taking revealed she had been pathologically diagnosed with multicentric reticulohistiocytosis (MRH) from skin biopsy, and the F-FDG PET/CT findings were consistent with MRH, a rare systemic inflammatory granulomatous disease of unknown etiology. Knowledge of the characteristic F-FDG PET/CT features of MRH is important to differentiate MRH from malignancy.

    DOI: 10.1097/RLU.0000000000001661

    Scopus

    PubMed

  87. The acceleration of glucose accumulation in renal cell carcinoma assessed by FDG PET/CT demonstrated acquisition of resistance to tyrosine kinase inhibitor therapy. International journal

    Noboru Nakaigawa, Keiichi Kondo, Daiki Ueno, Kazuhiro Namura, Kazuhide Makiyama, Kazuki Kobayashi, Koichi Shioi, Ichiro Ikeda, Takeshi Kishida, Tomohiro Kaneta, Ryogo Minamimoto, Ukihide Tateishi, Tomio Inoue, Masahiro Yao

    BMC cancer   Vol. 17 ( 1 ) page: 39 - 39   2017.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND: Tyrosine-kinase inhibitor (TKI) targeting angiogenesis improves the prognosis of patients with metastatic renal cell carcinoma (RCC), but its effect is temporary. In order to understand the mechanism by which RCC acquires resistance to TKI, we investigated the change of glucose accumulation in RCC by FDG PET/CT when they demonstrated progression disease (PD) against TKI. METHODS: We monitored the FDG accumulation in RCC of 38 patients treated with TKI by 162 PET/CT sequentially until they were judged to demonstrate PD. Standardized uptake value (SUV), a simplified index of tissue FDG accumulation rate, was measured, and the sequential changes of max SUVmax (the highest SUV in an individual patient) was analyzed. Additionally, the expression of glucose transporter 1 (GLUT-1) and associated proteins in 786-O cells cultured under hypoxia were analyzed. RESULTS: The 10 patients with RCC which FDG accumulation was accelerated after beginning of TKI treatment demonstrated PD soon. The other 28 patients with RCC which FDG accumulation was suppressed by TKI showed longer progression-free survival (3.6 months vs 6.5 months, P = 0.0026), but this suppression in most cases (96%) was temporary and FDG accumulation was accelerated when tumor demonstrated PD. Interestingly, the FDG accumulation at PD was higher than that before TKI treatment in the half cases. The acceleration of FDG accumulation was suppressed by following treatment by mammalian target of rapamycin (mTOR) inhibitor. Additionally, in vitro assay demonstrated that the expression of GLUT-1 was increased in the RCC cells surviving under hypoxia condition via mTOR pathway. CONCLUSIONS: The acceleration of glucose accumulation dependent on mTOR in RCC assessed by FDG PET/CT demonstrated acquisition of resistance to TKI. FDG PET/CT had potential as an assessment method monitoring not only the initial response but also following status of RCC during TKI treatment. TRIAL REGISTRATION: UMIN0000008141 , 11 Jun 2012. This trial was retrospectively registered.

    DOI: 10.1186/s12885-016-3044-0

    Scopus

    PubMed

  88. Impact of FDG PET/CT using point spread function (PSF) reconstruction compared with conventional FDG PET/CT and pelvic MRI for lymph node staging in rectal cancer

    Ryogo Minamimoto

    Journal of Nuclear Medicine     2017

     More details

    Publishing type:Research paper (scientific journal)  

    Web of Science

  89. Imaging Patients with Breast and Prostate Cancers Using Combined F-18 NaF/F-18 FDG and TOF simultaneous PET/MRI

    Ryogo Minamimoto

    Journal of Nuclear Medicine     2017

     More details

    Publishing type:Research paper (scientific journal)  

    Web of Science

  90. Conspicuity of Malignant Lesions on PET/CT and Simultaneous Time-Of-Flight PET/MRI. International journal

    Ryogo Minamimoto, Andrei Iagaru, Mehran Jamali, Dawn Holley, Amir Barkhodari, Shreyas Vasanawala, Greg Zaharchuk

    PloS one   Vol. 12 ( 1 ) page: e0167262   2017

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    PURPOSE: To compare the conspicuity of malignant lesions between FDG PET/CT and a new simultaneous, time-of-flight (TOF) enabled PET/MRI scanner. METHODS: All patients underwent a single-injection of FDG, followed by a dual imaging protocol consisting of PET/CT followed by TOF PET/MRI. PET/CT and PET/MRI images were evaluated by two readers independently for areas of FDG uptake compatible with malignancy, and then categorized into 5 groups (1: PET/MRI and PET/CT positive; 2: PET/MRI positive, PET/CT positive in retrospect; 3: PET/CT positive, PET/MRI positive in retrospect; 4: PET/MRI positive, PET/CT negative; 5: PET/MRI negative, PET/CT positive) by consensus. Patients with no lesions on either study or greater than 10 lesions based on either modality were excluded from the study. RESULTS: Fifty-two patients (mean±SD age: 58±14 years) underwent the dual imaging protocol; of these, 29 patients with a total of 93 FDG-avid lesions met the inclusion criteria. The majority of lesions (56%) were recorded prospectively in the same location on PET/CT and PET/MRI. About an equal small fraction of lesions were seen on PET/CT but only retrospectively on PET/MRI (9%) and vice versa (12%). More lesions were identified only on PET/MRI but not on PET/CT, even in retrospect (96% vs. 81%, respectively; p = 0.003). Discrepant lesions had lower maximum standardized uptake value (SUVmax) than concordant lesions on both modalities (p<0.001). CONCLUSIONS: While most lesions were identified prospectively on both modalities, significantly more lesions were identified with PET/MRI than with PET/CT.

    DOI: 10.1371/journal.pone.0167262

    Scopus

    PubMed

  91. Radionuclide imaging for diagnosis of cardiac amyloidosis

    Ryogo Minamimoto

    Journal of Nuclear Medicine     2017

     More details

    Publishing type:Research paper (scientific journal)  

    Web of Science

  92. Phase IIa clinical study of [<sup>18</sup>F]fluciclovine: efficacy and safety of a new PET tracer for brain tumors

    Kondo A., Ishii H., Aoki S., Suzuki M., Nagasawa H., Kubota K., Minamimoto R., Arakawa A., Tominaga M., Arai H.

    Annals of Nuclear Medicine   Vol. 30 ( 9 ) page: 608 - 618   2016.11

     More details

    Language:English   Publisher:Annals of Nuclear Medicine  

    Objective: [18F]Fluciclovine (anti-[18F]FACBC) has demonstrated diagnostic efficacy for cancers of the brain where [18F]fludeoxyglucose has limitations. We conducted a phase IIa study of anti-[18F]FACBC to assess its accumulation pattern and safety in patients with malignant glioma. Methods: Five patients with glioma scheduled for brain tumor resection received anti-[18F]FACBC. Brain positron emission tomography (PET) was performed following intravenous administration of anti-[18F]FACBC, and subsequently, preoperative gadolinium contrast-enhanced T1-weighted (CE-T1W) magnetic resonance imaging (MRI) was performed for surgery. Specimens for histopathological evaluation were collected during surgery, and their location was precisely determined on CE-T1W MRI and anti-[18F]FACBC PET/CT images. In addition, tumor extent defined on the MRI and PET/CT images was compared. To determine time–activity curves for anti-[18F]FACBC uptake in brain tumor and normal tissues, regions of interest were set in the brain tumor, contralateral normal tissue and the cerebellum, and their standardized uptake values (SUV) were calculated. The safety of anti-[18F]FACBC was assessed based on subjective symptoms and objective findings, electrocardiograms, vital signs, laboratory results, and the incidence of adverse events. Results: Anti-[18F]FACBC accumulated in the malignant gliomas of all patients. CE-T1W MRI detected gliomas in all patients, but anti-[18F]FACBC PET/CT generally delineated wider regions of tumor extent than CE-T1W MRI. Two of the histopathologically confirmed tumors were located in regions that were defined using anti-[18F]FACBC PET/CT, but not using CE-T1W MRI. Two patients experienced three mild adverse events: one complained of a dull headache and later a mild headache, and the other showed general malaise. These symptoms resolved spontaneously without treatment. Only the mild headache could not be ruled out from having a causal relationship with anti-[18F]FACBC. Favorable T/N ratios regarding anti-[18F]FACBC uptake between tumors and normal control tissues were demonstrated in this trial. Conclusions: It is suggested that anti-[18F]FACBC PET/CT has the ability to delineate glioma spread that is undetectable using CE-T1W MRI. Anti-[18F]FACBC is safe in patients with malignant glioma. This study was registered in the Japan Pharmaceutical Information Center Clinical Trials Information, which is one of the World Health Organization registries (registration number: JapicCTI-111387).

    DOI: 10.1007/s12149-016-1102-y

    Scopus

    PubMed

  93. Bombesin-Targeted PET of Prostate Cancer. International journal

    Rosalba Mansi, Ryogo Minamimoto, Helmut Mäcke, Andrei H Iagaru

    Journal of nuclear medicine : official publication, Society of Nuclear Medicine   Vol. 57 ( Suppl 3 ) page: 67S-72S - 72S   2016.10

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Imaging plays an important role in prostate cancer (PC), including accurate evaluation of the extent of disease, assessment of sites of recurrent disease, and monitoring of response to treatment. Molecular imaging techniques are among the novel developments related to the imaging of PC, and various SPECT and PET radiopharmaceuticals are now available in clinical trials or commercially. Here we describe the preclinical and clinical use of gastrin-releasing peptide receptors as targets for the imaging of PC, with a focus on the development of PET tracers for the imaging of gastrin-releasing peptide receptor-positive tumors.

    DOI: 10.2967/jnumed.115.170977

    Scopus

    PubMed

  94. Improvements in PET Image Quality in Time of Flight (TOF) Simultaneous PET/MRI. International journal

    Ryogo Minamimoto, Craig Levin, Mehran Jamali, Dawn Holley, Amir Barkhodari, Greg Zaharchuk, Andrei Iagaru

    Molecular imaging and biology   Vol. 18 ( 5 ) page: 776 - 81   2016.10

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    PURPOSE: An integrated positron emission tomography (PET)/magnetic resonance imaging (MRI) scanner with time of flight (TOF) technology is now available for clinical use. The aim of this study is to evaluate the potential of TOF PET in PET/MRI to reduce artifacts in PET images when compared to non-TOF PET/MRI, TOF PET/X-ray computed tomography (CT), and non-TOF PET/CT. PROCEDURES: All patients underwent a single 2-deoxy-2-[(18)F]fluoro-D-glucose ([(18)F]FDG) injection, followed first by PET/CT, and subsequently by PET/MRI. PET/CT exams were requested as standard-of-care for oncological indications. Using the PET acquisitions datasets, 4 series of images (TOF PET/CT, non-TOF PET/CT, TOF PET/MRI, and non-TOF PET/MRI) were reconstructed. These image series were visually evaluated for: (1) dental metal artifacts, (2) breathing artifacts, and (3) pelvic artifacts due to scatter correction errors from high bladder [(18)F]FDG concentration. PET image quality was assessed by a 3-point scale (1-clinically significant artifact, 2-non clinically significant artifact, and 3-no artifact). RESULTS: Twenty-five patients (mean ± SD age: 56 ± 13 years old; female: 10, male: 15) were enrolled. TOF PET/MRI, non-TOF PET/MRI, TOF PET/CT, and non-TOF PET/CT scores 2.8, 2.5, 2.4, and 2.3, respectively for the presence of dental artifacts, 2.8, 2.5, 2.2, and 1.9, respectively, for the presence of breathing artifacts, and 2.7, 1.7, 2.0, and 1.3, respectively, for the presence of pelvic artifacts TOF PET/MRI images showed the highest image quality scores among the 4 datasets of PET images. CONCLUSION: The superior timing resolution and resulting TOF capability of the new PET/MRI scanner improved PET image quality in this cohort by reducing artifacts compared to non-TOF PET/MRI, TOF PET/CT, and non-TOF PET/CT.

    DOI: 10.1007/s11307-016-0939-8

    Scopus

    PubMed

  95. Response to 'Commentary to "evaluation of a new motion correction algorithm in PET/CT: Combining the entire acquired PET data to create a single three-dimensional motion-corrected PET/CT image."'

    Minamimoto R.

    Nuclear Medicine Communications   Vol. 37 ( 8 ) page: 888   2016.8

     More details

    Language:English   Publisher:Nuclear Medicine Communications  

    DOI: 10.1097/MNM.0000000000000529

    Scopus

    PubMed

  96. Update on advances in molecular PET in urological oncology

    Kitajima K., Yamamoto S., Fukushima K., Minamimoto R., Kamai T., Jadvar H.

    Japanese Journal of Radiology   Vol. 34 ( 7 ) page: 470 - 485   2016.7

     More details

    Language:English   Publisher:Japanese Journal of Radiology  

    Integrated positron emission tomography/computed tomography (PET/CT) with 2-[18F]fluoro-2-deoxy-d-glucose (18F-FDG) has emerged as a powerful tool for the combined metabolic and anatomic evaluation of many cancers. In urological oncology, however, the use of 18F-FDG has been limited by a generally low tumor uptake, and physiological excretion of FDG through the urinary system. 18F-FDG PET/CT is useful when applied to specific indications in selected patients with urological malignancy. New radiotracers and positron emission tomography/magnetic resonance imaging (PET/MRI) are expected to further improve the performance of PET in uro-oncology.

    DOI: 10.1007/s11604-016-0553-3

    Scopus

    PubMed

  97. A Prospective, Matched Comparison Study of SUV Measurements From Time-of-Flight Versus Non-Time-of-Flight PET/CT Scanners. International journal

    Holly M Thompson, Ryogo Minamimoto, Mehran Jamali, Amir Barkhodari, Rie von Eyben, Andrei Iagaru

    Clinical nuclear medicine   Vol. 41 ( 7 ) page: e323-6 - e326   2016.7

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    PURPOSE: As quantitative F-FDG PET numbers and pooling of results from different PET/CT scanners become more influential in the management of patients, it becomes imperative that we fully interrogate differences between scanners to fully understand the degree of scanner bias on the statistical power of studies. PATIENTS AND METHODS: Participants with body mass index (BMI) greater than 25, scheduled on a time-of-flight (TOF)-capable PET/CT scanner, had a consecutive scan on a non-TOF-capable PET/CT scanner and vice versa. SUVmean in various tissues and SUVmax of malignant lesions were measured from both scans, matched to each subject. Data were analyzed using a mixed-effects model, and statistical significance was determined using equivalence testing, with P < 0.05 being significant. RESULTS: Equivalence was established in all baseline organs, except the cerebellum, matched per patient between scanner types. Mixed-effects method analysis of lesions, repeated between scan types and matched per patient, demonstrated good concordance between scanner types. CONCLUSIONS: Patients could be scanned on either a TOF or non-TOF-capable PET/CT scanner without clinical compromise to quantitative SUV measurements.

    DOI: 10.1097/RLU.0000000000001170

    Scopus

    PubMed

  98. Diffuse Large B-Cell Lymphoma: Prospective Multicenter Comparison of Early Interim FLT PET/CT versus FDG PET/CT with IHP, EORTC, Deauville, and PERCIST Criteria for Early Therapeutic Monitoring. International journal

    Ryogo Minamimoto, Luis Fayad, Ranjana Advani, Julie Vose, Homer Macapinlac, Jane Meza, Jordan Hankins, Felix Mottaghy, Malik Juweid, Andrew Quon

    Radiology   Vol. 280 ( 1 ) page: 220 - 9   2016.7

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Purpose To compare the performance characteristics of interim fluorine 18 ((18)F) fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) (after two cycles of chemotherapy) by using the most prominent standardized interpretive criteria (including International Harmonization Project [IHP] criteria, European Organization for Research and Treatment of Cancer [EORTC] criteria, and PET Response Criteria in Solid Tumors (PERCIST) versus those of interim (18)F fluorothymidine (FLT) PET/CT and simple visual interpretation. Materials and Methods This HIPAA-compliant prospective study was approved by the institutional review boards, and written informed consent was obtained. Patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL) underwent both FLT and FDG PET/CT 18-24 days after two cycles of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone or rituximab, etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin. For FDG PET/CT interpretation, IHP criteria, EORTC criteria, PERCIST, Deauville criteria, standardized uptake value, total lesion glycolysis, and metabolic tumor volume were used. FLT PET/CT images were interpreted with visual assessment by two reviewers in consensus. The interim (after cycle 2) FDG and FLT PET/CT studies were then compared with the end-of-treatment FDG PET/CT studies to determine which interim examination and/or criteria best predicted the result after six cycles of chemotherapy. Results From November 2011 to May 2014, there were 60 potential patients for inclusion, of whom 46 patients (24 men [mean age, 60.9 years ± 13.7; range, 28-78 years] and 22 women [mean age, 57.2 years ± 13.4; range, 25-76 years]) fulfilled the criteria. Thirty-four patients had complete response, and 12 had residual disease at the end of treatment. FLT PET/CT had a significantly higher positive predictive value (PPV) (91%) in predicting residual disease than did any FDG PET/CT interpretation method (42%-46%). No difference in negative predictive value (NPV) was found between FLT PET/CT (94%) and FDG PET/CT (82%-95%), regardless of the interpretive criteria used. FLT PET/CT showed statistically higher (P < .001-.008) or similar NPVs than did FDG PET/CT. Conclusion Early interim FLT PET/CT had a significantly higher PPV than standardized FDG PET/CT-based interpretation for therapeutic response assessment in DLBCL. (©) RSNA, 2016 Online supplemental material is available for this article.

    DOI: 10.1148/radiol.2015150689

    Scopus

    PubMed

  99. Pilot prospective evaluation of (18)F-FPPRGD2 PET/CT in patients with cervical and ovarian cancer. International journal

    Ryogo Minamimoto, Amer Karam, Mehran Jamali, Amir Barkhodari, Sanjiv Sam Gambhir, Oliver Dorigo, Andrei Iagaru

    European journal of nuclear medicine and molecular imaging   Vol. 43 ( 6 ) page: 1047 - 55   2016.6

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    PURPOSE: We report the effect of antiangiogenic therapy on the biodistribution of (18)F-FPPRGD2 (a surrogate biomarker of integrin αvβ3 expression), and the potential of (18)F-FPPRGD2 to predict the prognosis in patients with cervical cancer and ovarian cancer in this clinical scenario. METHODS: Data from six women, age range 30 - 59 years (mean ± SD 44.0 ± 12.5 years), who had undergone a (18)F-FPPRGD2 PET/CT scan and bevacizumab-containing therapy were prospectively collected and analyzed. We compared baseline (18)F-FPPRGD2 and (18)F-FDG uptake in the lesions and tumor-to-background (T/B) ratios. The maximum and mean (18)F-FPPRGD2 standardized uptake values (SUVmax and SUVmean) were recorded for 13 normal organs, as well as in all the identified malignant lesions on the pretreatment scan and the 1-week post-treatment scan. We also measured changes in (18)F-FPPRGD2 uptake from before to 1 week after treatment, and compared them to the changes in (18)F-FDG uptake from before to 6 weeks after treatment. Treatment outcomes were correlated with these changes. RESULTS: The uptake in lesions and T/B ratio of (18)F-FPPRGD2 were lower than those of (18)F-FDG (SUVmax 3.7 ± 1.3 vs. 6.0 ± 1.8, P < 0.001; SUVmean 2.6 ± 0.7 vs. 4.2 ± 1.3, P < 0.001; T/B ratio based on SUVmax 2.4 ± 1.0 vs. 2.6 ± 1.0, P < 0.04; T/B ratio based on SUVmean 1.9 ± 0.6 vs. 2.4 ± 1.0, P < 0.003). One patient did not return for the follow-up scan and in another patient no lesions were identified on the pretreatment scan. (18)F-FPPRGD2 uptake in lesions in the remaining four patients had significantly changed 1 week after treatment (SUVmean 3.3 ± 1.0 vs. 2.7 ± 1.0, P < 0.001), while uptake in all normal tissues analyzed was not affected by treatment. One patient with clinical disease progression had a decrease in lesional (18)F-FPPRGD2 SUVmean of 1.6 % and in (18)F-FDG SUVmean of 9.4 %. Two patients with a clinical complete response to treatment had decreases in lesional (18)F-FPPRGD2 SUVmean of 25.2 % and 25.0 % and in (18)F-FDG SUVmean of 6.1 % and 71.8 %. One patient with a clinical partial response had a decrease in lesional (18)F-FPPRGD2 SUVmean of 7.9 % and in (18)F-FDG SUVmean of 76.4 %. CONCLUSION: This pilot study showed that (18)F-FPPRGD2 and (18)F-FDG provide independent information about the biology of ovarian and cervical cancers. Bevacizumab-containing therapy does not affect (18)F-FPPRGD2 uptake in normal organs, but does result in statistically significant changes in lesions. In addition, (18)F-FPPRGD2 may have potential for early prediction of response to such treatments. These preliminary findings have to be confirmed in larger studies.

    DOI: 10.1007/s00259-015-3263-7

    Scopus

    PubMed

  100. [Traditional to latest imaging method for detection of bone metastasis].

    Ryogo Minamimoto, Kazuo Kubota

    Nihon rinsho. Japanese journal of clinical medicine   Vol. 74 Suppl 3   page: 330 - 4   2016.5

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

    PubMed

  101. Pilot Comparison of ⁶⁸Ga-RM2 PET and ⁶⁸Ga-PSMA-11 PET in Patients with Biochemically Recurrent Prostate Cancer. International journal

    Ryogo Minamimoto, Steven Hancock, Bernadette Schneider, Frederick T Chin, Mehran Jamali, Andreas Loening, Shreyas Vasanawala, Sanjiv Sam Gambhir, Andrei Iagaru

    Journal of nuclear medicine : official publication, Society of Nuclear Medicine   Vol. 57 ( 4 ) page: 557 - 62   2016.4

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    UNLABELLED: Glu-NH-CO-NH-Lys-(Ahx)-[(68)Ga(HBED-CC)] ((68)Ga-PSMA-11) is a PET tracer that can detect prostate cancer relapses and metastases by binding to the extracellular domain of PSMA. (68)Ga-labeled DOTA-4-amino-1-carboxymethyl-piperidine-D-Phe-Gln-Trp-Ala-Val-Gly-His-Sta-Leu-NH2 ((68)Ga-RM2) is a synthetic bombesin receptor antagonist that targets gastrin-releasing peptide receptors. We present pilot data on the biodistribution of these PET tracers in a small cohort of patients with biochemically recurrent prostate cancer. METHODS: Seven men (mean age ± SD, 74.3 ± 5.9 y) with biochemically recurrent prostate cancer underwent both (68)Ga-PSMA-11 PET/CT and (68)Ga-RM2 PET/MRI scans. SUVmax and SUVmean were recorded for normal tissues and areas of uptake outside the expected physiologic biodistribution. RESULTS: All patients had a rising level of prostate-specific antigen (mean ± SD, 13.5 ± 11.5) and noncontributory results on conventional imaging. (68)Ga-PSMA-11 had the highest physiologic uptake in the salivary glands and small bowel, with hepatobiliary and renal clearance noted, whereas (68)Ga-RM2 had the highest physiologic uptake in the pancreas, with renal clearance noted. Uptake outside the expected physiologic biodistribution did not significantly differ between (68)Ga-PSMA-11 and (68)Ga-RM2; however, (68)Ga-PSMA-11 localized in a lymph node and seminal vesicle in a patient with no abnormal (68)Ga-RM2 uptake. Abdominal periaortic lymph nodes were more easily visualized by(68)Ga-RM2 in two patients because of lack of interference by radioactivity in the small intestine. CONCLUSION: (68)Ga-PSMA-11 and (68)Ga-RM2 had distinct biodistributions in this small cohort of patients with biochemically recurrent prostate cancer. Additional work is needed to understand the expression of PSMA and gastrin-releasing peptide receptors in different types of prostate cancer.

    DOI: 10.2967/jnumed.115.168393

    Scopus

    PubMed

  102. Comparison of 11C-4DST and 18F-FDG PET/CT imaging for advanced renal cell carcinoma: preliminary study. International journal

    Ryogo Minamimoto, Noboru Nakaigawa, Yoji Nagashima, Jun Toyohara, Daiki Ueno, Kazuhiro Namura, Kazuhiko Nakajima, Masahiro Yao, Kazuo Kubota

    Abdominal radiology (New York)   Vol. 41 ( 3 ) page: 521 - 30   2016.3

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    PURPOSE: 4'-[Methyl-(11)C]-thiothymidine (4DST) has been developed as an in vivo cell proliferation marker based on its DNA incorporation mechanism. This study evaluated the potential of 4DST PET/CT for imaging cellular proliferation in advanced clear cell renal cell carcinoma (RCC), compared with FDG PET/CT. Both 4DST and FDG uptake were compared with biological findings based on surgical pathology. METHODS: Five patients (3 men and 2 women; mean (±SD) age 64.8 ± 11.0 years) with a single RCC (mean diameter: 9.3 ± 3.2 cm) were examined by PET/CT using 4DST and FDG. The dynamic emission scan of 4DST for RCC over 35 min followed by a static emission scan of the body for 4DST and FDG. Then we compared the maximum standardized uptake value (SUVmax) of 20 areas of RCC on both 4DST and FDG images with (1) the Ki-67 index of cellular proliferation (2) Fuhrman grade system for nuclear grade (G) in RCC and (3) pathological phosphorylated grade of mammalian target of rapamycin (pmTOR). RESULTS: All patient cases showed clear uptake of FDG and 4DST in RCC tumors, with mean 4DST SUVmax of 7.3 ± 2.2 (range 4.3-9.4) and mean FDG SUVmax of 6.0 ± 2.8 (range 3.4-10.4). The correlation coefficient between SUVmax and Ki-67 index was higher with 4DST (r = 0.61) than with FDG (r = 0.43). Tumor 4DST uptake (G0: 1.4, G2: 2.6, G2 5.6, G4: 5.7) and tumor FDG uptake (G0: 1.8, G2: 2.9, G2 3.7, G4: 4.1) were both related to Fuhrman grade system. The 4DST uptake increased as the pmTOR grade increases (G0: 3.1, G1: 4.8, G2: 4.7, G3: 6.2); in contrast FDG uptake was unrelated to pmTOR grade (G0: 2.8, G2: 4.0, G2 3.3, G4: 3.6). CONCLUSION: A higher correlation with the proliferation of RCC was observed for 4DST than for FDG. The 4DST uptake exhibits the possibility to predict pmTOR grade, indicating that 4DST has potential for the evaluation of therapeutic effect with mTOR inhibitor in patients with RCC.

    DOI: 10.1007/s00261-015-0601-y

    Scopus

    PubMed

  103. FDG PET/CT as a prognostic biomarker in the era of molecular-targeting therapies: max SUVmax predicts survival of patients with advanced renal cell carcinoma. International journal

    Noboru Nakaigawa, Keiichi Kondo, Ukihide Tateishi, Ryogo Minamimoto, Tomohiro Kaneta, Kazuhiro Namura, Daiki Ueno, Kazuki Kobayashi, Takeshi Kishida, Ichiro Ikeda, Hisashi Hasumi, Kazuhide Makiyama, Yoshinobu Kubota, Tomio Inoue, Masahiro Yao

    BMC cancer   Vol. 16   page: 67 - 67   2016.2

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND: Various molecular-targeting therapies have become available for the treatment of advanced renal cell carcinoma (RCC). Accurate prognostication is desirable for choosing the appropriate treatment for individual patients. (18)F-2-fluoro-2-deoxyglucose positron-emission tomography/computed tomography (FDG PET/CT) is a non-invasive tool for evaluating glucose accumulation, which can be an index of biological characteristics of cancer. We prospectively evaluated FDG PET/CT as a prognostic indicator in patients with advanced RCC. METHODS: A total of 101 patients slated for different systematic therapies for advanced RCC were enrolled between 2008 and 2014. A total of 61 patients had recurrent RCC (58 metastatic and 3 regional) and 40 patients had stage IV RCC (36 metastatic and 4 locoregional). Sixteen patients had not undergone nephrectomy. Pre-treatment FDG PET/CT was performed, and the max SUVmax (the highest SUV measurement in each patient) was recorded. The max SUVmax was compared with different clinical risk factors as prognostic indicators. The median observation period was 18 months (range 1-70 months). RESULTS: The max SUVmax of the 101 subjects ranged from undetectable to 23.0 (median 6.9). Patients with high max SUVmax had a poor prognosis. Multivariate analysis with standard risk factors revealed that max SUVmax was an independent predictor of survival (p < 0.001; hazard ratio 1.265; 95% confidence interval 1.159-1.380). A cutoff of 8.8 for max SUVmax advocated in our previous report was highly significant (p < 0.0001). When we subclassified the max SUVmax values, the median overall survival of subjects with max SUVmax < 7.0 was 41.9 months. That of subjects with max SUVmax between 7.0 and 12.0 was 20.6 months. That of subjects with max SUVmax ≥ 12.0 was 4.2 months. The differences were statistically significant. CONCLUSIONS: Pretreatment max SUVmax assessed by FDG PET/CT is a useful prognostic marker for patients with advanced RCC, providing helpful information for clinical decision making.

    DOI: 10.1186/s12885-016-2097-4

    Scopus

    PubMed

  104. Evaluation of a new motion correction algorithm in PET/CT: combining the entire acquired PET data to create a single three-dimensional motion-corrected PET/CT image. International journal

    Ryogo Minamimoto, Takuya Mitsumoto, Yoko Miyata, Fumio Sunaoka, Miyako Morooka, Momoko Okasaki, Andrei Iagaru, Kazuo Kubota

    Nuclear medicine communications   Vol. 37 ( 2 ) page: 162 - 70   2016.2

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    PURPOSE: This study evaluated the potential of Q.Freeze algorithm for reducing motion artifacts, in comparison with ungated imaging (UG) and respiratory-gated imaging (RG). PATIENTS AND METHODS: Twenty-nine patients with 53 lesions who had undergone RG F-FDG PET/CT were included in this study. Using PET list mode data, five series of PET images [UG, RG, and QF images with an acquisition duration of 3 min (QF3), 5 min (QF5), and 10 min (QF10)] were reconstructed retrospectively. The image quality was evaluated first. Next, quantitative metrics [maximum standardized uptake value (SUVmax), mean standardized uptake value (SUVmean), SD, metabolic tumor volume, signal to noise ratio, or lesion to background ratio] were calculated for the liver, background, and each lesion, and the results were compared across the series. RESULTS: QF10 and QF5 showed better image quality compared with all other images. SUVmax in the liver, background, and lesions was lower with QF10 and QF5 than with the others, but there were no statistically significant differences in SUVmean and the lesion to background ratios. The SD with UG and RG was significantly higher than that with QF5 and QF10. The metabolic tumor volume in QF3 and QF5 was significantly lower than that in UG. CONCLUSION: The Q.Freeze algorithm can improve the quality of PET imaging compared with RG and UG.

    DOI: 10.1097/MNM.0000000000000423

    Scopus

    PubMed

  105. Imaging of tumor-associated system xC-activity with 18F-fluoropropylglutamate (18F-FSPG) PET/CT for intracranial malignancies

    Ryogo Minamimoto

    Journal of Nuclear Medicine     2016

     More details

    Publishing type:Research paper (scientific journal)  

    Web of Science

  106. Fingerprints of mild HIV-associated neurocognitive disorders (HAND): FDG and VBM study

    Ryogo Minamimoto

    Journal of Nuclear Medicine     2016

     More details

    Publishing type:Research paper (scientific journal)  

    Web of Science

  107. Ga-68-DOTA-Bombesin (Ga-68-RM2 or Ga-68-Bombesin) PET versus Ga-68-PSMA PET: A pilot prospective evaluation in patients with biochemical recurrence of prostate cancer

    Ryogo Minamimoto

    Journal of Clinical Oncology     2016

     More details

    Publishing type:Research paper (scientific journal)  

    DOI: 10.1200/JCO.2016.34.2_SUPPL.331

    Web of Science

  108. Ga68 RM2 PET/MRI Evaluation of Gastrin-Releasing Peptide Receptor Status in Patients with Biochemically Recurrent Prostate Cancer and Negative Conventional Imaging

    Ryogo Minamimoto

    European Journal of Nuclear Medicine and Molecular Imaging     2016

     More details

    Publishing type:Research paper (scientific journal)  

    Web of Science

  109. Imaging of tumor-associated system xc- activity with 18F-fluoropropylglutamate (FSPG) PET/CT for intracranial malignancies

    Ryogo Minamimoto

    European Journal of Nuclear Medicine and Molecular Imaging     2016

     More details

    Publishing type:Research paper (scientific journal)  

    Web of Science

  110. Biochemically recurrent prostate cancer: 68Ga-RM2 (formerly known as 68Ga-Bombesin or BAY86-7548) PET/MRI is superior to conventional imaging

    Ryogo Minamimoto

    Journal of Nuclear Medicine     2016

     More details

    Publishing type:Research paper (scientific journal)  

    Web of Science

  111. Prognostic role of baseline 18F-FDG PET/CT in DLBCL patients

    Ryogo Minamimoto

    Journal of Nuclear Medicine     2016

     More details

    Publishing type:Research paper (scientific journal)  

    Web of Science

  112. Relative myocardial flow reserve (MFR) in N-13 ammonia PET may be useful to estimate fractional flow reserve (FFR)

    Ryogo Minamimoto

    European Heart Journal     2016

     More details

    Publishing type:Research paper (scientific journal)  

    Web of Science

  113. Prospective Comparison of 11C-4DST, 18F-FDG PET/CT and whole-body MRI in the patients with multiple myeloma

    Ryogo Minamimoto

    Journal of Nuclear Medicine     2016

     More details

    Publishing type:Research paper (scientific journal)  

    Web of Science

  114. Prognostic Value of Quantitative Metabolic Metrics on Baseline Pre-Sunitinib FDG PET/CT in Advanced Renal Cell Carcinoma. International journal

    Ryogo Minamimoto, Amir Barkhodari, Lauren Harshman, Sandy Srinivas, Andrew Quon

    PloS one   Vol. 11 ( 4 ) page: e0153321   2016

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    PURPOSE: The objective of this study was to prospectively evaluate various quantitative metrics on FDG PET/CT for monitoring sunitinib therapy and predicting prognosis in patients with metastatic renal cell cancer (mRCC). METHODS: Seventeen patients (mean age: 59.0 ± 11.6) prospectively underwent a baseline FDG PET/CT and interim PET/CT after 2 cycles (12 weeks) of sunitinib therapy. We measured the highest maximum standardized uptake value (SUVmax) of all identified lesions (highest SUVmax), sum of SUVmax with maximum six lesions (sum of SUVmax), total lesion glycolysis (TLG) and metabolic tumor volume (MTV) from baseline PET/CT and interim PET/CT, and the % decrease in highest SUVmax of lesion (%Δ highest SUVmax), the % decrease in sum of SUVmax, the % decrease in TLG (%ΔTLG) and the % decrease in MTV (%ΔMTV) between baseline and interim PET/CT, and the imaging results were validated by clinical follow-up at 12 months after completion of therapy for progression free survival (PFS). RESULTS: At 12 month follow-up, 6/17 (35.3%) patients achieved PFS, while 11/17 (64.7%) patients were deemed to have progression of disease or recurrence within the previous 12 months. At baseline, PET/CT demonstrated metabolically active cancer in all cases. Using baseline PET/CT alone, all of the quantitative imaging metrics were predictive of PFS. Using interim PET/CT, the %Δ highest SUVmax, %Δ sum of SUVmax, and %ΔTLG were also predictive of PFS. Otherwise, interim PET/CT showed no significant difference between the two survival groups regardless of the quantitative metric utilized including MTV and TLG. CONCLUSIONS: Quantitative metabolic measurements on baseline PET/CT appears to be predictive of PFS at 12 months post-therapy in patients scheduled to undergo sunitinib therapy for mRCC. Change between baseline and interim PET/CT also appeared to have prognostic value but otherwise interim PET/CT after 12 weeks of sunitinib did not appear to be predictive of PFS.

    DOI: 10.1371/journal.pone.0153321

    Scopus

    PubMed

  115. Prognostic value of LUGANO, EORTC, PERCIST and IHP criteria in patients with diffuse large B cell lymphoma based on 18F-FDG PET/CT

    Ryogo Minamimoto

    Journal of Nuclear Medicine     2016

     More details

    Publishing type:Research paper (scientific journal)  

    Web of Science

  116. The Bone Marrow Findings of FDG-PET/CT in Children with Acute Leukemia: Retrospective and Single Institute Experience

    Ryogo Minamimoto

    Pediatric Blood and Cancer     2016

     More details

    Publishing type:Research paper (scientific journal)  

    Web of Science

  117. The role of interim 18F-FDG PET/CT in DLBCL patients: SUV max, SUV mean and SUV peak as predictive metabolic parameters of prognosis

    Ryogo Minamimoto

    Journal of Nuclear Medicine     2016

     More details

    Publishing type:Research paper (scientific journal)  

    Web of Science

  118. Imaging patients with breast and prostate cancers using combined 18F NaF/18F FDG and TOF simultaneous PET/ MRI. International journal

    Andrei Iagaru, Ryogo Minamimoto, Mehran Jamali, Amir Barkodhodari, Sanjiv Sam Gambhir, Shreyas Vasanawala

    EJNMMI physics   Vol. 2 ( Suppl 1 ) page: A65   2015.12

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1186/2197-7364-2-S1-A65

    PubMed

  119. Prospective Comparison of 99mTc-MDP Scintigraphy, Combined 18F-NaF and 18F-FDG PET/CT, and Whole-Body MRI in Patients with Breast and Prostate Cancer. International journal

    Ryogo Minamimoto, Andreas Loening, Mehran Jamali, Amir Barkhodari, Camila Mosci, Tatianie Jackson, Piotr Obara, Valentina Taviani, Sanjiv Sam Gambhir, Shreyas Vasanawala, Andrei Iagaru

    Journal of nuclear medicine : official publication, Society of Nuclear Medicine   Vol. 56 ( 12 ) page: 1862 - 8   2015.12

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    UNLABELLED: We prospectively evaluated the use of combined (18)F-NaF/(18)F-FDG PET/CT in patients with breast and prostate cancer and compared the results with those for (99m)Tc-MDP bone scintigraphy and whole-body MRI. METHODS: Thirty patients (15 women with breast cancer and 15 men with prostate cancer) referred for standard-of-care bone scintigraphy were prospectively enrolled in this study. (18)F-NaF/(18)F-FDG PET/CT and whole-body MRI were performed after bone scintigraphy. The whole-body MRI protocol consisted of both unenhanced and contrast-enhanced sequences. Lesions detected with each test were tabulated, and the results were compared. RESULTS: For extraskeletal lesions, (18)F-NaF/(18)F-FDG PET/CT and whole-body MRI had no statistically significant differences in sensitivity (92.9% vs. 92.9%, P = 1.00), positive predictive value (81.3% vs. 86.7%, P = 0.68), or accuracy (76.5% vs. 82.4%, P = 0.56). However, (18)F-NaF/(18)F-FDG PET/CT showed significantly higher sensitivity and accuracy than whole-body MRI (96.2% vs. 81.4%, P < 0.001, 89.8% vs. 74.7%, P = 0.01) and bone scintigraphy (96.2% vs. 64.6%, P < 0.001, 89.8% vs. 65.9%, P < 0.001) for the detection of skeletal lesions. Overall, (18)F-NaF/(18)F-FDG PET/CT showed higher sensitivity and accuracy than whole-body MRI (95.7% vs. 83.3%, P < 0.002, 87.6% vs. 76.0%, P < 0.02) but not statistically significantly so when compared with a combination of whole-body MRI and bone scintigraphy (95.7% vs. 91.6%, P = 0.17, 87.6% vs. 83.0%, P = 0.53). (18)F-NaF/(18)F-FDG PET/CT showed no significant difference from a combination of (18)F-NaF/(18)F-FDG PET/CT and whole-body MRI. No statistically significant differences in positive predictive value were noted among the 3 examinations. CONCLUSION: (18)F-NaF/(18)F-FDG PET/CT is superior to whole-body MRI and (99m)Tc-MDP scintigraphy for evaluation of skeletal disease extent. Further, (18)F-NaF/(18)F-FDG PET/CT and whole-body MRI detected extraskeletal disease that may change the management of these patients. (18)F-NaF/(18)F-FDG PET/CT provides diagnostic ability similar to that of a combination of whole-body MRI and bone scintigraphy in patients with breast and prostate cancer. Larger cohorts are needed to confirm these preliminary findings, ideally using the newly introduced simultaneous PET/MRI scanners.

    DOI: 10.2967/jnumed.115.162610

    Scopus

    PubMed

  120. The potential of TOF PET-MRI for reducing artifacts in PET images. International journal

    Andrei Iagaru, Ryogo Minamimoto, Craig Levin, Amid Barkhodari, Mehran Jamali, Dawn Holley, Zaharchuk Greg

    EJNMMI physics   Vol. 2 ( Suppl 1 ) page: A77   2015.12

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1186/2197-7364-2-S1-A77

    PubMed

  121. Whole-body simultaneous time-of-flight PET-MRI: early experience with clinical studies. International journal

    Ryogo Minamimoto, Andrei Iagaru, Mehran Jamali, Amir Barkodhodari, Dawn Holley, Shreyas Vasanawala, Greg Zaharchuk

    EJNMMI physics   Vol. 2 ( Suppl 1 ) page: A64   2015.12

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1186/2197-7364-2-S1-A64

    PubMed

  122. Biodistribution of the ¹⁸F-FPPRGD₂ PET radiopharmaceutical in cancer patients: an atlas of SUV measurements. International journal

    Ryogo Minamimoto, Mehran Jamali, Amir Barkhodari, Camila Mosci, Erik Mittra, Bin Shen, Frederick Chin, Sanjiv Sam Gambhir, Andrei Iagaru

    European journal of nuclear medicine and molecular imaging   Vol. 42 ( 12 ) page: 1850 - 8   2015.11

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    PURPOSE: The aim of this study was to investigate the biodistribution of 2-fluoropropionyl-labeled PEGylated dimeric arginine-glycine-aspartic acid (RGD) peptide (PEG3-E[c{RGDyk}]2) ((18)F-FPPRGD2) in cancer patients and to compare its uptake in malignant lesions with (18)F-FDG uptake. METHODS: A total of 35 patients (11 men, 24 women, mean age 52.1 ± 10.8 years) were enrolled prospectively and had (18)F-FPPRGD2 PET/CT prior to treatment. Maximum standardized uptake values (SUVmax) and mean SUV (SUVmean) were measured in 23 normal tissues in each patient, as well as in known or suspected cancer lesions. Differences between (18)F-FPPRGD2 uptake and (18)F-FDG uptake were also evaluated in 28 of the 35 patients. RESULTS: Areas of high (18)F-FPPRGD2 accumulation (SUVmax range 8.9 - 94.4, SUVmean range 7.1 - 64.4) included the bladder and kidneys. Moderate uptake (SUVmax range 2.1 - 6.3, SUVmean range 1.1 - 4.5) was found in the choroid plexus, salivary glands, thyroid, liver, spleen, pancreas, small bowel and skeleton. Compared with (18)F-FDG, (18)F-FPPRGD2 showed higher tumor-to-background ratio in brain lesions (13.4 ± 8.5 vs. 1.1 ± 0.5, P < 0.001), but no significant difference in body lesions (3.2 ± 1.9 vs. 4.4 ± 4.2, P = 0.10). There was no significant correlation between the uptake values (SUVmax and SUVmean) for (18)F FPPRGD2 and those for (18)F-FDG. CONCLUSION: The biodistribution of (18)F-FPPRGD2 in cancer patients is similar to that of other RGD dimer peptides and it is suitable for clinical use. The lack of significant correlation between (18)F-FPPRGD2 and (18)F-FDG uptake confirms that the information provided by each PET tracer is different.

    DOI: 10.1007/s00259-015-3096-4

    Scopus

    PubMed

  123. Semiquantitative Analysis of the Biodistribution of the Combined ¹⁸F-NaF and ¹⁸F-FDG Administration for PET/CT Imaging. International journal

    Ryogo Minamimoto, Camila Mosci, Mehran Jamali, Amir Barkhodari, Frezghi Habte, Tatianie Jackson, Erik Mittra, Sanjiv Sam Gambhir, Andrei Iagaru

    Journal of nuclear medicine : official publication, Society of Nuclear Medicine   Vol. 56 ( 5 ) page: 688 - 94   2015.5

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    UNLABELLED: In this study, we evaluated the biodistribution of the (18)F(-)/(18)F-FDG administration, compared with separate (18)F-NaF and (18)F-FDG administrations. We also estimated the interaction of (18)F-NaF and (18)F-FDG in the (18)F(-)/(18)F-FDG administration by semiquantitative analysis. METHODS: We retrospectively analyzed the data of 49 patients (39 men, 10 women; mean age ± SD, 59.3 ± 15.2 y) who underwent separate (18)F-FDG PET/CT and (18)F-NaF PET/CT scans as well as (18)F(-)/(18)F-FDG PET/CT sequentially. The most common primary diagnosis was prostate cancer (n = 28), followed by sarcoma (n = 9) and breast cancer (n = 6). The mean standardized uptake values (SUVs) were recorded for 18 organs in all patients, and maximum SUV and mean SUV were recorded for all the identified malignant lesions. We also estimated the (18)F(-)/(18)F-FDG uptake as the sum of (18)F-FDG uptake and adjusted (18)F-NaF uptake based on the ratio of (18)F-NaF injected dose in (18)F(-)/(18)F-FDG PET/CT. Lastly, we compared the results to explore the interaction of (18)F-FDG and (18)F-NaF uptake in the (18)F(-)/(18)F-FDG scan. RESULTS: The (18)F(-)/(18)F-FDG uptake in the cerebral cortex, cerebellum, parotid grand, myocardium, and bowel mostly reflected the (18)F-FDG uptake, whereas the uptake in the other analyzed structures was influenced by both the (18)F-FDG and the (18)F-NaF uptake. The (18)F(-)/(18)F-FDG uptake in extraskeletal lesions showed no significant difference when compared with the uptake from the separate (18)F-FDG scan. The (18)F(-)/(18)F-FDG uptake in skeletal lesions reflected mostly the (18)F-NaF uptake. The tumor-to-background ratio of (18)F(-)/(18)F-FDG in extraskeletal lesions showed no significant difference when compared with that from (18)F-FDG alone (P = 0.73). For skeletal lesions, the tumor-to-background ratio of (18)F(-)/(18)F-FDG was lower than that from (18)F-NaF alone (P < 0.001); however, this difference did not result in missed skeletal lesions on the (18)F(-)/(18)F-FDG scan. CONCLUSION: The understanding of the biodistribution of radiopharmaceuticals and the lesion uptake of the (18)F(-)/(18)F-FDG scan as well as the variations compared with the uptake on the separate (18)F-FDG PET/CT and (18)F-NaF PET/CT are valuable for more in-depth evaluation of the combined scanning technique.

    DOI: 10.2967/jnumed.115.153767

    Scopus

    PubMed

  124. Comparison of (11)C-4'-thiothymidine, (11)C-methionine, and (18)F-FDG PET/CT for the detection of active lesions of multiple myeloma.

    Momoko Okasaki, Kazuo Kubota, Ryogo Minamimoto, Yoko Miyata, Miyako Morooka, Kimiteru Ito, Kiichi Ishiwata, Jun Toyohara, Tomio Inoue, Risen Hirai, Shotaro Hagiwara, Akiyoshi Miwa

    Annals of nuclear medicine   Vol. 29 ( 3 ) page: 224 - 32   2015.4

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    PURPOSE: The aims of this study were to evaluate the possibility of using (11)C-methionine ((11)C-MET) and (11)C-4'-thiothymidine ((11)C-4DST) whole-body PET/CT for the imaging of amino acid metabolism and DNA synthesis, respectively, when searching for bone marrow involvement in patients with multiple myeloma (MM) and to compare these findings with those for (18)F-FDG PET/CT and aspiration cytology. METHODS: A total of 64 patients with MM, solitary plasmacytoma, monoclonal gammopathy of undetermined significance, or an unspecified diagnosis were prospectively enrolled. All the patients underwent three whole-body PET/CT examinations within a period of 1 week. First, the tracer accumulation was visually evaluated as positive, equivocal, or negative for 55 focal lytic lesions visualized using CT in 24 patients. Second, the percentages of marrow plasma cells as calculated using a bone marrow aspiration smear and tracer accumulation were evaluated in the posterior iliac crests of 36 patients. RESULTS: Among the 55 lytic lesions, the (11)C-MET and (11)C-4DST findings tended to reveal more positive findings than the (18)F-FDG findings. Based on the standard criteria for the diagnosis of active myeloma using the percentage of marrow plasma cells, significant differences were found between the (18)F-FDG and (11)C-MET findings and between the (18)F-FDG and (11)C-4DST findings, but no significant difference was observed between the (11)C-MET and (11)C-4DST findings. CONCLUSION: The addition of (11)C-MET and (11)C-4DST to (18)F-FDG when performing PET/CT enabled clearer evaluations of equivocal lesions. Based on cytological diagnostic criteria, (11)C-MET and (11)C-4DST were more sensitive than (18)F-FDG for the detection of active lesions. (11)C-MET and (11)C-4DST were more useful than (18)F-FDG for the detection of active lesions, especially during the early stage of disease.

    DOI: 10.1007/s12149-014-0931-9

    Scopus

    PubMed

  125. Detection of breast cancer in an FDG-PET cancer screening program: results of a nationwide Japanese survey. International journal

    Ryogo Minamimoto, Michio Senda, Seishi Jinnouchi, Takashi Terauchi, Tsuyoshi Yoshida, Tomio Inoue

    Clinical breast cancer   Vol. 15 ( 2 ) page: e139-46 - e146   2015.4

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND: The [18F]-fluorodeoxyglucose positron emission tomography (FDG-PET) cancer screening program is defined as cancer screening for asymptomatic subjects using FDG-PET/computed tomography with or without combination of other screening tests. The aim of this study was to analyze the detection rate and effectiveness of the FDG-PET cancer screening program for breast cancer between 2006 and 2009 in Japan. PATIENTS AND METHODS: A total of 62,054 asymptomatic female subjects underwent FDG-PET cancer screening. We analyzed 473 cases with findings of possible breast cancer in any screening tests. RESULTS: Among 473 possible cases, 161 were verified as breast cancer. The relative sensitivity and positive predictive value (PPV) of FDG-PET for breast cancer were 83.9% and 41.7%, respectively. The relative sensitivity and PPV of mammography (MMG) for breast cancer was less than for FDG-PET; results for breast ultrasonography (US) were close to FDG-PET. The combination of FDG-PET with MMG and US might contribute to increased sensitivity but does not improve PPV. Most breast cancer cases (83.0%) detected using the FDG-PET cancer screening program were stage 0 or I based on the Union for International Cancer Control criteria. CONCLUSION: The FDG-PET screening program in Japan detected breast cancer at an early stage. A combination of FDG-PET and MMG and/or breast US yields the best results for detecting breast cancer. The FDG-PET cancer-screening program alone cannot detect all breast cancers.

    DOI: 10.1016/j.clbc.2014.09.008

    Scopus

    PubMed

  126. 18F-sodium fluoride PET/CT in oncology: an atlas of SUVs. International journal

    Nathanael Sabbah, Tatianie Jackson, Camila Mosci, Mehran Jamali, Ryogo Minamimoto, Andrew Quon, Erik S Mittra, Andrei Iagaru

    Clinical nuclear medicine   Vol. 40 ( 4 ) page: e228-31 - e231   2015.4

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    PURPOSE: The purpose of this study was to analyze the distribution of 18F Sodium Fluoride (18F-NaF) uptake in the normal skeleton, benign and malignant bone lesions, and extraskeletal tissues, using semiquantitative SUV measurements. PATIENTS AND METHODS: We retrospectively analyzed data from 129 patients who had 18F-NaF PET/CT at our institution for an oncological diagnosis between 2007 and 2014. There were 99 men and 30 women, 19 to 90 years old (mean [SD], 61.5 [15.5]). The range, average, and SD of SUV were measured for normal bone and extraskeletal tissues uptake for the entire patient population. A separate statistical analysis was performed to compare group A, which corresponds to the population of patient with no 18F-NaF-avid metastatic lesions, and group B, which corresponds to the population of patient with 18F-NaF-avid metastatic lesions. We also measured SUV max and SUV mean for bony metastases and degenerative changes RESULTS: The PET/CT images were acquired at 30 to 169 minutes (mean [SD], 76.5 [22.8]) after injection of 3.9 to 13.6 mCi (mean [SD], 7.3 [2.4]) of 18F-NaF. The range and mean (SD) of SUV max for 18F-NaF-avid metastasis were 4.5 to 103.3 and 25.9 (16.6) and for 18F-NaF-avid degenerative changes were 3.3 to 52.1 and 16.5 (7.9), respectively. CONCLUSIONS: Various skeletal sites have different normal SUVs. Skeletal metastases have different SUVs when compared with benign findings such as degenerative changes.

    DOI: 10.1097/RLU.0000000000000633

    Scopus

    PubMed

  127. Volumetric comparison of positron emission tomography/computed tomography using 4′-[methyl-11C]-thiothymidine with 2-deoxy-2-18F-fluoro-D-glucose in patients with advanced head and neck squamous cell carcinoma

    Ito K., Yokoyama J., Miyata Y., Toyohara J., Okasaki M., Minamimoto R., Morooka M., Ishiwata K., Kubota K.

    Nuclear Medicine Communications   Vol. 36 ( 3 ) page: 219 - 225   2015.3

     More details

    Language:English   Publisher:Nuclear Medicine Communications  

    OBJECTIVE: We prospectively compared the diagnostic value of PET/computed tomography (CT) findings using the tracers 4′-[methyl-C]-thiothymidine (C-4DST) and 2-deoxy-2-F-fluoro-D-glucose (F-FDG) in patients with head and neck squamous cell carcinoma (HNSCC). PATIENTS AND METHODS: Thirty-eight patients with advanced HNSCC underwent C-4DST PET/CT and F-FDG PET/CT before treatment. Maximum standardized uptake values (SUVmax) were measured for both PET/CT studies; in addition, total lesion glycolysis (TLG) of F-FDG PET/CT and total lesion proliferation (TLP) of C-4DST PET/CT were measured. Absolute TLG and TLP values as well as values with various SUV thresholds were measured. All patients were followed up for 13.5±7.5 months (mean±SD) to monitor recurrence. RESULTS: A statistically significant correlation was observed between the primary tumor SUVmax for C-4DST PET/CT and F-FDG PET/CT (r=0.46, P<0.01). TLP values with SUV thresholds strongly correlated with TLG values relative to the same thresholds (r=0.60-0.92, P<0.001). Nine of the 38 patients with post-treatment recurrence were identified. Receiver operating characteristic curves for TLG3.0 and TLP2.5 showed the highest prognostic ability for recurrence; the sensitivity and specificity of TLG3.0 were 89 and 72%, respectively, and the sensitivity and specificity of TLP2.5 were 89 and 55%, respectively. CONCLUSION: In patients with advanced HNSCC, the TLP of C-4DST PET/CT strongly correlated with the TLG of F-FDG PET/CT. Although there were no large differences between these values, the receiver operating characteristic curves of the absolute TLG had slightly better prognostic ability for recurrence..

    DOI: 10.1097/MNM.0000000000000241

    Scopus

    PubMed

  128. Simultaneous whole-body time-of-flight 18F-FDG PET/MRI: a pilot study comparing SUVmax with PET/CT and assessment of MR image quality. International journal

    Andrei Iagaru, Erik Mittra, Ryogo Minamimoto, Mehran Jamali, Craig Levin, Andrew Quon, Garry Gold, Robert Herfkens, Shreyas Vasanawala, Sanjiv Sam Gambhir, Greg Zaharchuk

    Clinical nuclear medicine   Vol. 40 ( 1 ) page: 1 - 8   2015.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    PURPOSE: The recent introduction of hybrid PET/MRI scanners in clinical practice has shown promising initial results for several clinical scenarios. However, the first generation of combined PET/MRI lacks time-of-flight (TOF) technology. Here we report the results of the first patients to be scanned on a completely novel fully integrated PET/MRI scanner with TOF. MATERIALS AND METHODS: We analyzed data from patients who underwent a clinically indicated F FDG PET/CT, followed by PET/MRI. Maximum standardized uptake values (SUVmax) were measured from F FDG PET/MRI and F FDG PET/CT for lesions, cerebellum, salivary glands, lungs, aortic arch, liver, spleen, skeletal muscle, and fat. Two experienced radiologists independently reviewed the MR data for image quality. RESULTS: Thirty-six patients (19 men, 17 women, mean [±standard deviation] age of 61 ± 14 years [range: 27-86 years]) with a total of 69 discrete lesions met the inclusion criteria. PET/CT images were acquired at a mean (±standard deviation) of 74 ± 14 minutes (range: 49-100 minutes) after injection of 10 ± 1 mCi (range: 8-12 mCi) of F FDG. PET/MRI scans started at 161 ± 29 minutes (range: 117 - 286 minutes) after the F FDG injection. All lesions identified on PET from PET/CT were also seen on PET from PET/MRI. The mean SUVmax values were higher from PET/MRI than PET/CT for all lesions. No degradation of MR image quality was observed. CONCLUSION: The data obtained so far using this investigational PET/MR system have shown that the TOF PET system is capable of excellent performance during simultaneous PET/MR with routine pulse sequences. MR imaging was not compromised. Comparison of the PET images from PET/CT and PET/MRI show no loss of image quality for the latter. These results support further investigation of this novel fully integrated TOF PET/MRI instrument.

    DOI: 10.1097/RLU.0000000000000611

    Scopus

    PubMed

  129. FDGPET/CT for Pseudomyxoma Peritonei (PMP) and other peritoneal malignancies: Diagnostic features and prognostic consideration

    Ryogo Minamimoto

    European Journal of Nuclear Medicine and Molecular Imaging     2015

     More details

    Publishing type:Research paper (scientific journal)  

    Web of Science

  130. Ga-68-DOTATATE uptake in patients with neuroendocrine tumors

    Ryogo Minamimoto

    Journal of Nuclear Medicine     2015

     More details

    Publishing type:Research paper (scientific journal)  

    Web of Science

  131. Imaging of tumor-associated system x(C)(-) activity with 18F-fluoropropylglutamate (FSPG) PET/CT for intracranial malignancies

    Ryogo Minamimoto

    Journal of Nuclear Medicine     2015

     More details

    Publishing type:Research paper (scientific journal)  

    Web of Science

  132. Differentiation of Brain Tumor Recurrence from Post-Radiotherapy Necrosis with 11C-Methionine PET: Visual Assessment versus Quantitative Assessment. International journal

    Ryogo Minamimoto, Toshiyuki Saginoya, Chisato Kondo, Noriaki Tomura, Kimiteru Ito, Yuka Matsuo, Shigeo Matsunaga, Takashi Shuto, Atsuya Akabane, Yoko Miyata, Shuji Sakai, Kazuo Kubota

    PloS one   Vol. 10 ( 7 ) page: e0132515   2015

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    PURPOSE: The aim of this multi-center study was to assess the diagnostic capability of visual assessment in L-methyl-11C-methionine positron emission tomography (MET-PET) for differentiating a recurrent brain tumor from radiation-induced necrosis after radiotherapy, and to compare it to the accuracy of quantitative analysis. METHODS: A total of 73 brain lesions (glioma: 31, brain metastasis: 42) in 70 patients who underwent MET-PET were included in this study. Visual analysis was performed by comparison of MET uptake in the brain lesion with MET uptake in one of four regions (around the lesion, contralateral frontal lobe, contralateral area, and contralateral cerebellar cortex). The concordance rate and logistic regression analysis were used to evaluate the diagnostic ability of visual assessment. Receiver-operating characteristic curve analysis was used to compare visual assessment with quantitative assessment based on the lesion-to-normal (L/N) ratio of MET uptake. RESULTS: Interobserver and intraobserver κ-values were highest at 0.657 and 0.714, respectively, when assessing MET uptake in the lesion compared to that in the contralateral cerebellar cortex. Logistic regression analysis showed that assessing MET uptake in the contralateral cerebellar cortex with brain metastasis was significantly related to the final result. The highest area under the receiver-operating characteristic curve (AUC) with visual assessment for brain metastasis was 0.85, showing no statistically significant difference with L/Nmax of the contralateral brain (AUC = 0.89) or with L/Nmean of the contralateral cerebellar cortex (AUC = 0.89), which were the areas that were the highest in the quantitative assessment. For evaluation of gliomas, no specific candidate was confirmed among the four areas used in visual assessment, and no significant difference was seen between visual assessment and quantitative assessment. CONCLUSION: The visual assessment showed no significant difference from quantitative assessment of MET-PET with a relevant cut-off value for the differentiation of recurrent brain tumors from radiation-induced necrosis.

    DOI: 10.1371/journal.pone.0132515

    Scopus

    PubMed

  133. Combined 18F NaF/18F FDG and TOF simultaneous PET/MRI: One-Stop Shop Staging of Patients with Breast and Prostate Cancers

    Ryogo Minamimoto

    European Journal of Nuclear Medicine and Molecular Imaging     2015

     More details

    Publishing type:Research paper (scientific journal)  

    Web of Science

  134. Comparison of 4DST and FDG PET/CT imaging for advanced clear cell renal cell carcinoma

    Ryogo Minamimoto

    Journal of Nuclear Medicine     2015

     More details

    Publishing type:Research paper (scientific journal)  

    Web of Science

  135. Evaluation of FDG PET/CT measurement parameters for prediction of the prognosis after Sunitinib Therapy in Renal Cell Carcinoma

    Ryogo Minamimoto

    Journal of Nuclear Medicine     2015

     More details

    Publishing type:Research paper (scientific journal)  

    Web of Science

  136. Semi-quantitative assessment of 18F FDG uptake in the normal skeleton using simultaneous PET/MRI: initial comparison to PET/CT in 50 patients

    Ryogo Minamimoto

    European Journal of Nuclear Medicine and Molecular Imaging     2015

     More details

    Publishing type:Research paper (scientific journal)  

    Web of Science

  137. Prospective multicenter comparison of early interim F-18-FLT PET/CT versus F-18-FDG PET/CT

    Ryogo Minamimoto

    Journal of Nuclear Medicine     2015

     More details

    Publishing type:Research paper (scientific journal)  

    Web of Science

  138. Prospective evaluation of Tc-99m MDP scintigraphy, F-18 NaF/F-18 FDG PET/CT and WBMRI in patients with breast and prostate cancers

    Ryogo Minamimoto

    Journal of Nuclear Medicine     2015

     More details

    Publishing type:Research paper (scientific journal)  

    Web of Science

  139. Physiological distribution of Ga-68-DOTA-TATE: an atlas of standardized uptake values

    Ryogo Minamimoto

    Journal of Nuclear Medicine     2015

     More details

    Publishing type:Research paper (scientific journal)  

    Web of Science

  140. Improvements in PET Image quality from TOF PET/MRI

    Ryogo Minamimoto

    European Journal of Nuclear Medicine and Molecular Imaging     2015

     More details

    Publishing type:Research paper (scientific journal)  

    Web of Science

  141. F-18 FPPRGD(2) PET as a Surrogate Biomarker of Integrin alpha(v)beta(3) Expression Before and After Anti-angiogenesis Treatment 18

    Ryogo Minamimoto

    Journal of Nuclear Medicine     2015

     More details

    Publishing type:Research paper (scientific journal)  

    Web of Science

  142. Lesion-based analysis of <sup>18</sup>F-FDG uptake and <sup>111</sup>In-Pentetreotide uptake by neuroendocrine tumors

    Kubota K., Okasaki M., Minamimoto R., Miyata Y., Morooka M., Nakajima K., Sato T.

    Annals of Nuclear Medicine   Vol. 28 ( 10 ) page: 1004 - 1010   2014.11

     More details

    Language:English   Publisher:Annals of Nuclear Medicine  

    Purpose: To characterize the heterogeneity of metastatic neuroendocrine tumor (NET) lesions, we compared the [18F]-fluorodeoxyglucose (FDG) uptake and the 111In-pentetreotide (SRS) uptake for somatostatin receptor scintigraphy using the CT-based fusion imaging techniques of PET/CT and SPECT/CT.

    DOI: 10.1007/s12149-014-0900-3

    Scopus

    PubMed

  143. Large vessel vasculitis in elderly patients: early diagnosis and steroid-response evaluation with FDG-PET/CT and contrast-enhanced CT

    Muto G., Yamashita H., Takahashi Y., Miyata Y., Morooka M., Minamimoto R., Kubota K., Kaneko H., Kano T., Mimori A.

    Rheumatology International   Vol. 34 ( 11 ) page: 1545 - 1554   2014.11

     More details

    Language:English   Publisher:Rheumatology International  

    Large vessel vasculitis (LVV) is an often-reported cause of inflammation of unknown origin (IUO) in elderly people. The objective of this study was to describe the usefulness of fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) and contrast-enhanced CT in early diagnosis and treatment follow-up of patients with LVV presenting as elderly onset IUO. We retrospectively compared contrast-enhanced CT findings and FDG-PET/CT findings of the patients diagnosed with LVV and 11 controls; all subjects were 50 years of age or older. We evaluated maximum standardised uptake value (SUVmax) and PET score of the aortic wall for quantitative comparison of FDG-PET/CT findings. We measured the aortic wall thickness (W) and its ratio against the radius (W/R) for quantitative comparison of aortic wall thickening by contrast-enhanced CT. After steroid treatment, we compared these values with those pre-treatment. Of 124 patients who were hospitalised due to advanced age and IUO, 88 underwent FDG-PET/CT and contrast-enhanced CT. Abnormal findings were observed on images from 78 patients. The findings were indicative of LVV in 13 patients (10.5 %), of whom more than half had only non-specific symptoms. Patients with LVV had significantly higher aortic wall SUVmax (3.85 vs. 1.95), PET scores by FDG-PET/CT, and aortic wall thicknesses by contrast-enhanced CT (3.8 vs. 2.6 mm) than controls. Significant improvement in aortic wall thickening was evidenced by reduced PET scores and by contrast-enhanced CT findings in patients who were followed up after treatment. LVV is an important cause of IUO with non-specific symptoms in elderly patients. Imaging examination comprising contrast-enhanced CT and FDG-PET/CT is useful for early diagnosis and early treatment evaluation of LVV, allowing for amelioration of reversible aortic wall thickening.

    DOI: 10.1007/s00296-014-2985-3

    Scopus

    PubMed

  144. Detection of thyroid cancer by an FDG-PET cancer screening program: A Japanese nation-wide survey

    Minamimoto R., Senda M., Jinnouchi S., Terauchi T., Yoshida T., Inoue T.

    Anticancer Research   Vol. 34 ( 8 ) page: 4439 - 4446   2014.8

     More details

    Publisher:Anticancer Research  

    Background/Aim: The [18F]-fluorodeoxyglucose positron emission tomography (FDG-PET) cancer screening program is defined as a cancer screening for asymptomatic subjects using FDG-PET (including PET/ computed tomography [CT]) with or without combination of other screening tests. The aim of the present study was to analyze the thyroid cancer detection rate in asymptomatic individuals through a FDG-PET cancer screening program in Japan. Materials and Methods: A total of 153,775 asymptomatic individuals underwent FDG-PET cancer screening. We analyzed 1,308 cases for possible thyroid cancer in all screening tests. Results: Among the 1,308 possible cases, 353 were verified as thyroid cancer. The relative sensitivity and positive predictive value (PPV) of FDG-PET were 90.7% and 29.5% for thyroid cancer, respectively. The relative sensitivity was equivalent to thyroid ultrasonography (US) (90.9%) and higher than neck computed tomography (CT) (75.7%, p<0.001), thyroglobulin (36.1%, p<0.001), and carcinoembryonic antigen (5.6%, p<0.001). The sensitivity with a PET/CT scanner was higher than that with a dedicated PET scanner (94.1% vs. 85.0%, p<0.001). Combining thyroid US with FDG-PET increased the relative sensitivity and PPV. The majority of thyroid carcinomas detected by FDG-PET screening were Union for International Cancer Control (UICC) stage I, but a significant number of cases were also detected as stage III or IV. Conclusion: The FDG-PET cancer screening program in Japan detected thyroid cancer at an early stage. FDG-PET showed high sensitivity in detecting thyroid cancer, and it may be more effective if combined with thyroid US.

    Scopus

  145. Utility of fluorodeoxyglucose positron emission tomography/computed tomography for early diagnosis and evaluation of disease activity of relapsing polychondritis: A case series and literature review

    Yamashita H., Takahashi H., Kubota K., Ueda Y., Ozaki T., Yorifuji H., Bannai E., Minamimoto R., Morooka M., Miyata Y., Okasaki M., Takahashi Y., Kaneko H., Kano T., Mimori A.

    Rheumatology (United Kingdom)   Vol. 53 ( 8 ) page: 1482 - 1490   2014.8

     More details

    Language:English   Publisher:Rheumatology (United Kingdom)  

    Objective. Relapsing polychondritis (RPC) is relatively rare and early diagnosis is difficult. We investigated the utility of fluorodeoxyglucose (FDG)-PET/CT for the diagnosis of RPC and evaluation of disease activity. Methods. Five RPC patients undergoing FDG-PET/CT in our hospital between 2006 and 2012 were studied. Eight RPC cases examined by PET reported in the literature were also assessed. Data from a total of 13 patients were analysed. Results. Typical FDG accumulation was noted in the tracheobronchial trees of nine patients, the costal cartilage of five, joints of five, larynx of four, nasal cavity/paranasal sinuses of three, auricles of three, lymph nodes of three and the aorta of one. One patient showed nasal chondritis on a PET scan despite the absence of nasal changes on physical examination. Of five patients with costochondritis, four remained asymptomatic. Of nine patients with airway FDG accumulation, eight developed respiratory symptoms and all had CT abnormalities. In the other patient, airway FDG accumulation was evident despite the absence of airway symptoms and a lack of abnormalities in the respiratory function test and CT. PET also revealed bronchial chondritis in asymptomatic patients. The mean maximum standardized uptake values (SUVmax) of the upper and lower airways was 5.79 (S.D. 2.87) and 6.47 (S.D. 4.08), respectively. In five patients with a PET after treatment, FDG accumulation had diminished with symptomatic and inflammatory improvement. Conclusion. FDG-PET/CT is a potentially powerful tool for the early diagnosis of RPC, especially in patients without easily biopsied organ involvement. This modality also facilitates evaluation of disease extent and disease activity during treatment. © The Author 2014. Published by Oxford University Press. All rights reserved.

    DOI: 10.1093/rheumatology/keu147

    Scopus

    PubMed

  146. Detection of thyroid cancer by an FDG-PET cancer screening program: a Japanese nation-wide survey. International journal

    Ryogo Minamimoto, Michio Senda, Seishi Jinnouchi, Takashi Terauchi, Tsuyoshi Yoshida, Tomio Inoue

    Anticancer research   Vol. 34 ( 8 ) page: 4439 - 45   2014.8

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND/AIM: The [(18)F]-fluorodeoxyglucose positron emission tomography (FDG-PET) cancer screening program is defined as a cancer screening for asymptomatic subjects using FDG-PET (including PET/ computed tomography [CT]) with or without combination of other screening tests. The aim of the present study was to analyze the thyroid cancer detection rate in asymptomatic individuals through a FDG-PET cancer screening program in Japan. MATERIALS AND METHODS: A total of 153,775 asymptomatic individuals underwent FDG-PET cancer screening. We analyzed 1,308 cases for possible thyroid cancer in all screening tests. RESULTS: Among the 1,308 possible cases, 353 were verified as thyroid cancer. The relative sensitivity and positive predictive value (PPV) of FDG-PET were 90.7% and 29.5% for thyroid cancer, respectively. The relative sensitivity was equivalent to thyroid ultrasonography (US) (90.9%) and higher than neck computed tomography (CT) (75.7%, p<0.001), thyroglobulin (36.1%, p<0.001), and carcinoembryonic antigen (5.6%, p<0.001). The sensitivity with a PET/CT scanner was higher than that with a dedicated PET scanner (94.1% vs. 85.0%, p<0.001). Combining thyroid US with FDG-PET increased the relative sensitivity and PPV. The majority of thyroid carcinomas detected by FDG-PET screening were Union for International Cancer Control (UICC) stage I, but a significant number of cases were also detected as stage III or IV. CONCLUSION: The FDG-PET cancer screening program in Japan detected thyroid cancer at an early stage. FDG-PET showed high sensitivity in detecting thyroid cancer, and it may be more effective if combined with thyroid US.

    PubMed

  147. Clinical value of ¹⁸F-fluoro-dexoxyglucose positron emission tomography/computed tomography in patients with adult-onset Still's disease: a seven-case series and review of the literature. International journal

    Hiroyuki Yamashita, Kazuo Kubota, Yuko Takahashi, Ryogo Minamimoto, Miyako Morooka, Hiroshi Kaneko, Toshikazu Kano, Akio Mimori

    Modern rheumatology   Vol. 24 ( 4 ) page: 645 - 50   2014.7

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    OBJECTIVES: While there are a few reports describing 18F-fluoro-dexoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) findings in patients with adult-onset Still's disease (AOSD), no summary report has yet been published. In this study, we evaluated the usefulness of FDG-PET/CT for diagnosis and activity evaluation in patients with AOSD by summarizing the findings of our patients and those reported in the literature. METHODS: Seven consecutive AOSD patients who had undergone PET/CT at our department between 2007 and 2012 were included. We evaluated FDG uptake for characteristic findings in patients with AOSD. In addition, we reviewed the literature on seven previously reported AOSD patients who had undergone PET/CT. RESULTS: FDG accumulation was positive mainly in the bone marrow (100%), spleen (90.9%), lymph nodes (80.0%) and joints (75.0%). In addition, FDG uptake was positive in the pericardium, pleura, salivary glands, eyelids, muscle and major blood vessels. Six patients underwent follow-up FDG PET/CT for evaluation of treatment efficacy. Follow-up PET/CT showed diminished FDG accumulation in the bone marrow, spleen and lymph nodes, with maximum standardized uptake value (SUVmax) being substantially reduced from 4.03 ± 0.95 to 2.20 ± 0.75 (p = 0.04), 4.04 ± 1.10 to 2.55 ± 1.13 (p = 0.04) and 5.63 ± 4.99 to 2.10 ± 1.91 (p = 0.11), respectively. No significant correlation was found between SUVmax in each lesion and the laboratory data, except for a significant correlation between lactate dehydrogenase (LDH) and spleen SUV. CONCLUSIONS: FDG-PET/CT is useful for long-term assessments of AOSD activity in individual patients. However, PET/CT findings alone are not sufficient to make a differential diagnosis of AOSD versus malignant lymphoma.

    DOI: 10.3109/14397595.2013.850998

    Scopus

    PubMed

  148. The early response of renal cell carcinoma to tyrosine kinase inhibitors evaluated by FDG PET/CT was not influenced by metastatic organ. International journal

    Manabu Kakizoe, Masahiro Yao, Ukihide Tateishi, Ryogo Minamimoto, Daiki Ueno, Kazuhiro Namura, Kazuhide Makiyama, Narihiko Hayashi, Futoshi Sano, Takeshi Kishida, Kazuki Kobayashi, Sumio Noguchi, Ichiro Ikeda, Yoshiharu Ohgo, Masataka Taguri, Satoshi Morita, Tomio Inoue, Yoshinobu Kubota, Noboru Nakaigawa

    BMC cancer   Vol. 14 ( 1 ) page: 390 - 390   2014.6

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND: Tyrosine kinase inhibitors (TKIs) have become the mainstay of treatment for advanced renal cell carcinoma (RCC), but it has been unclear whether the antitumor effect of TKIs depends on the organ where the RCC metastasis is located. We previously reported that the FDG accumulation assessed by FDG PET/CT, was a powerful index for evaluating the biological response to TKI. In this study we investigated the differences in FDG accumulation and the response to TKI as assessed by FDG PET/CT among various organs where RCC were located. METHODS: A total of 48 patients with advanced RCC treated with a TKI (25 with sunitinib and 23 with sorafenib) were evaluated by FDG PET/CT before and at 1 month after a TKI treatment initiation. The maximum standardized uptake value (SUVmax) of all RCC lesions were measured and analyzed. RESULTS: We evaluated 190 RCC lesions. The pretreatment SUVmax values (mean ± SD) were as follows: in the 49 lung metastases, 4.1 ± 3.3; in the 40 bone metastases, 5.4 ± 1.6; in the 37 lymph node metastases, 6.7 ± 2.7; in the 29 abdominal parenchymal organ metastases, 6.6 ± 2.7; in the 26 muscle or soft tissue metastases, 4.4 ± 2.6; and in the nine primary lesions, 8.9 ± 3.9. Significant differences in the SUVmax were revealed between metastases and primary lesions (p = 0.006) and between lung metastases and non-lung metastases (p < 0.001). The SUVmax change ratios at 1 month after TKI treatment started were -14.2 ± 48.4% in the lung metastases, -10.4 ± 23.3% in the bone metastases, -9.3 ± 47.4% in the lymph node metastases, -24.5 ± 41.7% in the abdominal parenchymal organ metastases, -10.6 ± 47.4% in the muscle or soft tissue metastases, and -24.2 ± 18.3% in the primary lesions. There was no significant difference among the organs (p = 0.531). CONCLUSIONS: The decrease ratio of FDG accumulation of RCC lesions evaluated by PET/CT at 1 month after TKI treatment initiation was not influenced by the organs where the RCC metastasis was located. This result suggests that TKIs can be used to treat patients with advanced RCC regardless of the metastatic site.

    DOI: 10.1186/1471-2407-14-390

    Scopus

    PubMed

  149. Performance profile of a FDG-PET cancer screening program for detecting gastric cancer: Results from a nationwide Japanese survey

    Minamimoto R., Senda M., Jinnouchi S., Terauchi T., Yoshida T., Inoue T.

    Japanese Journal of Radiology   Vol. 32 ( 5 ) page: 253 - 259   2014.5

     More details

    Language:English   Publisher:Japanese Journal of Radiology  

    Purpose: It has been reported that gastric cancer is the sixth most common cancer found during the 18F-fluorodeoxyglucose-positron emission tomography (FDG-PET) cancer screening program, which is defined as cancer screening of asymptomatic subjects using FDG-PET(/CT) (in combination with other screening tests or not). The aim of this study was to analyze the detection rate and the effectiveness of the FDG-PET cancer screening program at detecting gastric cancer between 2006 and 2009 in Japan. Materials and methods: A total of 153,775 asymptomatic subjects (92,255 men, 61,520 women) between 30 and 80 years old underwent the FDG-PET cancer screening program. Of these, we analyzed 790 cases with findings of possible gastric cancer in any screening test. Results: The number of cases who were verified to have gastric cancer was 124. Among these, only 47 cases were detected by FDG-PET, which resulted in a relative sensitivity of 37.9 % and a positive predictive value of 33.6 %. The relative sensitivity of FDG-PET was much lower than those of gastric endoscopy and the serum pepsinogen test. Conclusion: The FDG-PET screening program in Japan detected some cases of early-stage gastric cancer, but this was not achieved using FDG-PET alone but in combination with gastric endoscopy. Gastric endoscopy should be included in FDG-PET cancer screening programs to screen for gastric cancer. © 2014 Japan Radiological Society.

    DOI: 10.1007/s11604-014-0294-0

    Scopus

    PubMed

  150. Detection of colorectal cancer and adenomas by FDG-PET cancer screening program: results based on a nationwide Japanese survey.

    Ryogo Minamimoto, Michio Senda, Seishi Jinnouchi, Takashi Terauchi, Tsuyoshi Yoshida, Tomio Inoue

    Annals of nuclear medicine   Vol. 28 ( 3 ) page: 212 - 9   2014.4

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    PURPOSE: The aim of this study was to analyze the detection rate for CRC and adenomas for asymptomatic subjects in Japan by FDG-PET cancer screening program carried out between 2006 and 2009. METHODS: The "FDG-PET cancer screening program" included both PET and positron emission tomography with computed tomography (PET/CT) with or without other screening tests. A total of 154,783 asymptomatic subjects underwent FDG-PET cancer screening program; we analyzed the 1,808 cases with findings from any detection method that indicated suspected CRC. RESULTS: Among the 1,808 cases, the number of cases verified as CRC and adenoma was 394 and 679, respectively. The sensitivity and positive predictive value (PPV) of FDG-PET were 86.0 and 31.7% for CRC, and 63.6 and 63.8% for CRC and adenoma. The sensitivity and PPV of fecal occult blood test (FOBT) for CRC were lower than those of FDG-PET, but higher for adenoma. Therefore, FDG-PET and FOBT were complementary for screening for CRC, and CRC and adenoma. The majority of CRC detected by the FDG-PET imaging was UICC stage 0 or I, however, detection of smaller or less invasive cancer was limited. CONCLUSION: The FDG-PET screening program in Japan has detected CRC at an early stage and adenomas as premalignant lesions. A combination of FDG-PET and FOBT yields the best results if the intent is to detect either CRC or adenoma. However, it is absolutely clear that an FDG-PET cancer screening program cannot detect all colon lesions.

    DOI: 10.1007/s12149-013-0797-2

    Scopus

    PubMed

  151. Dramatic change in 18F-FDG uptake in a sarcoidosis case showing spontaneous recovery. International journal

    Kimiteru Ito, Yoko Miyata, Ryogo Minamimoto, Kazuo Kubota

    Clinical nuclear medicine   Vol. 39 ( 4 ) page: 376 - 8   2014.4

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    A 47-year-old man with treatment-naive sarcoidosis underwent 18F-FDG PET/CT. The image revealed clearly abnormal uptakes in his lymph nodes, muscles, and lungs, consistent with lesions of sarcoidosis. The patient had no symptoms and was under observation without treatment for sarcoidosis. At a 2-year follow-up, he underwent another 18F-FDG PET/CT scan, which revealed that several lesions with abnormal FDG uptake had significantly decreased, and some lesions had completely disappeared. Because sarcoidosis frequently shows spontaneous recovery, FDG uptake may show spontaneously dynamic changes in the associated lesions.

    DOI: 10.1097/RLU.0b013e31828e973b

    Scopus

    PubMed

  152. A pilot study of 4'-[methyl-11C]-thiothymidine PET/CT for detection of regional lymph node metastasis in non-small cell lung cancer. International journal

    Ryogo Minamimoto, Jun Toyohara, Hideyuki Ito, Ayako Seike, Yoko Miyata, Miyako Morooka, Momoko Okasaki, Kazuhiko Nakajima, Kimiteru Ito, Kiichi Ishiwata, Kazuo Kubota

    EJNMMI research   Vol. 4 ( 1 ) page: 10 - 10   2014.3

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND: 4'-[methyl-11C]-thiothymidine (4DST) is a novel positron emission tomography (PET) tracer to assess proliferation of malignancy. The diagnostic abilities of 4DST and 2-deoxy-2-18 F-fluoro-d-glucose (FDG) for detecting regional lymph node (LN) metastases of non-small cell lung cancer (NSCLC) were prospectively compared. In addition, the relationship between the PET result and the patient's prognosis was evaluated. METHODS: A total of 31 patients with NSCLC underwent 4DST PET/computed tomography (CT) and FDG PET/CT. The PET/CT images were evaluated qualitatively and quantitatively for focal uptake of each PET tracer, according to the staging system of the American Joint Committee on Cancer. Surgical and histological results provided the reference standards. Patients were followed for up to two years to assess disease-free survival. RESULTS: On a per-lesion basis, sensitivity, specificity, positive predictive value, negative predictive value, and accuracy for LN staging were 82%, 72%, 32%, 96%, and 73%, respectively, for 4DST, and 29%, 86%, 25%, 88%, and 78%, respectively, for FDG. The sensitivity of 4DST was significantly higher than that of FDG (P < 0.001). The disease-free survival rate with positive 4DST uptake in nodal lesions was 0.35, which was considerably lower than the rate of 0.83 with negative findings (P = 0.04). Among the factors tested, nodal staging by 4DST was the most influential prognostic factor (P = 0.05) in predicting the presence of a previously existing spread lesion or of a recurrence over the course of 2 years. CONCLUSION: 4DST PET/CT is sensitive for detecting mediastinal lymph node metastasis in NSCLC, but its low specificity is a limitation. However, it may be helpful in predicting the prognosis of NSCLC.

    DOI: 10.1186/2191-219X-4-10

    Scopus

    PubMed

  153. Prognostic value of post-treatment (18)F-FDG PET/CT for advanced head and neck cancer after combined intra-arterial chemotherapy and radiotherapy. International journal

    Kimiteru Ito, Keigo Shimoji, Yoko Miyata, Kouhei Kamiya, Ryogo Minamimoto, Kazuo Kubota, Momoko Okasaki, Miyako Morooka, Jyunkichi Yokoyama

    Chinese journal of cancer research = Chung-kuo yen cheng yen chiu   Vol. 26 ( 1 ) page: 30 - 7   2014.2

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    OBJECTIVE: To clarify the prognostic value of post-treatment (18)F-fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) in patients with advanced head and neck squamous cell carcinoma (HNSCC) after combined intra-arterial chemotherapy and radiotherapy (IACR). METHODS: Thirty-six patients with HNSCC who underwent IACR were recruited. The period from the end of IACR to the last post-treatment (18)F-FDG PET/CT examination was 8-12 weeks. Both patient-based and lesion-based analyses were used to evaluate the PET/CT images. For lesion-based analysis, 36 regions (12 lesions of recurrences and 24 scars at primary sites) were selected. The Kaplan-Meier method was used to assess the overall survival (OS) stratified by (18)F-FDG uptake or visual interpretation results. RESULTS: Twelve patients with recurrence were identified by six months after IACR. The sensitivity and specificity in the patient-based analysis were 67% (8/12) and 88% (21/24), respectively. The mean OS was estimated to be 12.1 months (95% CI, 6.3-18.0 months) for the higher maximum standardized uptake value (SUVmax) group (n=7) and 44.6 months (95% CI, 39.9-49.3 months) for the lower SUVmax group (n=29). OS in the higher SUVmax group (cut-off point, 6.1) or positive visual interpretation group was significantly shorter than that in the lower SUVmax or negative visual interpretation group (P<0.001 and P<0.05, respectively). CONCLUSIONS: The SUVmax and visual interpretation of HNSCC on post-IACR (18)F-FDG PET/CT can provide prognostic survival estimates.

    DOI: 10.3978/j.issn.1000-9604.2014.01.06

    PubMed

  154. Detection of lung cancer by FDG-PET cancer screening program: A nationwide Japanese survey

    Minamimoto R., Senda M., Jinnouchi S., Terauchi T., Yoshida T., Uno K., Iinuma T., Murano T., Nakashima R., Inoue T.

    Anticancer Research   Vol. 34 ( 1 ) page: 183 - 189   2014.1

     More details

    Publisher:Anticancer Research  

    Aim: The aim of this study was to analyze the lung cancer detection rate in asymptomatic individuals by the Fluorine-18 fluorodeoxyglucose-positron emission tomography FDG-PET cancer screening program in Japan. Materials and Methods: A total of 153,775 asymptomatic individuals underwent the FDG-PET cancer screening program; the 854 cases with findings that indicated suspected lung cancer by any detection method were analyzed. Results: Among the 854 cases, 319 were verified as lung cancer. The relative sensitivity and positive predictive value (PPV) of FDG-PET were 86.5% and 38.9% for lung cancer, respectively. The sensitivity of PET/computed tomography (CT) scanner was higher than that of dedicated PET (100.0% vs. 63.2%), indicating that CT imaging was effective for lung cancer screening. The majority of lung carcinomas detected by FDG-PET screening were UICC stage IA or IB, but detection of smaller or less invasive carcinomas was limited. Conclusion: The FDG-PET screening program in Japan detected lung cancer at an early stage.

    Scopus

  155. 18F-FDG PET/CT findings preceded elevation of serum proteinase 3 antineutrophil cytoplasmic antibodies in Wegener granulomatosis. International journal

    Kimiteru Ito, Ryogo Minamimoto, Hiroyuki Yamashita, Miyako Morooka, Momoko Okasaki, Akio Mimori, Kazuo Kubota

    Clinical nuclear medicine   Vol. 39 ( 1 ) page: e67-8 - 8   2014.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    A 67-year-old woman underwent F-FDG PET/CT after developing a fever of unknown origin. PET/CT revealed intensive FDG uptake at the nasal and lung lesions. On the laboratory data, serum myeloperoxidase antineutrophil cytoplasmic antibodies (ANCA) titer was elevated, although serum directed against proteinase 3 (PR3) ANCA titer was within normal limits. One month after treatment, follow-up PET/CT revealed decreased FDG uptake at the lesions. One year later, serum PR3-ANCA titer elevated, which finally led to a diagnosis of Wegener granulomatosis (WG). WG lesions may be detected earlier by FDG PET/CT than by serum PR3-ANCA titers.

    DOI: 10.1097/RLU.0b013e3182817a95

    Scopus

    PubMed

  156. Detection of lung cancer by FDG-PET cancer screening program: a nationwide Japanese survey. International journal

    Ryogo Minamimoto, Michio Senda, Seishi Jinnouchi, Takashi Terauchi, Tsuyoshi Yoshida, Kimiichi Uno, Takeshi Iinuma, Takeshi Murano, Rumi Nakashima, Tomio Inoue

    Anticancer research   Vol. 34 ( 1 ) page: 183 - 9   2014.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    AIM: The aim of this study was to analyze the lung cancer detection rate in asymptomatic individuals by the Fluorine-18 fluorodeoxyglucose-positron emission tomography FDG-PET cancer screening program in Japan. MATERIALS AND METHODS: A total of 153,775 asymptomatic individuals underwent the FDG-PET cancer screening program; the 854 cases with findings that indicated suspected lung cancer by any detection method were analyzed. RESULTS: Among the 854 cases, 319 were verified as lung cancer. The relative sensitivity and positive predictive value (PPV) of FDG-PET were 86.5% and 38.9% for lung cancer, respectively. The sensitivity of PET/computed tomography (CT) scanner was higher than that of dedicated PET (100.0% vs. 63.2%), indicating that CT imaging was effective for lung cancer screening. The majority of lung carcinomas detected by FDG-PET screening were UICC stage IA or IB, but detection of smaller or less invasive carcinomas was limited. CONCLUSION: The FDG-PET screening program in Japan detected lung cancer at an early stage.

    PubMed

  157. First evaluation of a time-of-flight whole-body PET/MRI scanner in oncology patients: comparison with PET/CT

    Ryogo Minamimoto

    European Journal of Nuclear Medicine and Molecular Imaging     2014

     More details

    Publishing type:Research paper (scientific journal)  

    Web of Science

  158. Cu-62-Diacetyl-Bis (N-4-Methylthiosemicarbazone) PET in Human Gliomas: Comparative Study with [F-18]Fluorodeoxyglucose and L-Methyl-[C-11]Methionine PET

    Ryogo Minamimoto

    American Journal of Neuroradiology   Vol. 35 ( 2 ) page: 278 - 284   2014

     More details

    Publishing type:Research paper (scientific journal)  

    DOI: 10.3174/AJNR.A3679

    Web of Science

    Scopus

  159. Long fasting is effective in inhibiting physiological myocardial <sup>18</sup>F-FDG uptake and for evaluating active lesions of cardiac sarcoidosis

    Morooka M., Moroi M., Uno K., Ito K., Wu J., Nakagawa T., Kubota K., Minamimoto R., Miyata Y., Okasaki M., Okazaki O., Yamada Y., Yamaguchi T., Hiroe M.

    EJNMMI Research   Vol. 4 ( 1 ) page: 1 - 11   2014

     More details

    Language:English   Publisher:EJNMMI Research  

    Background: F-fluorodeoxyglucose (FDG) positron emission tomography (PET) is a promising modality for detecting active lesions of cardiac sarcoidosis (CS). However, determining whether 18F-FDG uptake in the myocardium is physiological is challenging due to metabolic shift in myocardial cells. Although methods for inhibiting physiological myocardial 18F-FDG uptake have been proposed, no standard methods exist. This study therefore aimed to compare the effect of an 18-h fast (long fasting (LF)) with heparin loading plus a 12-h fast (HEP) before 18F-FDG PET scan. Methods: We analyzed the effects of LF and HEP on the inhibition of physiological myocardial 18F-FDG uptake in healthy subjects (18 in HEP and 19 in LF) and in patients with known or suspected CS (96 in HEP and 69 in LF). In CS, the lower uptake of 18F-FDG in the myocardium was evaluated. A visual four-point scale was used to assess myocardial 18F-FDG uptake in comparison with hepatic uptake (1 lower, 2 similar, 3 somewhat higher, 4 noticeably higher). Results: Myocardial 18F-FDG uptake was 1.68 ± 1.06 in LF and 3.17 ± 1.16 in HEP in healthy subjects (p < 0.0001), whereas it was 1.48 ± 0.99 in LF and 2.48 ± 1.33 in HEP in CS patients (p < 0.0001). Logistic regression and regression trees revealed the LF was the most effective in inhibiting myocardial 18F-FDG uptake. In addition, 18rum free fatty acid levels on intravenous 18F-FDG injection were a possible biomarker. Conclusions: LF is effective in inhibiting myocardial 18F-FDG uptake, and consequently, it could be useful for evaluating active lesions of CS in 18F-FDG PET images. © 2014 Morooka et al.; licensee Springer.

    DOI: 10.1186/2191-219X-4-1

    Scopus

    PubMed

  160. Visual Findings of <sup>18</sup>F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Patients with Cardiac Sarcoidosis

    Ito Kimiteru, Okazaki Osamu, Morooka Miyako, Kubota Kazuo, Minamimoto Ryogo, Hiroe Michiaki

    Internal Medicine   Vol. 53 ( 18 ) page: 2041 - 2049   2014

     More details

    Language:English   Publisher:The Japanese Society of Internal Medicine  

    <b>Objective</b> The purpose of this study was to evaluate the cardiac sarcoidosis (CS) activity according to the classified visual uptake pattern using <sup>18</sup>F-fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) and assess the uptake pattern based on the free fatty acid (FFA) levels.<br> <b>Methods</b> Nineteen CS subjects who underwent <sup>18</sup>F-FDG PET/CT examinations with heparin loading (HL) were recruited to evaluate their CS activity. The <sup>18</sup>F-FDG uptake in the heart was classified into five categories ("none," "diffuse" and "diffuse at base," regarded as stable CS, and "focal" and "focal on diffuse," regarded as de novo or worsening CS). The subject data were compared with the <sup>18</sup>F-FDG PET/CT findings in 13 healthy volunteers. The FFA serum levels were assessed in 10 patients with CS and all volunteers.<br> <b>Results</b> The sensitivity and specificity of <sup>18</sup>F-FDG PET/CT with HL were 75% (6/8) and 73% (8/11), respectively. The major pattern of cardiac <sup>18</sup>F-FDG uptake was "diffuse at base." Ten of the 32 subjects, including the control group, exhibited this pattern. The FFA serum levels before heparin administration were statistically significantly different between the patients with the "none" pattern and those with the "diffuse" and "diffuse at base" patterns. There were no significant correlations between the FFA serum levels after heparin administration and the <sup>18</sup>F-FDG uptake patterns.<br> <b>Conclusion</b> "Diffuse at base" is the major <sup>18</sup>F-FDG uptake pattern associated with inadequate physiologic <sup>18</sup>F-FDG suppression. This pattern should be carefully interpreted when examining the <sup>18</sup>F-FDG PET/CT images of CS patients. Additionally, increased FFAs levels associated with HL may not completely suppress the physiologic myocardial FDG uptake.<br>

    DOI: 10.2169/internalmedicine.53.2491

    Scopus

    PubMed

    CiNii Research

  161. Detection of prostate cancer by an FDG-PET cancer screening program: results from a Japanese nationwide survey. International journal

    Ryogo Minamimoto, Michio Senda, Seishi Jinnouchi, Takashi Terauchi, Tomio Inoue

    Asia Oceania journal of nuclear medicine & biology   Vol. 2 ( 1 ) page: 19 - 23   2014

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    OBJECTIVES: The aim of this study was to analyze detection rates and effectiveness of (18)F-fluorodeoxyglucose positron emission tomography (FDG-PET) cancer screening program for prostate cancer in Japan, which is defined as a cancer-screening program for subjects without known cancer. It contains FDG-PET aimed at detection of cancer at an early stage with or without additional screening tests such as prostate-specific antigen (PSA) and magnetic resonance imaging (MRI). METHODS: A total of 92,255 asymptomatic men underwent the FDG-PET cancer screening program. Of these, 504 cases with findings of possible prostate cancer in any screening method were analyzed. RESULTS: Of the 504 cases, 165 were verified as having prostate cancer. Of these, only 61 cases were detected by FDG-PET, which result in 37.0% relative sensitivity and 32.8% positive predictive value (PPV). The sensitivity of PET/computed tomography (CT) scanner was higher than that of dedicated PET (44.0% vs. 20.4%). However, the sensitivity of FDG-PET was lower than that of PSA and pelvic MRI. FDG-PET did not contribute to improving the sensitivity and PPV when performed as combined screening. CONCLUSION: PSA should be included in FDG-PET cancer screening programs to screen for prostate cancer.

    PubMed

  162. Comparison of 4 '-[methyl-11C] thiothymidine (4DST) and FDG PET/CT for early therapy monitoring of advanced non small cell lung cancer

    Ryogo Minamimoto

    Journal of Nuclear Medicine     2014

     More details

    Publishing type:Research paper (scientific journal)  

    Web of Science

  163. 18F FPPRGD2 PET/CT evaluation of patients with suspected recurrence of glioblastoma multiforme

    Ryogo Minamimoto

    Journal of Nuclear Medicine     2014

     More details

    Publishing type:Research paper (scientific journal)  

    Web of Science

  164. Multicenter study for comparison of FLT and FDG PET/CT for early interim therapy monitoring of diffuse large B-cell lymphoma

    Ryogo Minamimoto

    Journal of Nuclear Medicine     2014

     More details

    Publishing type:Research paper (scientific journal)  

    Web of Science

  165. Qualitative and quantitative assessment of 4D PET/CT imaging based on Q.Freeze algorithm

    Ryogo Minamimoto

    Journal of Nuclear Medicine     2014

     More details

    Publishing type:Research paper (scientific journal)  

    Web of Science

  166. Qualitative and quantitative assessment of 4D PET/CT imaging based on Q.Freeze algorithm

    Ryogo Minamimoto

    Journal of Nuclear Medicine     2014

     More details

    Publishing type:Research paper (scientific journal)  

    Web of Science

  167. Observed standardized uptake values in normal tissues and malignant lesions on combined 18F-NaF/18F-FDG PET/CT

    Ryogo Minamimoto

    Journal of Nuclear Medicine     2014

     More details

    Publishing type:Research paper (scientific journal)  

    Web of Science

  168. Imaging spectrum and pitfalls of ¹⁸F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with tuberculosis.

    Kimiteru Ito, Miyako Morooka, Ryogo Minamimoto, Yoko Miyata, Momoko Okasaki, Kazuo Kubota

    Japanese journal of radiology   Vol. 31 ( 8 ) page: 511 - 20   2013.8

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Mycobacterium tuberculosis (TB) is one of the most prominant diseases frequently causing false positive lesions in oncologic surveys using (18)F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT), since TB granulomas are composed of activated macrophages and lymphocytes with high affinity for glucose. These pitfalls of (18)F-FDG PET/CT are important for radiologists. Being familiar with (18)F-FDG images of TB could assist in preventing unfavorable clinical results based on misdiagnoses. In addition, (18)F-FDG PET/CT has the advantage of being able to screen the whole body, and can clearly detect harboring TB lesions as high uptake foci. This article details the spectrum and pitfalls of (18)F-FDG PET/CT imaging in TB.

    DOI: 10.1007/s11604-013-0218-4

    Scopus

    PubMed

  169. Incidental focal FDG uptake in heart is a lighthouse for considering cardiac screening

    MINAMIMOTO Ryogo, MOROOKA Miyako, MIYATA Yoko, ITO Kimiteru, OKASAKI Momoko, HARA Hisao, OKAZAKI Osamu, MOROI Masao, KUBOTA Kazuo

      Vol. 27 ( 6 ) page: 572 - 580   2013.7

     More details

    Language:English  

    CiNii Research

  170. Incidental focal FDG uptake in heart is a lighthouse for considering cardiac screening

    Minamimoto R., Morooka M., Miyata Y., Ito K., Okasaki M., Hara H., Okazaki O., Moroi M., Kubota K.

    Annals of Nuclear Medicine   Vol. 27 ( 6 ) page: 572 - 580   2013.7

     More details

    Language:English   Publisher:Annals of Nuclear Medicine  

    Objectives: Cardiac FDG uptake is known to show a variety of patterns under clinical fasting conditions. We hypothesized that focal FDG uptake in the heart (FUH) represents a sign of cardiac disease risk, especially in coronary artery disease (CAD).The aim of this study was to clarify the relationship between FUH and cardiac disease. Methods: Cases showing FUH were selected based on comments in diagnostic reports or identification on retrospective review. Quantitative analysis was performed using maximum standardized uptake value (SUV max), with regions of interest drawn over focal uptake areas in the heart as confirmed by PET/CT and in lateral side of the same slice showing focal FDG uptake. Results: For the 20 patients (11 men, 9 women) with confirmed FUH, coronary artery stenosis or history of treatment for coronary disease was present in 11 patients (55.0 %), and 2 patients showed apical hypertrophy. Mean SUVmax of FUH did not differ significantly between patients with confirmed cardiac disease and those with no evidence of cardiac disease (P = 0.78). Conclusions: FUH suggests a high likelihood of CAD in patients without myocardial symptoms. Cardiac screening or a check of the history of cardiac disease is thus worth considering when FUH is seen incidentally on FDG-PET/CT. © 2013 The Japanese Society of Nuclear Medicine.

    DOI: 10.1007/s12149-013-0721-9

    Scopus

    PubMed

  171. Observer variation study of the assessment and diagnosis of incidental colonic FDG uptake

    MINAMIMOTO Ryogo, TERAUCHI Takashi, JINNOUCHI Seishi, YOSHIDA Tsuyoshi, TSUKAMOTO Eriko, SHIMBO Takuro, ITO Kimiteru, UNO Kimiichi, OHNO Hitoshi, OGUCHI Kazuhiro, KATO Satoshi, KANEKO Koichiro, SATOH Yoko, TAMAKI Tsuneo, NAKAHARA Tadaki, MOROOKA Miyako, INOUE Tomio, SENDA Michio

      Vol. 27 ( 5 ) page: 468 - 477   2013.6

     More details

    Language:English  

    CiNii Research

  172. Observer variation study of the assessment and diagnosis of incidental colonic FDG uptake

    Minamimoto R., Terauchi T., Jinnouchi S., Yoshida T., Tsukamoto E., Shimbo T., Ito K., Uno K., Ohno H., Oguchi K., Kato S., Kaneko K., Satoh Y., Tamaki T., Nakahara T., Morooka M., Inoue T., Senda M.

    Annals of Nuclear Medicine   Vol. 27 ( 5 ) page: 468 - 477   2013.6

     More details

    Language:English   Publisher:Annals of Nuclear Medicine  

    Purpose: The aim of this study was to evaluate the interpretations of incidental colonic 18F-FDG uptake made by 10 experienced readers and to more clearly identify the pattern of suspicious colonic FDG uptake. The potential contributions of delayed FDG-PET scanning and of immune fecal occult blood testing (FOBT) in making a diagnosis were also analyzed. Materials and methods: Visual interpretations by 10 readers were made for 147 FDG uptake sites from 126 PET scans (cancer, 38 sites; adenoma, 43 sites; and no abnormality, 66 sites) with colonic FDG uptake. Assessments for the early FDG-PET images were (1) FDG uptake pattern, (2) FDG uptake degree, and (3) likelihood of malignancy. For the delayed images, the assessments were (1) change in the FDG uptake position, (2) change in FDG uptake degree, and (3) likelihood of malignancy. The results of FOBT were analyzed independently of the visual interpretations. Results: Interobserver agreement (κ) was 0.501 for assessing FDG uptake patterns, while agreement on assessing changes in uptake degree and changes in uptake position between early and delayed imaging were low (κ = 0.213-0.229). Logistic regression analysis indicated that 'FDG uptake patterns' and 'FDG uptake degree' were significantly related to decide on the suspicion of malignancy (p < 0.001) and the final result (p < 0.001). "Small localized" and "large irregular localized" types had a high probability of a lesion regardless of either (1) FDG uptake degree or (2) variation in the uptake between the early and the delayed image. The delayed image decreased false-positive cases for some FDG uptake patterns, but it had little impact on distinguishing clearly between "cancer or adenoma" and "normal". The addition of FOBT had little impact on the diagnosis. Conclusion: There was highest agreement among readers with respect to the recognition of specified colonic FDG uptake patterns, and this pattern recognition had the most influence on the diagnosis. "Small localized" and "large irregular localized" types had a high probability of a lesion. The addition of delayed imaging and of FOBT results to the early imaging did not have much impact on the diagnosis. © 2013 The Japanese Society of Nuclear Medicine.

    DOI: 10.1007/s12149-013-0712-x

    Scopus

    PubMed

  173. Comment on Minamimoto: incidental focal FDG uptake in heart is a lighthouse for considering cardiac screening

    Francesco Bertagna, Giorgio Treglia

    Annals of Nuclear Medicine   Vol. 27 ( 9 ) page: 870 - 871   2013.6

     More details

    Publishing type:Research paper (scientific journal)   Publisher:Springer Science and Business Media {LLC}  

    DOI: 10.1007/s12149-013-0751-3

  174. Biodistribution and radiation dosimetry of [¹⁸F]-5-fluorouracil. International journal

    Ayako Hino-Shishikura, Akiko Suzuki, Ryogo Minamimoto, Kazuya Shizukuishi, Takashi Oka, Ukihide Tateishi, Sadatoshi Sugae, Yasushi Ichikawa, Choichi Horiuchi, Tomio Inoue

    Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine   Vol. 75   page: 11 - 7   2013.5

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    PURPOSE: To estimate the radiation dose and biodistribution of (18)F-5-fluorouracil ([(18)F]-5-FU) from positron emission tomography/computed tomography (PET/CT) data, and to extrapolate mouse data to human data in order to evaluate cross-species consistency. METHODS: Fifteen cancer patients (head and neck cancer (n=11), colon cancer (n=4)) were enrolled. Sequential PET/CT images were acquired for 2h after intravenous administration of [(18)F]-5-FU, and the percent of the injected dose delivered to each organ was derived. For comparison, [(18)F]-5-FU was administered to female BALB/cAJcl-nu/nu nude mice (n=19), and the percent of the injected dose delivered to mouse organs was extrapolated to the human model. Absorbed radiation dose was calculated using OLINDA/EXM 1.0 software. RESULTS: In human subjects, high [(18)F]-5-FU uptake was seen in the liver, gallbladder and kidneys. The absorbed dose was highest in the gallbladder wall. In mice, the biodistribution of [(18)F]-5-FU corresponded to that of humans. Estimated absorbed radiation doses for all organs were moderately correlated, and doses to organs (except the gallbladder and urinary bladder) were significantly correlated between mice and humans. The mean effective [(18)F]-5-FU dose was higher in humans (0.0124mSv/MBq) than in mice (0.0058mSv/MBq). CONCLUSION: Biodistribution and radiation dosimetry of [(18)F]-5-FU were compared between humans and mice: biodistribution in mice and humans was similar. Data from mice underestimated the effective dose in humans, suggesting that clinical measurements are needed for more detailed dose estimation in order to ensure radiation safety. The observed effective doses suggest the feasibility of [(18)F]-5-FU PET/CT for human studies.

    DOI: 10.1016/j.apradiso.2013.01.014

    Scopus

    PubMed

  175. Evaluation of Wegener's granulomatosis using 18F-fluorodeoxyglucose positron emission tomography/computed tomography

    ITO Kimiteru, MINAMIMOTO Ryogo, YAMASHITA Hiroyuki, YOSHIDA Setsuko, MOROOKA Miyako, OKASAKI Momoko, MIMORI Akio, KUBOTA Kazuo

      Vol. 27 ( 3 ) page: 209 - 216   2013.4

     More details

    Language:English  

    CiNii Research

  176. Evaluation of Wegener's granulomatosis using 18F-fluorodeoxyglucose positron emission tomography/computed tomography.

    Kimiteru Ito, Ryogo Minamimoto, Hiroyuki Yamashita, Setsuko Yoshida, Miyako Morooka, Momoko Okasaki, Akio Mimori, Kazuo Kubota

    Annals of nuclear medicine   Vol. 27 ( 3 ) page: 209 - 16   2013.4

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    OBJECTIVE: Wegener's granulomatosis (WG) is a relatively rare disease characterized by granulomatous necrotizing vasculitis that primarily involves small- and medium-sized vessels. Systemic findings observed on (18)F-fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) have not been well reported. The purpose of this study was to evaluate the FDG PET/CT imaging in the diagnosis and follow-up of patients with WG. MATERIALS AND METHODS: Thirteen FDG PET/CT images obtained for 8 patients (2 men and 6 women) with WG were retrospectively analyzed. Of these, 6 were performed for diagnosis, 2 for restaging and follow-up, and 5 for assessment of treatment efficacy. Maximum standardized uptake values (max SUVs) and visual analyses were used to interpret the FDG PET/CT images. In addition, nonenhanced CT findings obtained during FDG PET/CT were described. RESULTS: WG lesions of the upper respiratory tract and lung were more clearly detected by FDG PET/CT fusion imaging than by nonenhanced CT alone, and all of the active lesions showed decreased FDG uptake after treatment. In addition, FDG PET/CT can provide complementary information to indicate biopsy site based on FDG uptakes. CONCLUSIONS: FDG PET/CT is a feasible modality for evaluating lesion activities, therapeutic monitoring, and follow-up of WG. Furthermore, biopsy sites of WG lesions may be determined by FDG PET/CT.

    DOI: 10.1007/s12149-012-0675-3

    Scopus

    PubMed

  177. Similarities and differences in fluorodeoxyglucose positron emission tomography/computed tomography findings in spondyloarthropathy, polymyalgia rheumatica and rheumatoid arthritis

    Yamashita H., Kubota K., Takahashi Y., Minamimoto R., Morooka M., Kaneko H., Kano T., Mimori A.

    Joint Bone Spine   Vol. 80 ( 2 ) page: 171 - 177   2013.3

     More details

    Language:English   Publisher:Joint Bone Spine  

    Objectives: We assessed fluorine-18 (18F)-labelled fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) findings in patients with seronegative spondyloarthritis (SpA), polymyalgia rheumatica (PMR), and rheumatoid arthritis (RA). Methods: We studied 53 patients with SpA (n=21), PMR (n=16), or RA (n=16) admitted to our hospital between 2006 and 2011. Disease activity in the ischial tuberosities, greater trochanters, spinous processes, vertebral bodies, and sacroiliac joints (SIJ) were evaluated by determining FDG accumulation using maximum standardized uptake values (SUVmax) and FDG scores. Results: SUVmax for ischial tuberosities was significantly higher in PMR than SpA or RA. SUVmax for greater trochanters and spinous processes was significantly higher in PMR than RA (P<0.001) and significantly higher in SpA than in PMR or RA for SIJ (P=0.01). No significant difference in vertebral scores was observed among groups (P=0.488). FDG scores yielded similar results. X-ray findings were consistent with PET/CT findings in 3/15 (20%) patients with sacroiliitis, whereas magnetic resonance imaging findings were consistent with PET/CT findings in 4/7 (57.1%) patients. Conclusions: PET/CT detection of inflammation in the ischial tuberosities, greater trochanters, and spinous processes discriminated between PMR and RA, but not between SpA and PMR. PET/CT findings can distinguish SpA from RA and PMR and are useful for the early diagnosis of sacroiliitis. © 2012 Société française de rhumatologie.

    DOI: 10.1016/j.jbspin.2012.04.006

    Scopus

    PubMed

  178. The current status of an FDG-PET cancer screening program in Japan, based on a 4-year (2006-2009) nationwide survey

    MINAMIMOTO Ryogo, SENDA Michio, JINNOUCHI Seishi, TERAUCHI Takashi, YOSHIDA Tsuyoshi, MURANO Takeshi, FUKUDA Hiroshi, IINUMA Takeshi, UNO Kimiichi, NISHIZAWA Sadahiko, TSUKAMOTO Eriko, IWATA Hiroshi, INOUE Takeshi, OGUCHI Kazuhiro, NAKASHIMA Rumi, INOUE Tomio

      Vol. 27 ( 1 ) page: 46 - 57   2013.1

     More details

    Language:English  

    CiNii Research

  179. The current status of an FDG-PET cancer screening program in Japan, based on a 4-year (2006-2009) nationwide survey

    Minamimoto R., Senda M., Jinnouchi S., Terauchi T., Yoshida T., Murano T., Fukuda H., Iinuma T., Uno K., Nishizawa S., Tsukamoto E., Iwata H., Inoue T., Oguchi K., Nakashima R., Inoue T.

    Annals of Nuclear Medicine   Vol. 27 ( 1 ) page: 46 - 57   2013.1

     More details

    Language:English   Publisher:Annals of Nuclear Medicine  

    Objective: The aim of this study was to survey the 18F-fluorodeoxyglucose- positron emission tomography (FDG-PET) cancer screening program conducted in Japan. Methods: The "FDG-PET cancer screening program" included both FDG-PET and positron emission tomography with computed tomography (PET/CT) with or without other combined screening tests that were performed for cancer screening in asymptomatic subjects. A total of 155,456 subjects who underwent the FDG-PET cancer screening program during 2006-2009 were analyzed. Results: Of the 155,456 subjects, positive findings suggesting possible cancer were noted in 16,955 (10.9 %). The number of cases with detected cancer was 1,912 (1.23 % of the total screened cases, annual range 1.14-1.30 %). Of the 1,912 cases of detected cancer, positive findings on FDG-PET were present in 1,491 cases (0.96 % of the total number of screened cases). According to the results of further examinations, the true positive rate for subjects with suggested possible cancer (positive predictive value) was 32.3 % with FDG-PET. Cancers of the colon/rectum, thyroid, lung, and breast were most frequently found (396, 353, 319, and 163 cases, respectively) with high PET sensitivity (85.9, 90.7, 86.8, 84.0 %, respectively). Prostate cancer and gastric cancer (165 and 124 cases, respectively) had low PET sensitivity (37.0 and 37.9 %, respectively). The Union for International Cancer Control (UICC) clinical stage of cancer found with the FDG-PET cancer screening program was mainly Stage I. Conclusions: The FDG-PET screening program in Japan has detected a variety of cancers at an early stage. However, several cancers were found in repeated FDG-PET cancer screening program, indicating the limitation of a one-time FDG-PET cancer screening program. The value of the FDG-PET cancer screening program is left to the judgment of individuals with regard to its potentials and limitations. © 2012 The Japanese Society of Nuclear Medicine.

    DOI: 10.1007/s12149-012-0660-x

    Scopus

    PubMed

  180. Re-evaluating the potentials and limitations of (99m)Tc-aprotinin scintigraphy for amyloid imaging.

    Minamimoto R, Kubota K, Ishii K, Morooka M, Okasaki M, Miyata Y, Nakajima K, Sato T, Igari T, Hirai R, Okazaki O

    American journal of nuclear medicine and molecular imaging   Vol. 3 ( 3 ) page: 261 - 71   2013

     More details

    Language:English  

    PubMed

  181. Comparison of FDGPET/CT and 111In-Pentetreotide SPECT/CT for Neuroendocrine Tumours: a Lesion Based Analysis

    Ryogo Minamimoto

    European Journal of Nuclear Medicine and Molecular Imaging     2013

     More details

    Publishing type:Research paper (scientific journal)  

    Web of Science

  182. Interim FDG-PET/CT as a predictor of prognosis for HIV-related malignant lymphoma: Preliminary study

    Ryogo Minamimoto

    Journal of Solid Tumors     2013

     More details

    Publishing type:Research paper (scientific journal)  

    DOI: 10.5430/JST.V3N2P1

  183. Amyloid imaging mismatch. International journal

    Ryogo Minamimoto, Kenji Ishii, Kazuo Kubota, Miyako Morooka, Momoko Okasaki, Kimiteru Ito, Takuya Mitsumoto, Kazuhiko Nakajima, Takashi Sato, Makoto Mochizuki, Osamu Okazaki

    Clinical nuclear medicine   Vol. 37 ( 8 ) page: 807 - 9   2012.8

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    An 82-year-old man with suspected systemic amyloidosis and complete atrioventricular block underwent vascular biopsy during his pacemaker implantation with pathology showing amyloid deposits. 99mTc-aprotinin SPECT revealed increased radiotracer uptake along the left ventricular wall, consistent with cardiac amyloidosis. 11C-PiB PET/CT performed for the evaluation of amyloid deposits in the brain showed findings suggestive of Alzheimer disease without abnormal radiotracer concentration in the myocardium to match the 99mTc-aprotinin SPECT findings. Dynamic PET images showed increased 11C-PiB concentration in the left ventricular myocardium at 2 minutes after injection, with subsequent tracer clearance by approximately 5 minutes, consistent with normal 11C-PiB biodistribution.

    DOI: 10.1097/RLU.0b013e318251e1d3

    Scopus

    PubMed

  184. Lung amyloid nodule detected by ^<99m>Tc-aprotinin scintigraphy

    ISHII Satoru, KUBOTA Kazuo, MINAMIMOTO Ryogo, KOUKETU Rikiya, MOROOKA Miyako, KAWAI Shigeo, TAKEDA Yuichiro, KOBAYASHI Nobuyuki, SUGIYAMA Haruhito

      Vol. 26 ( 6 ) page: 522 - 526   2012.7

     More details

    Language:English  

    CiNii Research

  185. Lung amyloid nodule detected by <sup>99m</sup>Tc-aprotinin scintigraphy

    Ishii S., Kubota K., Minamimoto R., Kouketu R., Morooka M., Kawai S., Takeda Y., Kobayashi N., Sugiyama H.

    Annals of Nuclear Medicine   Vol. 26 ( 6 ) page: 522 - 526   2012.7

     More details

    Language:English   Publisher:Annals of Nuclear Medicine  

    We present a case in which an amyloid lung nodule was diagnosed preoperatively by amyloid scintigraphy 99mTc-aprotinin. A 65-year-old man complained of marked weight loss (9 kg) over a period of 6 months. An abnormal shadow in the middle field of the right lung was detected on chest X-ray, corresponding to a 16-mm nodule in the right middle lobe on thoracic computed tomography (CT). Total protein and immunoglobulin G levels were elevated to 8.3 and 2245 mg/dl, respectively, but other blood tests including several tumor marker levels and Cryptococcus antibodies were all within normal range. Fluorodeoxyglucose positron emission tomography showed no uptake by the lung nodule, so lung amyloidosis was considered as differential diagnosis. To avoid risk of bleeding on bronchoscopy, noninvasive amyloid scintigraphy using 99mTc-aprotinin was first performed. A nodular, abnormal accumulation was observed in the right middle lung lobe. Diagnostic imaging strongly suggested amyloidosis, so video-assisted thoracic surgery was performed rather than bronchoscopy. Pathological samples showed positive staining with Congo red, and A-λ amyloidosis was diagnosed on the basis of immunostaining. Scintigraphy using 99mTc-aprotinin offers a useful, noninvasive method for assessing lung amyloidosis. © The Japanese Society of Nuclear Medicine 2012.

    DOI: 10.1007/s12149-012-0606-3

    Scopus

    PubMed

  186. Reevaluation of FDG-PET/CT in patients with hoarseness caused by vocal cord palsy

    MINAMIMOTO Ryogo, KUBOTA Kazuo, MOROOKA Miyako, ITO Kimiteru, MITSUMOTO Takuya, OKASAKI Momoko, SHIMBO Takuro, TAYAMA Niro

      Vol. 26 ( 5 ) page: 405 - 411   2012.6

     More details

    Language:English  

    CiNii Research

  187. A case of gouty arthritis to tophi on 18F-FDG PET/CT imaging. International journal

    Kimiteru Ito, Ryogo Minamimoto, Miyako Morooka, Kazuo Kubota

    Clinical nuclear medicine   Vol. 37 ( 6 ) page: 614 - 7   2012.6

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    We report a case of gouty arthritis with tophi that was evaluated using 18F-fluorodeoxyglucose (FDG) positron emission tomography. A 77-year-old man with a history of gouty attacks was admitted with severe polyarticular pain and fever. 18F-FDG positron emission tomography/CT demonstrated focal uptake at multiple joints, including the juxta-articular soft-tissue-density masses of the elbows, and the bases of bilateral large toes. Gouty arthritis should be considered with focal 18F-FDG uptake in juxta-articular soft-tissue-density masses (tophi) with or without associated erosions.

    DOI: 10.1097/RLU.0b013e3182478a66

    Scopus

    PubMed

  188. Reevaluation of FDG-PET/CT in patients with hoarseness caused by vocal cord palsy

    Minamimoto R., Kubota K., Morooka M., Ito K., Mitsumoto T., Okasaki M., Shimbo T., Tayama N.

    Annals of Nuclear Medicine   Vol. 26 ( 5 ) page: 405 - 411   2012.6

     More details

    Language:English   Publisher:Annals of Nuclear Medicine  

    Objective: Vocal cord palsy (VCP) is a potential cause of hoarseness that results in decreasing mobility of the vocal cord. VCP can arise from a variety of causes; so, systematic screening is warranted for the management of patients with VCP. Asymmetrical fluorodeoxyglucose (FDG) uptake in vocal cords is a well-known feature in patients with VCP, but no detailed analysis has been performed. This study aimed at reevaluating the 18F-FDG positron emission tomography/computed tomography (PET/CT) for patients with VCP. Methods: We retrospectively surveyed the results of FDGPET/CT for 59 patients with VCP, compared to laryngoscopic findings. Quantitative analysis was performed using maximum standardized uptake value (SUV max), and regions of interest were drawn over bilateral vocal cords as confirmed from the CT portion of PET/CT. Patients were divided into 3 groups: Group 1 (n = 14), in which VCP was caused by the lesion of the laryngeal area; Group 2 (n = 40), in which VCP was caused by the lesion on the root of the recurrent laryngeal nerve; and Group 3 (n = 5), in which VCP was caused by the lesion from the vagal center to the proximal vagus nerve. Results: For Group 1, higher FDG uptake in the paralyzed vocal cord was seen in 86 % of patients (mean SUV max 8.1 ± 5.3 vs. 2.3 ± 0.4, paralyzed vs. non-paralyzed, respectively; P<0.002). The sensitivity of FDG-PET/CT for indicating the lesion causing VCP was 79 % for Group 1. Group 2 showed dominant FDG uptake in the non-paralyzed vocal cord (mean SUV max 2.1 ± 0.9 vs. 1.5 ± 0.4, non-paralyzed vs. paralyzed, respectively; P<0.001). The sensitivity of FDG-PET/CT for indicating the lesion causing VCP was 93 % for Group 2. Group 3 showed no statistically significant difference in FDG accumulation between non-paralyzed and paralyzed vocal cords (mean SUV max 1.8 ± 0.3 vs. 1.7 ± 0.3, non- paralyzed vs. paralyzed, respectively; P = 0.30). The sensitivity of FDG-PET/CT for indicating the lesion causing VCP was 60 % for Group 3. Conclusions: FDG accumulation in the vocal cords is dependent on the lesion site causing VCP. In addition, FDG-PET/CT can contribute to identification of the lesion responsible for inducing VCP. © The Japanese Society of Nuclear Medicine 2012.

    DOI: 10.1007/s12149-012-0588-1

    Scopus

    PubMed

  189. Early assessment by FDG-PET/CT of patients with advanced renal cell carcinoma treated with tyrosine kinase inhibitors is predictive of disease course. International journal

    Daiki Ueno, Masahiro Yao, Ukihide Tateishi, Ryogo Minamimoto, Kazuhide Makiyama, Narihiko Hayashi, Futoshi Sano, Takayuki Murakami, Takeshi Kishida, Takeshi Miura, Kazuki Kobayashi, Sumio Noguchi, Ichiro Ikeda, Yoshiharu Ohgo, Tomio Inoue, Yoshinobu Kubota, Noboru Nakaigawa

    BMC cancer   Vol. 12   page: 162 - 162   2012.5

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND: We reported previously that (18)F-2-fluoro-2-deoxyglucose positron emission tomography/ computed tomography (FDG PET/CT) had potential for evaluating early response to treatment by tyrosine kinase inhibitors (TKIs) in advanced renal cell carcinoma (RCC). This time we investigated the relation of the early assessment by FDG PET/CT to long-term prognosis with an expanded number of patients and period of observation. METHODS: Patients for whom TKI treatment for advanced RCC was planned were enrolled. FDG PET/CT was performed before TKI treatment and after one month of TKI treatment. The relations of the FDGPET/CT assessment to progression free survival (PFS) and overall survival (OS) were investigated. RESULTS: Thirty-five patients were enrolled (sunitinib 19 cases, sorafenib 16 cases). The patients with RCC showing high SUVmax in pretreatment FDG PET/CT demonstrated short PFS (P =0.024, hazard ratio 1.137, 95% CI 1.017-1.271) and short OS (P =0.004, hazard ratio 1.210 95% CI 1.062-1.379). Thirty patients (sunitinib 16 cases, sorafenib 14 cases) were evaluated again after 1 month. The PFS of the patients whose SUVmax decreased<20% was shorter than that of the patients whose SUVmax decreased<20% (P = 0.027, hazard ratio 3.043, 95% CI 1.134-8.167). The PFS of patients whose tumor diameter sum increased was shorter than that of the patient with tumors whose diameter sum did not (P =0.006, hazard ratio 4.555, 95% CI 1.543-13.448). The patients were classified into three response groups: good responder (diameter sum did not increase, and SUVmax decreased ≥ 20%), intermediate responder (diameter sum did not increase, and SUVmax decreased<20%), and poor responder (diameter sum increased, or one or more new lesions appeared). The median PFS of good, intermediate, and poor responders were 458 ± 146 days, 131 ± 9 days, and 88 ± 26 days (good vs. intermediate P = 0.0366, intermediate vs. poor P = 0.0097, log-rank test). Additionally the mean OSs were 999 ± 70 days, 469 ± 34 days, and 374 ± 125 days, respectively (good vs. intermediate P = 0.0385, intermediate vs. poor P = 0.0305, log-rank test). CONCLUSIONS: The evaluation of RCC response to TKI by tumor size and FDG uptake using FDG PET/CT after 1 month can predict PFS and OS.

    DOI: 10.1186/1471-2407-12-162

    Scopus

    PubMed

  190. 18F-FDG and 11C-methionine PET/CT findings in a case with anti-NMDA (NR2B) receptor encephalitis. International journal

    Miyako Morooka, Kazuo Kubota, Ryogo Minamimoto, Mariko Furuhata, Tadashi Abe, Kimiteru Ito, Momoko Okasaki, Kenji Ishii, Kiichi Ishiwata

    Clinical nuclear medicine   Vol. 37 ( 4 ) page: 400 - 2   2012.4

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1097/RLU.0b013e3182443c92

    Scopus

    PubMed

  191. FDG uptake by a condylomata acuminata in an HIV-infected patient mimicked urine contamination. International journal

    Tatsuya Wada, Kazuo Kubota, Ryogo Minamimoto, Miyako Morooka, Kanehiro Hasuo, Rie Yotsu, Hirohisa Yazaki, Shinichi Oka, Tetsuro Tujimoto, Mitsuhiko Noda

    Clinical nuclear medicine   Vol. 37 ( 4 ) page: 420 - 1   2012.4

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1097/RLU.0b013e318238f48e

    Scopus

    PubMed

  192. Validation for performing <sup>11</sup>C-methionine and <sup>18</sup>F-FDG-PET studies on the same day

    Mitsumoto T., Kubota K., Sato T., Morooka M., Minamimoto R., Shimbo T., Muramatsu Y., Sasaki T., Ito K., Fukushi M.

    Nuclear Medicine Communications   Vol. 33 ( 3 ) page: 297 - 304   2012.3

     More details

    Language:English   Publisher:Nuclear Medicine Communications  

    BACKGROUND AND OBJECTIVE: The performance of two PET examinations, one using L-[methyl- 11C] methionine (MET) and one using 2-[ 18F] fluoro-2-deoxy-D-glucose (FDG), on the same day may offer a clinical advantage for the investigation of brain tumors or other lesions. The purpose of this study was to investigate the effect of positron cross-talk (PCT) and to determine the optimal protocol for using MET and FDG on the same day. METHODS: The participants comprised 62 patients with head and neck cancer. We focused on the high physiological uptake of MET in the liver and evaluated the effect of PCT with MET on FDG uptake in the liver and muscle. Three FDG-PET scans [one: whole body (early image), two: head and neck, and three: one-bed-position scan of the liver (delayed image)] were performed after completing a MET-PET scan (head and neck) at varying injection intervals. Standard uptake value mean variations in the liver and muscle were calculated, assuming that the differences between the early and the delayed images reflected the PCT from carbon-11 on fluorine-18, on the basis of the results of a phantom study and a study in volunteers. The participants were categorized into four groups (G) according to the injection interval: G1 (n=15, 30-49 min), G2 (n=16, 50-69 min), G3 (n=17, 70-89 min), and G4 (n=14, ?90 min). RESULTS: The PCT level decreased from the G1 group through to the G3 group (analysis of variance, P<0.001) but was stable, with no further decrease in the G4 group. The PCT level in the muscle was not significantly different among the G1, G2, G3, and G4 groups (analysis of variance, P=0.693). Thus, PCT in the liver decreased at longer injection intervals, and PCT was no longer observed at injection intervals of more than 90 min. CONCLUSION: MET and FDG-PET examinations can be successfully performed on the same day without PCT between the studies if the injection interval is longer than 90 min. This method reduces the examination burden of patients and may be useful for performing multiple PET examinations while the patient's condition remains almost the same. © 2012 Wolters Kluwer Health.

    DOI: 10.1097/MNM.0b013e32834dfa38

    Scopus

    PubMed

  193. 4'-[Methyl-11C]-thiothymidine PET/CT for proliferation imaging in non-small cell lung cancer. International journal

    Ryogo Minamimoto, Jun Toyohara, Ayako Seike, Hideyuki Ito, Hisako Endo, Miyako Morooka, Kazuhiko Nakajima, Takuya Mitsumoto, Kimiteru Ito, Momoko Okasaki, Kiichi Ishiwata, Kazuo Kubota

    Journal of nuclear medicine : official publication, Society of Nuclear Medicine   Vol. 53 ( 2 ) page: 199 - 206   2012.2

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    UNLABELLED: A new tracer, 4'-[methyl-(11)C]-thiothymidine ((11)C-4DST), has been developed as an in vivo cell proliferation marker based on the DNA incorporation method. This study evaluated the potential of (11)C-4DST PET/CT for imaging proliferation in non-small cell lung cancer (NSCLC), compared with (18)F-FDG PET/CT. METHODS: Eighteen patients with lung lesions were examined by PET/CT using (11)C-4DST and (18)F-FDG. We constructed decay-corrected time-activity curves of 9 major regions as the mean standardized uptake value. We then compared the maximum standardized uptake value (SUVmax) of lung tumors on both (11)C-4DST and (18)F-FDG PET/CT with the Ki-67 index of cellular proliferation and with CD31-positive vessels as a marker of angiogenesis in surgical pathology. RESULTS: NSCLC was pathologically confirmed in 19 lesions of 18 patients. Physiologic accumulation of (11)C-4DST was high in liver, kidney, and bone marrow and low in aorta, brain, lung, and myocardium. Biodistribution of (11)C-4DST was almost stable by 20 min after injection of (11)C-4DST. Mean (11)C-4DST SUVmax for lung cancer was 2.9 ± 1.0 (range, 1.5-4.7), significantly different from mean (18)F-FDG SUVmax, which was 6.2 ± 4.5 (range, 0.9-17.3; P < 0.001). The correlation coefficient between SUVmax and Ki-67 index was higher with (11)C-4DST (r = 0.82) than with (18)F-FDG (r = 0.71). The correlation coefficient between SUVmax and CD31 was low with both (11)C-4DST (r = 0.21) and (18)F-FDG (r = 0.21), showing no significant difference between the tracers. CONCLUSION: A higher correlation with proliferation of lung tumors was seen for (11)C-4DST than for (18)F-FDG. (11)C-4DST PET/CT may allow noninvasive imaging of DNA synthesis in NSCLC.

    DOI: 10.2967/jnumed.111.095539

    Scopus

    PubMed

  194. Highly active anti-retrovirus therapy (HAART) effect on FDG uptake: a preliminary study

    Ryogo Minamimoto

    European Journal of Nuclear Medicine and Molecular Imaging     2012

     More details

    Publishing type:Research paper (scientific journal)  

    Web of Science

  195. A molecular imaging study of multiple myeloma: Comparison of 18F-FDG, 11C-Methionine (MET), and 11C-thiothymidine (4DST) PET

    Ryogo Minamimoto

    Journal of Nuclear Medicine     2012

     More details

    Publishing type:Research paper (scientific journal)  

    Web of Science

  196. Diagnosis of Kaposi's sarcoma in HIV positive patients: A change from Gallium negative Thallium positive to Gallium negative FDG positive

    Ryogo Minamimoto

    Journal of Nuclear Medicine     2012

     More details

    Publishing type:Research paper (scientific journal)  

    Web of Science

  197. Investigation of the usefulness of scintigraphy measuring fatty acid metabolism in staging diagnosis of nonalcoholic fatty liver diseases (NAFLD)

    Ryogo Minamimoto

    Hepatology     2012

     More details

    Publishing type:Research paper (scientific journal)  

    Web of Science

  198. Quantification of the total lung HU and the total lung SUV in normal lung with 18F-FDG-PET/CT: a multivariable analysis

    Ryogo Minamimoto

    European Journal of Nuclear Medicine and Molecular Imaging     2012

     More details

    Publishing type:Research paper (scientific journal)  

    Web of Science

  199. Proliferation imaging by 11C-4DST PET/CT for differentiation of malignant and benign lesion

    Ryogo Minamimoto

    Journal of Nuclear Medicine     2012

     More details

    Publishing type:Research paper (scientific journal)  

    Web of Science

  200. Myocardial inflammatory images: 18F-FDG PET/CT with heparin loading method in the patients with acute myocardial infarction

    Ryogo Minamimoto

    Journal of Nuclear Medicine     2012

     More details

    Publishing type:Research paper (scientific journal)  

    Web of Science

  201. The characteristics of the fully 3D-OSEM-PSF algorithm with PET/CT: Evaluation of NEMA body phantom of various concentrations models

    Ryogo Minamimoto

    Journal of Nuclear Medicine     2012

     More details

    Publishing type:Research paper (scientific journal)  

    Web of Science

  202. Validation of SUV body weight (SUVbw) vs SUV lean body mass (SUVlbm): The evaluation with each organ of the healthy subjects

    Ryogo Minamimoto

    Journal of Nuclear Medicine     2012

     More details

    Publishing type:Research paper (scientific journal)  

    Web of Science

  203. Evaluation of organ-specific glucose metabolism by ^<18>F-FDG in insulin receptor substrate-1 (IRS-1) knockout mice as a model of insulin resistance

    CHENG Chao, NAKAMURA Akinobu, MINAMIMOTO Ryogo, SHINODA Kazuaki, TATEISHI Ukihide, GOTO Atsushi, KADOWAKI Takashi, TERAUCHI Yasuo, INOUE Tomio

      Vol. 25 ( 10 ) page: 755 - 761   2011.12

     More details

    Language:English  

    CiNii Research

  204. Evaluation of organ-specific glucose metabolism by ¹⁸F-FDG in insulin receptor substrate-1 (IRS-1) knockout mice as a model of insulin resistance.

    Chao Cheng, Akinobu Nakamura, Ryogo Minamimoto, Kazuaki Shinoda, Ukihide Tateishi, Atsushi Goto, Takashi Kadowaki, Yasuo Terauchi, Tomio Inoue

    Annals of nuclear medicine   Vol. 25 ( 10 ) page: 755 - 61   2011.12

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    OBJECTIVE: Insulin resistance (IR) is a physiological condition in which the body produces insulin but does not result in a sufficient biological effect. Insulin resistance is usually asymptomatic but is associated with health problems and is a factor in the metabolic syndrome. The aim of the present study is to clarify organ-specific insulin resistance in normal daily conditions using [(18)F]-2-fluoro-2-deoxy-D: -glucose ([(18)F]-FDG). METHODS: The biodistribution of [(18)F]-FDG was examined in insulin receptor substrate-1 (IRS-1) knockout mice, an animal model of skeletal muscle insulin resistance, and C57BL/6J (wild-type) mice with and without insulin loading. Mice received 0.5 MBq of [(18)F]-FDG injected into the tail vein, immediately followed by nothing (control cohorts) or an intraperitoneal injection of 1.5 mU/g body weight of human insulin as an insulin loading test. Blood glucose concentrations for all of the experimental animals were assessed at 0, 20, 40, and 60 min post-injection. The mice were subsequently killed, and tissue was collected for evaluation of [(18)F]-FDG biodistribution. The radioactivity of each organ was measured using a gamma counter. RESULTS: In the absence of insulin, the blood glucose concentrations of wild-type mice (132 ± 26 mg/dl) and IRS-1 knockout mice (134 ± 18 mg/dl) were not significantly different. Blood glucose concentrations decreased following insulin administration, with lower concentrations in wild-type mice than in knockout mice at 20, 40, and 60 min. A statistically significant difference in [(18)F]-FDG uptake between wild-type mice and IRS-1 knockout mice was confirmed in the heart, abdominal muscle, and femoral muscle. With insulin loading, [(18)F]-FDG uptake in the heart, back muscle, and abdominal muscle was significantly increased compared to without insulin loading in both wild-type mice and knockout mice. CONCLUSION: Our results showed that IR significantly affected [(18)F]-FDG uptake in the heart in normal daily conditions. IR was associated with decreased [(18)F]-FDG uptake in the heart and was readily observed in the absence of insulin loading. [(18)F]-FDG-positron emission tomography (PET) could be a useful tool for evaluating insulin resistance in images by investigating tissue-specific differences in [(18)F]-FDG uptake.

    DOI: 10.1007/s12149-011-0522-y

    Scopus

    PubMed

  205. Positron emission tomography for future drug development

    Minamimoto R., Theeraladanon C., Suzuki A., Inoue T.

    Recent Patents on Medical Imaging   Vol. 1 ( 2 ) page: 137 - 151   2011.11

     More details

    Publisher:Recent Patents on Medical Imaging  

    Productivity in the drug discovery and development process has seen a drastic decline over the last few years. Clearly, traditional approaches to drug development are not working. The new concept called "microdosing studies" was recently announced as a promising methodology for accreting drug development. The microdosing studies is a concept by administrating a low dose (microdose) of a candidate compound to human volunteers to obtain in vivo human pharmacokinetic (PK) data at an early stage of drug development. As a result unpromising candidate drugs can be eliminated at an earlier stage of drug development. A key component for this concept is highly sensitive analytical methods such as positron emission tomography (PET), accelerator mass spectrometry (AMS) and liquid chromatography-mass spectrometry (LC/MS/MS). This issue focuses on PET methodology from basic to future prospects for drug development and patents related to it. © 2011 Bentham Science Publishers.

    DOI: 10.2174/1877613211101020137

    Scopus

  206. Radiation exposure and risk-benefit analysis in cancer screening using FDG-PET : results of a Japanese nationwide survey

    MURANO Takeshi, MINAMIMOTO Ryogo, SENDA Michio, UNO Kimiichi, JINNOUCHI Seishi, FUKUDA Hiroshi, IINUMA Takeshi, TSUKAMOTO Eriko, TERAUCHI Takashi, YOSHIDA Tsuyoshi, OKU Shinya, NISHIZAWA Sadahiko, ITO Kengo, OGUCHI Kazuhiro, KAWAMOTO Masami, NAKASHIMA Rumi, IWATA Hiroshi, INOUE Tomio

      Vol. 25 ( 9 ) page: 657 - 666   2011.11

     More details

    Language:English  

    CiNii Research

  207. Radiation exposure and risk-benefit analysis in cancer screening using FDG-PET: Results of a Japanese nationwide survey

    Murano T., Minamimoto R., Senda M., Uno K., Jinnouchi S., Fukuda H., Iinuma T., Tsukamoto E., Terauchi T., Yoshida T., Oku S., Nishizawa S., Ito K., Oguchi K., Kawamoto M., Nakashima R., Iwata H., Inoue T.

    Annals of Nuclear Medicine   Vol. 25 ( 9 ) page: 657 - 666   2011.11

     More details

    Publisher:Annals of Nuclear Medicine  

    Objective: The aim of this study was to estimate radiation exposure and evaluate the risks and benefits of 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) in cancer screening. Methods: A nationwide survey of FDG-PET cancer screening was conducted in 2006, and the results were analyzed with a common index, "extension/shortening of the average life expectancy." Results: The average estimated effective dose was 4.4 mSv (male 4.7 mSv; female 4.0 mSv) for dedicated PET and 13.5 mSv (male 14.2 mSv; female 12.8 mSv) for PET/computed tomography (CT). The risk-benefit break-even age from the viewpoint of radiation exposure was in the 40s for men and 30s for women for dedicated PET and in the 50s for men and 50s (variable injection dose) or 60s (constant injection dose) for women for PET/CT. Conclusions: FDG-PET cancer screening is beneficial for examinees above the break-even ages. The risks and benefits should be explained to examinees because of the larger radiation used in cancer FDG-PET screening compared with other X-ray tests. © 2011 The Japanese Society of Nuclear Medicine.

    DOI: 10.1007/s12149-011-0511-1

    Scopus

  208. Cut-off value for normal versus abnormal right-to-left shunt percentages using (99m)Tc-macroaggregated albumin. International journal

    Kimiteru Ito, Kyoko Kurihara, Akihiko Ishibashi, Miyako Morooka, Takuya Mitsumoto, Ryogo Minamimoto, Kazuo Kubota

    Nuclear medicine communications   Vol. 32 ( 10 ) page: 936 - 40   2011.10

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    OBJECTIVE: To determine the cut-off value for distinguishing a normal versus an abnormal right-to-left shunt percentage on lung perfusion scintigraphy using (99m)Tc-macroaggregated albumin (MAA). MATERIALS AND METHODS: Fifty-three patients (eight patients with a right-to-left shunt and 45 without a right-to-left shunt) who underwent MAA whole-body imaging for the evaluation of right-to-left shunts were divided into group 1 (eight patients with brain MAA uptake) and group 2 (45 patients without brain MAA uptake). Moreover, group 2 was subdivided into two categories (groups 2a and 2b) based on the results of lung computed tomography, electrocardiography examinations, and pulmonary function tests. The average and standard deviation (SD) of each group were compared. In addition, we estimated the cut-off value for a normal right-to-left shunt percentage using whole-body imaging. RESULTS: The average right-to-left shunt percentage values and SD were 23.67±12.17% in group 1, 6.68±1.04% in group 2a, and 6.60±0.84% in group 2b. The shunt percentages of groups 2a and 2b were not significantly different (P=0.77). The estimated normal value (mean±2 SD) of group 2 was 6.64±0.94%. Meanwhile, the cut-off value was estimated as 10% based on the distributions of MAA shunt percentages for groups 1 and 2. CONCLUSION: The normal range (mean±2 SD) was 6.64±1.88%. The cut-off value for the normal right-to-left shunt percentage in MAA scintigraphy was 10%.

    DOI: 10.1097/MNM.0b013e32834a123f

    Scopus

    PubMed

  209. Clinical role of FDG PET/CT for methotrexate-related malignant lymphoma. International journal

    Ryogo Minamimoto, Kimiteru Ito, Kazuo Kubota, Miyako Morooka, Yoko Masuda-Miyata, Risen Hirai, Hideaki Kitahara, Akira Tanimura, Shotaro Hagiwara, Akiyoshi Miwa

    Clinical nuclear medicine   Vol. 36 ( 7 ) page: 533 - 7   2011.7

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Methotrexate-related malignant lymphoma (MTX-RML) is a type of therapy-related lymphoma, and it often occurs in patients with rheumatoid arthritis. The most distinctive characteristic of MTX-RML is a quick response to withdrawal of MTX. However, because there is a risk of recurrence without a distinctive indicator of disease, close follow-up is needed. We present F-18 2-fluoro-2-deoxyglucose (FDG) postitron emission tomography (PET) or computed tomography (CT) images of MTX-RML along with the characteristic clinical presentation of MTX-RML. FDG PET/CT has the advantage of being able to detect malignant lymphoma in patients who have undergone MTX treatment. After withdrawal of MTX, FDG uptake decreases along with a reduction in the volume of lesions. Although recurrent lesion develops independent to the initial FDG PET/CT findings, FDG PET/CT is useful for early detection of unexpected recurrent lesions. FDG PET/CT allows for the assessment of malignant lymphoma and recurrent lesions in patients who received MTX therapy, which is crucial for the management of MTX-RML.

    DOI: 10.1097/RLU.0b013e3182177296

    Scopus

    PubMed

  210. A case of secondary hemochromatosis with high uptake of liver in F-18 FDG PET/CT imaging. International journal

    Kimiteru Ito, Ryogo Minamimoto, Miyako Morooka, Kazuo Kubota

    Clinical nuclear medicine   Vol. 36 ( 7 ) page: 606 - 8   2011.7

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Hemochromatosis is an iron storage disorder with progressive and massive deposition of iron in the parenchymal cells of various organs. A 72-year-old woman with rheumatoid arthritis diagnosed with secondary hemochromatosis underwent F-18 fluorodeoxyglucose (FDG) positron emission tomography(PET)/computed tomography (CT) to search for malignancy. F-18 FDG PET/CT incidentally showed homogeneous and high FDG uptake (mean SUV, 4.8) in the liver with high density. FDG uptake seemed to be reflected by the functional abnormality of liver. Hemochromatosis should be considered when making a diagnosis of homogeneous high F-18 FDG uptake in liver with high density on CT image.

    DOI: 10.1097/RLU.0b013e318217ae7c

    PubMed

  211. FDG-PET for the diagnosis of fever of unknown origin : a Japanese multi-center study

    KUBOTA Kazuo, NAKAMOTO Yuji, TAMAKI Nagara, KANEGAE Kakuko, FUKUDA Hiroshi, KANEDA Tomohiro, KITAJIMA Kazuhiro, TATEISHI Ukihide, MOROOKA Miyako, ITO Kimiteru, MINAMIMOTO Ryogo, MURAKAMI Koji

      Vol. 25 ( 5 ) page: 355 - 364   2011.6

     More details

    Language:English  

    CiNii Research

  212. FDG PET for rheumatoid arthritis: basic considerations and whole-body PET/CT. International journal

    Kazuo Kubota, Kimiteru Ito, Miyako Morooka, Ryogo Minamimoto, Yuko Miyata, Hiroyuki Yamashita, Yuko Takahashi, Akio Mimori

    Annals of the New York Academy of Sciences   Vol. 1228 ( 1 ) page: 29 - 38   2011.6

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    [(18) F]Fluorodeoxyglucose (FDG) is a tracer for glucose metabolism. Its distribution is not specific to cancer cells but is also observed in inflammatory tissue, including macrophages, capillaries, and fibroblasts. Rheumatoid arthritis (RA) is a systemic, chronic inflammation of the joints resulting in synovitis. The disease is characterized by fibrovascular proliferation leading to the formation of a pannus and causing high FDG uptake. Several clinical studies of RA have demonstrated that FDG uptake in affected joints reflects the disease activity of RA, with strong correlations between uptake and various clinical parameters having been noted. Furthermore, the use of FDG PET for the sensitive detection and monitoring of the response to RA therapy has been reported. FDG PET/computed tomography (CT) enables the detailed evaluation of disease in large joints throughout the whole body, which is a unique advantage of PET/CT. FDG PET/CT can also be used to detect high-risk disease complications, such as atlanto-axial joint involvement, at an early stage. The possible contribution of FDG PET to the management of patients with RA remains to be studied in detail.

    DOI: 10.1111/j.1749-6632.2011.06031.x

    Scopus

    PubMed

  213. FDG-PET for the diagnosis of fever of unknown origin: a Japanese multi-center study.

    Kazuo Kubota, Yuji Nakamoto, Nagara Tamaki, Kakuko Kanegae, Hiroshi Fukuda, Tomohiro Kaneda, Kazuhiro Kitajima, Ukihide Tateishi, Miyako Morooka, Kimiteru Ito, Ryogo Minamimoto, Koji Murakami

    Annals of nuclear medicine   Vol. 25 ( 5 ) page: 355 - 64   2011.6

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    OBJECTIVE: To evaluate the clinical value of 2-[(18)F]fluoro-2-deoxy-D: -glucose positron emission tomography (FDG-PET) for the diagnosis of fever of unknown origin (FUO), we performed a Japanese multi-center retrospective survey. METHODS: A total of 81 consecutive patients with FUO who underwent FDG-PET at 6 institutions between July 2006 and December 2007 were retrospectively evaluated. FDG uptake was visually evaluated using a 4-grade scale. The efficacy of FDG-PET for the evaluation of FUO, the provision of additional diagnostic information, the clinical impact on therapeutic decisions (4-grade scale), and the diagnostic performance compared with the final diagnosis were evaluated. RESULTS: The diagnostic results were analyzed according to 4 groups of final diagnoses: infection, arthritis/vasculitis/autoimmune/collagen disease (A/V), tumor/granuloma (T/G), and other/unknown (O/U). Sensitivity was highest in T/G, followed by infection, A/V and O/U [100%(7/7), 89%(24/27), 65%(11/17), 0%(0/1) respectively]. Clinical impact and mean FDG score showed the same tendency. Additional information was highest in infection followed by T/G, A/V, and O/U [76%(22/29), 75%(6/8), 43%(9/21), 23%(5/22), respectively]. The O/U group showed a high specificity (84%, 16/19) and accurately excluded active focal inflammatory diseases and malignancy. The use of steroids for the treatment of fever seemed to mask the lesions and modified the results, especially in the A/V group (4 false negatives in 8 steroid users out of 21 A/V patients). The prevalence of each disease in each hospital significantly affected the effectiveness of FDG-PET for the diagnosis of FUO. The mean FDG uptake score and additional information (70%, 31/44 vs. 30%, 11/37, respectively) in national hospital (NH) was significantly higher than in university hospitals (UH). A Grade 3 clinical impact, in which the FDG PET results changed the clinical decision, was seen in 50% (22/44) of the patients in the NH group and 13.5% (5/37) of the patients in the UH group. The sensitivity (91%, 30/33; 63%, 12/19) and specificity (60%, 6/10; 86%, 12/14) of the results in the NH and UH groups differed. The total sensitivity was 81% (42/52), specificity was 75% (18/24). The NH group included a large number of cases with infectious diseases (50%, 23/44), while the UH group included a large number of A/V cases (38%, 14/37) and O/U cases (41%, 15/37). CONCLUSION: FDG-PET for the diagnosis of FUO provided additional diagnostic information and had a high clinical impact, especially among patients with infectious diseases. It was also helpful in cases with unknown or other miscellaneous diseases by allowing the exclusion of focally active diseases. The prevalence of diseases in hospitals significantly affected the effectiveness of FDG-PET for the diagnosis of FUO. FDG-PET is a useful examination providing various degrees of clinical impact for the management of FUO, depending on the characteristics of the patient and the hospital.

    DOI: 10.1007/s12149-011-0470-6

    Scopus

    PubMed

  214. Value of FDG-PET/CT using unfractionated heparin for managing primary cardiac lymphoma and several key findings

    Minamimoto R., Morooka M., Kubota K., Ito K., Masuda-Miyata Y., Mitsumoto T., Hirai R., Okazaki O., Hiroe M.

    Journal of Nuclear Cardiology   Vol. 18 ( 3 ) page: 516 - 520   2011.5

     More details

    Language:English   Publisher:Journal of Nuclear Cardiology  

    DOI: 10.1007/s12350-011-9358-z

    Scopus

    PubMed

  215. Effects of blood glucose level on FDG uptake by liver: a FDG-PET/CT study. International journal

    Kazuo Kubota, Hiroshige Watanabe, Yuji Murata, Masashi Yukihiro, Kimiteru Ito, Miyako Morooka, Ryogo Minamimoto, Ai Hori, Hitoshi Shibuya

    Nuclear medicine and biology   Vol. 38 ( 3 ) page: 347 - 51   2011.4

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    UNLABELLED: In FDG-PET for abdominal malignancy, the liver may be assumed as an internal standard for grading abnormal FDG uptake both in early images and in delayed images. However, physiological variables of FDG uptake by the liver, especially the effects of blood glucose level, have not yet been elucidated. METHODS: FDG-PET studies of 70 patients examined at 50 to 70 min after injection (60 ± 10 min: early images) and of 68 patients examined at 80 to 100 min after injection (90 ± 10 min: delayed images) were analyzed for liver FDG uptake. Patients having lesions in the liver, spleen and pancreas; patients having bulk tumor in other areas; and patients early after chemotherapy or radiotherapy were excluded; also, patients with blood glucose level over 125 mg/dl were excluded. RESULTS: Mean standardized uptake value (SUV) of the liver, blood glucose level and sex showed no significant differences between early images and delayed images. However, liver SUV in the delayed image showed a larger variation than that in the early image and showed significant correlation to blood glucose level. The partial correlation coefficient between liver SUV and blood glucose level in the delayed image with adjustment for sex and age was 0.73 (P < .0001). Multivariate regression coefficient (95% confidence interval) of blood glucose was 0.017 (0.013-0.021). CONCLUSION: Blood glucose level is an important factor affecting the normal liver FDG uptake in nondiabetic patients. In the case of higher glucose level, liver FDG uptake is elevated especially in the delayed image. This may be due to the fact that the liver is the key organ responsible for glucose metabolism through gluconeogenesis and glycogen storage.

    DOI: 10.1016/j.nucmedbio.2010.09.004

    Scopus

    PubMed

  216. Usefulness of F-18 FDG PET/CT in a case of Kaposi sarcoma with an unexpected bone lesion.

    Morooka M., Ito K., Kubota K., Yanagisawa K., Teruya K., Hasuo K., Shida Y., Minamimoto R., Kikuchi Y., Oka S.

    Clinical nuclear medicine   Vol. 36 ( 3 ) page: 231 - 234   2011.3

     More details

    Language:English   Publisher:Clinical nuclear medicine  

    Bone lesions of Kaposi sarcoma are rare. A 56-year-old man who was HIV positive and was diagnosed with Kaposi sarcoma on the basis of the results of a biopsy of skin lesions, underwent F-18 FDG PET/CT scan for detecting Kaposi sarcoma lesions and other AIDS-related diseases. An abnormal uptake was observed in the lumbar spine. MRI showed a diffuse enhanced spine lesion, and Ga-67 and 21Tl scanning were negative. As a result, the lesion was considered to be a Kaposi sarcoma, and the shrinkage of the lesion was noted after the therapy for Kaposi sarcoma.

    DOI: 10.1097/rlu.0b013e318208f4ea

    Scopus

    PubMed

  217. The Actual Situation and Risk-Benefit Analysis of Radiation Exposure in Cancer Screening Using FDG-PET on the Basis of Japanese Nationwide Survey

    MURANO Takeshi, MINAMIMOTO Ryogo, SENDA Michio, UNO Kimiichi, JINNOUCHI Seishi, FUKUDA Hiroshi, IINUMA Takeshi, TSUKAMOTO Eriko, TERAUCHI Takashi, YOSHIDA Tsuyoshi, OKU Shinya, NISHIZAWA Sadahiko, ITO Kengo, OGUCHI Kazuhiro, KAWAMOTO Masami, NAKASHIMA Rumi, IWATA Hiroshi, INOUE Tomio

      Vol. 48 ( 1 ) page: 1 - 13   2011.2

     More details

    Language:Japanese  

    CiNii Research

  218. The actual situation and risk-benefit analysis of radiation exposure in cancer screening using FDG-PET on the basis of Japanese nationwide survey

    Murano T., Minamimoto R., Senda M., Uno K., Jinnouchi S., Fukuda H., Iinuma T., Tsukamoto E., Terauchi T., Yoshida T., Shinya O.K.U., Nishizawa S., Ito K., Oguchi K., Kawamoto M., Nakashima R., Iwata H., Inoue T.

    Kakuigaku   Vol. 48 ( 1 ) page: 1 - 13   2011.2

     More details

    Publisher:Kakuigaku  

    Objective: The aim of study was to estimate the radiation exposure and to evaluate the risk and benefit for FDG-PET cancer screening. Method: A common standard, "expansion and contraction of the average of life expectancy," was used for risk-benefit analysis based on the survey of FDG-PET cancer screening in 2006. Results: The average of the estimated effective dose was 4.4 mSv (male 4.7 mSv, female 4.0 mSv) for dedicated PET, and was 13.5 mSv (male 14.2 mSv, female 12.8 mSv) for PET/CT. As a result, the risk-benefit break-even age from a viewpoint of radiation exposure was 40's for male and 30's for female for dedicated PET, and was 50's for male, and 50's (variable injected activity) or 60's (constant injected activity) for female for PET/CT. Conclusions: FDG-PET cancer screening is beneficial for examinees, depending on the age, gender, and type of examination (PET or PET/CT). However, it is necessary to explain the risk and benefit to the subjects because of larger radiation exposure than other X-ray tests used for cancer screening.

    Scopus

  219. Analysis of various malignant neoplasms detected by FDG-PET cancer screening program : based on a Japanese Nationwide Survey

    MINAMIMOTO Ryogo, SENDA Michio, TERAUCHI Takashi, JINNOUCHI Seishi, INOUE Tomio, IINUMA Takeshi, INOUE Takeshi, ITO Kengo, IWATA Hiroshi, UNO Kimiichi, OKU Shinya, OGUCHI Kazuhiro, TSUKAMOTO Eriko, NAKASHIMA Rumi, NISHIZAWA Sadahiko, FUKUDA Hiroshi, MURANO Takeshi, YOSHIDA Tsuyoshi

    Ann Nucl Med   Vol. 25 ( 1 ) page: 45 - 54   2011.1

     More details

    Language:English  

    CiNii Research

  220. The potential of FDG-PET/CT for detecting prostate cancer in patients with an elevated serum PSA level

    MINAMIMOTO Ryogo, UEMURA Hiroji, SANO Futoshi, TERAO Hideyuki, NAGASHIMA Yoji, YAMANAKA Shoji, SHIZUKUISHI Kazuya, TATEISHI Ukihide, KUBOTA Yoshinobu, INOUE Tomio

    Ann Nucl Med   Vol. 25 ( 1 ) page: 21 - 27   2011.1

     More details

    Language:English  

    CiNii Research

  221. Analysis of various malignant neoplasms detected by FDG-PET cancer screening program: based on a Japanese Nationwide Survey.

    Ryogo Minamimoto, Michio Senda, Takashi Terauchi, Seishi Jinnouchi, Tomio Inoue, Takeshi Iinuma, Takeshi Inoue, Kengo Ito, Hiroshi Iwata, Kimiichi Uno, Shinya Oku, Kazuhiro Oguchi, Eriko Tsukamoto, Rumi Nakashima, Sadahiko Nishizawa, Hiroshi Fukuda, Takeshi Murano, Tsuyoshi Yoshida

    Annals of nuclear medicine   Vol. 25 ( 1 ) page: 45 - 54   2011.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    OBJECTIVE: The most distinctive feature of FDG-PET cancer screening program is the ability to find various kinds of malignant neoplasms in a single test. The aim of this survey is to clarify the range and frequency of various malignant neoplasms detected by FDG-PET cancer screening performed in Japan. METHODS: "FDG-PET cancer screening" was defined as FDG-PET or positron emission tomography and computed tomography (PET/CT) scan with or without other tests performed for cancer screening of healthy subjects. This survey was based on a questionnaire regarding FDG-PET cancer screening. We analyzed the situation of 9 less frequently found malignant neoplasms including malignant lymphoma, malignancy of head and neck, esophagus, hepatobiliary and gallbladder, pancreas, kidney, cervical and uterine, ovary, and bladder. RESULTS: The detailed information of subjects with the suspected 9 kinds of malignant neoplasms mentioned above in the FDG-PET cancer screening program was studied in a total of 1,219 cases from 212 facilities. A statistical significance between PET/CT and PET was found in relative sensitivity and PPV for renal cell cancer. Malignant lymphoma was frequently of indolent type, suspected head and neck cancers had many false-positive results, and pancreatic cancer detected in this program was often in the advanced stage even in asymptomatic subjects. The recommendation of combined screening modality to PET or PET/CT was as follows: gastric endoscopy for assessing early esophageal cancer; abdominal ultrasound for screening hepatobiliary and gallbladder cancer; pelvic magnetic resonance imaging for assessing gynecological and pelvic cancers; and the CA125 blood test for screening ovarian cancer. Delayed image was helpful depending on the type of suspected malignant neoplasm. CONCLUSION: We analyzed various types of malignant neoplasms detected by the FDG-PET cancer screening program and presented recommended combination of examinations to cover FDG-PET and PET/CT.

    DOI: 10.1007/s12149-010-0428-0

    Scopus

    PubMed

  222. The potential of FDG-PET/CT for detecting prostate cancer in patients with an elevated serum PSA level

    Minamimoto R., Uemura H., Sano F., Terao H., Nagashima Y., Yamanaka S., Shizukuishi K., Tateishi U., Kubota Y., Inoue T.

    Annals of Nuclear Medicine   Vol. 25 ( 1 ) page: 21 - 27   2011.1

     More details

    Language:English   Publisher:Annals of Nuclear Medicine  

    Purpose: The aim of this study is to evaluate the potential and limitation of FDG-PET/CT for detecting prostate cancer in subjects with an elevated serum prostate-specific antigen (PSA) level. Although [18F]-2-fluoro-2- deoxyglucose positron emission tomography (FDG-PET) has limited value in detecting prostate cancer, the potential of PET/CT has not been precisely evaluated, since positron emission tomography/computed tomography (PET/CT) provides accurate localization of functional findings obtained by PET. Methods: Subjects with an increasing PSA level suggestive of prostate cancer were enrolled in this study. FDG-PET/CT was performed prior to prostate biopsy and the findings were compared with the pathological results. Results: Fifty subjects with an elevated serum PSA level took part in this study. The sensitivity, specificity and positive predictive value (PPV) of FDG-PET/CT in the prostate were 51.9% (27/52 areas), 75.7% (112/148 areas) and 42.9% (27/63 areas), respectively; those in the peripheral zone were 73.3% (22/30 areas), 64.3% (45/70 areas) and 46.8% (22/47 areas), respectively; and those in the central gland were 22.7% (5/22 areas), 85.9% (67/78 areas) and 31.3% (5/16 areas), respectively. The estimated cut-off values according to the highest odds ratio (OR) were age of 70 years [OR: 7.00, 95% confidence interval (CI): 1.89-25.93] and a PSA value of 12.0 ng/ml (OR: 10.77, 95% CI: 2.78-41.74). The FDG-PET/CT could potentially detect cancer with 80.0% sensitivity and 87.0% PPV in cases with a Gleason score of 7 or greater. Conclusion: FDG-PET/CT was appropriate for detecting peripheral zone prostate cancer in patients at more than an intermediate risk. © 2010 The Japanese Society of Nuclear Medicine.

    DOI: 10.1007/s12149-010-0424-4

    Scopus

    PubMed

  223. 99mTc-Aprotinin scintigraphy for amyloid imaging

    Ryogo Minamimoto

    Journal of Nuclear Medicine     2011

     More details

    Publishing type:Research paper (scientific journal)  

    Web of Science

  224. Computer assisted cancer diagnosis from PET-CT using dynamic threshold adjustment method

    Ryogo Minamimoto

    Journal of Nuclear Medicine     2011

     More details

    Publishing type:Research paper (scientific journal)  

    Web of Science

  225. DNA synthesis imaging of non-small-cell lung cancer using a new PET tracer [11C]4DST

    Ryogo Minamimoto

    Journal of Nuclear Medicine     2011

     More details

    Publishing type:Research paper (scientific journal)  

    Web of Science

  226. FDG PET/CT AS IMAGING BIOMARKER FOR ADVANCED RENAL CELL CARCINOMA

    Ryogo Minamimoto

    Journal of Urology     2011

     More details

    Publishing type:Research paper (scientific journal)  

    DOI: 10.1016/J.JURO.2011.02.2106

    Web of Science

  227. The evaluation of the lesion detectability for performing C-11-Methionine and F-18-FDG PET on the same day based on NEMA/IEC body phantom

    Ryogo Minamimoto

    European Journal of Nuclear Medicine and Molecular Imaging     2011

     More details

    Publishing type:Research paper (scientific journal)  

    Web of Science

  228. Validation for two PET studies using 18F-FDG and 11C-Methionine on the same day

    Ryogo Minamimoto

    Journal of Nuclear Medicine     2011

     More details

    Publishing type:Research paper (scientific journal)  

    Web of Science

  229. Impact of maximum standardized uptake value (SUVmax) evaluated by 18-Fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography (18F-FDG-PET/CT) on survival for patients with advanced renal cell carcinoma: a preliminary report. International journal

    Kazuhiro Namura, Ryogo Minamimoto, Masahiro Yao, Kazuhide Makiyama, Takayuki Murakami, Futoshi Sano, Narihiko Hayashi, Ukihide Tateishi, Hanako Ishigaki, Takeshi Kishida, Takeshi Miura, Kazuki Kobayashi, Sumio Noguchi, Tomio Inoue, Yoshinobu Kubota, Noboru Nakaigawa

    BMC cancer   Vol. 10   page: 667 - 667   2010.12

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND: In this era of molecular targeting therapy when various systematic treatments can be selected, prognostic biomarkers are required for the purpose of risk-directed therapy selection. Numerous reports of various malignancies have revealed that 18-Fluoro-2-deoxy-D-glucose (18F-FDG) accumulation, as evaluated by positron emission tomography, can be used to predict the prognosis of patients. The purpose of this study was to evaluate the impact of the maximum standardized uptake value (SUVmax) from 18-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography (18F-FDG PET/CT) on survival for patients with advanced renal cell carcinoma (RCC). METHODS: A total of 26 patients with advanced or metastatic RCC were enrolled in this study. The FDG uptake of all RCC lesions diagnosed by conventional CT was evaluated by 18F-FDG PET/CT. The impact of SUVmax on patient survival was analyzed prospectively. RESULTS: FDG uptake was detected in 230 of 243 lesions (94.7%) excluding lung or liver metastases with diameters of less than 1 cm. The SUVmax of 26 patients ranged between 1.4 and 16.6 (mean 8.8 ± 4.0). The patients with RCC tumors showing high SUVmax demonstrated poor prognosis (P = 0.005 hazard ratio 1.326, 95% CI 1.089-1.614). The survival between patients with SUVmax equal to the mean of SUVmax, 8.8 or more and patients with SUVmax less than 8.8 were statistically different (P = 0.0012). This is the first report to evaluate the impact of SUVmax on advanced RCC patient survival. However, the number of patients and the follow-up period were still not extensive enough to settle this important question conclusively. CONCLUSIONS: The survival of patients with advanced RCC can be predicted by evaluating their SUVmax using 18F-FDG-PET/CT. 18F-FDG-PET/CT has potency as an "imaging biomarker" to provide helpful information for the clinical decision-making.

    DOI: 10.1186/1471-2407-10-667

    Scopus

    PubMed

  230. Primary sebaceous carcinoma of the tongue

    OSHIRO Hisashi, IWAI Toshinori, HIROTA Makoto, MITSUDO Kenji, TOHNAI Iwai, MINAMIMOTO Ryogo, OMURA MINAMISAWA Motoko, NAGASHIMA Yoji, YAMANAKA Shoji, FUKUI Takafumi, KANAZAWA Michiyo, SAGAWA Hiromi, MITA Kazuhiro, NAKAYAMA Takashi, INAYAMA Yoshiaki

    Med Mol Morphol   Vol. 43 ( 4 ) page: 246 - 252   2010.12

     More details

    Language:English  

    CiNii Research

  231. Evaluation of response to multikinase inhibitor in metastatic renal cell carcinoma by FDG PET/contrast-enhanced CT. International journal

    Ryogo Minamimoto, Noboru Nakaigawa, Ukihide Tateishi, Akiko Suzuki, Kazuya Shizukuishi, Takeshi Kishida, Takeshi Miura, Kazuhide Makiyama, Masahiro Yao, Yoshinobu Kubota, Tomio Inoue

    Clinical nuclear medicine   Vol. 35 ( 12 ) page: 918 - 23   2010.12

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    PURPOSE: Multikinase inhibitor (MKI) is a promising drug for treatment of metastatic renal cell carcinoma (mRCC). We explained the usefulness of [¹⁸F]-2-fluoro-2-deoxyglucose positron emission tomography/contrast-enhanced computed tomography (FDG PET/CECT) for mRCC in evaluating the early response to MKI and in predicting progression-free survival (PFS). METHODS: Patients who planned MKI treatment for mRCC were included in this prospective study. FDG PET/CECT was performed before MKI treatment and after one cycle of MKI treatment. Evaluation of the response to MKI was assessed by PET according to the European Organization for Research and Treatment of Cancer, by CT according to the Response Evaluation Criteria in Solid Tumors and appearance of central hypoattenuation (CHA). RESULTS: Twelve patients were enrolled in the study. Equality of response evaluation between PET and CT was in 8 patients (partial response [PR]: 1, stable disease [SD]: 6, progressive disease [PD]: 1). Among the other 4 patients, PET showed 2 patients with PR and 2 patients with PD, in contrast to the CT finding of SD in all 4 patients. PFS according to PET response showed a statistically significant difference between PR and SD (P < 0.05) and between PR and PD (P < 0.05), but not between PR and SD (P = 0.083). Positive CHA in metastatic lesions after MKI treatment was confirmed in 8 patients. PFS with positive CHA was 233.8 days, while that without CHA was 75.0 days (P < 0.05). CONCLUSION: FDG PET/CECT shows potential for evaluating early treatment response to MKI in mRCC and for predicting PFS.

    DOI: 10.1097/RLU.0b013e3181f9ddd9

    Scopus

    PubMed

  232. Whole-body <sup>18</sup>F-fluorodeoxyglucose positron emission tomography/computed tomography images before and after chemotherapy for Kaposi sarcoma and highly active antiretrovirus therapy

    Morooka M., Ito K., Kubota K., Minamimoto R., Shida Y., Hasuo K., Ito T., Tasato D., Honda H., Teruya K., Kikuchi Y., Ohtomo K.

    Japanese Journal of Radiology   Vol. 28 ( 10 ) page: 759 - 762   2010.12

     More details

    Language:English   Publisher:Japanese Journal of Radiology  

    Kaposi sarcoma is an acquired immunodeficiency syndrome-related disease that mainly involves the skin, gastrointestinal gut, and lungs. Whole-body 18F-fluorodeoxyglucose-positron emission tomography and computed tomography (FDG-PET/CT) scanning is useful for simultaneous detection of multiple lesions of Kaposi sarcoma. We present a 67-year-old man with a history of infection with human immunodeficiency virus who presented with numerous cutaneous lesions. FDG-PET/CT images showed lesions in the skin, lung, and lymph nodes. The gastrointestinal lesions were detected using gastric fiberscopy (GF) and colon fiberscopy (CF). After Kaposi sarcoma therapy, the uptake in the lesions of the skin, lung, and lymph nodes decreased, but new lesions were detected in the pancreas and lumbar spine. He had pancreatitis and Candida spondilitis. Whole-body FDG-PET/CT is useful for detecting lesions and determining the extension to which the disease has spread, adding the gastrointestinal lesions by GF and CF. After therapy, FDG-PET/CT can be used to demonstrate which lesions remain active and to determine the overall response to treatment. In this case, we show how useful FDG-PET/CT is and how difficult it is to treat Kaposi sarcoma. © 2010 Japan Radiological Society.

    DOI: 10.1007/s11604-010-0481-6

    Scopus

    PubMed

  233. Primary sebaceous carcinoma of the tongue.

    Hisashi Oshiro, Toshinori Iwai, Makoto Hirota, Kenji Mitsudo, Iwai Tohnai, Ryogo Minamimoto, Motoko Omura-Minamisawa, Yoji Nagashima, Shoji Yamanaka, Takafumi Fukui, Michiyo Kanazawa, Hiromi Sagawa, Kazuhiro Mita, Takashi Nakayama, Yoshiaki Inayama

    Medical molecular morphology   Vol. 43 ( 4 ) page: 246 - 52   2010.12

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Sebaceous carcinoma is the rarest type of oral malignancies. We report a case of primary sebaceous carcinoma of the tongue. Systemic imaging studies revealed that the patient had a T2N2cM0 (International Union Against Cancer guidelines) primary lingual tumor. Histopathological examination revealed neoplastic sebocytic and basaloid cells, and Sudan III staining and electron microscopy revealed intracytoplasmic lipid droplets. The neoplastic cells stained positive for adipophilin; epithelial membrane antigen; epithelial antigen; and cytokeratins 7, 8, and 15, but negative for cytokeratins 5/6, 18, 19, and 20; the androgen receptor; and carcinoembryonic antigen. Superselective intraarterial chemotherapy was administered via the superficial temporal artery concurrent with daily radiotherapy. Multiple biopsies confirmed a complete response of the primary lesion. The patient then underwent neck dissection followed by pathological examination, which revealed lymph nodes metastases. After postoperative radiotherapy to the neck, distant metastases were identified in the mediastinal lymph nodes and the lung. The patient died 17 months after completing the initial course of chemoradiotherapy. Our case demonstrates that superselective intraarterial chemotherapy combined with concurrent radiotherapy can be effective in treating the primary lesion of patients with a sebaceous carcinoma of the tongue. However, an effective strategy to eradicate metastases has yet to be established.

    DOI: 10.1007/s00795-010-0521-4

    Scopus

    PubMed

  234. A meta-analysis of ^<18>F-Fluoride positron emission tomography for assessment of metastatic bone tumor

    TATEISHI Ukihide, MORITA Satoshi, TAGURI Masataka, SHIZUKUISHI Kazuya, MINAMIMOTO Ryogo, KAWAGUCHI Masashi, MURANO Takeshi, TERAUCHI Takashi, INOUE Tomio, KIM E. Edmund

      Vol. 24 ( 7 ) page: 523 - 531   2010.8

     More details

    Language:English  

    CiNii Research

  235. Optimum emission time in deep-inspiration breath-hold PET-CT : a preliminary result

    MIYASHITA Koichi, TATEISHI Ukihide, NISHIYAMA Yuji, MINAMIMOTO Ryogo, SHIZUKUISHI Kazuya, INOUE Tomio

      Vol. 24 ( 7 ) page: 559 - 563   2010.8

     More details

    Language:English  

    CiNii Research

  236. A meta-analysis of (18)F-Fluoride positron emission tomography for assessment of metastatic bone tumor.

    Ukihide Tateishi, Satoshi Morita, Masataka Taguri, Kazuya Shizukuishi, Ryogo Minamimoto, Masashi Kawaguchi, Takeshi Murano, Takashi Terauchi, Tomio Inoue, E Edmund Kim

    Annals of nuclear medicine   Vol. 24 ( 7 ) page: 523 - 31   2010.8

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    PURPOSE: The aim of this study was to assess the diagnostic performance of (18)F-Fluoride positron emission tomography (PET) or positron emission tomography/computed tomography (PET/CT) compared with bone scintigraphy (BS) planar or BS planar and single photon emission computed tomography (SPECT) in evaluating patients with metastatic bone tumor. MATERIALS AND METHODS: We performed a meta-analysis of all available studies addressing the diagnostic accuracy of (18)F-Fluoride PET, (18)F-Fluoride PET/CT, BS planar, and BS planar and SPECT for detecting the metastatic bone tumor. We determined sensitivities and specificities across studies, calculated positive and negative likelihood ratios, and drew summary receiver operating characteristic curves using hierarchical regression models. We also compared the effective dose and cost-effectiveness estimated by data from the enrolled studies between (18)F-Fluoride PET or PET/CT and BS planar or BS planar and SPECT. RESULTS: When comparing all studies with data on (18)F-Fluoride PET or PET/CT, sensitivity and specificity were 96.2% [95% confidence interval (CI) 93.5-98.9%] and 98.5% (95% CI 97.0-100%), respectively, on a patient basis and 96.9% (95% CI 95.9-98.0%) and 98.0% (95% CI 97.1-98.9%), respectively, on a lesion basis. The Az values of (18)F-Fluoride PET or PET/CT were 0.986 for the patient basis and 0.905 for the lesion basis, whereas those of BS or BS and SPECT were 0.866 for the patient basis and 0.854 for the lesion basis. However, the estimated effective dose and average cost-effective ratio were poorer for (18)F-Fluoride PET or PET/CT than those of BS planar or BS planar and SPECT. CONCLUSION: (18)F-Fluoride PET or PET/CT has excellent diagnostic performance for the detection of metastatic bone tumor, but the estimated effective dose and average cost-effective ratio are at a disadvantage compared with BS planar or BS planar and SPECT.

    DOI: 10.1007/s12149-010-0393-7

    Scopus

    PubMed

  237. Optimum emission time in deep-inspiration breath-hold PET-CT: a preliminary result.

    Koichi Miyashita, Ukihide Tateishi, Yuji Nishiyama, Ryogo Minamimoto, Kazuya Shizukuishi, Tomio Inoue

    Annals of nuclear medicine   Vol. 24 ( 7 ) page: 559 - 63   2010.8

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    OBJECTIVE: The purpose of this study was to investigate optimum emission time of deep inspiration breath-hold (DIBH) positron emission tomography-computed tomography (PET-CT). METHODS: We collected 15 PET-CT data sets by adding data of every 10 s and acquisition time ranging from 10 s (1 x 10 s acquisition) to 150 s (15 x 10 s acquisition) for both of DIBH mode and free-breathing condition (continuous mode) in phantom study. The coefficient of variation (CV) of radioactivity concentration was compared to determine optimum emission time of PET-CT. We also compared images of DIBH mode and continuous mode to clarify the influence of diaphragmatic movement in clinical setting. RESULTS: The mean +/- SD of CV in DIBH mode was 1236.3 +/- 323.1. When compared with the CV at 120 s, the relative error of CV is within 10% at 110 s (0.204), 15% at 100 s (0.212), and 20% at 90 s (0.222), respectively. Optimum emission time greater than 90 s is required to obtain clinically available images in DIBH mode. In the clinical setting, the SUV of the lung base and measurements of uptake show little influence by respiration on DIBH PET-CT. CONCLUSIONS: Optimum emission time of DIBH technique greater than 90 s acquisition is preferable for clinical use.

    DOI: 10.1007/s12149-010-0396-4

    Scopus

    PubMed

  238. F-18 FDG PET/CT evaluation of radiotherapy response in rare case of mucosa-associated lymphoid tissue lymphoma

    MINAMIMOTO Ryogo, TATEISHI Ykihide, TOMITA Naoto, INAYAMA Yoshiaki, OMURA MINAMISAWA Motoko, TAYAMA Yoshibumi, HATA Masaharu, KUBOTA Yoshinobu, INOUE Tomio

      Vol. 24 ( 2 ) page: 115 - 119   2010.2

     More details

    Language:English  

    CiNii Research

  239. F-18 FDG PET/CT evaluation of radiotherapy response in rare case of mucosa-associated lymphoid tissue lymphoma.

    Ryogo Minamimoto, Ukihide Tateishi, Naoto Tomita, Yoshiaki Inayama, Motoko Omura-Minamisawa, Yoshibumi Tayama, Masaharu Hata, Yoshinobu Kubota, Tomio Inoue

    Annals of nuclear medicine   Vol. 24 ( 2 ) page: 115 - 9   2010.2

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    We experienced two cases of mucosa-associated lymphoid tissue (MALT) lymphoma arising at unusual locations and used F-18 fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) to evaluate their response to radiation therapy (RT). A 62-year-old male with proven prostatic MALT lymphoma and a 43-year-old woman with proven duodenal MALT lymphoma had diffuse FDG uptake in the lesion. Both cases were treated with RT; following FDG, PET/CT showed decreased FDG uptake in each lesion. Neither patient had evidence of recurrence at more than 18 months after RT. FDG PET/CT is useful for indicating the treatment site in MALT lymphoma and in evaluation of therapeutic response following RT.

    DOI: 10.1007/s12149-009-0335-4

    Scopus

    PubMed

  240. Correlation analysis of measurement result between accelerator mass spectrometry and gamma counter

    MINAMIMOTO Ryogo, HAMABE Yoshimi, CHENG Chao, SHIMODA Marika, OKA Takashi, INOUE Tomio

      Vol. 24 ( 1 ) page: 45 - 52   2010.1

     More details

    Language:English  

    CiNii Research

  241. Correlation analysis of measurement result between accelerator mass spectrometry and gamma counter.

    Ryogo Minamimoto, Yoshimi Hamabe, Chao Cheng, Marika Shimoda, Takashi Oka, Tomio Inoue

    Annals of nuclear medicine   Vol. 24 ( 1 ) page: 45 - 52   2010.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    OBJECTIVE: The guidelines for microdosing in clinical trials were published in Japan in 2008 following the guidelines of the European Medicines Agency and the Food and Drug Administration. They recommend utilizing accelerator mass spectrometry (AMS) and positron emission tomography as candidates for monitoring drug metabolites in preclinical studies. We correlate the two methods by measuring appropriately labeled tissue samples from various mouse organs using both AMS and gamma counter. METHODS: First, we measured the (14)C background levels in mouse organs using the AMS system. We then clarified the relationship between AMS and gamma counter by simultaneously administering (14)C-2-fluoro-2-deoxyglucose ((14)C-FDG) and (18)F-2-fluoro-2-deoxyglucose ((18)F-FDG). Tissue distribution was examined after 30 min, 1 h, 2 h and 4 h using the AMS system for (14)C-FDG and gamma counter for (18)F-FDG. Background (14)C levels were subtracted from the data obtained with radiotracer administration. RESULTS: The background (14)C concentration differed with tissue type measured. Background (14)C concentration in mouse liver was higher than in other organs, and was approximately 1.5-fold that in blood. The correlation coefficient (r) of the measurements between AMS ((14)C-FDG) and gamma counter ((18)F-FDG) was high in both normal (0.99 in blood, 0.91 in brain, 0.61 in liver and 0.78 in kidney) and tumor-bearing mice (0.95 in blood and 0.99 in tumor). The clearance profile of (18)F-FDG was nearly identical to that of (14)C-FDG measured with AMS. CONCLUSIONS: Accelerator mass spectrometry analysis has an excellent correlation with biodistribution measurements using gamma counter. Our results suggest that the combination of AMS and PET can act as a complementary approach to accelerate drug development.

    DOI: 10.1007/s12149-009-0327-4

    Scopus

    PubMed

  242. APP-068 <sup>18</sup>F-FDG PET/CTによる進行性腎細胞癌の臨床経過予測の検討(発表・討論,総会賞応募ポスター,第98回日本泌尿器科学総会)

    中井川 昇, 南村 和宏, 南本 亮吾, 佐野 太, 槙山 和秀, 小林 一樹, 野口 純男, 石垣 華子, 岸田 健, 三浦 猛, 井上 登美夫, 矢尾 正祐, 窪田 吉信

    日本泌尿器科学会雑誌   Vol. 101 ( 2 ) page: 214   2010

     More details

    Language:Japanese   Publisher:一般社団法人 日本泌尿器科学会  

    DOI: 10.5980/jpnjurol.101.214_2

    CiNii Research

  243. Correlation of PET and AMS analyses for early kinetics of 2-fluoro-2-deoxyglucose(FDG) Reviewed

    南本 亮吾

    Nuclear Instruments and Methods in Physics Research, section B, Beam Interaction with Materials and Atoms 268     page: 1321 - 1323   2010

     More details

  244. Correlation of PET and AMS analyses for early kinetics of 2-fluoro-2 deoxy-glucose (FDG) Nuclear Instruments and Methods in Physics Research Reviewed

    南本 亮吾

    section B, Beam Interaction with Materials and Atoms 268巻     page: 1321 - 1323   2010

     More details

  245. Correlation analysis of measurement result between accelerator mass spectrometry and gamma counter. Reviewed

    南本 亮吾

    Ann Nucl Med. 2010 24巻     page: 45 - 52   2010

     More details

  246. Correlation analysis of measurement result between accelerator mass spectrometry and gamma counter Reviewed

    南本 亮吾

    Annals of Nuclear Medicine 24     page: 45 - 52   2010

     More details

  247. Correlation of PET and AMS analyses for early kinetics of 2-fluoro-2-deoxyglucose (FDG)

    Ryogo Minamimoto

    Nuclear Instruments and Methods in Physics Research Section B: Beam Interactions with Materials and Atoms   Vol. 268 ( 7-8 ) page: 1321 - 1323   2010

     More details

    Publishing type:Research paper (scientific journal)  

    DOI: 10.1016/J.NIMB.2009.10.163

    Web of Science

    Scopus

  248. Evaluation of multikinase inhibitor treatment response for renal cell carcinoma by FDG-PET/contrast enhanced CT

    Ryogo Minamimoto

    Journal of Nuclear Medicine     2010

     More details

    Publishing type:Research paper (scientific journal)  

    Web of Science

  249. PET/AMS Applications in Drug Development

    Ryogo Minamimoto

    Molecular Imaging for Integrated Medical Therapy and Drug Development     2010

     More details

    Publishing type:Research paper (scientific journal)  

    DOI: 10.1007/978-4-431-98074-2_25

    Web of Science

  250. Normal 18F-FDG PET/CT images with heparin loading method; is it homogenous?

    Ryogo Minamimoto

    European Journal of Nuclear Medicine and Molecular Imaging     2010

     More details

    Publishing type:Research paper (scientific journal)  

    Web of Science

  251. FDG PET/CT as an imaging biomarker for patients with metastatic renal cell carcinoma

    Ryogo Minamimoto

    European Journal of Cancer, Supplement     2010

     More details

    Publishing type:Research paper (scientific journal)  

    DOI: 10.1016/S1359-6349(10)72330-2

    Web of Science

  252. Assessment of Diagnostic Criteria for FDG-PET Cancer Screening Program According to the Interpretation of FDG-PET and Combined Examination

    Minamimoto R., Senda M., Jinnouchi S., Yoshida T., Nakashima R., Nishizawa S., Terauchi T., Kawamoto M., Inoue T.

    Kakuigaku   Vol. 46 ( 2 ) page: 73 - 93   2009.8

     More details

    Publisher:Kakuigaku  

    Objection: The aim of this study is to establish the diagnostic criteria for FDG-PET cancer screening program of four kinds of organ (breast, thyroid, lung and colon/rectum) according to the interpretation of FDGPET cancer screening program of the case with proved clinical outcome. Methods: Among FDG-PET cancer screening examinations performed in two PET centers during 2003 to 2006, two hundreds of examinations with proved clinical outcome were evaluated. Interpretation of breast ultrasonography, thyroid ultrasonography, chest CT and fecal occult blood testing, which were regarded as combined examinations, were performed together with the interpretation of FDG-PET images. Results: As a result of the interpretation, localized FDG accumulating site in all four organs should be recommended for further inspections. In addition, essential point for diagnosis was considered as follows; ( 1 ) check over the slight localized FDG accumulation with screening of breast region, (2) combine chest CT with FDGPET for the evaluation of lung region and (3) check up the shift of FDG accumulation between early and delayed phase with screening of colon/rectum region. Conclusions: According to the interpretation results of this study, we establish diagnostic criteria of FDG-PET and combined examination of four kinds of organ.

    Scopus

  253. PETがん検診の疫学調査

    千田 道雄, 井上 登美夫, 宇野 公一, 陣之内 正史, 塚本 江利子, 寺内 隆司, 中島 留美, 西澤 貞彦, 南本 亮吾, 吉田 毅

    核医学 : 日本核医学会機関誌 : the Japanese journal of nuclear medicine   Vol. 46 ( 2 ) page: 100 - 102   2009.6

     More details

    Language:Japanese  

    CiNii Research

  254. Assessment of Diagnostic Criteria for FDG-PET Cancer Screening Program According to the Interpretation of FDG-PET and Combined Examination

    MINAMIMOTO Ryogo, SENDA Michio, JINNOUCHI Seishi, YOSHIDA Tsuyoshi, NAKASHIMA Rumi, NISHIZAWA Sadahiko, TERAUCHI Takashi, KAWAMOTO Masami, INOUE Tomio

      Vol. 46 ( 2 ) page: 73 - 93   2009.6

     More details

    Language:Japanese  

    CiNii Research

  255. [Assessment of diagnostic criteria for FDG-PET cancer screening program according to the interpretation of FDG-PET and combined examination].

    Ryogo Minamimoto, Michio Senda, Seishi Jinnouchi, Tsuyoshi Yoshida, Rumi Nakashima, Sadahiko Nishizawa, Takashi Terauchi, Masami Kawamoto, Tomio Inoue

    Kaku igaku. The Japanese journal of nuclear medicine   Vol. 46 ( 2 ) page: 73 - 93   2009.6

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

    OBJECTIVE: The aim of this study is to establish the diagnostic criteria for FDG-PET cancer screening program of four kinds of organ (breast, thyroid, lung and colon/rectum) according to the interpretation of FDG-PET cancer screening program of the case with proved clinical outcome. METHODS: Among FDG-PET cancer screening examinations performed in two PET centers during 2003 to 2006, two hundreds of examinations with proved clinical outcome were evaluated. Interpretation of breast ultrasonography, thyroid ultrasonography, chest CT and fecal occult blood testing, which were regarded as combined examinations, were performed together with the interpretation of FDG-PET images. RESULTS: As a result of the interpretation, localized FDG accumulating site in all four organs should be recommended for further inspections. In addition, essential point for diagnosis was considered as follows; (1) check over the slight localized FDG accumulation with screening of breast region, (2) combine chest CT with FDG-PET for the evaluation of lung region and (3) check up the shift of FDG accumulation between early and delayed phase with screening of colon/rectum region. CONCLUSIONS: According to the interpretation results of this study, we establish diagnostic criteria of FDG-PET and combined examination of four kinds of organ.

    PubMed

  256. Avid F-18 FDG uptake in prostatic sarcoma. International journal

    Ryogo Minamimoto, Ukihide Tateishi, Hiroji Uemira, Shoji Yamanaka, Yoshinobu Kubota, Tomio Inoue

    Clinical nuclear medicine   Vol. 34 ( 6 ) page: 388 - 9   2009.6

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1097/RLU.0b013e3181a34681

    Scopus

    PubMed

  257. [Epidemiological study on PET cancer screening].

    Michio Senda, Tomio Inoue, Koichi Uno, Masafumi Jinnouchi, Eriko Tsukamoto, Takashi Terauchi, Rumi Nakajima, Sadahiko Nishizawa, Ryogo Minamimoto, Tsuyoshi Yoshida

    Kaku igaku. The Japanese journal of nuclear medicine   Vol. 46 ( 2 ) page: 100 - 2   2009.6

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

    PubMed

  258. PP-395 FDG PET-CTを用いた前立腺癌診断の試み(第3報)(前立腺腫瘍/診断・画像,一般演題ポスター,第97回日本泌尿器科学会総会)

    三宅 見季, 寺尾 秀行, 佐野 太, 南本 亮吾, 中井川 昇, 三好 康秀, 上村 博司, 窪田 吉信, 井上 登美夫

    日本泌尿器科学会雑誌   Vol. 100 ( 2 ) page: 415   2009

     More details

    Language:Japanese   Publisher:一般社団法人 日本泌尿器科学会  

    DOI: 10.5980/jpnjurol.100.415_3

    CiNii Research

  259. A prospective comparison of tumor metabolic and hypoxic volume with Cu-ATSM and FDG PET/CT

    Ryogo Minamimoto

    Journal of Nuclear Medicine     2009

     More details

    Publishing type:Research paper (scientific journal)  

    Web of Science

  260. Advantage of accelerator mass spectrometry (AMS) for drug research

    Ryogo Minamimoto

    Journal of Nuclear Medicine     2009

     More details

    Publishing type:Research paper (scientific journal)  

    Web of Science

  261. Prospective evaluation of diagnostic performance to detect bone metastasis with F-18 NaF PET/CT and Tc-99m MDP bone scintigraphy

    Ryogo Minamimoto

    Journal of Nuclear Medicine     2009

     More details

    Publishing type:Research paper (scientific journal)  

    Web of Science

  262. Synthesis and labeling of a novel EGFR and HER-2 tyrosine kinase inhibitor containing 4-anilinoquinoline-3-carbonitrile nucleus

    Ryogo Minamimoto

    Journal of Nuclear Medicine     2009

     More details

    Publishing type:Research paper (scientific journal)  

    Web of Science

  263. Value of FDG-PET/CT to detect prostate cancer in patient with elevated serum PSA

    Ryogo Minamimoto

    Journal of Nuclear Medicine     2009

     More details

    Publishing type:Research paper (scientific journal)  

    Web of Science

  264. Whole-body FDG-PET in children with idiopathic juvenile arthritis: An evaluation study in relation to symptoms and clinical findings

    Ryogo Minamimoto

    Journal of Nuclear Medicine     2009

     More details

    Publishing type:Research paper (scientific journal)  

    Web of Science

  265. Accelerator mass spectrometry analysis of background ^<14>C-concentrations in human blood : aiming at reference data for further microdosing studies

    MINAMIMOTO Ryogo, HAMABE Yoshimi, MIYAOKA Teiji, HARA Takamitsu, YOSHIDA Keisuke, OKA Takashi, INOUE Tomio

    Ann. Nucl. Med.   Vol. 22 ( 10 ) page: 883 - 889   2008.12

     More details

    Language:English  

    CiNii Research

  266. Accelerator mass spectrometry analysis of background (14)C-concentrations in human blood: aiming at reference data for further microdosing studies.

    Ryogo Minamimoto, Yoshimi Hamabe, Teiji Miyaoka, Takamitsu Hara, Keisuke Yoshida, Takashi Oka, Tomio Inoue

    Annals of nuclear medicine   Vol. 22 ( 10 ) page: 883 - 9   2008.12

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    OBJECTIVE: Phase 0 clinical studies, which are known as microdose trials, are expected to promote drug development and reduce development costs. The accelerator mass spectrometry (AMS) system is expected to play an important role in the microdosing tests, as it is a highly sensitive measurement system that can be used to determine the drug concentrations in these tests. Using the AMS system, we measured the background (14)C-concentration in human blood and evaluated the data for use as a reference in microdose studies that administer (14)C-labeled compounds in humans. METHODS: Blood samples of five healthy Japanese volunteers (three men, two women, median age 40.4 +/- 9.8 years) were collected around the same time and just prior to when the subjects ate a meal (between 12:00 noon and 2:00 pm). Centrifugal separations of blood that was allowed to clot and the plasma were performed at 503 g for 2 min at 4 degrees C. Background (14)C-concentration for each of the samples was measured using the AMS system. The Institute of Accelerator Analysis, which is the first contract research organization in Japan that is capable of providing AMS analysis services for carbon dating and bioanalysis work, performed the AMS analysis. RESULTS: The mean (14)C-concentration in blood was 1.613 +/- 0.125 dpm/ml (men 1.668 +/- 0.114 dpm/ml, women 1.514 +/- 0.076 dpm/ml), in clots 2.373 +/- 0.087 dpm/ml (men 2.381 +/- 0.101 dpm/ml, women 2.357 +/- 0.060 dpm/ ml), and in plasma 0.648 +/- 0.049 dpm/ml (men 0.647 +/- 0.059 dpm/ml, women 0.649 +/- 0.032 dpm/ml). The coefficient variation (CV) for blood was 7.8% (men 6.9%, women 5.0%), for clots 3.7% (men 4.3%, women 2.5%), and for plasma 7.6% (men 9.1%, women 4.9%). The (14)C-concentrations of the clot and blood were higher than those of plasma. The (14)C-concentrations in the blood and plasma were slightly different between individuals when compared with the values for the clot, although the differences were quite small, with a CV value less than 7.8%. CONCLUSIONS: Even though the (14)C-concentration differed only slightly between individuals, (14)C-concentrations of the clot and blood were higher than those of the plasma. Therefore, the variation and difference of the background data for blood and plasma might be of use as a reference for microdosing test evaluations.

    DOI: 10.1007/s12149-008-0200-x

    Scopus

    PubMed

  267. PETがん検診の疫学調査

    千田 道雄, 南本 亮吾, 宇野 公一, 塚本 江利子, 中島 留美, 古田 毅, 井上 登美夫, 陣之内 正史, 寺内 隆司, 西澤 貞彦

    核医学 : 日本核医学会機関誌 : the Japanese journal of nuclear medicine   Vol. 45 ( 3 ) page: 229   2008.9

     More details

    Language:Japanese  

    CiNii Research

  268. Fluorine-18-labeled 5-fluorouracil is a useful radiotracer for differentiation of malignant tumors from inflammatory lesions

    SUGAE Sadatoshi, SUZUKI Akiko, TAKAHASHI Nobukazu, MINAMIMOTO Ryogo, CHENG Chao, THEERALADANON Chumpol, ENDO Itaru, TOGO Shinji, INOUE Tomio, SHIMADA Hiroshi

      Vol. 22 ( 1 ) page: 65 - 72   2008.1

     More details

    Language:English  

    CiNii Research

  269. Fluorine-18-labeled 5-fluorouracil is a useful radiotracer for differentiation of malignant tumors from inflammatory lesions.

    Sadatoshi Sugae, Akiko Suzuki, Nobukazu Takahashi, Ryogo Minamimoto, Chao Cheng, Chumpol Theeraladanon, Itaru Endo, Shinji Togo, Tomio Inoue, Hiroshi Shimada

    Annals of nuclear medicine   Vol. 22 ( 1 ) page: 65 - 72   2008.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    OBJECTIVE: [(18)F]-2-fluoro-2-deoxy-D-glucose ([(18)F]-FDG) is a useful radiotracer to detect malignant tumors. However, inflammatory processes are likely to be mistaken as malignant tumors owing to strong accumulation of [(18)F]-FDG. The fluorinated nucleoside base 5-fluorouracil has remained an important antimetabolite agent in the treatment of a variety of cancers. The objective of this study was to evaluate the possibility of discriminating between malignant tumors and inflammation by [(18)F]-5-fluorouracil ([(18)F]-5-FU). METHODS: [(18)F]-5-FU was made with >95% radiochemical purity in our laboratory. BALB/cAJcl-nu/nu mice were subcutaneously inoculated with colon carcinoma cell line, colon 26, into the left side of the back and turpentine oil into the right side of the back to cause chemical inflammation. We examined the biodistribution of [(18)F]-5-FU in control mice and tumor-inflammation mice. We also examined the biodistribution of [(18)F]-FDG as a baseline study. Approximately 1 MBq of either [(18)F]-5-FU or [(18)F]-FDG was injected into the tail vein of each mouse. The biodistribution study was performed at 1 and 2 h after injection. The radioactivity of each organ was measured by a gamma counter. RESULTS: [(18)F]-5-FU uptakes in the liver and the kidney were especially high. Tumor-to-blood ratios were significantly higher at 2 h than at 1 h (3.69 +/- 0.40 vs. 1.81 +/- 0.37, P < 0.001). Tumor-to-inflammation ratios at 2 h following injection were significantly higher than those at 1 h (1.94 +/- 0.44 vs. 1.26 +/- 0.20, P < 0.001). At 2 h after radiotracer injection, the tumor-to-inflammation ratio of [(18)F]-5-FU was significantly higher than that of [(18)F]-FDG (1.94 +/- 0.44 vs. 1.03 +/- 0.23, P = 0.001). CONCLUSIONS: Our data suggest that [(18)F]-5-FU has a diagnostic potential as a positron emission tomography ligand for differentiating malignant tumors from inflammatory lesions.

    DOI: 10.1007/s12149-007-0081-4

    Scopus

    PubMed

  270. WHAT CAN WE DO BY COMBINATION ANALYSIS OF PET IMAGING AND AMS?

    Hamabe Yoshimi, Minamimoto Ryogo, Inoue Tomio, Oka Takashi, Miyaoka Teiji, Shimoda Marika, Matsui Takao

    Abstracts of Annual meeting of Japanese Society for the Study of Xenobiotics   Vol. 23 ( 0 ) page: 292 - 292   2008

     More details

    Language:Japanese   Publisher:The Japanese Society for the Study of Xenobiotics  

    DOI: 10.14896/jssxmeeting.23.0.292.0

    CiNii Research

  271. Performance profile of FDG-PET and PET/CT for cancer screening on the basis of a Japanese Nationwide Survey

    MINAMIMOTO Ryogo, SENDA Michio, UNO Kimiichi, JINNOUCHI Seishi, IINUMA Takeshi, ITO Kengo, OKUYAMA Chio, OGUCHI Kazuhiro, KAWAMOTO Masami, SUZUKI Yutaka, TSUKAMOTO Eriko, TERAUCHI Takashi, NAKASHIMA Rumi, NISHIO Masami, NISHIZAWA Sadahiko, FUKUDA Hiroshi, YOSHIDA Tsuyoshi, INOUE Tomio

    Ann Nucl Med   Vol. 21 ( 9 ) page: 481 - 498   2007.11

     More details

    Language:English  

    CiNii Research

  272. Performance profile of FDG-PET and PET/CT for cancer screening on the basis of a Japanese Nationwide Survey

    Minamimoto R., Senda M., Uno K., Jinnouchi S., Iinuma T., Ito K., Okuyama C., Oguchi K., Kawamoto M., Suzuki Y., Tsukamoto E., Terauchi T., Nakashima R., Nishio M., Nishizawa S., Fukuda H., Yoshida T., Inoue T.

    Annals of Nuclear Medicine   Vol. 21 ( 9 ) page: 481 - 498   2007.11

     More details

    Publisher:Annals of Nuclear Medicine  

    Objective: The aim of this study is to survey the situation of 18F-fluorodeoxyglucose-positron emission tomography (FDG-PET) cancer screening in Japan and to describe its performance profile. Methods: "FDG-PET for cancer screening" was defined as FDG-PET or positron emission tomography and computed tomography (PET/CT) scan with or without other tests performed for cancer screening of healthy subjects. We sent questionnaires regarding FDG-PET cancer screening to 99 facilities in which FDG-PET tests were performed during the fiscal year 2005. Replies were obtained from 68 of the 99 facilities, of which 46 facilities performed FDG-PET cancer screening. The total number of subjects who underwent FDG-PET cancer screening was 50 558. From 38 of 46 facilities, reliable results of thorough examinations were obtained for the subjects who were positive by FDG-PET and/or one or more of the combined screening tests was performed and were referred for further evaluation. The total number of subjects in these 38 facilities amounted to 43 996. Results: A total of 50 558 healthy subjects underwent FDG-PET (including PET/CT) scanning with or without other tests for cancer screening in 46 PET centers during the fiscal year of 2005 in Japan. Thorough examination was indicated for 9.8% of the cases as a result of positive findings suggesting possible cancer. On analyzing 43 996 cases from 38 PET centers from which detailed information was obtained, 500 cases of cancers (1.14%) were found, of which 0.90% were PET positive and 0.24% were PET negative, resulting in the relative sensitivity of PET being 79.0%. Cancers of the thyroid, colon/rectum, lung, and breast were most frequently found (107, 102, 79, and 35 cases, respectively) with high PET sensitivity (88%, 90%, 80%, and 92%). PET showed an overall positive predictive value of 29.0%. PET/CT had a better detection rate, sensitivity, and positive predictive value than dedicated PET (P < 0.01). Conclusions: We were able to clarify the performance profile of "FDG-PET for cancer screening" on the basis of a Japanese nationwide survey. The number of facilities possessing PET is increasing steadily, highlighting the necessity of evaluating the usefulness of "FDG-PET cancer screening" as soon as possible by undertaking long-term investigations of large series of subjects. © 2007 The Japanese Society of Nuclear Medicine.

    DOI: 10.1007/s12149-007-0061-8

    Scopus

  273. Performance profile of FDG-PET and PET/CT for cancer screening based on a Japanese nationwide survey

    Minamimoto R., Senda M., Uno K., Jinnouchi S., Iinuma T., Ito K., Okuyama C., Oguchi K., Kawamoto M., Suzuki Y., Tsukamoto E., Terauchi T., Nakashima R., Nishio M., Nishizawa S., Fukuda H., Yoshida T., Inoue T.

    Kakuigaku   Vol. 44 ( 2 ) page: 105 - 124   2007.7

     More details

    Publisher:Kakuigaku  

    A total of 50,558 healthy subjects underwent an FDG-PET (including PET/CT) scan with or without combination of other tests for cancer screening in 46 PET centers during fiscal year of 2005 in Japan. Thorough examination was indicated for 9.8% of the cases due to positive findings suggesting possible cancer. On analyzing 43,996 cases from 38 PET centers, where detailed information was obtained, 500 cases of cancers (1.14%) were found, of which 0.90% was PET positive and 0.24% was PET negative, resulting in the relative sensitivity of PET being 79.0%. Cancers of thyroid, colon/rectum, lung and breast were most frequently found (107, 102, 79, 35 cases, respectively) with high PET sensitivity (88%, 90%, 80%, 92%). PET showed an overall positive predictive value of 29.0%. PET/CT had better detection rate, sensitivity, and positive predictive value than dedicated PET (p≤0.01).

    Scopus

  274. High FDG uptake on oncocytoma located in the retroperitoneum mimicking malignancy. International journal

    Ryogo Minamimoto, Shoji Yamanaka, Masami Kawamoto, Mareyuki Endoh, Reiko Nishito, Keisuke Yoshida, Noboru Nakaigawa, Masahiro Yao, Yoshinobu Kubota, Tomio Inoue

    Clinical nuclear medicine   Vol. 32 ( 7 ) page: 582 - 3   2007.7

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    DOI: 10.1097/RLU.0b013e31806541a4

    Scopus

    PubMed

  275. FDG-PET of patients with suspected renal failure : standardized uptake values in normal tissues

    MINAMIMOTO Ryogo, TAKAHASHI Nobukazu, INOUE Tomio

    Ann Nucl Med   Vol. 21 ( 4 ) page: 217 - 222   2007.6

     More details

    Language:English  

    CiNii Research

  276. FDG-PET of patients with suspected renal failure: standardized uptake values in normal tissues.

    Ryogo Minamimoto, Nobukazu Takahashi, Tomio Inoue

    Annals of nuclear medicine   Vol. 21 ( 4 ) page: 217 - 22   2007.6

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    OBJECTIVE: This study aims to clarify the effect of renal function on 2-[(18)F] fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) imaging and determine the clinical significance of renal function in this setting. We compared FDG distribution between normal volunteers and patients with suspected renal failure. METHODS: Twenty healthy volunteers and 20 patients with suspected renal failure who underwent FDG-PET between November 2002 and May 2005 were selected for this study. We define "patients with suspected renal failure" as having a blood serum creatinine level in excess of 1.1 mg/dl. The serum creatinine level was examined once in 2 weeks of the FDG-PET study. Regions of interest were placed over 15 regions for semi-quantitative analysis: the white matter, cortex, both upper lung fields, both middle lung fields, both lower lung fields, mediastinum, myocardium of the left ventricle, the left atrium as a cardiac blood pool, central region of the right lobe of the liver, left kidney, and both femoris muscles. RESULTS: The mean standardized uptake values (SUVs) of brain cortex and white matter were higher in healthy volunteers than in renal patients. The mean SUVs of the mediastinum at the level of the aortic arch and left atrium as a cardiac blood pool were lower in healthy volunteers than in patients with suspected renal failure. These regions differed between healthy volunteers and patients with suspected renal failure (P < 0.05). CONCLUSIONS: We found decreasing brain accumulation and increasing blood pool accumulation of FDG in patients with high plasma creatinine. Although the difference is small, this phenomenon will not have a huge effect on the assessment of FDG-PET imaging in patients with suspected renal failure.

    DOI: 10.1007/s12149-007-0012-4

    Scopus

    PubMed

  277. [Performance profile of FDG-PET and PET/CT for cancer screening based on a Japanese nationwide survey].

    Ryogo Minamimoto, Michio Senda, Kimiichi Uno, Seishi Jinnouchi, Takeshi Iinuma, Kengo Ito, Chio Okuyama, Kazuhiro Oguchi, Masami Kawamoto, Yutaka Suzuki, Eriko Tsukamoto, Takashi Terauchi, Rumi Nakashima, Masami Nishio, Sadahiko Nishizawa, Hiroshi Fukuda, Tsuyoshi Yoshida, Tomio Inoue

    Kaku igaku. The Japanese journal of nuclear medicine   Vol. 44 ( 2 ) page: 105 - 24   2007.5

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

    A total of 50,558 healthy subjects underwent an FDG-PET (including PET/CT) scan with or without combination of other tests for cancer screening in 46 PET centers during fiscal year of 2005 in Japan. Thorough examination was indicated for 9.8% of the cases due to positive findings suggesting possible cancer. On analyzing 43,996 cases from 38 PET centers, where detailed information was obtained, 500 cases of cancers (1.14%) were found, of which 0.90% was PET positive and 0.24% was PET negative, resulting in the relative sensitivity of PET being 79.0%. Cancers of thyroid, colon/rectum, lung and breast were most frequently found (107, 102, 79, 35 cases, respectively) with high PET sensitivity (88%, 90%, 80%, 92%). PET showed an overall positive predictive value of 29.0%. PET/CT had better detection rate, sensitivity, and positive predictive value than dedicated PET (p<0.01).

    PubMed

▼display all

Books 2

  1. FDG PET Imaging of Infection and Inflammation

    Minamimoto R.( Role: Contributor)

    Nuclear Medicine and Immunology  2021.1  ( ISBN:978-3-030-81260-7

     More details

    Language:English

    DOI: 10.1007/978-3-030-81261-4_7

  2. Total-body PET/MRI in oncological applications

    2018.1 

     More details

MISC 173

  1. 緊急企画 新規PET製剤「アキュミンⓇ」の基礎知識と今後の展望

    南本 亮吾, 加藤 克彦, 長縄 慎二

    臨床画像     2024.7

     More details

    Authorship:Lead author  

    DOI: 10.18885/ci.0000001757

  2. 131I-アドステロールを用いた副腎皮質シンチグラフィにおける検出限界濃度比と収集時間の検討

    藤井 めぐみ, 早野 将史, 堀川 大輔, 栗原 恵一, 齋藤 郁里, 梶原 宏則, 松永 太, 南本 亮吾

    核医学技術   Vol. 41 ( 予稿集 ) page: 418 - 418   2021.10

     More details

    Language:Japanese   Publisher:(NPO)日本核医学技術学会  

  3. 131I-アドステロールを用いた副腎皮質シンチグラフィにおける散乱線補正の有無による検討

    栗原 恵一, 早野 将史, 堀川 大輔, 藤井 めぐみ, 齋藤 郁里, 梶原 宏則, 松永 太, 南本 亮吾

    核医学技術   Vol. 41 ( 予稿集 ) page: 419 - 419   2021.10

     More details

    Language:Japanese   Publisher:(NPO)日本核医学技術学会  

  4. 131I-アドステロールを用いた副腎皮質シンチグラフィにおける定量評価の基礎検討 回転半径の検討及びSUVmax・SUVmeanの比較

    齋藤 郁里, 早野 将史, 藤井 めぐみ, 堀川 大輔, 栗原 恵一, 梶原 宏則, 松永 太, 南本 亮吾

    核医学技術   Vol. 41 ( 予稿集 ) page: 418 - 418   2021.10

     More details

    Language:Japanese   Publisher:(NPO)日本核医学技術学会  

  5. 131I-アドステロールを用いた副腎皮質シンチグラフィにおけるエネルギーウィンドウの検討

    早野 将史, 藤井 めぐみ, 堀川 大輔, 栗原 恵一, 齋藤 郁里, 梶原 宏則, 松永 太, 南本 亮吾

    核医学技術   Vol. 41 ( 予稿集 ) page: 418 - 418   2021.10

     More details

    Language:Japanese   Publisher:(NPO)日本核医学技術学会  

  6. FDG-PET/CTの不明熱診断への応用-ガリウムSPECTとの比較研究 先進医療による多施設研究(略称JPET-FUO)

    窪田 和雄, 南本 亮吾

    核医学   Vol. 58 ( Suppl. ) page: S233 - S233   2021.10

     More details

    Language:Japanese   Publisher:(一社)日本核医学会  

  7. 不明熱診断におけるFDG-PET/CTの有用性と限界

    南本 亮吾, 梶原 宏則, 児玉 清幸

    日本医学放射線学会秋季臨床大会抄録集   Vol. 57回   page: S426 - S426   2021.8

     More details

    Language:Japanese   Publisher:(公社)日本医学放射線学会  

  8. 新型コロナウイルス感染防止と画像検査所見

    南本 亮吾

    核医学技術   Vol. 41 ( 1 ) page: 79 - 80   2021.1

     More details

    Language:Japanese   Publisher:(NPO)日本核医学技術学会  

  9. 11C-コリンPET/CTを利用した去勢抵抗性前立腺癌に対する局所療法

    川合 剛人, 野崎 圭夏, 藤村 哲也, 松井 甫雄, 手島 太郎, 高橋 淳子, 佐藤 悠佑, 山田 大介, 堀田 昌利, 中島 和彦, 中山 秀次, 南本 亮吾, 久米 春喜

    日本泌尿器科学会総会   Vol. 108回   page: 1398 - 1398   2020.12

     More details

    Language:Japanese   Publisher:(一社)日本泌尿器科学会総会事務局  

  10. COVID-19既感染者へのPET/CT検査を経験して

    齋藤 郁里, 竹内 智弥, 堀川 大輔, 山田 唯, 水沼 孝文, 梶原 宏則, 光野 譲, 伊藤 昌司, 松永 太, 弘中 さつき, 堀田 昌利, 南本 亮吾

    国立病院総合医学会講演抄録集   Vol. 74回   page: O35 - 1   2020.10

     More details

    Language:Japanese   Publisher:国立病院総合医学会  

  11. 食道癌の術前化学療法に対するFDG-PET/CTの有用性 多施設共同研究

    甲斐田 勇人, 北島 一宏, 中條 正豊, 石橋 愛, 南本 亮吾, 平田 健司, 中谷 航也, Ao Hung, 服部 聡, 安田 卓司, 石井 一成

    核医学   Vol. 57 ( Suppl. ) page: S144 - S144   2020.10

     More details

    Language:Japanese   Publisher:(一社)日本核医学会  

  12. 新型コロナウイルス感染防止と画像検査所見

    南本 亮吾, 齋藤 郁里, 堀川 大輔, 竹内 智弥, 水沼 文孝, 山田 唯, 弘中 さつき, 梶原 宏則, 堀田 昌利, 松永 太

    核医学   Vol. 57 ( Suppl. ) page: S29 - S29   2020.10

     More details

    Language:Japanese   Publisher:(一社)日本核医学会  

  13. Interim PETにおける複数回の軽度集積像が残存腫瘍の検出に有用であったバーキットリンパ腫の一例

    山中 暖日, 下澤 克宜, 瓜生 英子, 高砂 聡志, 鈴木 優里, 田中 瑞恵, 山中 純子, 赤松 智久, 南本 亮吾, 七野 浩之

    日本小児血液・がん学会雑誌   Vol. 57 ( 4 ) page: 227 - 227   2020.10

     More details

    Language:Japanese   Publisher:(一社)日本小児血液・がん学会  

  14. 新型コロナウイルス感染防止と画像検査所見

    南本 亮吾, 齋藤 郁里, 堀川 大輔, 竹内 智弥, 水沼 文孝, 山田 唯, 弘中 さつき, 梶原 宏則, 堀田 昌利, 松永 太

    核医学技術   Vol. 40 ( 予稿集 ) page: 308 - 308   2020.10

     More details

    Language:Japanese   Publisher:(NPO)日本核医学技術学会  

  15. 原発性アルドステロン症に対する副腎皮質シンチグラフィの定量評価

    堀川 大輔, 齋藤 郁里, 梶原 宏則, 松永 太, 堀田 昌利, 南本 亮吾

    核医学技術   Vol. 40 ( 予稿集 ) page: 352 - 352   2020.10

     More details

    Language:Japanese   Publisher:(NPO)日本核医学技術学会  

  16. 胸管シンチグラフィにより漏出点を同定し得たKlippel-trenaunay-weber症候群による特発性乳び胸の1例

    嶋田 貴文, 川島 海, 大島 央之, 薮内 悠貴, 平野 瞳, 北岡 有香, 荒井 直樹, 兵頭 健太郎, 中澤 篤人, 金澤 潤, 三浦 由記子, 大石 修司, 林原 賢治, 南本 亮吾, 齋藤 武文

    日本結核・非結核性抗酸菌症学会関東支部学会・日本呼吸器学会関東地方会合同学会プログラム・抄録集   Vol. 178回・241回   page: 19 - 19   2020.9

     More details

    Language:Japanese   Publisher:日本結核・非結核性抗酸菌症学会関東支部学会・日本呼吸器学会関東地方会  

  17. 食道癌術前治療において、DNA合成を反映した4DST-PETとFDG-PETとの比較

    山田 和彦, 南本 亮吾, 堀田 昌利, 野原 京子, 榎本 直記, 三田 英明, 和氣 仁美, 寺山 仁祥, 片岡 温子, 清松 知充, 竹村 信行, 國土 典宏

    日本外科学会定期学術集会抄録集   Vol. 120回   page: SF - 6   2020.8

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

  18. 食道癌においてのDNA合成を反映した4DST-PETとFDG-PETとの比較

    三田 英明, 山田 和彦, 南本 亮吾, 堀田 昌利, 野原 京子, 榎本 直記, 和氣 仁美, 寺山 仁祥, 片岡 温子, 清松 知充, 竹村 信行, 國土 典宏

    日本外科学会定期学術集会抄録集   Vol. 120回   page: DP - 4   2020.8

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

  19. 【Q&Aでまとめる! 予後予測・治療効果予測の画像検査】消化管・肝・胆・膵 食道癌に対する外科手術の治療効果を予測する画像検査法は何か?

    南本 亮吾

    臨床放射線   Vol. 65 ( 8 ) page: 875 - 880   2020.8

     More details

    Language:Japanese   Publisher:金原出版(株)  

  20. 【COVID-19】COVID-19既感染者のPET/CT検査を実施して

    齋藤 郁里, 堀川 大輔, 竹内 智弥, 水沼 文孝, 山田 唯, 弘中 さつき, 梶原 宏則, 堀田 昌利, 松永 太, 南本 亮吾

    日本放射線技術学会雑誌   Vol. 76 ( 7 ) page: 761 - 767   2020.7

  21. なぜ今、核医学なのか 核医学が注目される理由と意義 セラノスティックス視点からのPET/SPECT/CTの意義とその効果の実際 経営的貢献も含め

    南本 亮吾

    新医療   Vol. 47 ( 3 ) page: 102 - 105   2020.3

     More details

    Language:Japanese   Publisher:(株)エムイー振興協会  

    「セラノスティックス(Theranostics)」とは、「治療(Therapeutics)」と「診断(Diagnostics)」の造語である。核医学分野でもセラノスティックスという言葉は非常に注目されており、研究、開発、臨床応用が加速している。特定の疾患の画像化ができれば、それを治療効果のある状態に工夫して患者に投与することで、画像で確認される部位を優位とした標的治療を行うことができる。(著者抄録)

  22. 大型血管炎の臨床・病理・画像 大型血管炎の画像診断

    南本 亮吾

    Japanese Journal of Diagnostic Imaging   Vol. 38 ( 1 ) page: 84 - 84   2020.1

     More details

    Language:Japanese   Publisher:日本画像医学会  

  23. 【内科医が押さえておくべき-検査の考えかたと落とし穴】よくオーダーするのに案外知らない検査の基本 FDG-PET検査

    堀田 昌利, 南本 亮吾

    Medicina   Vol. 56 ( 12 ) page: 2037 - 2041   2019.11

     More details

    Language:Japanese   Publisher:(株)医学書院  

    <文献概要>Point ◎FDG-PETの保険適用疾患は,てんかん,心疾患,悪性腫瘍,大血管炎である.◎FDG-PETの検査精度に影響する基礎疾患として,糖尿病や甲状腺機能亢進症がある.◎FDG-PET検査前は食事(6時間以上),運動,寒冷刺激,G-CSF製剤投与を避ける.

    Other Link: https://search.jamas.or.jp/default/link?pub_year=2019&ichushi_jid=J01440&link_issn=&doc_id=20191031090037&doc_link_id=10.11477%2Fmf.1402226595&url=https%3A%2F%2Fdoi.org%2F10.11477%2Fmf.1402226595&type=%E5%8C%BB%E6%9B%B8.jp_%E3%82%AA%E3%83%BC%E3%83%AB%E3%82%A2%E3%82%AF%E3%82%BB%E3%82%B9&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00024_2.gif

  24. 直腸癌の予後予測 機械学習を用いたラジオミクス解析

    堀田 昌利, 南本 亮吾

    核医学   Vol. 56 ( Suppl. ) page: S178 - S178   2019.10

     More details

    Language:Japanese   Publisher:(一社)日本核医学会  

  25. ソマトスタチン受容体シンチグラフィーによる心臓サルコイドーシスの活動性炎症評価

    粟屋 徹, 南本 亮吾, 窪田 和雄, 久保田 修司, 岡崎 徹, 岡崎 修, 原 久男, 廣井 透雄, 廣江 道昭, 諸井 雅男

    日本サルコイドーシス/肉芽腫性疾患学会雑誌   Vol. 39 ( 1-2 ) page: 55 - 58   2019.10

     More details

    Language:Japanese   Publisher:日本サルコイドーシス  

    心臓サルコイドーシスの活動性病変評価には,67Gaシンチグラフィーおよび18F-FDG PET(fluorodeoxyglucose positronemission computed tomography)がある.67Gaシンチグラフィーはその集積機序ははっきりと解明されておらず,感度が低く,18F-FDG PETは心筋への生理的集積や不全心筋への集積(偽陽性)がある.我々は心筋には発現せずにマクロファージに発現しているソマトスタチン受容体に注目し,ソマトスタチン受容体シンチグラフィー(SRS:somatostatin receptorscintigraphy)が活動性炎症(急性期)を画像化できるかを検討した.対象はSRS,18F-FDG PET,心臓MRI,心臓超音波検査を施行した心臓サルコイドーシスの4症例で心臓MRI検査(T2-BB:T2 weighted black bloodもしくは遅延造影)にて20病変が検出された(Table 1).20病変中11病変でSRS,18F-FDG PETともに集積を認め,そのうち8病変でT2-BBで高信号を認めたことからも,同部位は急性期の活動性病変と考えられた.SRSは心臓サルコイドーシスの活動性病変評価に有用な可能性がある.(著者抄録)

    Other Link: https://search.jamas.or.jp/default/link?pub_year=2019&ichushi_jid=J05628&link_issn=&doc_id=20191001410010&doc_link_id=%2Fch0jsarc%2F2019%2F003901%2F010%2F0055-0058%26dl%3D0&url=https%3A%2F%2Fwww.medicalonline.jp%2Fjamas.php%3FGoodsID%3D%2Fch0jsarc%2F2019%2F003901%2F010%2F0055-0058%26dl%3D0&type=MedicalOnline&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00004_2.gif

  26. 【注意したいFDG-PET/CTでの見逃しと読み過ぎ】胸部領域

    南本 亮吾, 堀田 昌利

    臨床放射線   Vol. 64 ( 9 ) page: 1127 - 1137   2019.8

  27. 【冠動脈疾患と心不全の診療に活かす心臓核医学の新技術】FDG画像で読む大型血管炎

    南本 亮吾, 堀田 昌利

    Rad Fan   Vol. 17 ( 9 ) page: 54 - 57   2019.7

     More details

    Language:Japanese   Publisher:(株)メディカルアイ  

    2018年4月から大型血管炎(高安動脈炎と巨細胞性動脈炎)にFDG-PET/CT検査の保険適用が拡大され、大型血管炎と診断された患者に対して、「病変の局在または活動性の診断(可視化)を目的」とする場合にFDG-PET/CT検査が実施可能になった。本稿では、FDG-PET/CT検査の大型血管炎に対する利点と、適応や読影時に注意すべき点、今後の期待に関して述べる。(著者抄録)

  28. PETから見たcT4食道癌に対する外科治療

    山田 和彦, 野原 京子, 相馬 大介, 榎本 直紀, 齋藤 範之, 和氣 仁美, 南本 亮吾, 堀田 昌利, 清松 知充, 竹村 信行, 國土 典宏

    日本外科学会定期学術集会抄録集   Vol. 119回   page: SF - 4   2019.4

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

  29. 平成28・29年度ワーキンググループ報告 FDG-PETを用いた悪性腫瘍の治療効果判定 多施設共同研究

    北島 一宏, 南本 亮吾, 平田 健司, 山根 登茂彦, 甲斐田 勇人, 中條 正豊, 森田 敬裕, 中谷 航也, 石橋 愛

    核医学   Vol. 56 ( 1 ) page: 45 - 46   2019

  30. FDG PET、PET/CT診療ガイドライン2018

    細野 眞, 千田 道雄, 佐々木 雅之, 百瀬 敏光, 伊藤 健吾, 岡村 光英, 織田 圭一, 川本 雅美, 久下 裕司, 櫻井 実, 立石 宇貴秀, 藤林 康久, 間賀田 泰寛, 村上 康二, 吉田 毅, 脇 厚生, 加藤 克彦, 橋本 禎介, 内山 眞幸, 絹谷 清剛, 東 達也, 待鳥 詔洋, 丸野 廣大, 南本 亮吾, 吉永 恵一郎, 日本核医学会, PET核医学委員会, 健保委員会

    核医学   Vol. 55 ( 1 ) page: 1 - 22   2018.12

  31. 腹膜偽粘液腫の予後予測におけるPET-Peritoneal Cancer Indexの有用性

    堀田 昌利, 南本 亮吾, 合田 良政, 矢野 秀朗

    核医学   Vol. 55 ( 1 ) page: 107 - 107   2018.12

     More details

    Language:Japanese   Publisher:(一社)日本核医学会  

  32. 各定量指標のPET解析ソフトウェア間差に関する検討

    清水 賢, 大崎 洋充, 上原 歩夏, 池本 裕貴, 野上 敬太, 柏倉 健一, 嶋田 博孝, 梶原 宏則, 南本 亮吾, 西田 広之

    核医学   Vol. 55 ( 1 ) page: 27 - 27   2018.12

     More details

    Language:Japanese   Publisher:(一社)日本核医学会  

  33. 脳腫瘍の放射線壊死と再発の鑑別におけるメチオニンPET/CT後期像の有用性

    堀田 昌利, 南本 亮吾, 横山 幸太, 亀山 征史, 中島 和彦

    核医学   Vol. 55 ( Suppl. ) page: S220 - S220   2018.11

     More details

    Language:Japanese   Publisher:(一社)日本核医学会  

  34. 巨細胞性動脈炎における18F-FDG PET/CT所見とMRI所見の比較

    横山 幸太, 南本 亮吾, 堀田 昌利, 野口 智幸, 田嶋 強

    核医学   Vol. 55 ( Suppl. ) page: S166 - S166   2018.11

     More details

    Language:Japanese   Publisher:(一社)日本核医学会  

  35. 13N-NH3 PET画像と冠動脈CTのFusion精度から検証した心臓領域におけるDIRの有用性

    田口 好晃, 南本 亮吾, 三輪 建太, 堀田 昌利, 児玉 清幸, 延澤 忠真, 今尾 仁, 谷島 義信

    核医学技術   Vol. 38 ( 予稿集 ) page: 402 - 402   2018.10

     More details

    Language:Japanese   Publisher:(NPO)日本核医学技術学会  

  36. 解析ソフトウェアによるPET定量指標のデータ依存性

    清水 賢, 大崎 洋充, 南本 亮吾, 池本 裕貴, 上原 歩夏, 野上 敬太, 嶋田 博孝, 西田 広之, 赤松 剛, 柏倉 健一, 櫻井 実, 筒井 悠治, 佐々木 雅之

    核医学技術   Vol. 38 ( 予稿集 ) page: 412 - 412   2018.10

     More details

    Language:Japanese   Publisher:(NPO)日本核医学技術学会  

  37. SPECT/CT定量解析ソフトの基礎検討

    市野 智史, 堀川 大輔, 児玉 清幸, 南本 亮吾, 谷島 義信

    核医学技術   Vol. 38 ( 予稿集 ) page: 453 - 453   2018.10

     More details

    Language:Japanese   Publisher:(NPO)日本核医学技術学会  

  38. SPECT定量解析ソフトウェアの比較検討

    堀川 大輔, 市野 智史, 児玉 清幸, 南本 亮吾, 谷島 義信

    核医学技術   Vol. 38 ( 予稿集 ) page: 470 - 470   2018.10

     More details

    Language:Japanese   Publisher:(NPO)日本核医学技術学会  

  39. 去勢抵抗性前立腺癌における炭素11標識コリンPET/CTの有用性と局所治療の有効性の検討

    手島 太郎, 野崎 圭夏, 高橋 淳子, 新美 文彩, 堀田 昌利, 中島 和彦, 中山 秀次, 南本 亮吾, 松井 甫雄, 佐藤 悠佑, 川合 剛人, 山田 大介, 松本 明彦, 井川 靖彦, 久米 春喜

    日本癌治療学会学術集会抄録集   Vol. 56回   page: P107 - 1   2018.10

     More details

    Language:English   Publisher:(一社)日本癌治療学会  

  40. 111In-ペンテトレオチドを用いたソマトスタチン受容体シンチグラフィの生理的集積について

    堀田 昌利, 南本 亮吾

    臨床核医学   Vol. 51 ( 2 ) page: 18 - 22   2018.3

     More details

    Language:Japanese   Publisher:放射線診療研究会  

    ソマトスタチン受容体シンチグラフィ(SRS)では、神経内分泌腫瘍(NET)等の病変以外にも肝臓等の正常臓器に集積するため、病変の正確な評価には生理的集積に関する知識が必須である。SRSでは一般に薬剤投与6時間後の早期相と24時間後の後期相を撮影するが、早期相・後期相それぞれの生理的集積を別個に検討した報告は少ない。そこで今回、早期相と後期相における臓器ごとの集積頻度・程度について検討した。対象は、NETが組織学的に確定、もしくは画像所見や臨床症状からNETが疑われた患者35例とした。検討の結果、早期相で集積頻度が高い臓器は肝臓・脾臓・腎臓・小腸・四肢関節などであり、後期相で集積頻度が高いのは肝臓・脾臓・腎臓・大腸・小腸などであった。集積程度は早期相・後期相とも腎臓・脾臓・肝臓で高く、早期相と後期相を比較すると、下垂体・甲状腺・肝臓・胆嚢・大腸は後期相にかけて集積が増加し、鼻腔・心臓・椎体・四肢関節は後期相にかけて集積が低下する傾向にあった。

  41. 食道癌術前治療効果予測におけるFDG-PETの意義

    相馬 大介, 山田 和彦, 野原 京子, 山下 智, 南本 亮吾, 堀田 昌利, 安田 秀光, 枝元 良広, 橋本 政典, 矢野 秀朗, 國土 典宏

    日本臨床外科学会雑誌   Vol. 78 ( 増刊 ) page: 621 - 621   2017.10

     More details

    Language:Japanese   Publisher:日本臨床外科学会  

  42. 脳PETに対するpenalized likelihood reconstruction法の至適β値の検討

    上高 祐人, 我妻 慧, 小池 笑也, 平塚 勢哉, 南本 亮吾, 石井 賢二, 三輪 建太

    核医学技術   Vol. 37 ( 予稿集 ) page: 462 - 462   2017.9

     More details

    Language:Japanese   Publisher:(NPO)日本核医学技術学会  

  43. 前立腺癌の診断における炭素11標識コリンPET/CTの有用性

    野崎 圭夏, 久米 春喜, 手島 太郎, 高橋 淳子, 山田 大介, 南本 亮吾, 本間 之夫

    泌尿器外科   Vol. 30 ( 8 ) page: 1257 - 1259   2017.8

     More details

    Language:Japanese   Publisher:医学図書出版(株)  

    前立腺癌の59症例に対してコリンPETを施行しこれを検討した。年齢は中央値72歳、PSAは中央値4.2ng/mLであった。治療前症例5/10例、根治的前立腺全摘除術後PSA再発の4/13例、放射線治療後再発の7/10例で転移や再発を認め、それぞれのPSA中央値は18.3、2.55、6.08ng/mLであった。去勢抵抗性前立腺癌の5/11例では、限局したコリン集積部位へ放射線治療を行い、全例でPSAの低下を認めた。症例を選べばコリンPETが局所治療を可能にする可能性が示唆された。(著者抄録)

  44. 【会心の症例・痛恨の症例から学ぶ画像診断のコツ】核医学分野

    堀田 昌利, 南本 亮吾

    臨床画像   Vol. 33 ( 7 ) page: 824 - 832   2017.7

     More details

    Language:Japanese   Publisher:(株)メジカルビュー社  

    核医学検査の特徴に生理的集積や偽病変のバリエーションが豊富な点が挙げられる。また,PETのように撮像範囲の広い検査も多く,悩ましい所見に遭遇する頻度が高い。本稿では核医学領域に特有な異常所見を呈する病態の診断ポイントを中心に解説する。(著者抄録)

    Other Link: https://search.jamas.or.jp/default/link?pub_year=2017&ichushi_jid=J01843&link_issn=&doc_id=20170707050008&doc_link_id=%2Fap4ringc%2F2017%2F003307%2F009%2F0824-0832%26dl%3D0&url=https%3A%2F%2Fwww.medicalonline.jp%2Fjamas.php%3FGoodsID%3D%2Fap4ringc%2F2017%2F003307%2F009%2F0824-0832%26dl%3D0&type=MedicalOnline&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00004_2.gif

  45. ソマトスタチン受容体シンチグラフィーにて心臓集積を認めた全身性サルコイドーシスの一例

    粟屋 徹, 南本 亮吾, 諸井 雅男, 岡崎 修, 原 久男, 廣井 透雄

    日本心臓核医学会ニュースレター   Vol. 19 ( 2 ) page: 74 - 74   2017.6

     More details

    Language:Japanese   Publisher:日本心臓核医学会  

  46. DNA合成を反映した11C-4DST-PETの食道癌診療における有用性について

    山田 和彦, 南本 亮吾, 堀田 昌利, 野原 京子, 相馬 大介, 山下 智, 横溝 悠里子, 枝元 良広, 橋本 政典, 矢野 秀朗, 猪狩 亨

    日本外科学会定期学術集会抄録集   Vol. 117回   page: SF - 7   2017.4

     More details

    Language:Japanese   Publisher:(一社)日本外科学会  

  47. 小児腫瘍性疾患に対するFDG-PETの有用性と課題

    植野 優, 平井 麻衣子, 谷川 俊太郎, 下澤 克宜, 谷ヶ崎 博, 諸岡 都, 南本 亮吾, 窪田 和雄, 松井 基浩, 末永 祐太, 大熊 香織, 山田 律子, 田中 瑞恵, 七野 浩之, 高橋 昌里

    日本小児科学会雑誌   Vol. 121 ( 4 ) page: 751 - 751   2017.4

     More details

    Language:Japanese   Publisher:(公社)日本小児科学会  

  48. 腫瘍PET検査の最前線と将来展望 PET/MRIを中心に

    南本 亮吾

    日本放射線技術学会総会学術大会予稿集   Vol. 73回   page: 97 - 97   2017.3

     More details

    Language:Japanese   Publisher:(公社)日本放射線技術学会  

  49. 小児腫瘍性疾患に対するFDG-PET検査の有用性と課題

    植野 優, 平井 麻衣子, 谷川 俊太郎, 下澤 克宜, 谷ヶ崎 博, 高橋 昌里, 諸岡 都, 南本 亮吾, 窪田 和雄, 松井 基浩, 末永 祐太, 大熊 香織, 山田 律子, 田中 瑞恵, 七野 浩之

    板橋区医師会医学会誌   Vol. 21   page: 129 - 129   2017.3

     More details

    Language:Japanese   Publisher:(公社)板橋区医師会  

  50. FDG-PET/CTが診断に有用であった抗NMDA受容体脳炎の1例

    横山 幸太, 堀田 昌利, 肥田 あゆみ, 田中 恵子, 南本 亮吾

    核医学   Vol. 54 ( 1 ) page: 645 - 645   2017.2

     More details

    Language:Japanese   Publisher:(一社)日本核医学会  

  51. 心アミロイドーシスの新しい画像診断

    岩間 健太郎, 粟屋 徹, 南本 亮吾, 原 久男, 廣井 透雄

    Japanese Journal of Diagnostic Imaging   Vol. 35 ( 1 ) page: 93 - 93   2017.2

     More details

    Language:Japanese   Publisher:日本画像医学会  

  52. 【形質細胞性疾患の病態と治療】多発性骨髄腫における画像検査

    堀田 昌利, 南本 亮吾

    血液内科   Vol. 74 ( 2 ) page: 138 - 143   2017.2

     More details

    Language:Japanese   Publisher:(有)科学評論社  

  53. 小児腫瘍性疾患に対するFDG-PET検査の有用性と課題

    植野 優, 平井 麻衣子, 谷川 俊太郎, 下澤 克宜, 谷ヶ崎 博, 諸岡 都, 南本 亮吾, 窪田 和雄, 松井 基浩, 末永 祐太, 大熊 香織, 山田 律子, 田中 瑞恵, 七野 浩之, 渕上 達夫, 高橋 昌里

    日本小児血液・がん学会雑誌   Vol. 53 ( 4 ) page: 231 - 231   2016.11

     More details

    Language:Japanese   Publisher:(一社)日本小児血液・がん学会  

  54. 11C-4DSTと18F-FDGにおける食道癌の描出能に関する比較検討

    堀田 昌利, 南本 亮吾, 豊原 潤, 諸岡 都, 亀山 征史, 中島 和彦, 野原 京子, 山田 和彦, 窪田 和雄

    核医学   Vol. 53 ( Suppl. ) page: S281 - S281   2016.10

     More details

    Language:Japanese   Publisher:(一社)日本核医学会  

  55. オンコロジーPETイメージング 様々な放射性医薬品の現状と可能性 臨床におけるメチオニンPETの有用性

    南本 亮吾

    核医学   Vol. 53 ( Suppl. ) page: S173 - S173   2016.10

     More details

    Language:Japanese   Publisher:(一社)日本核医学会  

  56. ソマトスタチン受容体シンチグラフィ(111In-ペントテレオクチド)の生理的集積に関する検討

    堀田 昌利, 南本 亮吾, 諸岡 都, 亀山 征史, 中島 和彦, 砂岡 史生, 児玉 清幸, 梶原 宏則, 窪田 和雄

    核医学   Vol. 53 ( Suppl. ) page: S270 - S270   2016.10

     More details

    Language:Japanese   Publisher:(一社)日本核医学会  

  57. 【新前立腺癌学-最新の基礎研究と診断・治療-】前立腺癌の検査・診断 画像診断 新しい骨転移の画像診断

    南本 亮吾, 窪田 和雄

    日本臨床   Vol. 74 ( 増刊3 新前立腺癌学 ) page: 330 - 334   2016.5

     More details

    Language:Japanese   Publisher:(株)日本臨床社  

  58. 英語の発表のブートキャンプ(English Presentation Boot Camp)

    南本 亮吾

    日本放射線技術学会総会学術大会予稿集   Vol. 72回   page: 114 - 114   2016.2

     More details

    Language:Japanese   Publisher:(公社)日本放射線技術学会  

  59. 【肺癌】これからの実地医家のための診断とストラテジー 診断 FDG PET/CTの上手な利用法

    南本 亮吾, 窪田 和雄

    Medical Practice   Vol. 33 ( 2 ) page: 205 - 207   2016.2

     More details

    Language:Japanese   Publisher:(株)文光堂  

  60. FDG PETによるHIV陽性患者の脳糖代謝変化

    諸岡 都, 田沼 順子, 石井 賢二, 窪田 和雄, 小松 賢亮, 仲里 愛, 渡辺 愛祈, 菊池 嘉, 亀山 征史, 南本 亮吾, 野口 智幸, 塚田 訓久, 潟永 博之, 照屋 勝治, 矢崎 博久, 本田 元人, 青木 孝弘, 木内 英, 西島 健, 小形 幹子, 岡 慎一

    日本エイズ学会誌   Vol. 17 ( 4 ) page: 499 - 499   2015.11

     More details

    Language:Japanese   Publisher:(一社)日本エイズ学会  

  61. 腹膜偽粘液腫のFDGPET/CT 所見の特徴と有用性

    窪田 和雄, 諸岡 都, 岡崎 百子, 亀山 征史, 宮田 陽子, 南本 亮吾, 合田 良政, 矢野 秀朗

    核医学   Vol. 52 ( 3 ) page: 249 - 249   2015.9

     More details

    Language:Japanese   Publisher:(一社)日本核医学会  

  62. 【代謝と癌-oncogenic metabolism研究の進歩-】癌の代謝異常を利用した新しいPET診断はどこまで進歩したか

    南本 亮吾, 窪田 和雄

    分子消化器病   Vol. 11 ( 4 ) page: 355 - 362   2014.12

     More details

    Language:Japanese   Publisher:(株)先端医学社  

    分子イメージングは、生体内の分子プロセスを可視化する方法である。Positron emission tomography(PET)はその代表であり、なかでも18F-FDG PET/CTはさまざまな診療ガイドラインに導入されるまで臨床に浸透している。悪性腫瘍にかかわる分子機構の解明とともに、分子イメージングの候補となる標的や代謝経路も明らかになっている。たとえば、血管新生、低酸素、アミノ酸代謝、脂質代謝などは、悪性腫瘍で特異的に亢進しており、PETによる臨床的評価も数多く公表されている。分子イメージングの多様化によって、疾患の性質を個別にさまざまな方面から評価することが可能となり、それを個々の治療方針に生かす「個別化医療」も実現可能となる。さらに、これらの分子イメージングは、β線放出核種を利用することにより、診断と治療が融合したtheranoticsへの発展も期待される。(著者抄録)

  63. 【すぐわかる!すぐできる!PET/CT読影のための基礎知識とpitfall】炎症性疾患

    窪田 和雄, 諸岡 都, 宮田 陽子, 岡崎 百子, 南本 亮吾, 伊藤 公輝, 諸井 雅男, 岡崎 修, 廣江 道昭, 山下 裕之, 三森 明夫

    臨床画像   Vol. 30 ( 10月増刊 ) page: 171 - 183   2014.10

     More details

    Language:Japanese   Publisher:(株)メジカルビュー社  

  64. 視覚フィードバック制御に基づいた4D-PET/CTイメージングシステムの開発

    三本 拓也, 砂岡 史生, 小山 和也, 小高 喜久雄, 幡野 和男, 南本 亮吾, 窪田 和雄, 福士 政広

    核医学   Vol. 51 ( 3 ) page: 313 - 313   2014.9

     More details

    Language:Japanese   Publisher:(一社)日本核医学会  

  65. アンモニアPETを用いた新たな下肢筋血流評価法

    宮田 陽子, 岡崎 百子, 南本 亮吾, 砂岡 史男, 梶原 宏則, 佐藤 敬, 諸岡 都, 窪田 和雄

    核医学   Vol. 51 ( 3 ) page: 332 - 332   2014.9

     More details

    Language:Japanese   Publisher:(一社)日本核医学会  

  66. ソマトスタチン受容体シンチグラフィーとFDGPET/CTによる神経内分泌腫瘍の評価

    窪田 和雄, 岡崎 百子, 南本 亮吾, 宮田 陽子, 諸岡 都, 砂岡 史生, 梶原 宏則, 佐藤 敬

    核医学   Vol. 51 ( 3 ) page: 269 - 269   2014.9

     More details

    Language:Japanese   Publisher:(一社)日本核医学会  

  67. 【脳・頭頸部腫瘍の治療効果判定に役立つ画像診断法】PETによる脳腫瘍の治療効果判定

    南本 亮吾

    映像情報Medical   Vol. 46 ( 7 ) page: 625 - 630   2014.7

  68. NASHスクリーニングにおける123I-BMIPP脂肪酸シンチグラフィの有用性

    野崎 雄一, 南本 亮吾, 三神 信太郎, 小島 康志, 櫻井 俊之, 永田 尚義, 横井 千寿, 小早川 雅男, 小野 正文, 窪田 和雄, 秋山 純一, 今村 雅俊, 正木 尚彦, 溝上 雅史, 柳瀬 幹雄

    日本消化器病学会雑誌   Vol. 111 ( 臨増総会 ) page: A324 - A324   2014.3

     More details

    Language:Japanese   Publisher:(一財)日本消化器病学会  

  69. 【PETを用いた心筋血流および虚血の評価】13NアンモニアPET研究 下肢血流評価としての試み

    岡崎 修, 廣江 道昭, 諸井 雅男, 春山 亜希子, 山本 正也, 原 久男, 廣井 透雄, 藤岡 俊一郎, 戸口 幸治, 福田 尚司, 保坂 茂, 岡崎 百子, 宮田 陽子, 南本 亮吾, 諸岡 都, 窪田 和雄

    日本心臓核医学会ニュースレター   Vol. 16 ( 1 ) page: 19 - 20   2014.1

     More details

    Language:Japanese   Publisher:日本心臓核医学会  

  70. FDG-PET/CTの不明熱診断への応用 先進医療をめざす多施設共同研究計画JPET-FUOについて

    窪田 和雄, 小早川 雅男, 田中 紀子, 田中 康弘, 和泉 静枝, 安原 明美, 佐藤 敬, 南本 亮吾, 諸岡 都, 岡崎 百子, 宮田 陽子

    核医学   Vol. 50 ( 3 ) page: S247 - S247   2013.9

     More details

    Language:Japanese   Publisher:(一社)日本核医学会  

  71. 非侵襲的肝病態評価法の適応と限界 BMIPP脂肪酸シンチグラフィのNASH診断における有用性 どういう脂肪肝を生検すべきか?

    野崎 雄一, 南本 亮吾, 柳瀬 幹雄

    肝臓   Vol. 54 ( Suppl.2 ) page: A492 - A492   2013.9

     More details

    Language:Japanese   Publisher:(一社)日本肝臓学会  

  72. サルコイドーシス診断における腹部リンパ節集積の意義 FDG PETでの検討

    宮田 陽子, 岡崎 百子, 諸岡 都, 南本 亮吾, 窪田 和雄

    核医学   Vol. 50 ( 3 ) page: S209 - S209   2013.9

     More details

    Language:Japanese   Publisher:(一社)日本核医学会  

  73. 多発性骨髄腫のFDG-PET、MET-PET、4DST-PETのCT病変および骨髄Aspirationとの比較検討

    岡崎 百子, 窪田 和雄, 南本 亮吾, 諸岡 都, 宮田 陽子, 三輪 哲義, 平井 理泉, 伊藤 公輝, 石渡 喜一, 豊原 潤

    核医学   Vol. 50 ( 3 ) page: S246 - S246   2013.9

     More details

    Language:Japanese   Publisher:(一社)日本核医学会  

  74. ヘパリンvs.長時間絶食 どちらが心臓へのFGD生理的集積をより抑制する?

    諸岡 都, 諸井 雅男, 宇野 公一, 伊藤 公輝, 廣江 道昭, 南本 亮吾, 宮田 陽子, 岡崎 百子, 窪田 和雄

    核医学   Vol. 50 ( 3 ) page: S246 - S246   2013.9

     More details

    Language:Japanese   Publisher:(一社)日本核医学会  

  75. Q&Aで綴るレジデント・ノート 専門医がわかりやすく解説(No.40) がん検診として、PETは有効ですか?

    南本 亮吾

    大腸癌Frontier   Vol. 6 ( 1 ) page: 66 - 68   2013.6

  76. 神経内分泌腫瘍のソマトスタチン受容体シンチグラフィーとFDGPETの比較

    窪田 和雄, 岡崎 百子, 南本 亮吾, 諸岡 都, 宮田 陽子

    日本内分泌学会雑誌   Vol. 89 ( 1 ) page: 233 - 233   2013.4

     More details

    Language:Japanese   Publisher:(一社)日本内分泌学会  

  77. 4D-PET/CTイメージングにおける呼吸精度向上に関する検証

    三本 拓也, 砂岡 史生, 南本 亮吾, 佐藤 敬, 佐々木 徹, 福士 政広, 窪田 和雄

    日本放射線技術学会総会学術大会予稿集   Vol. 69回   page: 264 - 264   2013.2

     More details

    Language:Japanese   Publisher:(公社)日本放射線技術学会  

  78. PSF補正に基づく3次元PET画像の臨床的有効性

    三本 拓也, 砂岡 史生, 南本 亮吾, 佐藤 敬, 佐々木 徹, 福士 政広, 窪田 和雄

    日本放射線技術学会総会学術大会予稿集   Vol. 69回   page: 210 - 211   2013.2

     More details

    Language:Japanese   Publisher:(公社)日本放射線技術学会  

  79. HIV関連認知症(HAND) 18F-FDG PETによる脳糖代謝評価

    諸岡 都, 窪田 和雄, 南本 亮吾, 宮田 陽子, 岡崎 百子, 田沼 順子, 岡 慎一, 飯田 敏晴, 今井 公文, 石井 賢二

    日本エイズ学会誌   Vol. 14 ( 4 ) page: 408 - 408   2012.11

     More details

    Language:Japanese   Publisher:(一社)日本エイズ学会  

  80. FDG-PET大腸領域の読影実験結果

    南本 亮吾, 寺内 隆司, 陣之内 正史, 吉田 毅, 塚本 江利子, 小口 和浩, 宇野 公一, 井上 登美夫, 千田 道雄

    核医学   Vol. 49 ( 4 ) page: 428 - 428   2012.11

     More details

    Language:Japanese   Publisher:(一社)日本核医学会  

  81. NAFLD患者の進行度診断における脂肪酸代謝シンチグラフィの有用性に関する検討

    野崎 雄一, 南本 亮吾, 櫻井 俊之, 永田 尚義, 横井 千寿, 小早川 雅男, 小島 康志, 秋山 純一, 今村 雅俊, 窪田 和雄, 後藤田 卓志, 正木 尚彦, 柳瀬 幹雄

    肝臓   Vol. 53 ( Suppl.2 ) page: A701 - A701   2012.9

     More details

    Language:Japanese   Publisher:(一社)日本肝臓学会  

  82. PET/CTにおける呼吸同期撮像法の検証 非線形処理に基づく体動補正PET画像の評価

    三本 拓也, 砂岡 史生, 田口 好晃, 佐藤 敬, 佐々木 徹, 南本 亮吾, 窪田 和雄, 福士 政広

    日本放射線技術学会雑誌   Vol. 68 ( 9 ) page: 1215 - 1215   2012.9

     More details

    Language:Japanese   Publisher:(公社)日本放射線技術学会  

  83. PET/CTにおける呼吸同期撮像法の検証 4DCTイメージの精度向上に関する検証

    砂岡 史生, 三本 拓也, 田口 好晃, 川口 晋吾, 佐藤 敬, 佐々木 徹, 南本 亮吾, 窪田 和雄

    日本放射線技術学会雑誌   Vol. 68 ( 9 ) page: 1215 - 1215   2012.9

     More details

    Language:Japanese   Publisher:(公社)日本放射線技術学会  

  84. HIV陽性患者の18F-FDG PETによる脳糖代謝評価

    諸岡 都, 窪田 和雄, 南本 亮吾, 宮田 陽子, 岡崎 百子, 石井 賢二, 坂田 宗之, 石渡 喜一, 豊原 潤, 岡 慎一

    核医学   Vol. 49 ( 3 ) page: S233 - S233   2012.8

     More details

    Language:Japanese   Publisher:(一社)日本核医学会  

  85. 18F-FDG PETによる急性心筋梗塞 糖負荷およびヘパリン負荷による画像評価

    諸岡 都, 窪田 和雄, 南本 亮吾, 宮田 陽子, 岡崎 百子, 三本 拓也, 佐藤 敬, 川口 晋吾, 砂岡 史生, 田口 好晃, 諸井 雅男

    核医学   Vol. 49 ( 3 ) page: S240 - S240   2012.8

     More details

    Language:Japanese   Publisher:(一社)日本核医学会  

  86. 脂肪酸代謝シンチグラフィによるNAFLD患者の進行度診断に関する検討

    南本 亮吾, 野崎 雄一, 窪田 和雄, 諸岡 都, 宮田 陽子, 岡崎 百子, 佐藤 敬, 川口 晋吾, 柳瀬 幹雄, 正木 尚彦, 溝上 雅史

    核医学   Vol. 49 ( 3 ) page: S201 - S201   2012.8

     More details

    Language:Japanese   Publisher:(一社)日本核医学会  

  87. FDG-PET/CTにおけるWegener肉芽腫症の活動性評価

    伊藤 公輝, 窪田 和雄, 南本 亮吾, 諸岡 都, 岡崎 百子, 宮田 陽子

    核医学   Vol. 49 ( 3 ) page: S275 - S275   2012.8

     More details

    Language:Japanese   Publisher:(一社)日本核医学会  

  88. DNA合成診断薬剤11C-4DSTによる肺癌リンパ節転移の検出能に関する検討

    南本 亮吾, 窪田 和雄, 豊原 潤, 伊藤 秀幸, 諸岡 都, 岡崎 百子, 宮田 陽子, 中島 和彦, 伊藤 公輝, 三本 拓也, 石渡 喜一

    核医学   Vol. 49 ( 3 ) page: S199 - S199   2012.8

     More details

    Language:Japanese   Publisher:(一社)日本核医学会  

  89. 18F-FDG-PETにおける体重、除脂肪体重、体表面積に基づくSUVの検証 健常者における各臓器の評価

    三本 拓也, 田口 好晃, 南本 亮吾, 諸岡 都, 窪田 和雄, 佐藤 敬, 佐々木 徹, 福士 政広

    核医学   Vol. 49 ( 3 ) page: S262 - S262   2012.8

     More details

    Language:Japanese   Publisher:(一社)日本核医学会  

  90. 18F-FDG-PET/CTによる正常肺におけるTotal SUVおよびTotal HUの定量化 多変量解析に基づく検証

    三本 拓也, 諸岡 都, 南本 亮吾, 窪田 和雄, 田口 好晃, 佐藤 敬, 佐々木 徹, 新保 卓郎, 福士 政広

    核医学   Vol. 49 ( 3 ) page: S206 - S206   2012.8

     More details

    Language:Japanese   Publisher:(一社)日本核医学会  

  91. 放射線治療後の再発脳腫瘍診断におけるメチオニンPETの視覚的評価に関する多施設共同研究

    南本 亮吾, 鷺野谷 利幸, 戸村 則昭, 伊藤 公輝, 松尾 有香, 近藤 千里, 松永 成生, 周頭 高, 赤羽 敦也, 坂井 修二, 窪田 和雄

    核医学   Vol. 49 ( 3 ) page: S277 - S277   2012.8

     More details

    Language:Japanese   Publisher:(一社)日本核医学会  

  92. PSF補正に基づく3次元PET画像におけるSUvmaxとSUVpeakの検証 Iterationによる影響

    三本 拓也, 田口 好晃, 南本 亮吾, 窪田 和雄, 佐藤 敬, 川口 晋吾, 佐々木 徹, 福士 政広

    核医学   Vol. 49 ( 3 ) page: S252 - S252   2012.8

     More details

    Language:Japanese   Publisher:(一社)日本核医学会  

  93. PET/CT検査室における患者の不安感と環境デザインに関する研究

    窪田 和雄, 長澤 夏子, 馬淵 大宇, 村元 萌, 福元 啓祐, 岡崎 百子, 諸岡 都, 南本 亮吾

    核医学   Vol. 49 ( 3 ) page: S213 - S213   2012.8

     More details

    Language:Japanese   Publisher:(一社)日本核医学会  

  94. PET/CTにおける体動補正に基づく呼吸同期PETイメージの検証

    三本 拓也, 田口 好晃, 南本 亮吾, 諸岡 都, 窪田 和雄, 砂岡 史生, 福士 政広

    核医学   Vol. 49 ( 3 ) page: S262 - S262   2012.8

     More details

    Language:Japanese   Publisher:(一社)日本核医学会  

  95. 内分泌腫瘍のIn-111オクトレオチドシンチグラフィとFDG-PETによる評価

    岡崎 百子, 窪田 和雄, 南本 亮吾, 諸岡 都, 宮田 陽子

    核医学   Vol. 49 ( 3 ) page: S267 - S267   2012.8

     More details

    Language:Japanese   Publisher:(一社)日本核医学会  

  96. 多発性骨髄腫のFDG-PET、メチオニンPET、4DST-PETの比較検討

    岡崎 百子, 窪田 和雄, 南本 亮吾, 諸岡 都, 宮田 陽子, 三輪 哲義, 平井 理泉, 伊藤 公輝, 石渡 喜一, 豊原 潤

    核医学   Vol. 49 ( 3 ) page: S268 - S268   2012.8

     More details

    Language:Japanese   Publisher:(一社)日本核医学会  

  97. Impact of maximum standardized uptake value (SUVmax) evaluated by 18-fluoro-2-deoxy-d-glucose positron emission tomography/computed tomography (FDG PET/CT) on survival for patients with advanced renal cell carcinoma.

    Noboru Nakaigawa, Masahiro Yao, Ukihide Tateishi, Ryogo Minamimoto, Hiroji Uemura, Tomio Inoue, Yoshinobu Kubota

    JOURNAL OF CLINICAL ONCOLOGY   Vol. 30 ( 15 )   2012.5

     More details

    Language:English   Publishing type:Research paper, summary (international conference)   Publisher:AMER SOC CLINICAL ONCOLOGY  

    Web of Science

  98. 111InオクトレオチドシンチグラフィとPETで評価した胸腺カルチノイドの一例

    岡崎 百子, 窪田 和雄, 南本 亮吾, 諸岡 都

    核医学   Vol. 49 ( 2 ) page: 67 - 67   2012.5

     More details

    Language:Japanese   Publisher:(一社)日本核医学会  

  99. PET/CT検査室における患者の不安感低減のための環境デザインに関する研究

    長澤 夏子, 馬渕 大宇, 村元 萌, 福元 啓祐, 岡崎 百子, 諸岡 都, 南本 亮吾, 窪田 和雄

    核医学   Vol. 49 ( 2 ) page: 68 - 68   2012.5

     More details

    Language:Japanese   Publisher:(一社)日本核医学会  

  100. HIV陽性患者のFDG PET/CT心臓集積

    諸岡 都, 窪田 和雄, 南本 亮吾, 岡崎 百子, 岡 慎一

    日本医学放射線学会学術集会抄録集   Vol. 71回   page: S345 - S345   2012.2

     More details

    Language:Japanese   Publisher:(公社)日本医学放射線学会  

  101. 11C-methionineと18F-FDG同日PET検査における異なる診断法による検証

    三本 拓也, 田口 好晃, 南本 亮吾, 新保 卓郎, 伊藤 公輝, 窪田 和雄, 福士 政広

    日本放射線技術学会総会学術大会予稿集   Vol. 68回   page: 182 - 182   2012.2

     More details

    Language:Japanese   Publisher:(公社)日本放射線技術学会  

  102. HIV関連リンパ腫におけるFDG-PET/CTによる予後予測の検討

    南本 亮吾, 田沼 順子, 窪田 和雄, 諸岡 都, 岡崎 百子, 伊藤 公輝, 宮田 陽子, 三本 拓也, 佐藤 敬, 岡 慎一

    日本医学放射線学会学術集会抄録集   Vol. 71回   page: S214 - S214   2012.2

     More details

    Language:Japanese   Publisher:(公社)日本医学放射線学会  

  103. 18F-FDG-PET/CTによる肺野全体SUV、HU定量化ソフトウェアの開発 正常肺に関して

    三本 拓也, 田口 好晃, 南本 亮吾, 新保 卓郎, 佐々木 徹, 窪田 和雄, 福士 政広

    日本放射線技術学会総会学術大会予稿集   Vol. 68回   page: 182 - 182   2012.2

     More details

    Language:Japanese   Publisher:(公社)日本放射線技術学会  

  104. 多発性骨髄腫のFDG、メチオニン、4DST-PETによる比較検討

    岡崎 百子, 窪田 和雄, 諸岡 都, 南本 亮吾, 伊藤 公輝, 平井 理泉, 三輪 哲義

    日本医学放射線学会学術集会抄録集   Vol. 71回   page: S214 - S214   2012.2

     More details

    Language:Japanese   Publisher:(公社)日本医学放射線学会  

  105. HIV陽性患者のFDG PET/CTの心臓集積

    諸岡 都, 窪田 和雄, 南本 亮吾, 岡崎 百子, 伊藤 公輝, 岡 慎一, 菊池 嘉, 田沼 順子, 照屋 勝治, 本田 美和子

    日本エイズ学会誌   Vol. 13 ( 4 ) page: 361 - 361   2011.11

     More details

    Language:Japanese   Publisher:(一社)日本エイズ学会  

  106. HIV/AIDS患者の18F-FDG PET/CT所見 A pictorial review

    諸岡 都, 窪田 和雄, 南本 亮吾, 岡崎 百子, 伊藤 公輝, 岡 慎一, 菊池 嘉, 田沼 順子, 照屋 勝治, 本田 美和子

    日本エイズ学会誌   Vol. 13 ( 4 ) page: 507 - 507   2011.11

     More details

    Language:Japanese   Publisher:(一社)日本エイズ学会  

  107. カポジ肉腫の診断にガリウムシンチは有用か?

    窪田 和雄, 諸岡 都, 岡崎 百子, 伊藤 公輝, 南本 亮吾, 田沼 順子, 本田 美和子, 照屋 勝治, 菊池 嘉, 岡 慎一

    日本エイズ学会誌   Vol. 13 ( 4 ) page: 506 - 506   2011.11

     More details

    Language:Japanese   Publisher:(一社)日本エイズ学会  

  108. 原発性肺癌における新規DNA合成診断薬剤11C-4DST-PETの有用性の検討

    清家 彩子, 北沢 伸祐, 長阪 智, 喜納 五月, 桑田 裕美, 伊藤 秀幸, 南本 亮吾, 諸岡 都, 窪田 和雄

    肺癌   Vol. 51 ( 5 ) page: 449 - 449   2011.10

     More details

    Language:Japanese   Publisher:(NPO)日本肺癌学会  

  109. 11C-methionineと18F-FDGを用いた同日PET検査法(Part1) 定量値に基づく検証

    三本 拓也, 窪田 和雄, 南本 亮吾, 岡崎 百子, 諸岡 都, 佐藤 敬, 佐々木 徹, 伊藤 公輝, 福士 政広

    核医学   Vol. 48 ( 3 ) page: S276 - S276   2011.9

     More details

    Language:Japanese   Publisher:(一社)日本核医学会  

  110. 11C-methionineと18F-FDGを用いた同日PET検査法(Part2) 視覚評価に基づく検証

    三本 拓也, 南本 亮吾, 伊藤 公輝, 岡崎 百子, 諸岡 都, 窪田 和雄, 佐々木 徹, 福士 政広

    核医学   Vol. 48 ( 3 ) page: S275 - S276   2011.9

     More details

    Language:Japanese   Publisher:(一社)日本核医学会  

  111. 18F-FDG-PET/CTにおける肺野全体のSUV、HU定量化ソフトウェアの開発

    三本 拓也, 諸岡 都, 窪田 和雄, 南本 亮吾, 岡崎 百子, 佐藤 敬, 佐々木 徹, 中西 哲也, 福士 政広

    核医学   Vol. 48 ( 3 ) page: S299 - S299   2011.9

     More details

    Language:Japanese   Publisher:(一社)日本核医学会  

  112. 癌性腹膜炎(播種)に似た所見を呈した、播種性結核の3例

    諸岡 都, 窪田 和雄, 南本 亮吾, 岡崎 百子, 伊藤 公輝, 宮田 陽子, 三本 拓也, 佐藤 敬, 川口 晋吾, 田口 好晃

    核医学   Vol. 48 ( 3 ) page: S257 - S258   2011.9

     More details

    Language:Japanese   Publisher:(一社)日本核医学会  

  113. 腫瘍 FDG-PET

    南本 亮吾

    日本医学放射線学会秋季臨床大会抄録集   Vol. 47回   page: S459 - S459   2011.9

     More details

    Language:Japanese   Publisher:(公社)日本医学放射線学会  

  114. 進行性腎細胞癌に対する予後予測法としてのFDG PET/CTの有用性

    中井川 昇, 矢尾 正祐, 立石 宇貴秀, 南村 和宏, 上野 大樹, 南本 亮吾, 槙山 和秀, 三浦 猛, 岸田 健, 小林 一樹, 池田 伊知郎, 梅本 晋, 大古 美治, 井上 登美雄, 窪田 吉信

    日本癌治療学会誌   Vol. 46 ( 2 ) page: 508 - 508   2011.9

     More details

    Language:Japanese   Publisher:(一社)日本癌治療学会  

  115. 関節・腱付着部のFDG集積 健常人の加齢変化について

    窪田 和雄, 南本 亮吾, 諸岡 都, 岡崎 百子, 伊藤 公輝, 宮田 陽子, 三本 拓也, 佐藤 敬

    核医学   Vol. 48 ( 3 ) page: S283 - S283   2011.9

     More details

    Language:Japanese   Publisher:(一社)日本核医学会  

  116. 99mTcアプロチニンシンチグラフィーによるアミロイドイメージング

    南本 亮吾, 窪田 和雄, 諸岡 都, 岡崎 百子, 伊藤 公輝, 中島 和彦, 三本 拓也, 田口 好晃, 川口 晋吾, 佐藤 敬

    核医学   Vol. 48 ( 3 ) page: S283 - S283   2011.9

     More details

    Language:Japanese   Publisher:(一社)日本核医学会  

  117. 201Tl+123I-BMIPP同時収集におけるミスマッチ領域定量化ツールの研究

    三本 拓也, 伊藤 公輝, 南本 亮吾, 岡崎 百子, 諸岡 都, 窪田 和雄, 佐藤 敬, 佐々木 徹, 福士 政広

    核医学技術   Vol. 31 ( 予稿集 ) page: 327 - 327   2011.9

     More details

    Language:Japanese   Publisher:(NPO)日本核医学技術学会  

  118. 新規DNA合成診断薬剤11C-4DSTの非小細胞肺癌における有用性の検討

    南本 亮吾, 窪田 和雄, 諸岡 都, 岡崎 百子, 伊藤 公輝, 中島 和彦, 清家 彩子, 伊藤 秀幸, 遠藤 久子, 豊原 潤, 石渡 喜一

    核医学   Vol. 48 ( 3 ) page: S299 - S299   2011.9

     More details

    Language:Japanese   Publisher:(一社)日本核医学会  

  119. NEMA/IECファントムに基づく同日中に11C-Methionineと18F-FDG PETを行うための検証

    三本 拓也, 南本 亮吾, 窪田 和雄, 諸岡 都, 岡崎 百子, 川口 晋吾, 佐藤 敬, 佐々木 徹, 福士 政広

    核医学技術   Vol. 31 ( 予稿集 ) page: 310 - 310   2011.9

     More details

    Language:Japanese   Publisher:(NPO)日本核医学技術学会  

  120. NEMA/IECファントムに基づくVUE Point HD-Sに関する検証

    三本 拓也, 佐藤 敬, 川口 晋吾, 田口 好晃, 佐々木 徹, 岡崎 百子, 諸岡 都, 南本 亮吾, 窪田 和雄, 福士 政広

    核医学技術   Vol. 31 ( 予稿集 ) page: 309 - 309   2011.9

     More details

    Language:Japanese   Publisher:(NPO)日本核医学技術学会  

  121. 嗄声を生じた患者におけるFDG-PET/CTの有用性の検討

    南本 亮吾, 窪田 和雄, 諸岡 都, 岡崎 百子, 田山 二朗, 伊藤 公輝, 田口 好晃, 三本 拓也, 川口 晋吾, 佐藤 敬

    核医学   Vol. 48 ( 3 ) page: S281 - S281   2011.9

     More details

    Language:Japanese   Publisher:(一社)日本核医学会  

  122. 多発性骨髄腫のFDG-PET、メチオニンPET、チミジンPETの比較検討

    岡崎 百子, 窪田 和雄, 諸岡 都, 南本 亮吾, 伊藤 公輝, 三輪 哲義

    核医学   Vol. 48 ( 3 ) page: S283 - S283   2011.9

     More details

    Language:Japanese   Publisher:(一社)日本核医学会  

  123. 【炎症のFDG-PET】炎症性腸疾患におけるPETの有用性

    南本 亮吾

    PET Journal   ( 14 ) page: 12 - 13   2011.6

     More details

    Language:Japanese   Publisher:先端医療技術研究所  

  124. 不明熱精査で発見されたcardiac lymphomaの一例

    南本 亮吾, 窪田 和雄, 諸岡 都, 伊藤 公輝, 宮田 陽子, 平井 理泉, 岡崎 修, 廣江 道昭

    核医学   Vol. 48 ( 2 ) page: 156 - 156   2011.5

     More details

    Language:Japanese   Publisher:(一社)日本核医学会  

  125. 【ここまでわかる!!関節疾患の画像診断】核医学診断

    窪田 和雄, 伊藤 公輝, 諸岡 都, 南本 亮吾, 桂川 陽三, 黒木 啓文

    整形・災害外科   Vol. 54 ( 5 ) page: 491 - 498   2011.4

     More details

    Language:Japanese   Publisher:金原出版(株)  

  126. 【炎症のFDG-PET】不明熱のFDG-PET診断

    窪田 和雄, 南本 亮吾, 諸岡 都, 増田 陽子, 伊藤 公輝

    PET Journal   ( 13 ) page: 35 - 37   2011.3

     More details

    Language:Japanese   Publisher:先端医療技術研究所  

  127. 今後のPET検診はどうあるべきか

    南本 亮吾

    PET Journal   ( 13 ) page: 41 - 43   2011.3

  128. HIV/AIDS関連疾患のPET所見

    諸岡 都, 窪田 和雄, 南本 亮吾, 伊藤 公輝, 蓮尾 金博, 菊池 嘉

    日本医学放射線学会学術集会抄録集   Vol. 70回   page: S156 - S156   2011.2

     More details

    Language:Japanese   Publisher:(公社)日本医学放射線学会  

  129. 11C-メチオニンと18F-FDGを用いた同日PET検査の方法論

    三本 拓也, 佐藤 敬, 南本 亮吾, 窪田 和雄, 新保 卓郎, 伊藤 公輝, 福士 政広

    日本放射線技術学会総会学術大会予稿集   Vol. 67回   page: 250 - 250   2011.2

     More details

    Language:Japanese   Publisher:(公社)日本放射線技術学会  

  130. FDG-PETがん検診における放射線被曝の実態とリスク・ベネフィット解析

    村野 剛志, 南本 亮吾, 千田 道雄, 宇野 公一, 陣之内 正史, 福田 寛, 飯沼 武, 塚本 江利子, 寺内 隆司, 吉田 毅, 奥 真也, 西澤 貞彦, 伊藤 健吾, 小口 和浩, 川本 雅美, 中島 留美, 岩田 宏, 井上 登美夫

    核医学   Vol. 48 ( 1 ) page: 1 - 13   2011.2

     More details

    Language:Japanese   Publisher:(一社)日本核医学会  

    [目的]FDG-PETがん検診に伴う放射線被曝の状況を把握し、そのリスク・ベネフィット解析を行うことを目的とした。[方法]2006年度にFDG-PETがん検診の実態調査を実施し、集計した。リスク・ベネフィット解析には「平均余命の伸縮」という共通の尺度を用いた。[結果]実効線量の平均はPET専用機では男性4.7mSv、女性4.0mSv、PET/CTでは男性14.2mSv、女性12.8mSvであり、放射線被曝の観点から検診のリスクとベネフィットが均衡する年齢はPET専用機では男性が40歳代、女性が30歳代であり、PET/CT検査では男性が50歳代、女性がFDGの投与方法により50から60歳代であった。[結論]これらの年齢以上の受診者ではFDG-PETがん検診の有効性が示唆されたが、他のX線検査と比較して被曝線量が多いため、検診を行う際には検査による利益と不利益を十分説明する必要がある。(著者抄録)

  131. 若年性特発性関節炎(JIA)におけるFDG-PETの有用性の検討

    金沢 紀子, 立石 宇貴秀, 岡部 哲彦, 吉田 啓介, 南本 亮吾, 鈴木 晶子, 雫石 一也, 李 進, 井上 登美夫

    核医学   Vol. 48 ( 1 ) page: 71 - 71   2011.2

     More details

    Language:Japanese   Publisher:(一社)日本核医学会  

  132. FDG-PETによる不明熱の診断 多施設共同研究

    窪田 和雄, 中本 裕士, 玉木 長良, 福田 寛, 立石 宇貴秀, 諸岡 都, 伊藤 公輝, 南本 亮吾, 村上 康二

    日本医学放射線学会学術集会抄録集   Vol. 70回   page: S365 - S365   2011.2

     More details

    Language:English   Publisher:(公社)日本医学放射線学会  

  133. メソトレキセート関連リンパ腫に対するFDG-PET/CTの有用性の検討

    南本 亮吾, 窪田 和雄, 諸岡 都, 伊藤 公輝, 平井 理泉, 萩原 將太郎, 三輪 哲義

    日本医学放射線学会学術集会抄録集   Vol. 70回   page: S227 - S227   2011.2

     More details

    Language:Japanese   Publisher:(公社)日本医学放射線学会  

  134. 泌尿器科医に必要なPET検査の知識 有用性と問題点 尿路上皮癌とPET検査

    南本 亮吾, 立石 宇貴秀, 井上 登美夫

    臨床泌尿器科   Vol. 64 ( 13 ) page: 1009 - 1015   2010.12

     More details

    Language:Japanese   Publisher:(株)医学書院  

    尿路上皮癌とは,腎盂,尿管,膀胱,尿道の内腔を覆う移行上皮から発生する癌を総称する。PET検査は,全身を一度に非侵襲的スクリーニングできるという特徴を有し,悪性腫瘍をマネージメントする際に有用な情報を提供し得る。尿路上皮癌に対しては,PET核種の尿排泄,解像度の限界,保険適用外であることなどさまざまな問題がある。しかし留意点を熟知し,適切に利用すれば,PET検査は尿路上皮癌の診断,治療に大きく貢献すると考えられる。(著者抄録)

    Other Link: https://search.jamas.or.jp/default/link?pub_year=2010&ichushi_jid=J01561&link_issn=&doc_id=20101201060009&doc_link_id=10.11477%2Fmf.1413102171&url=https%3A%2F%2Fdoi.org%2F10.11477%2Fmf.1413102171&type=%E5%8C%BB%E6%9B%B8.jp_%E3%82%AA%E3%83%BC%E3%83%AB%E3%82%A2%E3%82%AF%E3%82%BB%E3%82%B9&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00024_2.gif

  135. 泌尿器科医に必要なPET検査の知識 有用性と問題点 腎細胞癌とPET検査

    中井川 昇, 南村 和宏, 南本 亮吾, 岸田 健, 三浦 猛, 矢尾 正祐, 井上 登美夫, 窪田 吉信

    臨床泌尿器科   Vol. 64 ( 12 ) page: 935 - 942   2010.11

     More details

    Language:Japanese   Publisher:(株)医学書院  

    腎癌の画像診断の領域において,形態学的,解剖学的な診断法という視点で比較した場合に, PETは従来の画像診断を凌駕するものではない。しかし,PETが従来の画像診断と大きく異なる点は,生体内の生物学的活動の評価が可能な点である。この特性を利用し,腎癌病巣の悪性度診断,予後の予測や治療効果の判定として活用することによってそのポテンシャルは最大限に発揮されるものと思われた。(著者抄録)

    Other Link: https://search.jamas.or.jp/default/link?pub_year=2010&ichushi_jid=J01561&link_issn=&doc_id=20101111210010&doc_link_id=10.11477%2Fmf.1413102157&url=https%3A%2F%2Fdoi.org%2F10.11477%2Fmf.1413102157&type=%E5%8C%BB%E6%9B%B8.jp_%E3%82%AA%E3%83%BC%E3%83%AB%E3%82%A2%E3%82%AF%E3%82%BB%E3%82%B9&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00024_2.gif

  136. 【Nuclear Medicine Today 2010 成熟期に入ったFDG-PET PET/CTの臨床的有用性と可能性を中心に】PETをめぐる課題と未来への提言 総合がん検診としてのFDG-PETがん検診の考察

    南本 亮吾

    INNERVISION   Vol. 25 ( 12 ) page: 62 - 64   2010.11

     More details

    Language:Japanese   Publisher:(株)インナービジョン  

    現在、全国で行われているFDG-PET検査もしくはPET/CT検査(以下、合わせてPET検査)を用いたがん検診は、"PETがん検診"や"PET検診"などと一般名称化されている。マスコミ報道等から推察するに、このPETがん検診やPET検診という呼称は、PET検査のみに依存したがん検診ととらえられている場合も少なくない。PET検査は、非侵襲的に全身の悪性病変をスクリーニングできるという利点がある一方、がんの種類や大きさによってはその検出に限界がある。そのため、PET検査に加え、PET検査の限界を補いうる検査を併用する総合がん検診プログラムが"FDG-PETがん検診"の定義とされている。(著者抄録)

  137. PETイメージにおける高集積部位が画像に与える影響についての基礎的検討

    藤木 尚, 三本 拓也, 佐藤 敬, 村松 禎久, 小高 喜久雄, 諸岡 都, 南本 亮吾, 窪田 和雄

    国立病院総合医学会講演抄録集   Vol. 64回   page: 682 - 682   2010.11

     More details

    Language:Japanese   Publisher:国立病院総合医学会  

  138. 人工膝関節置換術(TKA)患者の3相骨シンチグラフィが有用であった症例

    皆川 梓, 三本 拓也, 佐藤 敬, 鈴木 勝則, 村松 禎久, 小高 喜久雄, 諸岡 都, 南本 亮吾, 窪田 和雄, 桂川 陽三

    国立病院総合医学会講演抄録集   Vol. 64回   page: 682 - 682   2010.11

     More details

    Language:Japanese   Publisher:国立病院総合医学会  

  139. CD36欠損症の18F-FDG PET画像

    諸岡 都, 窪田 和雄, 南本 亮吾, 伊藤 公輝, 宮田 陽子, 三本 拓也, 佐藤 敬, 藤田 勝則, 野平 敬之

    核医学   Vol. 47 ( 3 ) page: 367 - 367   2010.9

     More details

    Language:Japanese   Publisher:(一社)日本核医学会  

  140. 肝臓への生理的なFDG集積は血糖値の影響を受ける

    窪田 和雄, 渡辺 博重, 村田 雄二, 伊藤 公輝, 諸岡 都, 宮田 陽子, 南本 亮吾, 堀 愛

    核医学   Vol. 47 ( 3 ) page: 390 - 390   2010.9

     More details

    Language:Japanese   Publisher:(一社)日本核医学会  

  141. 胸腺由来腫瘍におけるFDG-PETの有用性の検討

    南本 亮吾, 窪田 和雄, 諸岡 都, 伊藤 公輝, 宮田 陽子

    核医学   Vol. 47 ( 3 ) page: 395 - 395   2010.9

     More details

    Language:Japanese   Publisher:(一社)日本核医学会  

  142. 新規DNA合成診断薬剤11C-4DSTの初期臨床評価 全身PET画像の評価

    窪田 和雄, 諸岡 都, 南本 亮吾, 伊藤 公輝, 宮田 陽子, 中島 和彦, 成相 直, 豊原 潤, 坂田 宗之, 石渡 喜一

    核医学   Vol. 47 ( 3 ) page: 373 - 373   2010.9

     More details

    Language:Japanese   Publisher:(一社)日本核医学会  

  143. 放射線治療後の悪性脳腫瘍における再発、壊死の鑑別を目的とした11C-メチオニンPET/CTの有用性の検討

    南本 亮吾, 松永 成生, 諸岡 都, 伊藤 公輝, 宮田 陽子

    日本医学放射線学会秋季臨床大会抄録集   Vol. 46回   page: S530 - S530   2010.8

     More details

    Language:Japanese   Publisher:(公社)日本医学放射線学会  

  144. FDG-PETがん検診アンケート調査集計結果(2005-2006年度)

    南本 亮吾, 宇野 公一, 西澤 貞彦, 陣之内 正史, 飯沼 武, 井上 登美夫

    日本がん検診・診断学会誌   Vol. 17 ( 3 ) page: 223 - 228   2010.3

     More details

    Language:Japanese   Publisher:(NPO)日本がん検診・診断学会  

    本研究は、18F-fluorodeoxyglucose-positron emission tomography(FDG-PET)がん検診の実情をアンケート調査によって把握し、その結果をもとに「FDG-PETがん検診」の成績を報告することを目的とする。FDG-PETがん検診は、PET専用機もしくはPET/CT機器による検査に、がんをスクリーニングするための検査を併用した総合的ながん検診と定義する。2005年度と2006年度に、PET専用機およびPET/CT機器を保有する施設に「FDG-PETがん検診」に関するアンケート調査を配布し、がん検診に関する詳細な情報が得られた延べ97施設における87,057件のFDG-PETがん検診の結果について検討を行った。がんの疑いがあるため要精査とされたのは受診件数の9.8%であり、受診件数の1.14%(FDG-PET所見陽性0.89%、陰性0.25%)にあたる合計991件にがんが発見された。PETおよびPET/CTの相対感度は78.6%、陽性適中率は29.2%であり、相対感度の高い発見がんの種類としては、大腸癌(発見件数218件、感度89%)、甲状腺癌(194件、89%)、肺癌(173件、78%)、乳癌(64件、88%)が、相対感度の低いものとしては前立腺癌(91件、39%)、胃癌(56件、39%)があげられた。発見件数の多い大腸がん、甲状腺がん、肺がん、乳がんに関しては、UICC病期分類のStage Iで大部分が発見されており、高い5年生存率が期待できる。FDG-PETがん検診では多種類のがんが発見されており、従来の臓器特異性の検診とは趣が異なる。長期にわたる調査とその解析をもとに「FDG-PETがん検診」の有効性の有無を評価する必要がある。(著者抄録)

    Other Link: https://search.jamas.or.jp/default/link?pub_year=2010&ichushi_jid=J03648&link_issn=&doc_id=20100521440010&doc_link_id=%2Fdo5candd%2F2010%2F001703%2F011%2F0223-0228%26dl%3D0&url=https%3A%2F%2Fwww.medicalonline.jp%2Fjamas.php%3FGoodsID%3D%2Fdo5candd%2F2010%2F001703%2F011%2F0223-0228%26dl%3D0&type=MedicalOnline&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00004_2.gif

  145. 前立腺癌MAB療法中に発症した前立腺肉腫に対するIMRT治療を行った1例

    河原 崇司, 上村 博司, 南本 亮吾, 山中 正二, 関口 善吉, 喜多 かおる, 槙山 和秀, 中井川 昇, 小川 毅彦, 矢尾 正祐, 井上 登美夫, 窪田 吉信

    泌尿器外科   Vol. 23 ( 臨増 ) page: 521 - 521   2010.3

     More details

    Language:Japanese   Publisher:医学図書出版(株)  

  146. 18F-FDG PET/CTによる進行性腎細胞癌の臨床経過予測の検討

    中井川 昇, 南村 和宏, 南本 亮吾, 佐野 太, 槙山 和秀, 小林 一樹, 野口 純男, 石垣 華子, 岸田 健, 三浦 猛, 井上 登美夫, 矢尾 正祐, 窪田 吉信

    日本泌尿器科学会雑誌   Vol. 101 ( 2 ) page: 214 - 214   2010.2

  147. 心臓原発B胞リンパ腫の一例

    岡崎 百子, 立石 宇貴秀, 南本 亮吾, 西井 俊晶, 関川 善二郎, 雫石 一也, 萩原 浩明, 井上 登美夫

    日本画像医学雑誌   Vol. 28 ( 2 ) page: 133 - 133   2010.2

     More details

    Language:Japanese   Publisher:日本画像医学会  

  148. FDG-PET/CTによる進行性腎細胞癌における分子標的治療薬の効果判定

    南本 亮吾, 立石 宇貴秀, 雫石 一也, 中井川 昇, 窪田 吉信, 井上 登美夫

    核医学   Vol. 46 ( 3 ) page: 294 - 295   2009.9

     More details

    Language:Japanese   Publisher:(一社)日本核医学会  

  149. 転移性骨腫瘍の診断精度 NaF-PET/CTとBone Scintigraphyの対比

    雫石 一也, 立石 宇貴秀, 川口 将司, 吉田 啓介, 南本 亮吾, 萩原 浩明, 井上 登美夫

    核医学   Vol. 46 ( 3 ) page: 325 - 325   2009.9

     More details

    Language:Japanese   Publisher:(一社)日本核医学会  

  150. FDG-PETがん検診の全国調査結果

    南本 亮吾, 千田 道雄, 宇野 公一, 陣之内 正史, 伊藤 健吾, 寺内 隆司, 西澤 貞彦, 福田 寛, 吉田 毅, 井上 登美夫

    日本がん検診・診断学会誌   Vol. 17 ( 2 ) page: 133 - 133   2009.9

     More details

    Language:Japanese   Publisher:(NPO)日本がん検診・診断学会  

  151. 新たながん検診検査方法の有効性 PETを用いたがん検診の全国調査結果について

    井上 登美夫, 南本 亮吾

    日本がん検診・診断学会誌   Vol. 17 ( 2 ) page: 119 - 119   2009.9

     More details

    Language:Japanese   Publisher:(NPO)日本がん検診・診断学会  

  152. 【Nuclear Medicine 2009 FDG-PETを超えて 核医学の可能性と方向性】FDG-PETの最新動向 18F FDG-PETがん検診はいま 現状と課題

    南本 亮吾, 井上 登美夫

    INNERVISION   Vol. 24 ( 10 ) page: 83 - 86   2009.9

     More details

    Language:Japanese   Publisher:(株)インナービジョン  

    18F FDG-PET(以下、FDG-PET)検査は、がん細胞の増殖に伴う相対的な現象の一つである糖代謝の亢進を利用して、非侵襲的に全身の悪性病変をスクリーニングすることが可能である。1995年、山中湖クリニックは、世界に先んじてがん検診にFDG-PET検査を導入し、それを補助する超音波検査、CT検査などを併用した総合的ながん検診方法(山中湖方式)を確立した結果、多岐にわたるがんを早期に発見することが可能となった。その山中湖方式をモデルとした、FDG-PET検査に他の検査を併用する総合がん検診を、現在では"FDG-PETがん検診"と呼称する。本稿では、2005~2007年にわたるアンケート調査の結果をもとに、調査に当たって筆者が得た情報といささかの考察を交え、FDG-PETがん検診の現状を述べる。(著者抄録)

  153. 18F-FDG PET-CTによる前立腺がんの診断

    河原 崇司, 上村 博司, 寺尾 秀行, 佐野 太, 村上 貴之, 槙山 和秀, 中井川 昇, 小川 毅彦, 矢尾 正祐, 南本 亮吾, 井上 登美夫, 窪田 吉信

    泌尿器外科   Vol. 22 ( 8 ) page: 1057 - 1059   2009.8

     More details

    Language:Japanese   Publisher:医学図書出版(株)  

    18F-FDG PETによる前立腺がんの診断は、従来難しいと考えられてきた。CTとの融合によるPET-CTの導入で、前立腺がんの診断向上の可能性があると考えられ前立腺がんの診断の有用性について検討した。PSA高値(PSA平均値17.7ng/ml)の患者27名に対して、前立腺針生検の前にPET-CTを施行し、病理結果との比較検討を行った。前立腺がんが見つかった患者でのPET-CTの陽性率は37%であった。臨床病期別でPET-CTでの陽性率は、T1cでは25%、T2aでは50%、T2cでは67%、T3aでは100%であった。T2以上の比較的進行した前立腺がんでのPET陽性率は高く、有用性が高いと考えられた。(著者抄録)

  154. [18F]FDG-PETで異常集積を認めた後腹膜腫瘍の一例

    西戸 玲子, 吉田 啓介, 宍倉 彩子, 小田切 一将, 南本 亮吾, 雫石 一也, 長嶋 敏幸, 李 進, 井上 登美夫, 山中 正二, 川本 雅美

    核医学   Vol. 46 ( 2 ) page: 121 - 122   2009.6

     More details

    Language:Japanese   Publisher:(一社)日本核医学会  

  155. 集積パターンと併用検査に基づくFDG-PETがん検診の要精査判定方法

    南本 亮吾, 千田 道雄, 陣之内 正史, 吉田 毅, 中島 留美, 西澤 貞彦, 寺内 隆司, 川本 雅美, 井上 登美夫

    核医学   Vol. 46 ( 2 ) page: 73 - 93   2009.6

     More details

    Language:Japanese   Publisher:(一社)日本核医学会  

    [目的]本研究は、4臓器(乳腺、甲状腺、肺、大腸)に関して、精査結果の判明しているFDG-PETがん検診の症例を対象とした読影判定試験を行い、これをもとにFDG-PETがん検診における読影基準を作成することを目的とする。[方法]対象は2003~2006年に2施設で行われたがん検診を対象としたFDG-PET検査のうち、精査結果が判明している200件とした。また乳腺超音波、甲状腺超音波、胸部CT検査、便潜血反応(二日法)を併用する検査として定め、FDG-PET所見と同時に検討を行った。[結果]読影判定結果から、FDGの「限局性の集積」を認めた場合は全臓器に共通して精査を勧めるべきと考えられた。さらに、乳腺では限局性かつ軽度のFDGの集積を確認すること、肺では胸部CTを併用し総合的に判定を行うこと、大腸では遅延像におけるFDGの集積の変化を確認することが有用と考えられた。[結論]これらの知見に基づいて、対象とした4臓器のFDG-PETおよび併用検査所見に関する診断基準案を作成した。(著者抄録)

    Other Link: https://search.jamas.or.jp/default/link?pub_year=2009&ichushi_jid=J00251&link_issn=&doc_id=20090716140001&doc_link_id=1570291225929809280&url=https%3A%2F%2Fcir.nii.ac.jp%2Fcrid%2F1570291225929809280&type=CiNii&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00003_1.gif

  156. Neurolymphomatosisにて再燃したNHLのPET/CT画像

    宍倉 彩子, 西戸 玲子, 吉田 啓介, 南本 亮吾, 雫石 一也, 鈴木 晶子, 高橋 延和, 長嶋 敏幸, 李 進, 井上 登美夫

    核医学   Vol. 46 ( 2 ) page: 129 - 129   2009.6

     More details

    Language:Japanese   Publisher:(一社)日本核医学会  

  157. PETがん検診の疫学調査

    千田 道雄, 井上 登美夫, 宇野 公一, 陣之内 正史, 塚本 江利子, 寺内 隆司, 中島 留美, 西澤 貞彦, 南本 亮吾, 吉田 毅

    核医学   Vol. 46 ( 2 ) page: 100 - 102   2009.6

  158. FDG PET-CTを用いた前立腺癌診断の試み

    寺尾 秀行, 佐野 太, 南本 亮吾, 中井川 昇, 三好 康秀, 上村 博司, 窪田 吉信, 井上 登美夫

    泌尿器外科   Vol. 22 ( 臨増 ) page: 362 - 362   2009.3

     More details

    Language:Japanese   Publisher:医学図書出版(株)  

  159. FDG PET-CTを用いた前立腺癌診断の試み(第3報)

    三宅 見季, 寺尾 秀行, 佐野 太, 南本 亮吾, 中井川 昇, 三好 康秀, 上村 博司, 窪田 吉信, 井上 登美夫

    日本泌尿器科学会雑誌   Vol. 100 ( 2 ) page: 415 - 415   2009.2

  160. 高PSA患者におけるFDG-PET/CTによる前立腺癌検出能の検討

    南本 亮吾, 雫石 一也, 立石 宇貴秀, 李 進, 寺尾 秀行, 佐野 太, 上村 博司, 長嶋 洋治, 窪田 吉信, 井上 登美夫

    日本医学放射線学会学術集会抄録集   Vol. 68回   page: S321 - S321   2009.2

     More details

    Language:Japanese   Publisher:(公社)日本医学放射線学会  

  161. 前立癌治療中に発生した前立腺腫瘤の一例

    南本 亮吾, 萩原 浩明, 井上 登美夫, 立石 宇貴秀, 李 進

    神奈川医学会雑誌   Vol. 36 ( 1 ) page: 85 - 86   2009.1

     More details

    Language:Japanese   Publisher:(公社)神奈川県医師会  

  162. 開発早期における薬効評価はできるのか? 分子イメージング法とAMS法の併用による検討

    濱邉 好美, 南本 亮吾, 井上 登美夫, 岡 卓志, 宮岡 貞次, 下田 麻里佳, 松井 隆雄

    臨床薬理   Vol. 39 ( Suppl. ) page: S303 - S303   2008.11

     More details

    Language:Japanese   Publisher:(一社)日本臨床薬理学会  

  163. FDG PET-CTを用いた前立腺癌診断の試み

    寺尾 秀行, 佐野 太, 南本 亮吾, 中井川 昇, 三好 康秀, 上村 博司, 窪田 吉信, 井上 登美夫

    日本癌治療学会誌   Vol. 43 ( 2 ) page: 774 - 774   2008.10

     More details

    Language:Japanese   Publisher:(一社)日本癌治療学会  

  164. PETがん検診の疫学調査

    千田 道雄, 南本 亮吾, 井上 登美夫, 宇野 公一, 陣之内 正史, 塚本 江利子, 寺内 隆司, 中島 留美, 西澤 貞彦, 古田 毅

    核医学   Vol. 45 ( 3 ) page: S153 - S153   2008.9

     More details

    Language:Japanese   Publisher:(一社)日本核医学会  

  165. PETとAMS(Accelerator Mass Spectrometry)の相関性に関する検討

    南本 亮吾, 松井 隆雄, 宮岡 貞次, 濱邉 好美, 岡 卓志, 井上 登美夫

    核医学   Vol. 45 ( 3 ) page: S190 - S191   2008.9

     More details

    Language:Japanese   Publisher:(一社)日本核医学会  

  166. FDG PET-CTを用いた前立腺癌診断の試み

    佐野 太, 中井川 昇, 南本 亮吾, 三好 康秀, 上村 博司, 窪田 吉信, 井上 登美夫

    泌尿器外科   Vol. 21 ( 臨増 ) page: 434 - 434   2008.3

     More details

    Language:Japanese   Publisher:医学図書出版(株)  

  167. Accelerator Mass Spectrometry(AMS)による生物試料中C14濃度測定とC14製剤のbiomarkerとしての可能性

    南本 亮吾, 松井 隆雄, 岡 卓志, 原 孝光, 吉田 啓介, 井上 登美夫

    核医学   Vol. 44 ( 3 ) page: 264 - 264   2007.10

     More details

    Language:Japanese   Publisher:(一社)日本核医学会  

  168. 頭頸部癌の再発診断におけるPET/CTの役割

    鈴木 晶子, 吉田 啓介, 南本 亮吾, 雫石 一也, 軽部 美佐子, 岡 卓志, 高橋 延和, 李 進, 井上 登美夫

    核医学   Vol. 44 ( 3 ) page: 292 - 292   2007.10

     More details

    Language:Japanese   Publisher:(一社)日本核医学会  

  169. 中間報告(1)PETがん検診の疫学調査

    千田 道雄, 井上 登美夫, 宇野 公一, 陣之内 正史, 塚本 江利子, 寺内 隆司, 中島 留美, 西澤 貞彦, 南本 亮吾, 吉田 毅

    核医学   Vol. 44 ( 3 ) page: 235 - 235   2007.10

     More details

    Language:Japanese   Publisher:(一社)日本核医学会  

  170. FDG-PETがん検診の実態と成績 全国調査に基づく検討

    南本 亮吾, 千田 道雄, 宇野 公一, 陣之内 正史, 飯沼 武, 伊藤 健吾, 奥山 智緒, 小口 和浩, 川本 雅美, 鈴木 豊, 塚本 江利子, 寺内 隆司, 中島 留美, 西尾 正美, 西澤 貞彦, 福田 寛, 吉田 毅, 井上 登美夫

    核医学   Vol. 44 ( 2 ) page: 105 - 124   2007.5

     More details

    Language:Japanese   Publisher:(一社)日本核医学会  

    2005年度に、18F-fluorodeoxyglucose-positron emission tomography(FDG-PET)がん検診[FDG-PET(PET/CTを含む)による健常者を対象とするがんのスクリーニング検査、他の検査を併用する場合を含む]を施行した46施設、受診件数50,558件について検討した。総合判定での要精査例(受診者の9.8%)は可及的精査結果の提出を求め、精査結果の回答が不十分であった8施設を除く38施設、受診件数43,996件につき詳細な解析を行った。受診者の年代分布は50,60代に多く、全体の約61%を占めていた。がんの発見は合計500件で受診者の1.14%(FDG-PET所見陽性0.90%、陰性0.24%)、発見されたがんのうちFDG-PET所見陽性は79.0%であった。発見例の多かったがんの種別とPET陽性率(感度)は、併用検査項目に依存するが、実態としては、PET感度の高いものでは甲状腺癌(発見107件、PET感度88%)、大腸癌(102件、90%)、肺癌(79件、80%)、乳癌(35件、92%)、PET感度の低いものでは前立腺癌(47件、45%)、胃癌(30件、30%)があげられた。またPETの陽性適中率は29.0%であった。PET専用機とPET/CT装置では、要精査率はPET/CTの方が高かったが(p<0.01)、発見率、感度、陽性適中率はPET/CTが勝っていた(p<0.01)。(著者抄録)

    Other Link: https://search.jamas.or.jp/default/link?pub_year=2007&ichushi_jid=J00251&link_issn=&doc_id=20070611050002&doc_link_id=1573105975981330048&url=https%3A%2F%2Fcir.nii.ac.jp%2Fcrid%2F1573105975981330048&type=CiNii&icon=https%3A%2F%2Fjk04.jamas.or.jp%2Ficon%2F00003_1.gif

  171. 【脳加齢現象における形態・機能診断の最前線】頭蓋内・頸部血管

    伊藤 隆志, 長嶋 敏幸, 南本 亮吾, 田之畑 一則

    臨床画像   Vol. 20 ( 8 ) page: 961 - 971   2004.8

     More details

    Language:Japanese   Publisher:(株)メジカルビュー社  

    加齢に伴い頭蓋内・頸部血管の動脈硬化は進行するが,生理的加齢性変化と病的変化の境界は必ずしも明瞭ではない.そこで,ルーチン検査として頻用されているMRAの加齢性変化,限界,ピットフォールと,それを補完するCTAの役割について述べた

  172. 橋出血後の小脳萎縮

    南本 亮吾, 長嶋 敏幸, 伊藤 隆志, 田之畑 一則

    神奈川医学会雑誌   Vol. 29 ( 1 ) page: 92 - 92   2002.1

     More details

    Language:Japanese   Publisher:(公社)神奈川県医師会  

  173. 【胸部の最新画像診断2002】Accessory cardiac bronchusのCT所見

    長嶋 敏幸, 伊藤 隆志, 田之畑 一則, 南本 亮吾, 安藤 和夫

    臨床放射線   Vol. 47 ( 1 ) page: 199 - 204   2002.1

     More details

    Language:Japanese   Publisher:金原出版(株)  

    accessory cardiac bronchus(ACB)7例について検討した.背景は喀血2例,肺炎1例,悪性腫瘍2例,気管支喘息1例,肺結核症1例であった.全例単純胸部CTを施行した.異常気管支は全例で中間気管支幹の内側より分岐していたが,中間気管支幹からの分岐レベルは一定ではなかった.ACBは通常は無症状であったが,喀血の原因となることがあった.ACBとB7欠損との関連が示唆された.3D-CT等の再構成画像はACB等の中枢気道のanomalyの診断に有用であった

▼display all

KAKENHI (Grants-in-Aid for Scientific Research) 3

  1. 新規PET薬剤4DSTによるDNA合成イメージングを用いた胸部放射線治療の最適化

    Grant number:15K10015  2015.4 - 2016.3

    科学研究費助成事業  基盤研究(C)

    川瀬 貴嗣, 窪田 和雄, 南本 亮吾

      More details

    Authorship:Coinvestigator(s) 

    胸部悪性腫瘍、特に食道癌の病期診断・治療効果判定・再発診断において新規放射性薬剤11C-チオチミジン(4DST) によるポジトロン放出断層撮影検査(PET)が如何に寄与しうるかを精査した。治療前の病期診断時、放射線治療施行症例については治療の中間評価・治療後効果判定に、治療後経過観察症例については再発有無診断として4DST検査、従来の放射性フルオロデオキシグルコース(FDG)-PETを併施し、さらにコンピューター断層撮影検査を施行してそれらを対比することによって4DST検査の特性を探索した。本研究に際しては事前に施設内倫理委員会の審査・承認を得た。4DST画像はポジトロン放出断層撮影撮影検査及びコンピューター断層撮影検査との融合画像(PET/CT)、最大値投影画像(MIP)として画像再構成され、病態の観察、画像診断に供された。同検査の検査特性に加え、4DSTによるPET/CTにおいては骨髄への集積が比較的強く、病変の観察の際に注意すべき点であることが判明した。今後はさらに対象症例数を増し、その知見から4DST-PET/CTが食道癌の治療計画策定に寄与しうる病態・使用目的を絞り込み、前向きコホート研究を行うことが見込まれる。また同検査によって放射線治療計画時の適切な標的体積設定ができる場合は、本検査結果を反映させた治療計画により放射線治療による晩期有害事象、特に放射線性肺臓炎のリスク低減を目指した研究の展開が期待できる。

  2. DNA合成を反映する新規PET製剤4DSTを利用した病変の悪性度評価と予後予測

    Grant number:24791362  2012.4 - 2014.3

    科学研究費助成事業  若手研究(B)

    南本 亮吾

      More details

    Authorship:Principal investigator 

    Grant amount:\4420000 ( Direct Cost: \3400000 、 Indirect Cost:\1020000 )

    本研究は、放射線診療分野におけるがん患者の個別化医療の実現を目指し、日本国内で開発されたDNA合成を反映する新規PET製剤(11C-4DST)を利用し、「病変の悪性度評価」と再発予測を行った。DNA合成を反映するPET製剤である4DSTを用いて非侵襲的にDNA合成の画像化を行い、病変個々の悪性度を病理学的診断と比較した。4DST-PET/CTにおけるDデータと血清チミジンキナーゼ値、患者の再発までの期間を比較し、4DST-PET/CTによる再発予測の可能性についても検討した。
    肺がん患者31名に対して4DST、FDG-PET/CTを行い、原発巣とリンパ節における病理診断との比較を行った。4DSTの転移リンパ節検出感度は82%であり、FDG(30%)と比較して優位に高値であった。一方、4DSTはリンパ節への非特異的集積を示し、特異度はFDGと比較して低値を示し、病理学的な特徴も認められなかった。しかし、4DST及びFDG検査所見と術後2年以内の再発率を比較した結果、4DSTのリンパ節への集積は、再発における最も優位な因子と考えられ(オッズ比=27)、さらに原発巣の4DST集積度(SUVmax)も優位な因子と考えられた。
    頭頚部腫瘍患者42名に対して、4DSTとFDG-PET/CTを施行した。病変における集積度の比較において、FDG低集積病変(SUVmax < 3)では4DST集積と高い相関性が認められたが(r=0.8)、FDG高集積例(SUVmax >3)では相関性はそれと比較して低値であった (r=0.5-0.7)。細胞増殖の間接的指標である血清チミジンキナーゼと直接的指標である4DST集積度との相関性は認められず、独立した因子と考えられた。
    今後は、多数例におけるより詳細な解析と臨床経過との比較によって、4DSTの臨床的意義を解明する必要があると考えられた。

  3. Establishment of early therapeutic assessment method for cancer by combination of AMS and PET

    Grant number:20890186  2008 - 2009

    Grants-in-Aid for Scientific Research  Grant-in-Aid for Young Scientists (Start-up)

    MINAMIMOTO Ryogo

      More details

    Authorship:Principal investigator 

    Grant amount:\2925000 ( Direct Cost: \2250000 、 Indirect Cost:\675000 )

    First we clarified the 14C concentration in blood and tumor as background. Second, as for FDG tracer, we showed that Accelerator mass spectrometry (AMS) analysis has an excellent correlation with biodistribution measurements using gamma counter regarded as PET measurement. Third, we evaluated the therapeutic effect by alternation of C14 concentration in blood compared to alternation of free DNA in the blood. At 24 hours post therapy, free DNA and C14 concentration in 5FU treatment group has difference compared to other groups.

Industrial property rights 2

  1. NASH診断プログラム、NASH診断方法及び装置

    窪田 和雄, 南本 亮吾, 野崎 雄一, 林 明希男

     More details

    Applicant:国立研究開発法人国立国際医療研究センター

    Application no:特願2014-022570  Date applied:2014.2

    Announcement no:特開2015-148555  Date announced:2015.8

    J-GLOBAL

  2. NASH診断プログラム、NASH診断装置の作動方法、及びNASH診断装置

    窪田 和雄, 南本 亮吾, 野崎 雄一, 林 明希男

     More details

    Applicant:国立研究開発法人国立国際医療研究センター

    Application no:特願2014-022570  Date applied:2014.2

    Announcement no:特開2015-148555  Date announced:2015.8

    Patent/Registration no:特許第6272065号  Date registered:2018.1 

    J-GLOBAL